

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



WIPO | PCT



(10) International Publication Number

WO 2012/162243 A2

(43) International Publication Date

29 November 2012 (29.11.2012)

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)  
C12N 15/13 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2012/038844

(22) International Filing Date:

21 May 2012 (21.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/488,660 20 May 2011 (20.05.2011) US

(71) Applicant (for all designated States except US): **ALDER-BIO HOLDINGS LLC** [US/US]; 101 Convention Center Dr., Ste. 850, Las Vegas, Nevada 89109 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KOVACEVICH, Brian Robert** [US/US]; 13916 233rd St. SE, Snohomish, Washington 98296 (US). **GARCIA-MARTINEZ, Leon F.** [US/US]; 4926 214th St. SE, Woodinville, Washington 98072 (US). **OLSON, Katie** [US/US]; 6700 NE 182nd St. #D207, Kenmore, Washington 98028 (US). **DUTZAR, Benjamin H.** [US/US]; 3124A Franklin Ave. E, Seattle, Washington 98102 (US). **BILLGREN, Jens J.** [US/US]; 7309 Sand Point Way NE #B948, Seattle, Washington 98115 (US). **LATHAM, John A.** [US/US]; 2409 10th Ave. NW, Seattle, Washington 98119 (US). **MITCHELL, Danielle M.** [US/US]; 6522B 24th Ave. NE, Seattle,

Washington 98115 (US). **MCNEILL, Patricia Dianne** [US/US]; 1333 South 290th Place, Federal Way, Washington 98003 (US). **JANSON, Nicole M.** [US/US]; 1413 N. 47th St., Seattle, Washington 98103 (US). **LOOMIS, Maria-Cristina** [US/US]; 4807 196th St. SE, Bothell, Washington 98012 (US).

(74) Agent: **TESKIN, Robin L.**; Hunton & Williams LLP, 2200 Pennsylvania Ave. NW, Washington, District of Columbia 20037 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTI-CGRP COMPOSITIONS AND USE THEREOF

Figure 39

Reduction in Vasodilatation Following Capsaicin Administration



(57) **Abstract:** The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V<sub>H</sub>, V<sub>L</sub> and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

WO 2012/162243 A2

**Declarations under Rule 4.17:**

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

## ANTI-CGRP COMPOSITIONS AND USE THEREOF

This application claims the benefit of U.S. Provisional Application No. 61/488,660 (Atty. Docket No. 67858.730300) filed May 20, 2011, entitled "ANTI-CGRP COMPOSITIONS AND USE THEREOF" which is hereby incorporated by reference in its entirety.

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 18, 2012, is named 678580730301.txt and is 203,815 bytes in size.

### BACKGROUND OF THE INVENTION

#### *Field of the Invention*

**[0001]** This invention pertains to antibodies and fragments thereof (including Fab fragments) having binding specificity to human Calcitonin Gene Related Peptide (hereinafter "CGRP"). The invention also pertains to methods of screening for diseases and disorders associated with CGRP, and methods of preventing or treating diseases and disorders associated with CGRP by administering said antibodies or fragments thereof.

#### *Description of Related Art*

**[0002]** Calcitonin Gene Related Peptide (CGRP) is produced as a multifunctional neuropeptide of 37 amino acids in length. Two forms of CGRP, the CGRP-alpha and CGRP-beta forms, exist in humans and have similar activities. CGRP-alpha and CGRP-beta differ by three amino acids in humans, and are derived from different genes. The CGRP family of peptides includes amylin, adrenomedullin, and calcitonin, although each has distinct receptors and biological activities. Doods, H., *Curr. Op. Invest. Drugs*, 2(9):1261-68 (2001).

**[0003]** CGRP is released from numerous tissues such as trigeminal nerves, which when activated release neuropeptides within the meninges, mediating neurogenic inflammation that is characterized by vasodilation, vessel leakage, and mast-cell degradation. Durham, P.L., *New Eng. J. Med.*, 350 (11):1073-75 (2004). The biological effects of CGRP are

mediated via the CGRP receptor (CGRP-R), which consists of a seven-transmembrane component, in conjunction with receptor-associated membrane protein (RAMP). CGRP-R further requires the activity of the receptor component protein (RCP), which is essential for an efficient coupling to adenylate cyclase through G proteins and the production of cAMP. Doods, H., *Curr. Op. Invest. Drugs*, 2(9):1261-68 (2001).

**[0004]** Migraines are neurovascular disorder affecting approximately 10% of the adult population in the U.S., and are typically accompanied by intense headaches. Approximately 20-30% of migraine sufferers experience aura, comprising focal neurological phenomena that precede and/or accompany the event. CGRP is believed to play a prominent role in the development of migraines. For example, plasma concentrations of CGRP were identified elevated in jugular venous blood during the headache phase of migraines, to the exclusion of other neuropeptides. Moreover, according to Arulmozhi *et al*, the following has been identified in migraine sufferers: (1) a strong correlation between plasma CGRP concentrations and migraines; (2) the infusion of CGRP produced a migraine-like headache; (3) baseline CGRP levels were elevated; and (4) changes in plasma CGRP levels during migraine attacks significantly correlated with headache intensity. Arulmozhi, D.K., *et al.*, *Vas. Pharma.*, 43: 176-187 (2005).

**[0005]** One effective treatment for migraines is the administration of triptans, which are a family of tryptamine-based drugs, including sumatriptan and rizatriptan. Members of this family have an affinity for multiple serotonin receptors, including 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>1F</sub>. Members of this family of drugs selectively constrict cerebral vessels, but also cause vasoconstrictive effects on coronary vessels. Durham, P.L., *New Eng. J. Med.*, 350 (11):1073-75 (2004). There is a theoretical risk of coronary spasm in patients with established heart disease following administration, and cardiac events after taking triptans may rarely occur. Noted to be contraindicated for patients with coronary vascular disease.

**[0006]** Similarly, pain may often be addressed through the administration of certain narcotics or non-steroidal anti-inflammatory drugs (NSAIDs). However, the administration of these treatments may occur at the cost of certain negative consequences. NSAIDs have the potential to cause kidney failure, intestinal bleeding, and liver dysfunction. Narcotics have the potential to cause nausea, vomiting, impaired mental

functioning, and addiction. Therefore, it is desirable to identify alternative treatments for pain in order to avoid certain of these negative consequences.

[0007] CGRP is believed to play a role in a multitude of diseases and disorders, including but not limited to migraines, headaches, and pain.

[0008] For example, CGRP reportedly may correlate to or even play a causal role in overactive bladder. Evidence that CGRP may correlate to overactive bladder condition includes the fact that CGRP is present in urinary tract, DRG and spinal cord - (Wharton et al., 1986 *Neurosci* (3):727) and also that C-fiber afferents are critical for carrying impulses involved in micturition to spinal cord (Yoshida et al., 2011 *J Pharmacol Sci* (112):128). Further, it has been reported that the intravesical administration of Botox suppresses CGRP and significantly reduces intercontraction interval in acetic acid - induced bladder pain model (Chuang et al., 2004 *J Urol* (172):1529; Chuang et al., 2009 *J Urol* (182):786)

[0009] Evidence that CGRP may play a causal role in this condition is a recent published patent application containing data purportedly suggesting that an anti-CGRP Ab disclosed therein reduced the number of bladder contractions in a turpentine-oil – induced overactive bladder model –(Pfizer WO 2011/024113)).

[00010] Due to the perceived involvement of CGRP in these and other disorders, there remains a need in the art for compositions and methods useful for preventing or treating diseases and disorders associated with CGRP, while avoiding adverse side effects. There remains a need in the art for compositions or methods that reduce or inhibit diseases or disorders associated with CGRP, such as migraines, headaches, overactive bladder, and pain.

#### BRIEF SUMMARY OF THE INVENTION

[00011] The present invention is directed to specific antibodies and fragments thereof having binding specificity for CGRP, in particular antibodies having desired epitopic specificity, high affinity or avidity and/or functional properties. Another embodiment of this invention relates to the antibodies described herein, comprising the sequences of the V<sub>H</sub>, V<sub>L</sub> and CDR polypeptides described herein, and the polynucleotides encoding them. A preferred embodiment of the invention is directed to chimeric or humanized antibodies and

fragments thereof (including Fab fragments) capable of binding to CGRP and/or inhibiting the biological activities mediated by the binding of CGRP to the CGRP receptor ("CGRP-R").

**[00012]** In another preferred embodiment of the invention, full length antibodies and Fab fragments thereof are contemplated that inhibit the CGRP-alpha-, CGRP-beta-, and rat CGRP-driven production of cAMP. In a further preferred embodiment of the invention, full length and Fab fragments thereof are contemplated that reduce vasodilation in a recipient following administration.

**[0010]** In another embodiment of the invention, chimeric or humanized antibodies and fragments thereof (including Fab fragments) capable of binding to CGRP are useful in methods directed to reducing, treating, or preventing migraines (with or without aura), cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, weight loss, pain, hemiplagic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), and allergy-induced headaches or migraines. The antibodies and antibody fragments of the present invention particularly have utility in treating, preventing, ameliorating, controlling or reducing the risk of one or more of the following conditions or diseases: overactive bladder and other urinary conditions including bladder infection, pain; chronic pain; neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; post-surgical pain, trauma related pain, burn related pain, diabetes; non-insulin dependent diabetes mellitus and other inflammatory autoimmune disorders, vascular disorders; inflammation; arthritis; bronchial hyperreactivity, asthma; shock; sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes in men and women; allergic dermatitis; psoriasis; encephalitis; brain trauma; epilepsy; neurodegenerative diseases; skin diseases including pruritis, neurogenic cutaneous redness, skin rosaceousness and erythema; inflammatory bowel disease, irritable bowel syndrome, cystitis; dysmenorrhea, and other conditions that potentially may be treated or prevented or the symptoms ameliorated by antagonism of CGRP receptors. Of

particular importance is the acute or prophylactic treatment of headache, including migraine and cluster headache, and other pain related conditions as well as overactive bladder.

**[0011]** In another embodiment of the invention, chimeric or humanized antibodies and fragments thereof (including Fab fragments) capable of binding to CGRP are preferably useful in methods directed to reducing, treating, or preventing gastro-esophageal reflux, and visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, or pancreatitis.

**[0012]** In another embodiment of the invention these antibodies and humanized versions may be derived from rabbit immune cells (B lymphocytes) and may be selected based on their homology (sequence identity) to human germ line sequences. These antibodies may require minimal or no sequence modifications, thereby facilitating retention of functional properties after humanization. A further embodiment of the invention is directed to fragments from anti-CGRP antibodies encompassing V<sub>H</sub>, V<sub>L</sub> and CDR polypeptides, e.g., derived from rabbit immune cells and the polynucleotides encoding the same, as well as the use of these antibody fragments and the polynucleotides encoding them in the creation of novel antibodies and polypeptide compositions capable of binding to CGRP and/or CGRP/CGRP-R complexes.

**[0013]** The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said chimeric or humanized anti-CGRP or anti-CGRP/CGRP-R complex antibodies and binding fragments thereof. In one embodiment, binding fragments include, but are not limited to, Fab, Fab', F(ab')<sub>2</sub>, Fv, scFv fragments, SMIPs (small molecule immunopharmaceuticals), camelbodies, nanobodies, and IgNAR.

**[0014]** Embodiments of the invention pertain to the use of anti-CGRP antibodies and binding fragments thereof for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP or aberrant expression thereof. The invention also

contemplates the use of fragments of anti-CGRP antibodies for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP or aberrant expression thereof. Other embodiments of the invention relate to the production of anti-CGRP antibodies or fragments thereof in recombinant host cells, for example mammalian cells such as CHO, NSO or HEK 293 cells, or yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains.

#### BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

- [0015] Figure 1 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab1.
- [0016] Figure 2 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab2.
- [0017] Figure 3 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab3.
- [0018] Figure 4 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab4.
- [0019] Figure 5 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab5.
- [0020] Figure 6 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab6.
- [0021] Figure 7 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab7.
- [0022] Figure 8 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab8.
- [0023] Figure 9 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab9.
- [0024] Figure 10 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab10.

[0025] Figure 11 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab11.

[0026] Figure 12 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab12.

[0027] Figure 13 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab13.

[0028] Figure 14 provides polynucleotide and polypeptide sequences corresponding to the full-length Antibody Ab14.

[0029] Figure 15 provides the CGRP-alpha ELISA binding data obtained following the protocol in Example 1 *infra* for antibodies Ab1, Ab2, Ab3, and Ab4.

[0030] Figure 16 provides the CGRP-alpha ELISA binding data obtained following the protocol in Example 1 *infra* for antibodies Ab5, Ab6, Ab7, and Ab8.

[0031] Figure 17 provides the CGRP-alpha ELISA binding data obtained following the protocol in Example 1 *infra* for antibodies Ab9, Ab10, and Ab14.

[0032] Figure 18 provides the CGRP-alpha ELISA binding data obtained following the protocol in Example 1 *infra* for antibodies Ab11, Ab12, and Ab13.

[0033] Figure 19 demonstrates the inhibition of CGRP-alpha-driven cAMP production by antibodies Ab1, Ab2, and Ab4, obtained following the protocol in Example 1 *infra*.

[0034] Figure 20 demonstrates the inhibition of CGRP-alpha-driven cAMP production by antibody Ab3, obtained following the protocol in Example 1 *infra*.

[0035] Figure 21 demonstrates the inhibition of CGRP-alpha-driven cAMP production by antibodies Ab5 and Ab6, obtained following the protocol in Example 1 *infra*.

[0036] Figure 22 demonstrates the inhibition of CGRP-alpha-driven cAMP production by antibodies Ab7, Ab8, Ab9, and Ab10, obtained following the protocol in Example 1 *infra*.

[0037] Figure 23 demonstrates the inhibition of CGRP-alpha-driven cAMP production by antibodies Ab11, Ab12, and Ab13, obtained following the protocol in Example 1 *infra*.

[0038] Figure 24 demonstrates the inhibition of CGRP-alpha-driven cAMP production by antibody Ab14, obtained following the protocol in Example 1 *infra*.

[0039] Figure 25 demonstrates the inhibition of CGRP-beta-driven cAMP production by antibodies Ab1, Ab2, and Ab3, obtained following the protocol in Example 1 *infra*.

[0040] Figure 26 demonstrates the inhibition of CGRP-beta-driven cAMP production by antibodies Ab4, Ab5, and Ab6, obtained following the protocol in Example 1 *infra*.

[0041] Figure 27 demonstrates the inhibition of CGRP-beta-driven cAMP production by antibodies Ab7 and Ab8, obtained following the protocol in Example 1 *infra*.

[0042] Figure 28 demonstrates the inhibition of CGRP-beta-driven cAMP production by antibodies Ab9, Ab10, and Ab14, obtained following the protocol in Example 1 *infra*.

[0043] Figure 29 demonstrates the inhibition of CGRP-beta-driven cAMP production by antibodies Ab11, Ab12, and Ab13, obtained following the protocol in Example 1 *infra*.

[0044] Figure 30 demonstrates the inhibition of rat CGRP-driven cAMP production by antibodies Ab1, Ab2, Ab4, and Ab5, obtained following the protocol in Example 1 *infra*.

[0045] Figure 31 demonstrates the inhibition of rat CGRP -driven cAMP production by antibodies Ab3 and Ab6, obtained following the protocol in Example 1 *infra*.

[0046] Figure 32 demonstrates the inhibition of rat CGRP-driven cAMP production by antibodies Ab7 and Ab8, obtained following the protocol in Example 1 *infra*.

[0047] Figure 33 demonstrates the inhibition of rat CGRP-driven cAMP production by antibody Ab9, obtained following the protocol in Example 1 *infra*.

[0048] Figure 34 demonstrates the inhibition of rat CGRP-driven cAMP production by antibody Ab10, obtained following the protocol in Example 1 *infra*.

[0049] Figure 35 demonstrates the inhibition of rat CGRP-driven cAMP production by antibodies Ab11 and Ab12, obtained following the protocol in Example 1 *infra*.

[0050] Figure 36 demonstrates the inhibition of rat CGRP-driven cAMP production by antibody Ab13, obtained following the protocol in Example 1 *infra*.

[0051] Figure 37 demonstrates the inhibition of rat CGRP-driven cAMP production by antibody Ab14, obtained following the protocol in Example 1 *infra*.

[0052] Figure 38 demonstrates the inhibition of binding of radiolabeled CGRP to CGRP-R by antibodies Ab1-Ab13, obtained following the protocol in Example 6 *infra*.

[0053] Figure 39 demonstrates a reduction in vasodilation obtained by administering antibodies Ab3 and Ab6 following capsaicin administration in a rat model, relative to a control antibody, obtained following the protocol in Example 7 *infra*.

[0054] Figure 40 demonstrates a reduction in vasodilation obtained by administering antibody Ab6 at differing concentrations following capsaicin administration in a rat model, relative to a control antibody, obtained following the protocol in Example 7 *infra*.

[0055] FIG. 41A-C shows the beneficial effect of Ab3 on bladder capacity during saline infusion. Animals were administered Ab3 or a negative control antibody, then monitored during infusion of saline into the bladder. ICI (panel A) was increased and MF (panel B) was decreased, indicating increased bladder capacity. Differences in AM (panel C) were within the standard deviation and not statistically significant. Asterisks indicate statistically significant improvement ( $p < 0.05$  unpaired Student's t-test, comparison to Negative control Ab). Legend: filled bars: Ab3 treated (10 mg/kg); open bars: negative control antibody (10 mg/kg). Error bars indicate the standard deviation. Abbreviations: ICI : Intercontraction Interval; MF : Micturition Frequency; AM : Amplitude of Micturition.

[0056] FIG. 42 shows the effect Ab2 in a model of neuropathic pain. Mechanical allodynia was induced by Chung surgery (L5/L6 spinal nerve ligation), and degree of sensitivity was compared between Ab2 treated animals (hashed bars) and control animals (filled bars). Higher values indicate less sensitivity. Average sensitivity was similar at day 13 (prior to Ab2 administration) but improved at days 14 and 17. Error bars indicate the standard error of the mean.

[0057] FIG. 43 shows the analgesic effect of Ab2 and morphine. Pain sensitivity was assessed by the tail withdrawal time (y-axis, seconds) for animals administered morphine (open squares), Ab2 (10 mg/kg, filled triangles), or vehicle (negative control, open circles). Animals developed morphine tolerance and exhibited tail withdrawal times similar to control animals by day 4. In contrast, Ab2-treated animals exhibited a sustained improvement in tail withdrawal time over the course of the experiment (to day 7). The improvement in Ab2-treated animals was statistically significant ( $p < 0.05$  one-way ANOVA followed by Dunnett's test, comparison to vehicle, indicated by asterisks). Error bars indicate the standard error of the mean.

[0058] FIG. 44 shows the dosage-dependent analgesic effect of Ab2. On day 0 (subsequent to the first tail withdrawal time test), rats were administered antibody Ab2 at a dosage of 1 mg/kg (filled squares), 3 mg/kg (filled downward-pointing triangles), or 10 mg/kg (filled upward-pointing triangles), or a vehicle (open circles) or negative control antibody (open squares). The rats' tail withdrawal time in response to a painful thermal stimulus was assessed daily (higher times indicate relative insensitivity to pain). Tail withdrawal time was increased in a dosage-dependent manner by the administration of Ab2. Asterisks indicate statistically significant increases in tail withdrawal time ( $p < 0.05$  one-way ANOVA followed by Dunnett's test, comparison to vehicle). Error bars indicate the standard error of the mean.

[0059] FIG. 45 shows the analgesic effect of Ab2 in combination with morphine, and when morphine is withdrawn after the onset of morphine tolerance. On day 0 (subsequent to the first tail withdrawal time test), rats were administered antibody Ab2 at a dosage of 10 mg/kg (filled squares and filled triangles) or vehicle (open circles). The rats were then daily administered morphine on days 1 to 10 (filled squares) or only on days 1 to 4 (filled triangles). The tail withdrawal time initially was greatly increased in the morphine-treated mice, but decreased on subsequent days indicating morphine tolerance. However, in the mice from which morphine was withdrawn after day 4, tail withdrawal time increased and remained elevated between days 5 and 8. Error bars indicate the standard error of the mean.

[0060] FIG. 46 shows the effect of Ab2 in a rat model of visceral pain. Visceral pain was quantified by measuring the colonic distension threshold (higher values indicate less sensitivity) for naïve animals (open bar) or animals treated with TNBS to provoke chronic colonic hypersensitivity which either received a negative control antibody (filled bars) or Ab2 (hashed bars). Hypersensitivity was alleviated by 27% by the Ab2-treated animals, and distension threshold was significantly improved by administration of Ab2 ( $p < 0.05$  Student's t-test, comparison to TNBS + Negative control group). Error bars indicate the standard error of the mean.

## DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

***Definitions***

**[0061]** It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, and reagents described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. As used herein the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the protein" includes reference to one or more proteins and equivalents thereof known to those skilled in the art, and so forth. All technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs unless clearly indicated otherwise.

**[0062]** *Calcitonin Gene Related Peptide (CGRP):* As used herein, CGRP encompasses not only the following *Homo sapiens* CGRP-alpha and *Homo sapiens* CGRP-beta amino acid sequences available from American Peptides (Sunnyvale CA) and Bachem (Torrance, CA):

CGRP-alpha: ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH<sub>2</sub> (SEQ ID NO: 281), wherein the N-terminal phenylalanine is amidated;

CGRP-beta: ACNTATCVTHRLAGLLSRSGGMVKSNFVPTNVGSKAF-NH<sub>2</sub> (SEQ ID NO: 282), wherein the N-terminal phenylalanine is amidated; but also any membrane-bound forms of these CGRP amino acid sequences, as well as mutants (mutiens), splice variants, isoforms, orthologues, homologues and variants of this sequence.

**[0063]** *Mating competent yeast species:* In the present invention this is intended to broadly encompass any diploid or tetraploid yeast which can be grown in culture. Such species of yeast may exist in a haploid, diploid, or other polyploid form. The cells of a given ploidy may, under appropriate conditions, proliferate for an indefinite number of generations in that form. Diploid cells can also sporulate to form haploid cells. Sequential mating can result in tetraploid strains through further mating or fusion of diploid strains.

The present invention contemplates the use of haploid yeast, as well as diploid or other polyploid yeast cells produced, for example, by mating or spheroplast fusion.

**[0064]** In one embodiment of the invention, the mating competent yeast is a member of the *Saccharomycetaceae* family, which includes the genera *Arxiozyma*; *Ascobotryozyma*; *Citeromyces*; *Debaryomyces*; *Dekkera*; *Eremothecium*; *Issatchenkia*; *Kazachstania*; *Kluyveromyces*; *Kodamaea*; *Lodderomyces*; *Pachysolen*; *Pichia*; *Saccharomyces*; *Saturnispora*; *Tetrasisporina*; *Torulaspora*; *Williopsis*; and *Zygosaccharomyces*. Other types of yeast potentially useful in the invention include *Yarrowia*; *Rhodosporidium*; *Candida*; *Hansenula*; *Filobasidella*; *Filobasidella*; *Sporidiobolus*; *Bullera*; *Leucosporidium* and *Filobasidella*.

**[0065]** In a preferred embodiment of the invention, the mating competent yeast is a member of the genus *Pichia*. In a further preferred embodiment of the invention, the mating competent yeast of the genus *Pichia* is one of the following species: *Pichia pastoris*, *Pichia methanolica*, and *Hansenula polymorpha* (*Pichia angusta*). In a particularly preferred embodiment of the invention, the mating competent yeast of the genus *Pichia* is the species *Pichia pastoris*.

**[0066]** *Haploid Yeast Cell*: A cell having a single copy of each gene of its normal genomic (chromosomal) complement.

**[0067]** *Polyplloid Yeast Cell*: A cell having more than one copy of its normal genomic (chromosomal) complement.

**[0068]** *Diploid Yeast Cell*: A cell having two copies (alleles) of essentially every gene of its normal genomic complement, typically formed by the process of fusion (mating) of two haploid cells.

**[0069]** *Tetraploid Yeast Cell*: A cell having four copies (alleles) of essentially every gene of its normal genomic complement, typically formed by the process of fusion (mating) of two haploid cells. Tetraploids may carry two, three, four or more different expression cassettes. Such tetraploids might be obtained in *S. cerevisiae* by selective mating homozygotic heterothallic a/a and alpha/alpha diploids and in *Pichia* by sequential mating of haploids to obtain auxotrophic diploids. For example, a [met his] haploid can be mated with [ade his] haploid to obtain diploid [his]; and a [met arg] haploid can be mated

with [ade arg] haploid to obtain diploid [arg]; then the diploid [his] x diploid [arg] to obtain a tetraploid prototroph. It will be understood by those of skill in the art that reference to the benefits and uses of diploid cells may also apply to tetraploid cells.

**[0100] Yeast Mating:** The process by which two haploid yeast cells naturally fuse to form one diploid yeast cell.

**[0101] Meiosis:** The process by which a diploid yeast cell undergoes reductive division to form four haploid spore products. Each spore may then germinate and form a haploid vegetatively growing cell line.

**[0102] Selectable Marker:** A selectable marker is a gene or gene fragment that confers a growth phenotype (physical growth characteristic) on a cell receiving that gene as, for example through a transformation event. The selectable marker allows that cell to survive and grow in a selective growth medium under conditions in which cells that do not receive that selectable marker gene cannot grow. Selectable marker genes generally fall into several types, including positive selectable marker genes such as a gene that confers on a cell resistance to an antibiotic or other drug, temperature when two temperature sensitive (“ts”) mutants are crossed or a ts mutant is transformed; negative selectable marker genes such as a biosynthetic gene that confers on a cell the ability to grow in a medium without a specific nutrient needed by all cells that do not have that biosynthetic gene, or a mutagenized biosynthetic gene that confers on a cell inability to grow by cells that do not have the wild type gene; and the like. Suitable markers include but are not limited to: ZEO; G418; LYS3; MET1; MET3a; ADE1; ADE3; URA3; and the like.

**[0103] Expression Vector:** These DNA vectors contain elements that facilitate manipulation for the expression of a foreign protein within the target host cell. Conveniently, manipulation of sequences and production of DNA for transformation is first performed in a bacterial host, *e.g. E. coli*, and usually vectors will include sequences to facilitate such manipulations, including a bacterial origin of replication and appropriate bacterial selection marker. Selection markers encode proteins necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or

other toxins, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media. Exemplary vectors and methods for transformation of yeast are described, for example, in Burke, D., Dawson, D., & Stearns, T. (2000). Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual. Plainview, N.Y.: Cold Spring Harbor Laboratory Press.

**[0104]** Expression vectors for use in the methods of the invention will further include yeast specific sequences, including a selectable auxotrophic or drug marker for identifying transformed yeast strains. A drug marker may further be used to amplify copy number of the vector in a yeast host cell.

**[0105]** The polypeptide coding sequence of interest is operably linked to transcriptional and translational regulatory sequences that provide for expression of the polypeptide in yeast cells. These vector components may include, but are not limited to, one or more of the following: an enhancer element, a promoter, and a transcription termination sequence. Sequences for the secretion of the polypeptide may also be included, e.g. a signal sequence, and the like. A yeast origin of replication is optional, as expression vectors are often integrated into the yeast genome. In one embodiment of the invention, the polypeptide of interest is operably linked, or fused, to sequences providing for optimized secretion of the polypeptide from yeast diploid cells.

**[0106]** Nucleic acids are "operably linked" when placed into a functional relationship with another nucleic acid sequence. For example, DNA for a signal sequence is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites or alternatively via a PCR/recombination method familiar to those skilled in the art (Gateway<sup>®</sup> Technology; Invitrogen, Carlsbad California). If such sites do not exist, the synthetic oligonucleotide adapters or linkers are used in accordance with conventional practice.

**[0107]** Promoters are untranslated sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of particular nucleic acid sequences to which they are operably linked. Such promoters fall into several classes: inducible, constitutive, and repressible promoters (that increase levels of transcription in response to absence of a repressor). Inducible promoters may initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, *e.g.*, the presence or absence of a nutrient or a change in temperature.

**[0108]** The yeast promoter fragment may also serve as the site for homologous recombination and integration of the expression vector into the same site in the yeast genome; alternatively a selectable marker is used as the site for homologous recombination. *Pichia* transformation is described in Cregg *et al.* (1985) Mol. Cell. Biol. **5**:3376-3385.

**[0109]** Examples of suitable promoters from *Pichia* include the AOX1 and promoter (Cregg *et al.* (1989) Mol. Cell. Biol. **9**:1316-1323); ICL1 promoter (Menendez *et al.* (2003) Yeast **20**(13):1097-108); glyceraldehyde-3-phosphate dehydrogenase promoter (GAP) (Waterham *et al.* (1997) Gene **186**(1):37-44); and FLD1 promoter (Shen *et al.* (1998) Gene **216**(1):93-102). The GAP promoter is a strong constitutive promoter and the AOX and FLD1 promoters are inducible.

**[0110]** Other yeast promoters include ADH1, alcohol dehydrogenase II, GAL4, PHO3, PHO5, Pyk, and chimeric promoters derived therefrom. Additionally, non-yeast promoters may be used in the invention such as mammalian, insect, plant, reptile, amphibian, viral, and avian promoters. Most typically the promoter will comprise a mammalian promoter (potentially endogenous to the expressed genes) or will comprise a yeast or viral promoter that provides for efficient transcription in yeast systems.

**[0111]** The polypeptides of interest may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, *e.g.* a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the polypeptide coding sequence that is inserted into the vector. The

heterologous signal sequence selected preferably is one that is recognized and processed through one of the standard pathways available within the host cell. The *S. cerevisiae* alpha factor pre-pro signal has proven effective in the secretion of a variety of recombinant proteins from *P. pastoris*. Other yeast signal sequences include the alpha mating factor signal sequence, the invertase signal sequence, and signal sequences derived from other secreted yeast polypeptides. Additionally, these signal peptide sequences may be engineered to provide for enhanced secretion in diploid yeast expression systems. Other secretion signals of interest also include mammalian signal sequences, which may be heterologous to the protein being secreted, or may be a native sequence for the protein being secreted. Signal sequences include pre-peptide sequences, and in some instances may include propeptide sequences. Many such signal sequences are known in the art, including the signal sequences found on immunoglobulin chains, e.g., K28 preprotoxin sequence, PHA-E, FACE, human MCP-1, human serum albumin signal sequences, human Ig heavy chain, human Ig light chain, and the like. For example, see Hashimoto *et. al.* Protein Eng 11(2) 75 (1998); and Kobayashi *et. al.* Therapeutic Apheresis 2(4) 257 (1998).

**[0112]** Transcription may be increased by inserting a transcriptional activator sequence into the vector. These activators are cis-acting elements of DNA, usually about from 10 to 300 bp, which act on a promoter to increase its transcription. Transcriptional enhancers are relatively orientation and position independent, having been found 5' and 3' to the transcription unit, within an intron, as well as within the coding sequence itself. The enhancer may be spliced into the expression vector at a position 5' or 3' to the coding sequence, but is preferably located at a site 5' from the promoter.

**[0113]** Expression vectors used in eukaryotic host cells may also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from 3' to the translation termination codon, in untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA.

**[0114]** Construction of suitable vectors containing one or more of the above-listed components employs standard ligation techniques or PCR/recombination methods.

Isolated plasmids or DNA fragments are cleaved, tailored, and re-ligated in the form desired to generate the plasmids required or via recombination methods. For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform host cells, and successful transformants selected by antibiotic resistance (e.g. ampicillin or Zeocin) where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion and/or sequenced.

**[0115]** As an alternative to restriction and ligation of fragments, recombination methods based on att sites and recombination enzymes may be used to insert DNA sequences into a vector. Such methods are described, for example, by Landy (1989) *Ann.Rev.Biochem.* 58:913-949; and are known to those of skill in the art. Such methods utilize intermolecular DNA recombination that is mediated by a mixture of lambda and *E.coli* -encoded recombination proteins. Recombination occurs between specific attachment (att) sites on the interacting DNA molecules. For a description of att sites see Weisberg and Landy (1983) Site-Specific Recombination in Phage Lambda, in *Lambda II*, Weisberg, ed.(Cold Spring Harbor, NY:Cold Spring Harbor Press), pp. 211-250. The DNA segments flanking the recombination sites are switched, such that after recombination, the att sites are hybrid sequences comprised of sequences donated by each parental vector. The recombination can occur between DNAs of any topology.

**[0116]** *Att* sites may be introduced into a sequence of interest by ligating the sequence of interest into an appropriate vector; generating a PCR product containing att B sites through the use of specific primers; generating a cDNA library cloned into an appropriate vector containing att sites; and the like.

**[0117]** *Folding*, as used herein, refers to the three-dimensional structure of polypeptides and proteins, where interactions between amino acid residues act to stabilize the structure. While non-covalent interactions are important in determining structure, usually the proteins of interest will have intra- and/or intermolecular covalent disulfide bonds formed by two cysteine residues. For naturally occurring proteins and polypeptides or derivatives and variants thereof, the proper folding is typically the arrangement that results in optimal biological activity, and can conveniently be monitored by assays for activity, *e.g.* ligand binding, enzymatic activity, *etc.*

**[0118]** In some instances, for example where the desired product is of synthetic origin, assays based on biological activity will be less meaningful. The proper folding of such molecules may be determined on the basis of physical properties, energetic considerations, modeling studies, and the like.

**[0119]** The expression host may be further modified by the introduction of sequences encoding one or more enzymes that enhance folding and disulfide bond formation, *i.e.* foldases, chaperonins, *etc.* Such sequences may be constitutively or inducibly expressed in the yeast host cell, using vectors, markers, *etc.* as known in the art. Preferably the sequences, including transcriptional regulatory elements sufficient for the desired pattern of expression, are stably integrated in the yeast genome through a targeted methodology.

**[0120]** For example, the eukaryotic PDI is not only an efficient catalyst of protein cysteine oxidation and disulfide bond isomerization, but also exhibits chaperone activity. Co-expression of PDI can facilitate the production of active proteins having multiple disulfide bonds. Also of interest is the expression of BIP (immunoglobulin heavy chain binding protein); cyclophilin; and the like. In one embodiment of the invention, each of the haploid parental strains expresses a distinct folding enzyme, *e.g.* one strain may express BIP, and the other strain may express PDI or combinations thereof.

**[0121]** The terms "*desired protein*" or "*desired antibody*" are used interchangeably and refer generally to a parent antibody specific to a target, *i.e.*, CGRP or a chimeric or humanized antibody or a binding portion thereof derived therefrom as described herein. The term "antibody" is intended to include any polypeptide chain-containing molecular structure with a specific shape that fits to and recognizes an epitope, where one or more non-covalent binding interactions stabilize the complex between the molecular structure and the epitope. The archetypal antibody molecule is the immunoglobulin, and all types of immunoglobulins, IgG, IgM, IgA, IgE, IgD, etc., from all sources, *e.g.* human, rodent, rabbit, cow, sheep, pig, dog, other mammals, chicken, other avians, etc., are considered to be "antibodies." A preferred source for producing antibodies useful as starting material according to the invention is rabbits. Numerous antibody coding sequences have been described; and others may be raised by methods well-known in the art. Examples thereof include chimeric antibodies, human antibodies and other non-human mammalian

antibodies, humanized antibodies, single chain antibodies (such as scFvs), camelbodies, nanobodies, IgNAR (single-chain antibodies derived from sharks), small-modular immunopharmaceuticals (SMIPs), and antibody fragments such as Fabs, Fab', F(ab')<sub>2</sub> and the like. See Streltsov VA, et al., Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype, *Protein Sci.* 2005 Nov;14(11):2901-9. Epub 2005 Sep 30; Greenberg AS, et al., A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks, *Nature*. 1995 Mar 9;374(6518):168-73; Nuttall SD, et al., Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries, *Mol Immunol.* 2001 Aug;38(4):313-26; Hamers-Casterman C, et al., Naturally occurring antibodies devoid of light chains, *Nature*. 1993 Jun 3;363(6428):446-8; Gill DS, et al., Biopharmaceutical drug discovery using novel protein scaffolds, *Curr Opin Biotechnol.* 2006 Dec; 17(6):653-8. Epub 2006 Oct 19.

**[0122]** For example, antibodies or antigen binding fragments may be produced by genetic engineering. In this technique, as with other methods, antibody-producing cells are sensitized to the desired antigen or immunogen. The messenger RNA isolated from antibody producing cells is used as a template to make cDNA using PCR amplification. A library of vectors, each containing one heavy chain gene and one light chain gene retaining the initial antigen specificity, is produced by insertion of appropriate sections of the amplified immunoglobulin cDNA into the expression vectors. A combinatorial library is constructed by combining the heavy chain gene library with the light chain gene library. This results in a library of clones which co-express a heavy and light chain (resembling the Fab fragment or antigen binding fragment of an antibody molecule). The vectors that carry these genes are co-transfected into a host cell. When antibody gene synthesis is induced in the transfected host, the heavy and light chain proteins self-assemble to produce active antibodies that can be detected by screening with the antigen or immunogen.

**[0123]** Antibody coding sequences of interest include those encoded by native sequences, as well as nucleic acids that, by virtue of the degeneracy of the genetic code, are not identical in sequence to the disclosed nucleic acids, and variants thereof. Variant polypeptides can include amino acid (aa) substitutions, additions or deletions. The amino

acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids, such as to alter a glycosylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Variants can be designed so as to retain or have enhanced biological activity of a particular region of the protein (*e.g.*, a functional domain, catalytic amino acid residues, *etc*). Variants also include fragments of the polypeptides disclosed herein, particularly biologically active fragments and/or fragments corresponding to functional domains. Techniques for *in vitro* mutagenesis of cloned genes are known. Also included in the subject invention are polypeptides that have been modified using ordinary molecular biological techniques so as to improve their resistance to proteolytic degradation or to optimize solubility properties or to render them more suitable as a therapeutic agent.

[0124] Chimeric antibodies may be made by recombinant means by combining the variable light and heavy chain regions ( $V_L$  and  $V_H$ ), obtained from antibody producing cells of one species with the constant light and heavy chain regions from another. Typically chimeric antibodies utilize rodent or rabbit variable regions and human constant regions, in order to produce an antibody with predominantly human domains. The production of such chimeric antibodies is well known in the art, and may be achieved by standard means (as described, *e.g.*, in U.S. Patent No. 5,624,659, incorporated herein by reference in its entirety). It is further contemplated that the human constant regions of chimeric antibodies of the invention may be selected from IgG1, IgG2, IgG3, and IgG4 constant regions.

[0125] Humanized antibodies are engineered to contain even more human-like immunoglobulin domains, and incorporate only the complementarity-determining regions of the animal-derived antibody. This is accomplished by carefully examining the sequence of the hyper-variable loops of the variable regions of the monoclonal antibody, and fitting them to the structure of the human antibody chains. Although facially complex, the process is straightforward in practice. See, *e.g.*, U.S. Patent No. 6,187,287, incorporated fully herein by reference.

[0126] In addition to entire immunoglobulins (or their recombinant counterparts), immunoglobulin fragments comprising the epitope binding site (*e.g.*,  $Fab'$ ,  $F(ab')_2$ , or other fragments) may be synthesized. “Fragment,” or minimal immunoglobulins may be

designed utilizing recombinant immunoglobulin techniques. For instance "Fv" immunoglobulins for use in the present invention may be produced by synthesizing a fused variable light chain region and a variable heavy chain region. Combinations of antibodies are also of interest, *e.g.* diabodies, which comprise two distinct Fv specificities. In another embodiment of the invention, SMIPs (small molecule immunopharmaceuticals), camelbodies, nanobodies, and IgNAR are encompassed by immunoglobulin fragments.

**[0127]** Immunoglobulins and fragments thereof may be modified post-translationally, *e.g.* to add effector moieties such as chemical linkers, detectable moieties, such as fluorescent dyes, enzymes, toxins, substrates, bioluminescent materials, radioactive materials, chemiluminescent moieties and the like, or specific binding moieties, such as streptavidin, avidin, or biotin, and the like may be utilized in the methods and compositions of the present invention. Examples of additional effector molecules are provided *infra*.

**[0128]** A polynucleotide sequence "corresponds" to a polypeptide sequence if translation of the polynucleotide sequence in accordance with the genetic code yields the polypeptide sequence (*i.e.*, the polynucleotide sequence "encodes" the polypeptide sequence), one polynucleotide sequence "corresponds" to another polynucleotide sequence if the two sequences encode the same polypeptide sequence.

**[0129]** A "heterologous" region or domain of a DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous region is a construct where the coding sequence itself is not found in nature (*e.g.*, a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

**[0130]** A "coding sequence" is an in-frame sequence of codons that (in view of the genetic code) correspond to or encode a protein or peptide sequence. Two coding sequences correspond to each other if the sequences or their complementary sequences encode the same amino acid sequences. A coding sequence in association with appropriate

regulatory sequences may be transcribed and translated into a polypeptide. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence. A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. Promoter sequences typically contain additional sites for binding of regulatory molecules (e.g., transcription factors) which affect the transcription of the coding sequence. A coding sequence is "under the control" of the promoter sequence or "operatively linked" to the promoter when RNA polymerase binds the promoter sequence in a cell and transcribes the coding sequence into mRNA, which is then in turn translated into the protein encoded by the coding sequence.

[0131] Vectors are used to introduce a foreign substance, such as DNA, RNA or protein, into an organism or host cell. Typical vectors include recombinant viruses (for polynucleotides) and liposomes (for polypeptides). A "DNA vector" is a replicon, such as plasmid, phage or cosmid, to which another polynucleotide segment may be attached so as to bring about the replication of the attached segment. An "expression vector" is a DNA vector which contains regulatory sequences which will direct polypeptide synthesis by an appropriate host cell. This usually means a promoter to bind RNA polymerase and initiate transcription of mRNA, as well as ribosome binding sites and initiation signals to direct translation of the mRNA into a polypeptide(s). Incorporation of a polynucleotide sequence into an expression vector at the proper site and in correct reading frame, followed by transformation of an appropriate host cell by the vector, enables the production of a polypeptide encoded by said polynucleotide sequence.

[0132] "Amplification" of polynucleotide sequences is the *in vitro* production of multiple copies of a particular nucleic acid sequence. The amplified sequence is usually in the form of DNA. A variety of techniques for carrying out such amplification are described in a review article by Van Brunt (1990, Bio/Technol., 8(4):291-294). Polymerase chain reaction or PCR is a prototype of nucleic acid amplification, and use of PCR herein should be considered exemplary of other suitable amplification techniques.

[0133] The general structure of antibodies in vertebrates now is well understood (Edelman, G. M., Ann. N.Y. Acad. Sci., 190: 5 (1971)). Antibodies consist of two

identical light polypeptide chains of molecular weight approximately 23,000 daltons (the “light chain”), and two identical heavy chains of molecular weight 53,000-70,000 (the “heavy chain”). The four chains are joined by disulfide bonds in a “Y” configuration wherein the light chains bracket the heavy chains starting at the mouth of the “Y” configuration. The “branch” portion of the “Y” configuration is designated the  $F_{ab}$  region; the stem portion of the “Y” configuration is designated the  $F_c$  region. The amino acid sequence orientation runs from the N-terminal end at the top of the “Y” configuration to the C-terminal end at the bottom of each chain. The N-terminal end possesses the variable region having specificity for the antigen that elicited it, and is approximately 100 amino acids in length, there being slight variations between light and heavy chain and from antibody to antibody.

**[0134]** The variable region is linked in each chain to a constant region that extends the remaining length of the chain and that within a particular class of antibody does not vary with the specificity of the antibody (i.e., the antigen eliciting it). There are five known major classes of constant regions that determine the class of the immunoglobulin molecule (IgG, IgM, IgA, IgD, and IgE corresponding to  $\gamma$ ,  $\mu$ ,  $\alpha$ ,  $\delta$ , and  $\epsilon$  (gamma, mu, alpha, delta, or epsilon) heavy chain constant regions). The constant region or class determines subsequent effector function of the antibody, including activation of complement (Kabat, E. A., Structural Concepts in Immunology and Immunochemistry, 2nd Ed., p. 413-436, Holt, Rinehart, Winston (1976)), and other cellular responses (Andrews, D. W., *et al.*, Clinical Immunobiology, pp 1-18, W. B. Sanders (1980); Kohl, S., *et al.*, Immunology, 48: 187 (1983)); while the variable region determines the antigen with which it will react. Light chains are classified as either  $\kappa$  (kappa) or  $\lambda$  (lambda). Each heavy chain class can be prepared with either kappa or lambda light chain. The light and heavy chains are covalently bonded to each other, and the “tail” portions of the two heavy chains are bonded to each other by covalent disulfide linkages when the immunoglobulins are generated either by hybridomas or by B cells.

**[0135]** The expression “variable region” or “VR” refers to the domains within each pair of light and heavy chains in an antibody that are involved directly in binding the antibody to the antigen. Each heavy chain has at one end a variable domain ( $V_H$ ) followed by a

number of constant domains. Each light chain has a variable domain ( $V_L$ ) at one end and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain.

[0136] The expressions “complementarity determining region,” “hypervariable region,” or “CDR” refer to one or more of the hyper-variable or complementarity determining regions (CDRs) found in the variable regions of light or heavy chains of an antibody (See Kabat, E. A. *et al.*, Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., (1987)). These expressions include the hypervariable regions as defined by Kabat *et al.* (“Sequences of Proteins of Immunological Interest,” Kabat E., *et al.*, US Dept. of Health and Human Services, 1983) or the hypervariable loops in 3-dimensional structures of antibodies (Chothia and Lesk, *J Mol. Biol.* 196 901-917 (1987)). The CDRs in each chain are held in close proximity by framework regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site. Within the CDRs there are select amino acids that have been described as the selectivity determining regions (SDRs) which represent the critical contact residues used by the CDR in the antibody-antigen interaction (Kashmiri, S., *Methods*, 36:25-34 (2005)).

[0137] The expressions “framework region” or “FR” refer to one or more of the framework regions within the variable regions of the light and heavy chains of an antibody (See Kabat, E. A. *et al.*, Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., (1987)). These expressions include those amino acid sequence regions interposed between the CDRs within the variable regions of the light and heavy chains of an antibody.

***Anti-CGRP Antibodies and Binding Fragments Thereof Having Binding Activity for CGRP***

**Antibody Ab1**

[0138] In one embodiment, the invention includes chimeric antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the

sequence	set	forth	below:
QVLTQTASPVAAGSTVTINCQASQSVYDNNYLAWYQQKPGQPPKQLIYSTSTL ASGVSSRFKGSGSGTQFTLTISDLECADAATYYCLGSYDCSSGDCFVFGGGTEVVV KR (SEQ ID NO: 1).			

**[0139]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLTQTASPVAAGSTVTINCQASQSVYDNNYLAWYQQKPGQPPKQLIYSTSTL ASGVSSRFKGSGSGTQFTLTISDLECADAATYYCLGSYDCSSGDCFVFGGGTEVVV KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE SVTEQDSKDSTYLSSTTLSKADYEHKVYACEVTHQGLSSPVTKSFNRGEC
--

(SEQ ID NO: 2).

**[0140]** The invention further includes chimeric antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

QSLEESGGRLVTPGTPLTLTCTVSGLDLSSYYMQWVRQAPGKGLEWIGVIGINDNT YYASWAKGRFTISRASSTTVDLKMTSLTTEDTATYFCARGDIWGPGLTVSSA
--

(SEQ ID NO: 3).

**[0141]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

QSLEESGGRLVTPGTPLTLTCTVSGLDLSSYYMQWVRQAPGKGLEWIGVIGINDNT YYASWAKGRFTISRASSTTVDLKMTSLTTEDTATYFCARGDIWGPGLTVSSA KGPSVFPLAPSSKSTSGTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSLSSGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWFYVDGVEVHNAK TKPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQP REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 4).
---

**[0142]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 5; SEQ ID NO: 6; and SEQ ID NO: 7 which

correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 1 or the light chain sequence of SEQ ID NO: 2, and/or one or more of the polypeptide sequences of SEQ ID NO: 8; SEQ ID NO: 9; and SEQ ID NO: 10 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 3 or the heavy chain sequence of SEQ ID NO: 4, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0143]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 1 or SEQ ID NO: 2. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

**[0144]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 5; SEQ ID NO: 6; and SEQ ID NO: 7 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 1 or the light chain sequence of SEQ ID NO: 2.

**[0145]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 8; SEQ ID NO: 9; and SEQ ID NO: 10 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 3 or the heavy chain sequence of SEQ ID NO: 4.

**[0146]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention,

fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 1; the variable heavy chain region of SEQ ID NO: 3; the complementarity-determining regions (SEQ ID NO: 5; SEQ ID NO: 6; and SEQ ID NO: 7) of the variable light chain region of SEQ ID NO: 1; and the complementarity-determining regions (SEQ ID NO: 8; SEQ ID NO: 9; and SEQ ID NO: 10) of the variable heavy chain region of SEQ ID NO: 3.

**[0147]** In a particularly preferred embodiment of the invention, the chimeric anti-CGRP antibody is Ab1, comprising, or alternatively consisting of, SEQ ID NO: 2 and SEQ ID NO: 4, and having at least one of the biological activities set forth herein.

**[0148]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab1, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 1 and the variable heavy chain sequence of SEQ ID NO: 3. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 1 and/or SEQ ID NO: 3 in said Fab while retaining binding specificity for CGRP.

**[0149]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab1. In another embodiment of the invention, anti-CGRP antibodies such as Ab1 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab2

**[0150]** In one embodiment, the invention includes humanized antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:  
QVLTQSPSSLSASVGDRVVTINCQASQSVYDNNYLAWYQQKPGKVPKQLIYSTSTL

ASGVPSRSGSGSGTDFLTISLQPEDVATYYCLGSYDCSSGDCFVFGGGTKVEIKR (SEQ ID NO: 11).

[0151] The invention also includes humanized antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:  
QVLTQSPSSLSASVGDRVINCQASQSVYDNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRSGSGSGTDFLTISLQPEDVATYYCLGSYDCSSGDCFVFGGGTKVEIK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES  
VTEQDSKDSTYSLSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 12).

[0152] The invention further includes humanized antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYMQWVRQAPGKGLEWVGVIGIN  
DNTYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSS (SEQ ID NO: 13).

[0153] The invention also includes humanized antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:  
EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYMQWVRQAPGKGLEWVGVIGIN  
DNTYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVWSNSGALTSGVHTF  
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTC  
PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV  
EVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 14).

[0154] The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 15; SEQ ID NO: 16; and SEQ ID NO: 17 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 11 or the light chain sequence of SEQ

ID NO: 12, and/or one or more of the polypeptide sequences of SEQ ID NO: 18; SEQ ID NO: 19; and SEQ ID NO: 20 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 13 or the heavy chain sequence of SEQ ID NO: 14, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0155]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 11 or SEQ ID NO: 12. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 13 or SEQ ID NO: 14.

**[0156]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 15; SEQ ID NO: 16; and SEQ ID NO: 17 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 11 or the light chain sequence of SEQ ID NO: 12.

**[0157]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 18; SEQ ID NO: 19; and SEQ ID NO: 20 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 13 or the heavy chain sequence of SEQ ID NO: 14.

**[0158]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the

variable light chain region of SEQ ID NO: 11; the variable heavy chain region of SEQ ID NO: 13; the complementarity-determining regions (SEQ ID NO: 15; SEQ ID NO: 16; and SEQ ID NO: 17) of the variable light chain region of SEQ ID NO: 11; and the complementarity-determining regions (SEQ ID NO: 18; SEQ ID NO: 19; and SEQ ID NO: 20) of the variable heavy chain region of SEQ ID NO: 13.

**[0159]** In a particularly preferred embodiment of the invention, the humanized anti-CGRP antibody is Ab2, comprising, or alternatively consisting of, SEQ ID NO: 12 and SEQ ID NO: 14, and having at least one of the biological activities set forth herein.

**[0160]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab2, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 11 and the variable heavy chain sequence of SEQ ID NO: 13. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 11 and/or SEQ ID NO: 13 in said Fab while retaining binding specificity for CGRP.

**[0161]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab2. In another embodiment of the invention, anti-CGRP antibodies such as Ab2 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab3

**[0162]** In one embodiment, the invention includes humanized antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:  
QVLTQSPSSLSASVGDRVTINCQASQSVYDNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSGSGTDFLTISLQPEDVATYYCLGSYDCSSGDCFVFGGKVEIK  
R (SEQ ID NO: 21).

**[0163]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:  
QVLTQSPSSLSASVGDRVVTINCQASQSVYDNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSGSGTDFLTISLQPEDVATYYCLGSYDCSSGDCFVFGGGTKVEIK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES  
VTEQDSKDSTYSLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFRGEC  
(SEQ ID NO: 22).

**[0164]** The invention further includes humanized antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYMQWVRQAPGKGLEWVGVIGIN  
DNTYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSS (SEQ ID NO: 23).

**[0165]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYMQWVRQAPGKGLEWVGVIGIN  
DNTYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF  
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDARVEPKSCDKTHTC  
PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV  
EVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 24).

**[0166]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 25; SEQ ID NO: 26; and SEQ ID NO: 27 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 21 or the light chain sequence of SEQ ID NO: 22, and/or one or more of the polypeptide sequences of SEQ ID NO: 28; SEQ ID NO: 29; and SEQ ID NO: 30 which correspond to the complementarity-determining

regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 23 or the heavy chain sequence of SEQ ID NO: 24, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0167]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 21 or SEQ ID NO: 22. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 23 or SEQ ID NO: 24.

**[0168]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 25; SEQ ID NO: 26; and SEQ ID NO: 27 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 21 or the light chain sequence of SEQ ID NO: 22.

**[0169]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 28; SEQ ID NO: 29; and SEQ ID NO: 30 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 23 or the heavy chain sequence of SEQ ID NO: 24.

**[0170]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 21; the variable heavy chain region of SEQ ID NO: 23; the complementarity-determining regions (SEQ ID NO: 25; SEQ ID NO: 26; and

SEQ ID NO: 27) of the variable light chain region of SEQ ID NO: 21; and the complementarity-determining regions (SEQ ID NO: 28; SEQ ID NO: 29; and SEQ ID NO: 30) of the variable heavy chain region of SEQ ID NO: 23.

**[0171]** In a particularly preferred embodiment of the invention, the chimeric anti-CGRP antibody is Ab3, comprising, or alternatively consisting of, SEQ ID NO: 22 and SEQ ID NO: 24, and having at least one of the biological activities set forth herein.

**[0172]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab3, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 21 and the variable heavy chain sequence of SEQ ID NO: 23. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 21 and/or SEQ ID NO: 23 in said Fab while retaining binding specificity for CGRP.

**[0173]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab3. In another embodiment of the invention, anti-CGRP antibodies such as Ab3 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab4

**[0174]** In one embodiment, the invention includes chimeric antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLTQTPSPVSAAVGSTVTINCQASQSVYHNTYLAWYQQKPGQPPKQLIYDASTL  
ASGVPSRFSGSGSGTQFTLTISGVQCNDAAAYYCLGSYDCTNGDCFVFGGGTEVV  
VKR (SEQ ID NO: 31).

**[0175]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLTQTPSPVSAAVGSTVTINCQASQSVYHNTYLAWYQQKPGQPPKQLIYDASTL

ASGVPSRFSGSGSGTQFTLTISGVQCNDAAAYYCLGSYDCTNGDCFVFGGGTEVV  
VKRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQ  
ESVTEQDSKDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 32).

**[0176]** The invention further includes chimeric antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

QSLEESGGRLVTPGTPLTCSVSGIDLSGYYMWNVRQAPGKGLEWIGVIGINGAT  
YYASWAKGRFTISKTSSTVDLKMTSLTTEDTATYFCARGDIWGPGLTVSS  
(SEQ ID NO: 33).

**[0177]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

QSLEESGGRLVTPGTPLTCSVSGIDLSGYYMWNVRQAPGKGLEWIGVIGINGAT  
YYASWAKGRFTISKTSSTVDLKMTSLTTEDTATYFCARGDIWGPGLTVSSAST  
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPAVLQS  
SGLYSLSSVVTVPSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHCPPCPAPE  
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK  
TKPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQP  
REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLD  
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID  
NO: 34).

**[0178]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 35; SEQ ID NO: 36; and SEQ ID NO: 37 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 31 or the light chain sequence of SEQ ID NO: 32, and/or one or more of the polypeptide sequences of SEQ ID NO: 38; SEQ ID NO: 39; and SEQ ID NO: 40 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 33 or the heavy chain sequence of SEQ ID NO: 34, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the

invention or fragments thereof comprise, or alternatively consist of, combinations of one or more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0179]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 31 or SEQ ID NO: 32. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 33 or SEQ ID NO: 34.

**[0180]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 35; SEQ ID NO: 36; and SEQ ID NO: 37 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 31 or the light chain sequence of SEQ ID NO: 32.

**[0181]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 38; SEQ ID NO: 39; and SEQ ID NO: 40 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 33 or the heavy chain sequence of SEQ ID NO: 34.

**[0182]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 31; the variable heavy chain region of SEQ ID NO: 33; the complementarity-determining regions (SEQ ID NO: 35; SEQ ID NO: 36; and SEQ ID NO: 37) of the variable light chain region of SEQ ID NO: 31; and the complementarity-determining regions (SEQ ID NO: 38; SEQ ID NO: 39; and SEQ ID NO: 40) of the variable heavy chain region of SEQ ID NO: 33.

**[0183]** In a particularly preferred embodiment of the invention, the humanized anti-CGRP antibody is Ab4, comprising, or alternatively consisting of, SEQ ID NO: 32 and SEQ ID NO: 34, and having at least one of the biological activities set forth herein.

**[0184]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab4, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 31 and the variable heavy chain sequence of SEQ ID NO: 33. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 31 and/or SEQ ID NO: 33 in said Fab while retaining binding specificity for CGRP.

**[0185]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab4. In another embodiment of the invention, anti-CGRP antibodies such as Ab4 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab5

**[0186]** In one embodiment, the invention includes humanized antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTL  
ASGVPSRFSGSQSGTDFLTISLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK  
R (SEQ ID NO: 41).

**[0187]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTL  
ASGVPSRFSGSQSGTDFLTISLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES

VTEQDSKDSTYLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 42).

**[0188]** The invention further includes humanized antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMWNVRQAPGKGLEWVGVIGIN  
GATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSS (SEQ ID NO: 43).

**[0189]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMWNVRQAPGKGLEWVGVIGIN  
GATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF  
PAVLQSSGLYSLSSVVTVPSQLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTC  
PPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV  
EVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 44).

**[0190]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 45; SEQ ID NO: 46; and SEQ ID NO: 47 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 41 or the light chain sequence of SEQ ID NO: 42, and/or one or more of the polypeptide sequences of SEQ ID NO: 48; SEQ ID NO: 49; and SEQ ID NO: 50 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 43 or the heavy chain sequence of SEQ ID NO: 44, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0191]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 41 or SEQ ID NO: 42. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 43 or SEQ ID NO: 44.

**[0192]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 45; SEQ ID NO: 46; and SEQ ID NO: 47 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 41 or the light chain sequence of SEQ ID NO: 42.

**[0193]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 48; SEQ ID NO: 49; and SEQ ID NO: 50 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 43 or the heavy chain sequence of SEQ ID NO: 44.

**[0194]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 41; the variable heavy chain region of SEQ ID NO: 43; the complementarity-determining regions (SEQ ID NO: 45; SEQ ID NO: 46; and SEQ ID NO: 47) of the variable light chain region of SEQ ID NO: 41; and the complementarity-determining regions (SEQ ID NO: 48; SEQ ID NO: 49; and SEQ ID NO: 50) of the variable heavy chain region of SEQ ID NO: 43.

**[0195]** In a particularly preferred embodiment of the invention, the chimeric anti-CGRP antibody is Ab5, comprising, or alternatively consisting of, SEQ ID NO: 42 and SEQ ID NO: 44, and having at least one of the biological activities set forth herein.

**[0196]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab5, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 41 and the variable heavy chain sequence of SEQ ID NO: 43. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 41 and/or SEQ ID NO: 43 in said Fab while retaining binding specificity for CGRP.

**[0197]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab5. In another embodiment of the invention, anti-CGRP antibodies such as Ab5 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab6

**[0198]** In one embodiment, the invention includes humanized antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTL  
ASGVPSRFSGSQGTDFLTISLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK  
R (SEQ ID NO: 51).

**[0199]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTL  
ASGVPSRFSGSQGTDFLTISLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES

VTEQDSKDSTYSLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 52).

**[0200]** The invention further includes humanized antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMWNVRQAPGKGLEWVGVIGIN  
GATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSS (SEQ ID NO: 53).

**[0201]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMWNVRQAPGKGLEWVGVIGIN  
GATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF  
PAVLQSSGLYSLSSVVTVPSQLGTQTYICNVNHKPSNTKVDARVEPKSCDKTHTC  
PPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV  
EVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 54).

**[0202]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 55; SEQ ID NO: 56; and SEQ ID NO: 57 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 51 or the light chain sequence of SEQ ID NO: 52, and/or one or more of the polypeptide sequences of SEQ ID NO: 58; SEQ ID NO: 59; and SEQ ID NO: 60 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 53 or the heavy chain sequence of SEQ ID NO: 54, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0203]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 51 or SEQ ID NO: 52. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 53 or SEQ ID NO: 54.

**[0204]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 55; SEQ ID NO: 56; and SEQ ID NO: 57 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 51 or the light chain sequence of SEQ ID NO: 52.

**[0205]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 58; SEQ ID NO: 59; and SEQ ID NO: 60 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 53 or the heavy chain sequence of SEQ ID NO: 54.

**[0206]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 51; the variable heavy chain region of SEQ ID NO: 53; the complementarity-determining regions (SEQ ID NO: 55; SEQ ID NO: 56; and SEQ ID NO: 57) of the variable light chain region of SEQ ID NO: 51; and the complementarity-determining regions (SEQ ID NO: 58; SEQ ID NO: 59; and SEQ ID NO: 60) of the variable heavy chain region of SEQ ID NO: 53.

**[0207]** In a particularly preferred embodiment of the invention, the humanized anti-CGRP antibody is Ab6, comprising, or alternatively consisting of, SEQ ID NO: 52 and SEQ ID NO: 54, and having at least one of the biological activities set forth herein.

**[0208]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab6, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 51 and the variable heavy chain sequence of SEQ ID NO: 53. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 51 and/or SEQ ID NO: 53 in said Fab while retaining binding specificity for CGRP.

**[0209]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab6. In another embodiment of the invention, anti-CGRP antibodies such as Ab6 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab7

**[0210]** In one embodiment, the invention includes chimeric antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLQTASPVSAAVGSTVTINCQASQSVYNLYAWYQQKPGQPPKQLIYSTSTL  
ASGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLGSYDCSTGDCFVFGGGTEVV  
VKR (SEQ ID NO: 61).

**[0211]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLQTASPVSAAVGSTVTINCQASQSVYNLYAWYQQKPGQPPKQLIYSTSTL  
ASGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLGSYDCSTGDCFVFGGGTEVV  
VKRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQ

ESVTEQDSKDSTYLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 62).

**[0212]** The invention further includes chimeric antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

QEQLKESGGRLVTPGTSLTLTCTVSGIDLSNHYMQWVRQAPGKGLEWIGVVGING  
RTYYASWAKGRFTISRTSSTTVDLKMTRLTTEDTATYFCARGDIWGPGLTVSS  
(SEQ ID NO: 63).

**[0213]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

QEQLKESGGRLVTPGTSLTLTCTVSGIDLSNHYMQWVRQAPGKGLEWIGVVGING  
RTYYASWAKGRFTISRTSSTTVDLKMTRLTTEDTATYFCARGDIWGPGLTVSSA  
STKGPSVFLAPSSKSTSGGTAAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL  
QSSGLYSLSSVVTVPSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKHTCPPCP  
APELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH  
NAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAK  
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPP  
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ  
ID NO: 64).

**[0214]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 65; SEQ ID NO: 66; and SEQ ID NO: 67 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 61 or the light chain sequence of SEQ ID NO: 62, and/or one or more of the polypeptide sequences of SEQ ID NO: 68; SEQ ID NO: 69; and SEQ ID NO: 70 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 63 or the heavy chain sequence of SEQ ID NO: 64, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0215]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 61 or SEQ ID NO: 62. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 63 or SEQ ID NO: 64.

**[0216]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 65; SEQ ID NO: 66; and SEQ ID NO: 67 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 61 or the light chain sequence of SEQ ID NO: 62.

**[0217]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 68; SEQ ID NO: 69; and SEQ ID NO: 70 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 63 or the heavy chain sequence of SEQ ID NO: 64.

**[0218]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 61; the variable heavy chain region of SEQ ID NO: 63; the complementarity-determining regions (SEQ ID NO: 65; SEQ ID NO: 66; and SEQ ID NO: 67) of the variable light chain region of SEQ ID NO: 61; and the complementarity-determining regions (SEQ ID NO: 68; SEQ ID NO: 69; and SEQ ID NO: 70) of the variable heavy chain region of SEQ ID NO: 63.

**[0219]** In a particularly preferred embodiment of the invention, the chimeric anti-CGRP antibody is Ab7, comprising, or alternatively consisting of, SEQ ID NO: 62 and SEQ ID NO: 64, and having at least one of the biological activities set forth herein.

**[0220]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab7, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 61 and the variable heavy chain sequence of SEQ ID NO: 63. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 61 and/or SEQ ID NO: 63 in said Fab while retaining binding specificity for CGRP.

**[0221]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab7. In another embodiment of the invention, anti-CGRP antibodies such as Ab7 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab8

**[0222]** In one embodiment, the invention includes humanized antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:  
QVLTQSPSSLSASVGDRVTINCQASQSVNYNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSGSGTDFLTISLQPEDVATYYCLGSYDCSTGDCFVFGGGTKVEIK  
R (SEQ ID NO: 71).

**[0223]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:  
QVLTQSPSSLSASVGDRVTINCQASQSVNYNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSGSGTDFLTISLQPEDVATYYCLGSYDCSTGDCFVFGGGTKVEIK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES

VTEQDSKDSTYSLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 72).

**[0224]** The invention further includes humanized antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSNHMQWVRQAPGKGLEWVGVVGIN  
GRTYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSS (SEQ ID NO: 73).

**[0225]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSNHMQWVRQAPGKGLEWVGVVGIN  
GRTYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVT  
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF  
PAVLQSSGLYSLSSVVTVPSQLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTC  
PPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV  
EVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 74).

**[0226]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 75; SEQ ID NO: 76; and SEQ ID NO: 77 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 71 or the light chain sequence of SEQ ID NO: 72, and/or one or more of the polypeptide sequences of SEQ ID NO: 78; SEQ ID NO: 79; and SEQ ID NO: 80 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 73 or the heavy chain sequence of SEQ ID NO: 74, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0227]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 71 or SEQ ID NO: 72. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 73 or SEQ ID NO: 74.

**[0228]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 75; SEQ ID NO: 76; and SEQ ID NO: 77 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 71 or the light chain sequence of SEQ ID NO: 72.

**[0229]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 78; SEQ ID NO: 79; and SEQ ID NO: 80 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 73 or the heavy chain sequence of SEQ ID NO: 74.

**[0230]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 71; the variable heavy chain region of SEQ ID NO: 73; the complementarity-determining regions (SEQ ID NO: 75; SEQ ID NO: 76; and SEQ ID NO: 77) of the variable light chain region of SEQ ID NO: 71; and the complementarity-determining regions (SEQ ID NO: 78; SEQ ID NO: 79; and SEQ ID NO: 80) of the variable heavy chain region of SEQ ID NO: 73.

**[0231]** In a particularly preferred embodiment of the invention, the humanized anti-CGRP antibody is Ab8, comprising, or alternatively consisting of, SEQ ID NO: 72 and SEQ ID NO: 74, and having at least one of the biological activities set forth herein.

**[0232]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab8, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 71 and the variable heavy chain sequence of SEQ ID NO: 73. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 71 and/or SEQ ID NO: 73 in said Fab while retaining binding specificity for CGRP.

**[0233]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab8. In another embodiment of the invention, anti-CGRP antibodies such as Ab8 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab9

**[0234]** In one embodiment, the invention includes chimeric antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLQTTPSPVSAAVGSTVTINCQASQNVNNYLAWYQQKPGQPPKQLIYSTSTL  
ASGVSSRFRGSGSGTQFTLTISDVQCDDAATYYCLGSYDCSRGDCFVFGGGTEVV  
VKR (SEQ ID NO: 81).

**[0235]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLQTTPSPVSAAVGSTVTINCQASQNVNNYLAWYQQKPGQPPKQLIYSTSTL  
ASGVSSRFRGSGSGTQFTLTISDVQCDDAATYYCLGSYDCSRGDCFVFGGGTEVV  
VKRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQ

ESVTEQDSKDSTYLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 82).

**[0236]** The invention further includes chimeric antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

QSLEESGGRLVTPGTPLTLTCTVSGIGLSSYYMQWVRQSPGRGLEWIGVIGSDGKT  
YYATWAKGRFTISKTSSTVDLRMASLTTEDTATYFCTRVDIWPGLTVSS  
(SEQ ID NO: 83).

**[0237]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

QSLEESGGRLVTPGTPLTLTCTVSGIGLSSYYMQWVRQSPGRGLEWIGVIGSDGKT  
YYATWAKGRFTISKTSSTVDLRMASLTTEDTATYFCTRVDIWPGLTVSS  
KGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPAVLQS  
SGLYSLSSVVTVPSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHCPPCPAPE  
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWFYVDGVEVHNAK  
TKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIASKAGQP  
REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLD  
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID  
NO: 84).

**[0238]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 85; SEQ ID NO: 86; and SEQ ID NO: 87 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 81 or the light chain sequence of SEQ ID NO: 82, and/or one or more of the polypeptide sequences of SEQ ID NO: 88; SEQ ID NO: 89; and SEQ ID NO: 90 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 83 or the heavy chain sequence of SEQ ID NO: 84, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0239]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 81 or SEQ ID NO: 82. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 83 or SEQ ID NO: 84.

**[0240]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 85; SEQ ID NO: 86; and SEQ ID NO: 87 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 81 or the light chain sequence of SEQ ID NO: 82.

**[0241]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 88; SEQ ID NO: 89; and SEQ ID NO: 90 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 83 or the heavy chain sequence of SEQ ID NO: 84.

**[0242]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 81; the variable heavy chain region of SEQ ID NO: 83; the complementarity-determining regions (SEQ ID NO: 85; SEQ ID NO: 86; and SEQ ID NO: 87) of the variable light chain region of SEQ ID NO: 81; and the complementarity-determining regions (SEQ ID NO: 88; SEQ ID NO: 89; and SEQ ID NO: 90) of the variable heavy chain region of SEQ ID NO: 83.

**[0243]** In a particularly preferred embodiment of the invention, the chimeric anti-CGRP antibody is Ab9, comprising, or alternatively consisting of, SEQ ID NO: 82 and SEQ ID NO: 84, and having at least one of the biological activities set forth herein.

**[0244]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab9, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 81 and the variable heavy chain sequence of SEQ ID NO: 83. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 81 and/or SEQ ID NO: 83 in said Fab while retaining binding specificity for CGRP.

**[0245]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab9. In another embodiment of the invention, anti-CGRP antibodies such as Ab9 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab10

**[0246]** In one embodiment, the invention includes humanized antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVINCQASQNVNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSGSGTDFLTISLQPEDVATYYCLGSYDCSRGDCFVFGGGTKVEIK  
R (SEQ ID NO: 91).

**[0247]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVINCQASQNVNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSGSGTDFLTISLQPEDVATYYCLGSYDCSRGDCFVFGGGTKVEIK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES

VTEQDSKDSTYSLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 92).

**[0248]** The invention further includes humanized antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVRQAPGKGLEWVGVIGSD  
GKTYYATWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCTRVDIWGQGTLVT  
VSS (SEQ ID NO: 93).

**[0249]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVRQAPGKGLEWVGVIGSD  
GKTYYATWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCTRVDIWGQGTLVT  
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF  
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTC  
PPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV  
EVHNAKTKPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 94).

**[0250]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 95; SEQ ID NO: 96; and SEQ ID NO: 97 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 91 or the light chain sequence of SEQ ID NO: 92, and/or one or more of the polypeptide sequences of SEQ ID NO: 98; SEQ ID NO: 99; and SEQ ID NO: 100 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 93 or the heavy chain sequence of SEQ ID NO: 94, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0251]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 91 or SEQ ID NO: 92. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 93 or SEQ ID NO: 94.

**[0252]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 95; SEQ ID NO: 96; and SEQ ID NO: 97 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 91 or the light chain sequence of SEQ ID NO: 92.

**[0253]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 98; SEQ ID NO: 99; and SEQ ID NO: 100 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 93 or the heavy chain sequence of SEQ ID NO: 94.

**[0254]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 91; the variable heavy chain region of SEQ ID NO: 93; the complementarity-determining regions (SEQ ID NO: 95; SEQ ID NO: 96; and SEQ ID NO: 97) of the variable light chain region of SEQ ID NO: 91; and the complementarity-determining regions (SEQ ID NO: 98; SEQ ID NO: 99; and SEQ ID NO: 100) of the variable heavy chain region of SEQ ID NO: 93.

**[0255]** In a particularly preferred embodiment of the invention, the humanized anti-CGRP antibody is Ab10, comprising, or alternatively consisting of, SEQ ID NO: 92 and SEQ ID NO: 94, and having at least one of the biological activities set forth herein.

**[0256]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab10, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 91 and the variable heavy chain sequence of SEQ ID NO: 93. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 91 and/or SEQ ID NO: 93 in said Fab while retaining binding specificity for CGRP.

**[0257]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab10. In another embodiment of the invention, anti-CGRP antibodies such as Ab10 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab11

**[0258]** In one embodiment, the invention includes chimeric antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLQTASPVSPA VGSTVTINCRASQSVYYNNYLAWYQQKPGQPPKQLIYSTSTLA  
SGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLGSYDCSNGDCFVFGGGTEVVV  
KR (SEQ ID NO: 101).

**[0259]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLQTASPVSPA VGSTVTINCRASQSVYYNNYLAWYQQKPGQPPKQLIYSTSTLA  
SGVSSRFKGSGSGTQFTLTISDVQCDDAATYYCLGSYDCSNGDCFVFGGGTEVVV  
KRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQE

SVTEQDSKDSTYSLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 102).

**[0260]** The invention further includes chimeric antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

QSLEESGGRLVTPGGSLTLTCTVSGIDVTNYYMQWVRQAPGKGLEWIGVIGVNGK  
RYYASWAKGRFTISKTSSTVDLKMTSLTTEDTATYFCARGDIWGPGLTVVSS  
(SEQ ID NO: 103).

**[0261]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

QSLEESGGRLVTPGGSLTLTCTVSGIDVTNYYMQWVRQAPGKGLEWIGVIGVNGK  
RYYASWAKGRFTISKTSSTVDLKMTSLTTEDTATYFCARGDIWGPGLTVVSSAS  
TKGPSVFLAPSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQ  
SSGLYSLSSVVTVPSSSLGTQTYICNVNHPNTKVDKRVEPKSCDKTHTCPPCPAP  
ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA  
KTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ  
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLD  
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID  
NO: 104).

**[0262]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 105; SEQ ID NO: 106; and SEQ ID NO: 107 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 101 or the light chain sequence of SEQ ID NO: 102, and/or one or more of the polypeptide sequences of SEQ ID NO: 108; SEQ ID NO: 109; and SEQ ID NO: 110 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 103 or the heavy chain sequence of SEQ ID NO: 104, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0263]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 101 or SEQ ID NO: 102. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 103 or SEQ ID NO: 104.

**[0264]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 105; SEQ ID NO: 106; and SEQ ID NO: 107 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 101 or the light chain sequence of SEQ ID NO: 102.

**[0265]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 108; SEQ ID NO: 109; and SEQ ID NO: 110 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 103 or the heavy chain sequence of SEQ ID NO: 104.

**[0266]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 101; the variable heavy chain region of SEQ ID NO: 103; the complementarity-determining regions (SEQ ID NO: 105; SEQ ID NO: 106; and SEQ ID NO: 107) of the variable light chain region of SEQ ID NO: 101; and the complementarity-determining regions (SEQ ID NO: 108; SEQ ID NO: 109; and SEQ ID NO: 110) of the variable heavy chain region of SEQ ID NO: 103.

**[0267]** In a particularly preferred embodiment of the invention, the chimeric anti-CGRP antibody is Ab11, comprising, or alternatively consisting of, SEQ ID NO: 102 and SEQ ID NO: 104, and having at least one of the biological activities set forth herein.

**[0268]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab11, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 101 and the variable heavy chain sequence of SEQ ID NO: 103. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 101 and/or SEQ ID NO: 103 in said Fab while retaining binding specificity for CGRP.

**[0269]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab11. In another embodiment of the invention, anti-CGRP antibodies such as Ab11 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab12

**[0270]** In one embodiment, the invention includes humanized antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVVTINCRASQSVYYNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSQSGTDFLTISLQPEDVATYYCLGSYDCSNGDCFVFGGGTKVEIK  
R (SEQ ID NO: 111).

**[0271]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVVTINCRASQSVYYNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSQSGTDFLTISLQPEDVATYYCLGSYDCSNGDCFVFGGGTKVEIK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES

VTEQDSKDSTYLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 112).

[0272] The invention further includes humanized antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIDVTNYYMQWVRQAPGKGLEWVGIVGVN  
GKRYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQQTLVT  
VSS (SEQ ID NO: 113).

[0273] The invention also includes humanized antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIDVTNYYMQWVRQAPGKGLEWVGIVGVN  
GKRYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQQTLVT  
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF  
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTC  
PPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV  
EVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 114).

[0274] The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 115; SEQ ID NO: 116; and SEQ ID NO: 117 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 111 or the light chain sequence of SEQ ID NO: 112, and/or one or more of the polypeptide sequences of SEQ ID NO: 118; SEQ ID NO: 119; and SEQ ID NO: 120 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 113 or the heavy chain sequence of SEQ ID NO: 114, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0275]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 111 or SEQ ID NO: 112. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 113 or SEQ ID NO: 114.

**[0276]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 115; SEQ ID NO: 116; and SEQ ID NO: 117 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 111 or the light chain sequence of SEQ ID NO: 112.

**[0277]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 118; SEQ ID NO: 119; and SEQ ID NO: 120 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 113 or the heavy chain sequence of SEQ ID NO: 114.

**[0278]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 111; the variable heavy chain region of SEQ ID NO: 113; the complementarity-determining regions (SEQ ID NO: 115; SEQ ID NO: 116; and SEQ ID NO: 117) of the variable light chain region of SEQ ID NO: 111; and the complementarity-determining regions (SEQ ID NO: 118; SEQ ID NO: 119; and SEQ ID NO: 120) of the variable heavy chain region of SEQ ID NO: 113.

**[0279]** In a particularly preferred embodiment of the invention, the humanized anti-CGRP antibody is Ab12, comprising, or alternatively consisting of, SEQ ID NO: 112 and SEQ ID NO: 114, and having at least one of the biological activities set forth herein.

**[0280]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab12, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 111 and the variable heavy chain sequence of SEQ ID NO: 113. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 111 and/or SEQ ID NO: 113 in said Fab while retaining binding specificity for CGRP.

**[0281]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab12. In another embodiment of the invention, anti-CGRP antibodies such as Ab12 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab13

**[0282]** In one embodiment, the invention includes chimeric antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:  
AIVMTQTPSSKSVPVGDTVTINCQASESLYNNNALAWFQQKPGQPPKRLIYDASKL  
ASGVPSRFSGGSGTQFTLTISGVQCDDAATYYCGGYRSDSVDGVAFAGGTEVVV  
KR (SEQ ID NO: 121).

**[0283]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:  
AIVMTQTPSSKSVPVGDTVTINCQASESLYNNNALAWFQQKPGQPPKRLIYDASKL  
ASGVPSRFSGGSGTQFTLTISGVQCDDAATYYCGGYRSDSVDGVAFAGGTEVVV  
KRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQE

SVTEQDSKDSTYSLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 122).

**[0284]** The invention further includes chimeric antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

QSVEESGGGLVQPEGSLTLTCTASGFDFSSNAMWWVRQAPGKGLEWIGIIYNGDG  
STYYASWVNNGRFSISKTSSTTVTLQLNSLTVAADTATYYCARDSDLWGPGLTVVS  
S (SEQ ID NO: 123).

**[0285]** The invention also includes chimeric antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

QSVEESGGGLVQPEGSLTLTCTASGFDFSSNAMWWVRQAPGKGLEWIGCIYNGD  
GSTYYASWVNNGRFSISKTSSTTVTLQLNSLTVAADTATYYCARDSDLWGPGLTV  
SSASTKGPSVFPLAPSSKSTSGTAALGCLVKDYFPEPVTWSNSGALTSGVHTFP  
AVLQSSGLYSLSSVTVPSQLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP  
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE  
VHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKISK  
AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT  
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 124).

**[0286]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 125; SEQ ID NO: 126; and SEQ ID NO: 127 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 121 or the light chain sequence of SEQ ID NO: 122, and/or one or more of the polypeptide sequences of SEQ ID NO: 128; SEQ ID NO: 129; and SEQ ID NO: 130 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 123 or the heavy chain sequence of SEQ ID NO: 124, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0287]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 121 or SEQ ID NO: 122. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 123 or SEQ ID NO: 124.

**[0288]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 125; SEQ ID NO: 126; and SEQ ID NO: 127 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 121 or the light chain sequence of SEQ ID NO: 122.

**[0289]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 128; SEQ ID NO: 129; and SEQ ID NO: 130 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 123 or the heavy chain sequence of SEQ ID NO: 124.

**[0290]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 121; the variable heavy chain region of SEQ ID NO: 123; the complementarity-determining regions (SEQ ID NO: 125; SEQ ID NO: 126; and SEQ ID NO: 127) of the variable light chain region of SEQ ID NO: 121; and the complementarity-determining regions (SEQ ID NO: 128; SEQ ID NO: 129; and SEQ ID NO: 130) of the variable heavy chain region of SEQ ID NO: 123.

**[0291]** In a particularly preferred embodiment of the invention, the chimeric anti-CGRP antibody is Ab13, comprising, or alternatively consisting of, SEQ ID NO: 122 and SEQ ID NO: 124, and having at least one of the biological activities set forth herein.

**[0292]** In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab13, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 121 and the variable heavy chain sequence of SEQ ID NO: 123. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 121 and/or SEQ ID NO: 123 in said Fab while retaining binding specificity for CGRP.

**[0293]** In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab13. In another embodiment of the invention, anti-CGRP antibodies such as Ab13 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab14

**[0294]** In one embodiment, the invention includes humanized antibodies having binding specificity to CGRP and possessing a variable light chain sequence comprising the sequence set forth below:

QVLTQSPSSLSASVGDRVINCQASQNVNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSGSGTDFLTISLQPEDVATYYCLGSYDCSRGDCFVFGGGTKVEIK  
R (SEQ ID NO: 131).

**[0295]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a light chain sequence comprising the sequence set forth below:  
QVLTQSPSSLSASVGDRVINCQASQNVNNYLAWYQQKPGKVPKQLIYSTSTL  
ASGVPSRFSGSGSGTDFLTISLQPEDVATYYCLGSYDCSRGDCFVFGGGTKVEIK  
RTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQES

VTEQDSKDSTYLSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 132).

**[0296]** The invention further includes humanized antibodies having binding specificity to CGRP and possessing a variable heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVRQAPGKGLEWVGVIGSD  
GKTYYATWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCTRVDIWGQGTLVT  
VSS (SEQ ID NO: 133).

**[0297]** The invention also includes humanized antibodies having binding specificity to CGRP and possessing a heavy chain sequence comprising the sequence set forth below:

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVRQAPGKGLEWVGVIGSD  
GKTYYATWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCTRVDIWGQGTLVT  
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF  
PAVLQSSGLYSLSSVVTVPSQLGTQTYICNVNHKPSNTKVDARVEPKSCDKTHTC  
PPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV  
EVHNAKTKPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPQREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK  
TPPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK  
(SEQ ID NO: 134).

**[0298]** The invention further contemplates antibodies comprising one or more of the polypeptide sequences of SEQ ID NO: 135; SEQ ID NO: 136; and SEQ ID NO: 137 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 131 or the light chain sequence of SEQ ID NO: 132, and/or one or more of the polypeptide sequences of SEQ ID NO: 138; SEQ ID NO: 139; and SEQ ID NO: 140 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 133 or the heavy chain sequence of SEQ ID NO: 134, or combinations of these polypeptide sequences. In another embodiment of the invention, the antibodies of the invention or fragments thereof comprise, or alternatively consist of, combinations of one or

more of the CDRs, the variable heavy and variable light chain sequences, and the heavy and light chain sequences set forth above, including all of them.

**[0299]** The invention also contemplates fragments of the antibody having binding specificity to CGRP. In one embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 131 or SEQ ID NO: 132. In another embodiment of the invention, antibody fragments of the invention comprise, or alternatively consist of, the polypeptide sequence of SEQ ID NO: 133 or SEQ ID NO: 134.

**[0300]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 135; SEQ ID NO: 136; and SEQ ID NO: 137 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable light chain sequence of SEQ ID NO: 131 or the light chain sequence of SEQ ID NO: 132.

**[0301]** In a further embodiment of the invention, fragments of the antibody having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polypeptide sequences of SEQ ID NO: 138; SEQ ID NO: 139; and SEQ ID NO: 140 which correspond to the complementarity-determining regions (CDRs, or hypervariable regions) of the variable heavy chain sequence of SEQ ID NO: 133 or the heavy chain sequence of SEQ ID NO: 134.

**[0302]** The invention also contemplates antibody fragments which include one or more of the antibody fragments described herein. In one embodiment of the invention, fragments of the antibodies having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following antibody fragments: the variable light chain region of SEQ ID NO: 131; the variable heavy chain region of SEQ ID NO: 133; the complementarity-determining regions (SEQ ID NO: 135; SEQ ID NO: 136; and SEQ ID NO: 137) of the variable light chain region of SEQ ID NO: 131; and the complementarity-determining regions (SEQ ID NO: 138; SEQ ID NO: 139; and SEQ ID NO: 140) of the variable heavy chain region of SEQ ID NO: 133.

[0303] In a particularly preferred embodiment of the invention, the humanized anti-CGRP antibody is Ab14, comprising, or alternatively consisting of, SEQ ID NO: 132 and SEQ ID NO: 134, and having at least one of the biological activities set forth herein.

[0304] In a further particularly preferred embodiment of the invention, antibody fragments comprise, or alternatively consist of, Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab14, the Fab fragment includes the variable light chain sequence of SEQ ID NO: 131 and the variable heavy chain sequence of SEQ ID NO: 133. This embodiment of the invention further contemplates additions, deletions, and variants of SEQ ID NO: 131 and/or SEQ ID NO: 133 in said Fab while retaining binding specificity for CGRP.

[0305] In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab14. In another embodiment of the invention, anti-CGRP antibodies such as Ab14 or Fab fragments thereof may be produced *via* expression in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

[0306] In another embodiment, antibody fragments may be present in one or more of the following non-limiting forms: Fab, Fab', F(ab')<sub>2</sub>, Fv and single chain Fv antibody forms. In a preferred embodiment, the anti-CGRP antibodies described herein further comprises the kappa constant light chain sequence comprising the sequence set forth below:

[0307] VAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWKVDNALQSGN  
SQESVTEQDSKDSTYSLSSTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
(SEQ ID NO: 283).

[0308] In another preferred embodiment, the anti-CGRP antibodies described herein further comprises the gamma-1 constant heavy chain polypeptide sequence comprising the sequence set forth below:

[0309] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV  
HTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT  
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV

DGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE  
KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN  
NYKTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL  
PGK (SEQ ID NO: 284).

**[0310]** In another embodiment, the invention contemplates an isolated anti-CGRP antibody comprising a V<sub>H</sub> polypeptide sequence selected from: SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133, or a variant thereof; and further comprising a V<sub>L</sub> polypeptide sequence selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, or 131, or a variant thereof, wherein one or more of the framework residues (FR residues) in said V<sub>H</sub> or V<sub>L</sub> polypeptide has been substituted with another amino acid residue resulting in an anti-CGRP antibody that specifically binds CGRP. The invention contemplates humanized and chimeric forms of these antibodies. The chimeric antibodies may include an Fc derived from IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, IgG7, IgG8, IgG9, IgG10, IgG11, IgG12, IgG13, IgG14, IgG15, IgG16, IgG17, IgG18 or IgG19 constant regions.

**[0311]** In one embodiment of the invention, the antibodies or V<sub>H</sub> or V<sub>L</sub> polypeptides originate or are selected from one or more rabbit B cell populations prior to initiation of the humanization process referenced herein.

**[0312]** In another embodiment of the invention, the anti-CGRP antibodies and fragments thereof do not have binding specificity for CGRP-R. In a further embodiment of the invention, the anti-CGRP antibodies and fragments thereof inhibit the association of CGRP with CGRP-R. In another embodiment of the invention, the anti-CGRP antibodies and fragments thereof inhibit the association of CGRP with CGRP-R and/or additional proteins and/or multimers thereof, and/or antagonizes the biological effects thereof.

**[0313]** As stated in paragraph [0127] herein, antibodies and fragments thereof may be modified post-translationally to add effector moieties such as chemical linkers, detectable moieties such as for example fluorescent dyes, enzymes, substrates, bioluminescent materials, radioactive materials, and chemiluminescent moieties, or functional moieties such as for example streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, and radioactive materials.

**[0314]** Antibodies or fragments thereof may also be chemically modified to provide additional advantages such as increased solubility, stability and circulating time (in vivo half-life) of the polypeptide, or decreased immunogenicity (See U.S. Pat. No. 4,179,337). The chemical moieties for derivatization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The antibodies and fragments thereof may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

**[0315]** The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa. Branched polyethylene glycols are described, for example, in U.S. Pat. No. 5,643,575; Morpurgo et al., *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev et al., *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti et al., *Bioconjug. Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

**[0316]** There are a number of attachment methods available to those skilled in the art, *See e.g.*, EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), *See also* Malik et al., *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF

using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

[0317] As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to polypeptides via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof).

[0318] Alternatively, antibodies or fragments thereof may have increased *in vivo* half lives via fusion with albumin (including but not limited to recombinant human serum albumin or fragments or variants thereof (See, e.g., U.S. Pat. No. 5,876,969, issued Mar. 2, 1999, EP Patent 0 413 622, and U.S. Pat. No. 5,766,883, issued Jun. 16, 1998, herein incorporated by reference in their entirety)) or other circulating blood proteins such as transferrin or ferritin. In a preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with the mature form of human serum albumin (i.e., amino acids 1-585 of human serum albumin as shown in FIGS. 1 and 2 of EP Patent 0 322 094) which is herein incorporated by reference in its entirety. Polynucleotides encoding fusion proteins of the invention are also encompassed by the invention.

[0319] Regarding detectable moieties, further exemplary enzymes include, but are not limited to, horseradish peroxidase, acetylcholinesterase, alkaline phosphatase, *beta*-galactosidase and luciferase. Further exemplary fluorescent materials include, but are not

limited to, rhodamine, fluorescein, fluorescein isothiocyanate, umbelliferone, dichlorotriazinylamine, phycoerythrin and dansyl chloride. Further exemplary chemiluminescent moieties include, but are not limited to, luminol. Further exemplary bioluminescent materials include, but are not limited to, luciferin and aequorin. Further exemplary radioactive materials include, but are not limited to, Iodine 125 ( $^{125}\text{I}$ ), Carbon 14 ( $^{14}\text{C}$ ), Sulfur 35 ( $^{35}\text{S}$ ), Tritium ( $^3\text{H}$ ) and Phosphorus 32 ( $^{32}\text{P}$ ).

**[0320]** Regarding functional moieties, exemplary cytotoxic agents include, but are not limited to, methotrexate, aminopterin, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine; alkylating agents such as mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU), mitomycin C, lomustine (CCNU), 1-methylnitrosourea, cyclophosphamide, mechlorethamine, busulfan, dibromomannitol, streptozotocin, mitomycin C, cis-dichlorodiamine platinum (II) (DDP) cisplatin and carboplatin (paraplatin); anthracyclines include daunorubicin (formerly daunomycin), doxorubicin (adriamycin), detorubicin, carminomycin, idarubicin, epirubicin, mitoxantrone and bisantrene; antibiotics include dactinomycin (actinomycin D), bleomycin, calicheamicin, mithramycin, and anthramycin (AMC); and antimyotic agents such as the vinca alkaloids, vincristine and vinblastine. Other cytotoxic agents include paclitaxel (taxol), ricin, pseudomonas exotoxin, gemcitabine, cytochalasin B, gramicidin D, ethidium bromide, emetine, etoposide, tenoposide, colchicin, dihydroxy anthracin dione, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, procarbazine, hydroxyurea, asparaginase, corticosteroids, mytotane (O,P'- (DDD)), interferons, and mixtures of these cytotoxic agents.

**[0321]** Further cytotoxic agents include, but are not limited to, chemotherapeutic agents such as carboplatin, cisplatin, paclitaxel, gemcitabine, calicheamicin, doxorubicin, 5-fluorouracil, mitomycin C, actinomycin D, cyclophosphamide, vincristine and bleomycin. Toxic enzymes from plants and bacteria such as ricin, diphtheria toxin and *Pseudomonas* toxin may be conjugated to the humanized or chimeric antibodies, or binding fragments thereof, to generate cell-type-specific-killing reagents (Youle, et al., Proc. Nat'l Acad. Sci. USA 77:5483 (1980); Gilliland, et al., Proc. Nat'l Acad. Sci. USA 77:4539 (1980); Krolick, et al., Proc. Nat'l Acad. Sci. USA 77:5419 (1980)).

**[0322]** Other cytotoxic agents include cytotoxic ribonucleases as described by Goldenberg in U.S. Pat. No. 6,653,104. Embodiments of the invention also relate to radioimmunoconjugates where a radionuclide that emits alpha or beta particles is stably coupled to the antibody, or binding fragments thereof, with or without the use of a complex-forming agent. Such radionuclides include beta-emitters such as Phosphorus-32 ( $^{32}\text{P}$ ), Scandium-47 ( $^{47}\text{Sc}$ ), Copper-67 ( $^{67}\text{Cu}$ ), Gallium-67 ( $^{67}\text{Ga}$ ), Yttrium-88 ( $^{88}\text{Y}$ ), Yttrium-90 ( $^{90}\text{Y}$ ), Iodine-125 ( $^{125}\text{I}$ ), Iodine-131 ( $^{131}\text{I}$ ), Samarium-153 ( $^{153}\text{Sm}$ ), Lutetium-177 ( $^{177}\text{Lu}$ ), Rhenium-186 ( $^{186}\text{Re}$ ) or Rhenium-188 ( $^{188}\text{Re}$ ), and alpha-emitters such as Astatine-211 ( $^{211}\text{At}$ ), Lead-212 ( $^{212}\text{Pb}$ ), Bismuth-212 ( $^{212}\text{Bi}$ ) or -213 ( $^{213}\text{Bi}$ ) or Actinium-225 ( $^{225}\text{Ac}$ ).

**[0323]** Methods are known in the art for conjugating an antibody or binding fragment thereof to a detectable moiety and the like, such as for example those methods described by Hunter *et al*, Nature 144:945 (1962); David *et al*, Biochemistry 13:1014 (1974); Pain *et al*, J. Immunol. Meth. 40:219 (1981); and Nygren, J., Histochem. and Cytochem. 30:407 (1982).

**[0324]** Embodiments described herein further include variants and equivalents that are substantially homologous to the antibodies, antibody fragments, diabodies, SMIPs, camelbodies, nanobodies, IgNAR, polypeptides, variable regions and CDRs set forth herein. These may contain, e.g., conservative substitution mutations, (i.e., the substitution of one or more amino acids by similar amino acids). For example, conservative substitution refers to the substitution of an amino acid with another within the same general class, e.g., one acidic amino acid with another acidic amino acid, one basic amino acid with another basic amino acid, or one neutral amino acid by another neutral amino acid. What is intended by a conservative amino acid substitution is well known in the art.

**[0325]** In another embodiment, the invention contemplates polypeptide sequences having at least 90% or greater sequence homology to any one or more of the polypeptide sequences of antibody fragments, variable regions and CDRs set forth herein. More preferably, the invention contemplates polypeptide sequences having at least 95% or greater sequence homology, even more preferably at least 98% or greater sequence homology, and still more preferably at least 99% or greater sequence homology to any one

or more of the polypeptide sequences of antibody fragments, variable regions and CDRs set forth herein. Methods for determining homology between nucleic acid and amino acid sequences are well known to those of ordinary skill in the art.

**[0326]** In another embodiment, the invention further contemplates the above-recited polypeptide homologs of the antibody fragments, variable regions and CDRs set forth herein further having anti-CGRP activity. Non-limiting examples of anti-CGRP activity are set forth herein, for example, in paragraphs [0329]-[0350] *infra*.

**[0327]** In another embodiment, the invention further contemplates the generation and use of anti-idiotypic antibodies that bind any of the foregoing sequences. In an exemplary embodiment, such an anti-idiotypic antibody could be administered to a subject who has received an anti-CGRP antibody to modulate, reduce, or neutralize, the effect of the anti-CGRP antibody. Such anti-idiotypic antibodies could also be useful for treatment of an autoimmune disease characterized by the presence of anti-CGRP antibodies. A further exemplary use of such anti-idiotypic antibodies is for detection of the anti-CGRP antibodies of the present invention, for example to monitor the levels of the anti-CGRP antibodies present in a subject's blood or other bodily fluids.

**[0328]** The present invention also contemplates anti-CGRP antibodies comprising any of the polypeptide or polynucleotide sequences described herein substituted for any of the other polynucleotide sequences described herein. For example, without limitation thereto, the present invention contemplates antibodies comprising the combination of any of the variable light chain and variable heavy chain sequences described herein, and further contemplates antibodies resulting from substitution of any of the CDR sequences described herein for any of the other CDR sequences described herein.

#### *Additional Exemplary Embodiments of the Invention*

**[0329]** In another embodiment, the invention contemplates one or more anti-human CGRP antibodies or antibody fragments thereof which specifically bind to the same overlapping linear or conformational epitope(s) and/or competes for binding to the same overlapping linear or conformational epitope(s) on an intact human CGRP polypeptide or fragment thereof as an anti-human CGRP antibody selected from Ab1, Ab2, Ab3, Ab4,

Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, or Ab14. In a preferred embodiment, the anti-human CGRP antibody or fragment thereof specifically binds to the same overlapping linear or conformational epitope(s) and/or competes for binding to the same overlapping linear or conformational epitope(s) on an intact human CGRP polypeptide or a fragment thereof as Ab3, Ab6, Ab13, or Ab14.

**[0330]** A preferred embodiment of the invention is directed to chimeric or humanized antibodies and fragments thereof (including Fab fragments) having binding specificity for CGRP and inhibiting biological activities mediated by the binding of CGRP to the CGRP receptor. In a particularly preferred embodiment of the invention, the chimeric or humanized anti-CGRP antibodies are selected from Ab3, Ab6, Ab13, or Ab14.

**[0331]** In a further embodiment of the invention is contemplated a method of reducing, treating or preventing diseases or disorders associated with CGRP by affecting those biological activities mediated *via* CGRP, thereby avoiding the biological activities mediated via binding of CGRP to CGRP-R. In one embodiment, the disease or disorder associated with CGRP is migraine or another disorder wherein CGRP elicits pain, headache, pain, cancer, overactive bladder, or weightloss. A further non-limiting listing of diseases and disorders associated with CGRP is provided herein.

**[0332]** Another preferred embodiment of the invention contemplates the use of Fab polypeptide sequences for the treatment of migraines and headaches in a patient. Non-limiting types of migraines and headaches that may be treated using Fab polypeptide sequences are provided elsewhere in this disclosure.

**[0333]** In another embodiment of the invention, the anti-human CGRP antibody is an antibody which specifically binds to the same overlapping linear or conformational epitopes on an intact CGRP polypeptide or fragment thereof that is (are) specifically bound by Ab3, Ab6, Ab13, or Ab14 as ascertained by epitopic mapping using overlapping linear peptide fragments which span the full length of the native human CGRP polypeptide.

**[0334]** The invention is also directed to an anti-CGRP antibody that binds with the same CGRP epitope and/or competes with an anti-CGRP antibody for binding to CGRP as an antibody or antibody fragment disclosed herein, including but not limited to an anti-CGRP

antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, or Ab14.

**[0335]** In another embodiment, the invention is also directed to an isolated anti-CGRP antibody or antibody fragment comprising one or more of the CDRs contained in the  $V_H$  polypeptide sequences selected from: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133, or a variant thereof, and/or one or more of the CDRs contained in the  $V_L$  polypeptide sequences selected from: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, or 131, or a variant thereof.

**[0336]** In one embodiment of the invention, the anti-human CGRP antibody discussed in the two prior paragraphs comprises at least 2 complementarity determining regions (CDRs) in each the variable light and the variable heavy regions which are identical to those contained in an anti-human CGRP antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, or Ab14.

**[0337]** In a preferred embodiment, the anti-human CGRP antibody discussed above comprises at least 2 complementarity determining regions (CDRs) in each the variable light and the variable heavy regions which are identical to those contained in Ab3 or Ab6. In another embodiment, all of the CDRs of the anti-human CGRP antibody discussed above are identical to the CDRs contained in an anti-human CGRP antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, or Ab14. In a preferred embodiment of the invention, all of the CDRs of the anti-human CGRP antibody discussed above are identical to the CDRs contained in an anti-human CGRP antibody selected from Ab3 or Ab6.

**[0338]** The invention further contemplates that the one or more anti-human CGRP antibodies discussed above are aglycosylated; that contain an Fc region that has been modified to alter effector function, half-life, proteolysis, and/or glycosylation; are human, humanized, single chain or chimeric; and are a humanized antibody derived from a rabbit (parent) anti-human CGRP antibody.

**[0339]** The invention further contemplates one or more anti-human CGRP antibodies wherein the framework regions (FRs) in the variable light region and the variable heavy regions of said antibody respectively are human FRs which are unmodified or which have

been modified by the substitution of one or more human FR residues in the variable light or heavy chain region with the corresponding FR residues of the parent rabbit antibody, and wherein said human FRs have been derived from human variable heavy and light chain antibody sequences which have been selected from a library of human germline antibody sequences based on their high level of homology to the corresponding rabbit variable heavy or light chain regions relative to other human germline antibody sequences contained in the library.

**[0340]** In one embodiment of the invention, the anti-human CGRP antibody or fragment specifically binds to CGRP expressing human cells and/or to circulating soluble CGRP molecules *in vivo*, including CGRP expressed on or by human cells in a patient with a disease associated with cells that express CGRP.

**[0341]** In another embodiment, the disease is selected from migraines (with or without aura), weight loss, cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, hemiplagic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), allergy-induced headaches or migraines, pain, inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, chronic pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, abdominal pain, pain associated with sickle cell crises, and other nociceptive pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptive pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarian pain, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or pain or visceral pain associated with: gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, irritable colon, spastic colon, mucous colitis, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, pancreatitis, renal colic, dysmenorrhea, cystitis, including

interstitial cystitis (IC), surgery associated with the ileus, diverticulitis, peritonitis, pericarditis, hepatitis, appendicitis, colitis, cholecystitis, endometriosis, chronic and/or acute pancreatitis, myocardial infarction, kidney pain, pleural pain, prostatitis, pelvic pain, trauma to an organ, chronic nociceptive pain, chronic neuropathic pain, chronic inflammatory pain, fibromyalgia, breakthrough pain and persistent pain.

**[0342]** In another embodiment of the invention, the disease is cancer pain arising from malignancy or from cancer preferably selected from one or more of: adenocarcinoma in glandular tissue, blastoma in embryonic tissue of organs, carcinoma in epithelial tissue, leukemia in tissues that form blood cells, lymphoma in lymphatic tissue, myeloma in bone marrow, sarcoma in connective or supportive tissue, adrenal cancer, AIDS-related lymphoma, anemia, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoid tumours, cervical cancer, chemotherapy, colon cancer, cytopenia, endometrial cancer, esophageal cancer, gastric cancer, head cancer, neck cancer, hepatobiliary cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, Hodgkin's disease, lymphoma, non-Hodgkin's, nervous system tumours, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, urethral cancer, bone cancer, sarcomas cancer of the connective tissue, cancer of bone tissue, cancer of blood-forming cells, cancer of bone marrow, multiple myeloma, leukaemia, primary or secondary bone cancer, tumours that metastasize to the bone, tumours infiltrating the nerve and hollow viscus, tumours near neural structures. Further preferably the cancer pain comprises visceral pain, preferably visceral pain which arises from pancreatic cancer and/or metastases in the abdomen. Further preferably the cancer pain comprises somatic pain, preferably somatic pain due to one or more of bone cancer, metastasis in the bone, postsurgical pain, sarcomas cancer of the connective tissue, cancer of bone tissue, cancer of blood-forming cells of the bone marrow, multiple myeloma, leukaemia, primary or secondary bone cancer.

**[0343]** The invention further contemplates anti-human CGRP antibodies or fragments directly or indirectly attached to a detectable label or therapeutic agent.

**[0344]** The invention also contemplates one or more nucleic acid sequences which result in the expression of an anti-human CGRP antibody or antibody fragment as set forth

above, including those comprising, or alternatively consisting of, yeast or human preferred codons. The invention also contemplates vectors (including plasmids or recombinant viral vectors) comprising said nucleic acid sequence(s). The invention also contemplates host cells or recombinant host cells expressing at least one of the antibodies set forth above, including a mammalian, yeast, bacterial, and insect cells. In a preferred embodiment, the host cell is a yeast cell. In a further preferred embodiment, the yeast cell is a diploidal yeast cell. In a more preferred embodiment, the yeast cell is a *Pichia* yeast.

**[0345]** The invention also contemplates a method of treatment comprising administering to a patient with a disease or condition associated with CGRP expressing cells a therapeutically effective amount of at least one anti-human CGRP antibody or fragment described herein. The invention also contemplates that the treatment method may involve the administration of two or more anti-CGRP antibodies or fragments thereof and disclosed herein. If more than one antibody is administered to the patient, the multiple antibodies may be administered simultaneously or concurrently, or may be staggered in their administration. The diseases that may be treated are presented in the non-limiting list set forth above and elsewhere herein. In a preferred embodiment, the disease is selected from migraine, headache, weight loss, pain, cancer pain or neuropathic pain. In another embodiment the treatment further includes the administration of another therapeutic agent or regimen selected from chemotherapy, radiotherapy, cytokine administration or gene therapy.

**[0346]** In a non-limiting embodiment of the invention, another therapeutic agent or regimen includes Taxol (paclitaxel) or its derivatives, platinum compounds such as carboplatin or cisplatin, anthrocyclines such as doxorubicin, alkylating agents such as cyclophosphamide, anti-metabolites such as 5-fluorouracil, or etoposide.

**[0347]** The invention further contemplates a method of *in vivo* imaging which detects the presence of cells which express CGRP comprising administering a diagnostically effective amount of at least one anti-human CGRP antibody. In one embodiment, said administration further includes the administration of a radionuclide or fluorophore that facilitates detection of the antibody at CGRP expressing disease sites. In a further embodiment, the results of said *in vivo* imaging method are used to facilitate the design of

an appropriate therapeutic regimen, including therapeutic regimens including radiotherapy, chemotherapy or a combination thereof.

**[0348]** The anti-CGRP activity of the anti-CGRP antibodies of the present invention, and fragments thereof having binding specificity to CGRP, may also be described by their strength of binding or their affinity for CGRP. In one embodiment of the invention, the anti-CGRP antibodies of the present invention, and fragments thereof having binding specificity to CGRP, bind to CGRP with a dissociation constant ( $K_D$ ) of less than or equal to  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M, or  $10^{-13}$  M. Preferably, the anti-CGRP antibodies and fragments thereof bind CGRP with a dissociation constant of less than or equal to  $10^{-11}$  M,  $5 \times 10^{-12}$  M, or  $10^{-12}$  M. In another embodiment of the invention, the anti-CGRP antibodies of the present invention, and fragments thereof having binding specificity to CGRP, bind to a linear or conformational CGRP epitope.

**[0349]** In another embodiment of the invention, the anti-CGRP activity of the anti-CGRP antibodies of the present invention, and fragments thereof having binding specificity to CGRP, bind to CGRP with an off-rate of less than or equal to  $10^{-4}$  S<sup>-1</sup>,  $5 \times 10^{-5}$  S<sup>-1</sup>,  $10^{-5}$  S<sup>-1</sup>,  $5 \times 10^{-6}$  S<sup>-1</sup>,  $10^{-6}$  S<sup>-1</sup>,  $5 \times 10^{-7}$  S<sup>-1</sup>, or  $10^{-7}$  S<sup>-1</sup>.

**[0350]** In a further embodiment of the invention, the anti-CGRP activity of the anti-CGRP antibodies of the present invention, and fragments thereof having binding specificity to CGRP, exhibit anti-CGRP activity by preventing, ameliorating or reducing the symptoms of, or alternatively treating, diseases and disorders associated with CGRP. Non-limiting examples of diseases and disorders associated with CGRP are set forth herein.

### *Polynucleotides Encoding Anti-CGRP Antibody Polypeptides*

#### *Antibody Ab1*

**[0351]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following

polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 1:

[0352] CAAGTGCTGACCCAGACTGCATCCCCGTGTCTGCAGCTGTGGAAAG  
CACAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTATGATAACAACTACC  
TAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCT  
ACATCCACTCTGGCATCTGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGG  
GACACAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCATGCTGCCACTTA  
CTACTGTCTAGGCAGTTATGATTGATTGAGTGGTATTGTTTGTTCGGCGG  
AGGGACCGAGGTGGTGGTCAAACGT (SEQ ID NO: 141).

[0353] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 2:

[0354] CAAGTGCTGACCCAGACTGCATCCCCGTGTCTGCAGCTGTGGAAAG  
CACAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTATGATAACAACTACC  
TAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCT  
ACATCCACTCTGGCATCTGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGG  
GACACAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCATGCTGCCACTTA  
CTACTGTCTAGGCAGTTATGATTGATTGAGTGGTATTGTTTGTTCGGCGG  
AGGGACCGAGGTGGTGGTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCT  
TCCCGCCATCTGATGAGCAGTTGAAATCTGGAACCTGCCTCTGTTGTGCCTGC  
TGAATAACTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCC  
CTCCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACA  
GCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGAA  
ACACAAAGTCTACGCCCTGCGAAGTCACCCATCAGGGCCTGAGCTGCCCGTCA  
CAAAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 142).

[0355] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 3:

[0356] CAGTCGCTGGAGGAGTCCGGGGTCGCCTGGTCACGCCTGGACACC  
CCTGACACTCACCTGCACAGTCTCTGGACTCGACCTCAGTAGCTACTACATGCA

ATGGGTCCGCCAGGCTCCAGGGAAAGGGCTGGAATGGATCGGAGTCATTGGTA  
TTAATGATAACACATACTACGCGAGCTGGCGAAAGGCCGATTCACCATCTCC  
AGAGCCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAACCGAGGA  
CACGGCCACCTATTCTGTGCCAGAGGGGACATCTGGGGCCCAGGCACCCTCG  
TCACCGTCTCGAGC (SEQ ID NO: 143).

**[0357]** In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 4:

CAGTCGCTGGAGGAGTCCGGGGTCGCCTGGTCACGCCTGGACACCCCTGAC  
ACTCACCTGCACAGTCTCTGGACTCGACCTCAGTAGCTACTACATGCAATGGGT  
CCGCCAGGCTCCAGGGAAAGGGGCTGGAATGGATCGGAGTCATTGGTATTAATG  
ATAACACATACTACGCGAGCTGGCGAAAGGCCGATTCACCATCTCCAGAGCC  
TCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAACCGAGGACACGGC  
CACCTATTCTGTGCCAGAGGGGACATCTGGGGCCCAGGCACCCTCGTCACCG  
TCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCCCTCCTCCA  
AGAGCACCTCTGGGGCACAGCGGCCCTGGCTGCCTGGTCAAGGACTACTTC  
CCCGAACCGGTGACGGTGTGGAACTCAGGCGCCCTGACCAGCGCGTGCA  
CACCTTCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG  
GACCGTGCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACGTGAATC  
ACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCAAATCTGTGA  
CAAAACTCACACATGCCACCGTGCCCAGCACCTGAACCTCCTGGGGGACCGT  
CAGTCTCCTCTTCCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCC  
CTGAGGTCACATGCGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAG  
TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG  
GGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCTGC  
ACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAGGTCTCCAACAAAGC  
CCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCCCGAG  
AACACAGGTGTACACCCCTGCCCTGCCCCATCCGGGAGGAGATGACCAAGAAC  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTGGA  
GTGGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCCCTCCCGTG

CTGGACTCCGACGGCTCCTTCTCCTACAGCAAGCTACCGTGGACAAGAGC  
AGGTGGCAGCAGGGAACGTCTCATGCTCCGTGATGCATGAGGCTTGCA  
CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGTAAATGA (SEQ ID  
NO: 144).

**[0358]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 145; SEQ ID NO: 146; and SEQ ID NO: 147 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 1 or the light chain sequence of SEQ ID NO: 2.

**[0359]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 148; SEQ ID NO: 149; and SEQ ID NO: 150 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 3 or the heavy chain sequence of SEQ ID NO: 4.

**[0360]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 141 encoding the light chain variable sequence of SEQ ID NO: 1; the polynucleotide SEQ ID NO: 142 encoding the light chain sequence of SEQ ID NO: 2; the polynucleotide SEQ ID NO: 143 encoding the heavy chain variable sequence of SEQ ID NO: 3; the polynucleotide SEQ ID NO: 144 encoding the heavy chain sequence of SEQ ID NO: 4; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 145; SEQ ID NO: 146; and SEQ ID NO: 147) of the light chain variable sequence of SEQ ID NO: 1 or the light chain sequence of SEQ ID NO: 2; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 148; SEQ ID NO: 149;

and SEQ ID NO: 150) of the heavy chain variable sequence of SEQ ID NO: 3 or the heavy chain sequence of SEQ ID NO: 4.

**[0361]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab1, the polynucleotides encoding the full length Ab1 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 142 encoding the light chain sequence of SEQ ID NO: 2 and the polynucleotide SEQ ID NO: 144 encoding the heavy chain sequence of SEQ ID NO: 4.

**[0362]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast *Pichia*. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab1 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab1 or Fab fragments thereof may be produced *via* expression of Ab1 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab2

**[0363]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 11:

**[0364]** CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTATGATAACAACTACCT

AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTCAGTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTAGGCAGTTATGATTGTAGTAGTGGTATTGTTTGTTCGGCGGAG  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 151).

[0365] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 12:

[0366] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTATGATAACAACACTACCT  
AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTCAGTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTAGGCAGTTATGATTGTAGTAGTGGTATTGTTTGTTCGGCGGAG  
GAACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 152).

[0367] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 13:

[0368] GAGGTGCAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGCCTGGGG  
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGACTCGACCTCAGTAGCTACTACAT  
GCAATGGGTCCGTCAAGGCTCCAGGGAAAGGGCTGGAGTGGTCGGAGTCATTG  
GTATCAATGATAACACATACTACGCGAGCTGGCGAAAGGCCGATTCAACCATC  
TCCAGAGACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGC

TGAGGACACTGCTGTATTCTGTGCTAGAGGGACATCTGGGCCAAGGGA  
CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 153).

**[0369]** In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 14:

GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTGGTCCAGCCTGGGGTCCCT  
GAGACTCTCCTGTGCAGTCTCTGGACTCGACCTCAGTAGCTACTACATGCAATG  
GGTCCGTCAGGCTCCAGGGAAAGGGCTGGAGTGGCTGGAGTCATTGGTATCA  
ATGATAACACATACTACCGAGCTGGCGAAAGGCCGATTACCATCTCCAGA  
GACAATTCCAAGACCACGGTGTATCTCAAATGAACAGCCTGAGAGCTGAGGA  
CACTGCTGTATTCTGTGCTAGAGGGACATCTGGGCCAAGGGACCCTCG  
TCACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCC  
CCTCCAAGAGCACCTCTGGGGCACAGCGCCCTGGCTGCCTGGTCAAGGAC  
TACTTCCCCGAACCGGTGACGGTGTGGAACTCAGGCCTCAGGACTCTCCCTCAGCAG  
CGTGGTACCGTGCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACG  
TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGGCCAAATC  
TTGTGACAAAACTCACACATGCCACCGTGCCTACAGCCTCAGGACTCTCCCTCAGCAG  
GACCGTCAGTCTCCTCTTCCCCCAAAACCAAGGACACCTCATGATCTCCC  
GGACCCCTGAGGTACATCGTGGTGGACGTGAGCCACGAAGACCTGAG  
GTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAA  
GCCGGGGAGGAGCAGTACGCCACGTACCGTGTGGTCAGCGCCTCACCG  
TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTCAAGGTCTCCAAC  
AAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAGGGCAGCC  
CCGAGAACACAGGTGTACACCTGCCCTGGGGAGGAGATGACCAAGA  
ACCAGGTACGCCTGACCTGCCCTGGTCAAAGGCTTCTACAGCAAGCTACCGTGGACA  
GTGGAGTGGAGAGCAATGGCAGCCGGAGAACAAACTACAAGACCACGCCTC  
CCGTGCTGGACTCCGACGGCTCCTCTACAGCAAGCTACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTGATGCATGAGGCT

CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGTAAATGA  
(SEQ ID NO: 154).

**[0370]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 155; SEQ ID NO: 156; and SEQ ID NO: 157 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 11 or the light chain sequence of SEQ ID NO: 12.

**[0371]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 158; SEQ ID NO: 159; and SEQ ID NO: 160 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 13 or the heavy chain sequence of SEQ ID NO: 14.

**[0372]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 151 encoding the light chain variable sequence of SEQ ID NO: 11; the polynucleotide SEQ ID NO: 152 encoding the light chain sequence of SEQ ID NO: 12; the polynucleotide SEQ ID NO: 153 encoding the heavy chain variable sequence of SEQ ID NO: 13; the polynucleotide SEQ ID NO: 154 encoding the heavy chain sequence of SEQ ID NO: 14; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 155; SEQ ID NO: 156; and SEQ ID NO: 157) of the light chain variable sequence of SEQ ID NO: 11 or the light chain sequence of SEQ ID NO: 12; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 158; SEQ ID NO: 159; and SEQ ID NO: 160) of the heavy chain variable sequence of SEQ ID NO: 13 or the heavy chain sequence of SEQ ID NO: 14.

**[0373]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab2, the polynucleotides encoding the full length Ab2 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 152 encoding the light chain sequence of SEQ ID NO: 12 and the polynucleotide SEQ ID NO: 154 encoding the heavy chain sequence of SEQ ID NO: 14.

**[0374]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast *Pichia*. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab2 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab2 or Fab fragments thereof may be produced *via* expression of Ab2 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab3

**[0375]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 21:

**[0376]** CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTATGATAACAACCTACCT  
AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCATCTCGTTCAGTGGCAGTGGATCTGGGA

CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTAGGCAGTTATGATTGTAGTAGTGGTATTGTTTGGCGGGAG  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 161).

[0377] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 22:

[0378] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTATGATAACAACACTACCT  
AGCCTGGTATCAGCAGAAACCAGGGAAAGTCCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTAGTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTAGGCAGTTATGATTGTAGTAGTGGTATTGTTTGGCGGGAG  
GAACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAACTTGGAACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCTGAGCTCGCCCGTCACA  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 162).

[0379] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 23:

[0380] GAGGTGCAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGCCTGGGG  
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGACTCGACCTCAGTAGCTACTACAT  
GCAATGGGTCCGTCAAGGCTCCAGGGAAAGGGCTGGAGTGGTCGGAGTCATTG  
GTATCAATGATAACACATACTACGCGAGCTGGCGAAAGGCCGATTCAACCATC  
TCCAGAGACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGC  
TGAGGACACTGCTGTATTCTGTCTAGAGGGACATCTGGGCCAAGGGA  
CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 163).

[0381] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 24:

GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCT  
GAGACTCTCCTGTGCAGTCTCTGGACTCGACCTCAGTAGCTACTACATGCAATG  
GGTCCGTCAGGCTCCAGGGAAAGGGCTGGAGTGGGTGGAGTCATTGGTATCA  
ATGATAACACATACTACGCGAGCTGGCGAAAGGCCGATTACCACATCTCCAGA  
GACAATTCCAAGACCACGGTGTATCTCAAATGAACAGCCTGAGAGCTGAGGA  
CACTGCTGTGTATTCTGTGCTAGAGGGACATCTGGGCCAAGGGACCCTCG  
TCACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCCCT  
CCTCCAAGAGCACCTCTGGGGCACAGCGGCCCTGGCTGCCTGGTCAAGGAC  
TACTTCCCCGAACCGGTGACGGTGTGGAACTCAGGCCTCAGGACTCTACTCCCTCAGCAG  
CGTGGTACCGTGCCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACG  
TGAATCACAAGCCCAGCAACACCAAGGTGGACGCGAGAGTTGAGCCAAATCT  
TGTGACAAAACTCACACATGCCACCAGTGTGCCAGCACCTGAACCTCCTGGGGGG  
ACCGTCAGTCTCCTCTTCCCCCAAAACCAAGGACACCCTCATGATCTCCCG  
GACCCCTGAGGTACATGCGTGGTGGACGTGAGCCACGAAGACCCTGAGG  
TCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAG  
CCGCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGT  
CCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACA  
AAGCCCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAGGGCAGCCC  
CGAGAACACAGGTGTACACCCTGCCCATCCGGAGGAGATGACCAAGA  
ACCAGGTACGCCTGACCTGCCTGGTCAAAGGCTTCTACAGCAAGCTACCGTGGACA  
GTGGAGTGGAGAGCAATGGCAGCCGGAGAACAAACTACAAGACCAACGCCTC  
CCGTGCTGGACTCCGACGGCTCTTCTACAGCAAGCTACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTATGCATGAGGCT  
CTGCACAACCAACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA  
(SEQ ID NO: 164).

[0382] In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 165; SEQ ID NO: 166; and SEQ ID NO: 167 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 21 or the light chain sequence of SEQ ID NO: 22.

[0383] In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 168; SEQ ID NO: 169; and SEQ ID NO: 170 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 23 or the heavy chain sequence of SEQ ID NO: 24.

[0384] The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 161 encoding the light chain variable sequence of SEQ ID NO: 21; the polynucleotide SEQ ID NO: 162 encoding the light chain sequence of SEQ ID NO: 22; the polynucleotide SEQ ID NO: 163 encoding the heavy chain variable sequence of SEQ ID NO: 23; the polynucleotide SEQ ID NO: 164 encoding the heavy chain sequence of SEQ ID NO: 24; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 165; SEQ ID NO: 166; and SEQ ID NO: 167) of the light chain variable sequence of SEQ ID NO: 21 or the light chain sequence of SEQ ID NO: 22; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 168; SEQ ID NO: 169; and SEQ ID NO: 170) of the heavy chain variable sequence of SEQ ID NO: 23 or the heavy chain sequence of SEQ ID NO: 24.

[0385] In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab3,

the polynucleotides encoding the full length Ab3 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 162 encoding the light chain sequence of SEQ ID NO: 22 and the polynucleotide SEQ ID NO: 164 encoding the heavy chain sequence of SEQ ID NO: 24.

**[0386]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast Pichia. Suitable Pichia species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab3 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab3 or Fab fragments thereof may be produced *via* expression of Ab3 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable Pichia species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab4

**[0387]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 31:

**[0388]** CAAGTGCTGACCCAGACTCCATCCCCGTGTCTGCAGCTGTGGAAAG  
CACAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTTCATAACACACCTACCT  
GGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAACAACACTGATCTATGATG  
CATCCACTCTGGCGTCTGGGTCCCATCGCGGTTCAGCGGCAGTGGATCTGG  
ACACAGTTCACTCTACCATCAGCGCGTGCAGTGTAAACGATGCTGCCGCTTAC  
TACTGTCTGGGCAGTTATGATTGTACTAATGGTATTGTTGTTTCGGCGGA  
GGGACCGAGGTGGTGGTCAAACGT (SEQ ID NO: 171).

[0389] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 32:

[0390] CAAGTGCTGACCCAGACTCCATCCCCGTGTCTGCAGCTGTGGGAAG  
CACAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTATCATAACACCTACCT  
GGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAACAACTGATCTATGATG  
CATCCACTCTGGCGTCTGGGTCCCATCGCGGTTAGCGGCAGTGGATCTGGG  
ACACAGTTCACTCTACCATCAGCGCGTGCAGTGTAAACGATGCTGCCGCTTAC  
TACTGTCTGGGCAGTTATGATTGTACTAATGGTATTGTTGTTTCGGCGGA  
GGGACCGAGGTGGTGGTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAACTTGGAACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 172).

[0391] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 33:

[0392] CAGTCGCTGGAGGAGTCCGGGGTCGCCTGGTCACGCCTGGACACC  
CCTGACACTCACCTGTTCCGTCTGGCATCGACCTCAGTGGCTACTACATGAA  
CTGGGTCCGCCAGGCTCCAGGGAAAGGGCTGGAATGGATCGGAGTCATTGGTA  
TTAATGGTGCCACATACTACGCGAGCTGGCGAAAGGCCATTACCATCTCC  
AAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAACCGAGGA  
CACGGCCACCTATTCTGTGCCAGAGGGACATCTGGGGCCCGGGCACCTCG  
TCACCGTCTCGAGC (SEQ ID NO: 173).

[0393] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 34:

CAGTCGCTGGAGGAGTCCGGGGTCGCCTGGTCACGCCTGGACACCCCTGAC  
ACTCACCTGTTCCCGTCTCTGGCATCGACCTCAGTGGCTACTACATGAACCTGGT  
CCGCCAGGCTCCAGGGAAGGGGCTGGAATGGATCGGAGTCATTGGTATTAATG  
GTGCCACATACTACCGCGAGCTGGCGAAAGGCCGATTCACCATCTCCAAAACC  
TCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAACCGAGGACACGGC  
CACCTATTCTGTGCCAGAGGGGACATCTGGGGCCCGGGCACCCCTCGTCACCG  
TCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCCCTCCTCCA  
AGAGCACCTCTGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTC  
CCCGAACCGGTGACGGTGTGGAACTCAGGCGCCCTGACCAGCGCGTGCA  
CACCTCCCGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG  
GACCGTGCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACGTGAATC  
ACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCAAATCTTGTGA  
CAAAACTCACACATGCCACCAGTGCCTGCCCAGCACCTGAACTCCTGGGGGACCGT  
CAGTCTCCTCTTCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCC  
CTGAGGTCACATGCGTGGTGGACGGCGTGAGGTGCATAATGCCAAGACAAAGCCGCG  
GGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGC  
ACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACAAAGC  
CCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAGGGCAGCCCCGAG  
AACACAGGTGTACACCCTGCCCTGCCCCATCCGGAGGAGATGACCAAGAACAG  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTGGA  
GTGGGAGAGCAATGGCAGCCGGAGAACAAACTACAAGACCACGCCCTCCGTG  
CTGGACTCCGACGGCTCCTCTTCTACAGCAAGCTCACCGTGGACAAGAGC  
AGGTGGCAGCAGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTTGCA  
CAACCACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA (SEQ ID  
NO: 174).

**[0394]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 175; SEQ ID NO: 176; and SEQ ID NO: 177 which correspond to polynucleotides encoding the complementarity-determining

regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 31 or the light chain sequence of SEQ ID NO: 32.

**[0395]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 178; SEQ ID NO: 179; and SEQ ID NO: 180 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 33 or the heavy chain sequence of SEQ ID NO: 34.

**[0396]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 171 encoding the light chain variable sequence of SEQ ID NO: 31; the polynucleotide SEQ ID NO: 172 encoding the light chain sequence of SEQ ID NO: 32; the polynucleotide SEQ ID NO: 173 encoding the heavy chain variable sequence of SEQ ID NO: 33; the polynucleotide SEQ ID NO: 174 encoding the heavy chain sequence of SEQ ID NO: 34; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 175; SEQ ID NO: 176; and SEQ ID NO: 177) of the light chain variable sequence of SEQ ID NO: 31 or the light chain sequence of SEQ ID NO: 32; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 178; SEQ ID NO: 179; and SEQ ID NO: 180) of the heavy chain variable sequence of SEQ ID NO: 33 or the heavy chain sequence of SEQ ID NO: 34.

**[0397]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab4, the polynucleotides encoding the full length Ab4 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 172 encoding the light chain sequence of SEQ ID NO: 32 and the polynucleotide SEQ ID NO: 174 encoding the heavy chain sequence of SEQ ID NO: 34.

**[0398]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast Pichia. Suitable Pichia species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab4 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab4 or Fab fragments thereof may be produced *via* expression of Ab4 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable Pichia species include, but are not limited to, *Pichia pastoris*.

Antibody Ab5

**[0399]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 41:

**[0400]** CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTTCATCATAACACCTACCT  
GGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATGATG  
CATCCACTCTGGCATCTGGGTCCCCTCGTTCACTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTGGCAGTTATGATTGTACTAATGGTATTGTTGTTCTGGCGGAG  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 181).

**[0401]** In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 42:

[0402] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCCTCAATTGCCAGGCCAGTCAGAGTGTATCATAACACCTACCT  
GGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATGATG  
CATCCACTCTGGCATCTGGGCTCCATCTCGTTCACTGGCAGTGGATCTGGGA  
CAGATTCACACTCACCACAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTGGCAGTTATGATTGACTAATGGTGTGATTGTTGTTGGCGAG  
GAACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAATCTGGAACACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACCTCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCCTGAGCTGCCGTAC  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 182).

[0403] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 43:

[0404] GAGGTGCAGCTTGTGGAGTCTGGGGAGGGCTGGTCCAGCCTGGGG  
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGAATCGACCTCAGTGGCTACTACAT  
GAACCTGGGTCCCGTCAGGCTCCAGGGAAAGGGGCTGGAGTGGTCGGAGTCATTG  
GTATTAATGGTGCCACATACTACGCGAGCTGGCGAAAGGCCGATTCAACCATC  
TCCAGAGACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGC  
TGAGGACACTGCTGTATTCTGTCTAGAGGGACATCTGGGCCAAGGG  
CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 183).

[0405] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 44:

GAGGTGCAGCTTGTGGAGTCTGGGGAGGGCTGGTCCAGCCTGGGGTCC  
GAGACTCTCCTGTGCAGTCTCTGGAATCGACCTCAGTGGCTACTACATGAAC  
GGTCCCGTCAGGCTCCAGGGAAAGGGCTGGAGTGGTCGGAGTCATTGGTATTA  
ATGGTGCCACATACTACGCGAGCTGGCGAAAGGCCGATTCAACCATCTCCAGA

GACAATTCCAAGACCACGGTGTATCTCAAATGAACAGCCTGAGAGCTGAGGA  
CACTGCTGTGTATTCTGTGCTAGAGGGGACATCTGGGCAAGGGACCCTCG  
TCACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCC  
CCTCCAAGAGCACCTCTGGGGCACAGCGGCCCTGGCTGCCTGGTCAAGGAC  
TACTCCCCGAACCGGTGACGGTGTGGAACTCAGGCCTGACCAGCG  
CGTGCACACCTCCCGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAG  
CGTGGTACCCTGCCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACG  
TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGGCCAAATC  
TTGTGACAAAACACATGCCCACCGTGCCTACAGCCTGAACTCCTGGGG  
GACCGTCAGTCTCCTCTTCCCCCAAAACCAAGGACACCCCTCATGATCTCCC  
GGACCCCTGAGGTACATGCGTGGTGGACGTGAGCCACGAAGACCTGAG  
GTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAA  
GCCGCGGGAGGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCG  
TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC  
AAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCC  
CCGAGAACACAGGTGTACACCCCTGCCCTGGTCAAAGGCTTCTACAGCAGCTCACCG  
ACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACAGCAGCTCACCG  
GTGGAGTGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCCTC  
CCGTGCTGGACTCCGACGGCTCCTCTACAGCAAGCTCACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTGATGCATGAGGCT  
CTGCACAACCACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA  
(SEQ ID NO: 184).

**[0406]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 185; SEQ ID NO: 186; and SEQ ID NO: 187 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 41 or the light chain sequence of SEQ ID NO: 42.

**[0407]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or

more of the polynucleotide sequences of SEQ ID NO: 188; SEQ ID NO: 189; and SEQ ID NO: 190 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 43 or the heavy chain sequence of SEQ ID NO: 44.

**[0408]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 181 encoding the light chain variable sequence of SEQ ID NO: 41; the polynucleotide SEQ ID NO: 182 encoding the light chain sequence of SEQ ID NO: 42; the polynucleotide SEQ ID NO: 183 encoding the heavy chain variable sequence of SEQ ID NO: 43; the polynucleotide SEQ ID NO: 184 encoding the heavy chain sequence of SEQ ID NO: 44; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 185; SEQ ID NO: 186; and SEQ ID NO: 187) of the light chain variable sequence of SEQ ID NO: 41 or the light chain sequence of SEQ ID NO: 42; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 188; SEQ ID NO: 189; and SEQ ID NO: 190) of the heavy chain variable sequence of SEQ ID NO: 43 or the heavy chain sequence of SEQ ID NO: 44.

**[0409]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab5, the polynucleotides encoding the full length Ab5 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 182 encoding the light chain sequence of SEQ ID NO: 42 and the polynucleotide SEQ ID NO: 184 encoding the heavy chain sequence of SEQ ID NO: 44.

**[0410]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast Pichia. Suitable Pichia species include, but are not limited to, *Pichia pastoris*. In one

embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab5 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab5 or Fab fragments thereof may be produced *via* expression of Ab5 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

Antibody Ab6

[0411] The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 51:

[0412] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCCTCAATTGCCAGGCCAGTCAGAGTGTTCATCATAACACCTACCT  
GGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATGATG  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTCAAGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTGGCAGTTATGATTGACTAATGGTATTGTTTCTGGCGGAG  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 191).

[0413] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 52:

[0414] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCCTCAATTGCCAGGCCAGTCAGAGTGTTCATCATAACACCTACCT  
GGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATGATG  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTCAAGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT

ACTGTCTGGGCAGTTATGATTGTACTAATGGTATTGTTTGGCGAG  
GAACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAATCTGGAACACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCCTGAGCTCGCCCCGTACA  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 192).

[0415] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 53:

[0416] GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGG  
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGAATCGACCTCAGTGGCTACTACAT  
GAACCTGGGTCCCGTCAGGCTCCAGGGAAGGGGCTGGAGTGGTCGGAGTCATTG  
GTATTAATGGTGCCACATACTACCGAGCTGGCGAAAGGCCGATTACCATC  
TCCAGAGACAATTCCAAGACCACGGGTATCTTCAAATGAACAGCCTGAGAGC  
TGAGGACACTGCTGTATTCTGTCTAGAGGGACATCTGGGCCAAGGGA  
CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 193).

[0417] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 54:

GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCT  
GAGACTCTCCTGTGCAGTCTCTGGAATCGACCTCAGTGGCTACTACATGAACCTG  
GGTCCCGTCAGGCTCCAGGGAAGGGGCTGGAGTGGTCGGAGTCATTGGTATTA  
ATGGTGCCACATACTACCGAGCTGGCGAAAGGCCGATTACCATCTCCAGA  
GACAATTCCAAGACCACGGGTATCTTCAAATGAACAGCCTGAGAGCTGAGGA  
CACTGCTGTATTCTGTCTAGAGGGACATCTGGGCCAAGGGACCCCTCG  
TCACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTCCCCCTGGCACCC  
CCTCCAAGAGCACCTCTGGGGCACAGCGGCCCTGGCTGCCTGGTCAAGGAC  
TACTTCCCCGAACCGGTGACGGTGTGGAACTCAGGCGCCCTGACCAGCGG

CGTGCACACCTTCCCGCTGCTTACAGTCCTCAGGACTCTACTCCCTCAGCAG  
CGTGGTACCGTGCCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACG  
TGAATCACAAGCCCAGCAACACCAAGGTGGACGCGAGAGTTGAGCCCAAATCT  
TGTGACAAAACACTCACACATGCCACCCTGCCCCAGCACCTGAACTCCTGGGGGG  
ACCGTCAGTCTCCTCTTCCCCAAAACCCAAGGACACCCTCATGATCTCCCG  
GACCCCTGAGGTCACATGCGTGGTGGACGTGAGCCACGAAGACCCGTGAGG  
TCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAG  
CCGCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGT  
CCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA  
AAGCCCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCC  
CGAGAACACAGGTGTACACCCTGCCCATCCCGGAGGAGATGACCAAGA  
ACCAGGTCACTGACCTGCCTGGTCAAAGGCTTCTACAGCAAGCTCACCGTGGACA  
GTGGAGTGGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCCTC  
CCGTGCTGGACTCCGACGGCTCCTCTCCTACAGCAAGCTCACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTATGCATGAGGCT  
CTGCACAACCACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA  
(SEQ ID NO: 194).

**[0418]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 195; SEQ ID NO: 196; and SEQ ID NO: 197 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 51 or the light chain sequence of SEQ ID NO: 52.

**[0419]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 198; SEQ ID NO: 199; and SEQ ID NO: 200 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 53 or the heavy chain sequence of SEQ ID NO: 54.

**[0420]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 191 encoding the light chain variable sequence of SEQ ID NO: 51; the polynucleotide SEQ ID NO: 192 encoding the light chain sequence of SEQ ID NO: 52; the polynucleotide SEQ ID NO: 193 encoding the heavy chain variable sequence of SEQ ID NO: 53; the polynucleotide SEQ ID NO: 194 encoding the heavy chain sequence of SEQ ID NO: 54; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 195; SEQ ID NO: 196; and SEQ ID NO: 197) of the light chain variable sequence of SEQ ID NO: 51 or the light chain sequence of SEQ ID NO: 52; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 198; SEQ ID NO: 199; and SEQ ID NO: 200) of the heavy chain variable sequence of SEQ ID NO: 53 or the heavy chain sequence of SEQ ID NO: 54.

**[0421]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab6, the polynucleotides encoding the full length Ab6 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 192 encoding the light chain sequence of SEQ ID NO: 52 and the polynucleotide SEQ ID NO: 194 encoding the heavy chain sequence of SEQ ID NO: 54.

**[0422]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast Pichia. Suitable Pichia species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab6 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab6 or Fab fragments thereof may be produced *via* expression of Ab6

polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

Antibody Ab7

**[0423]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 61:

**[0424]** CAAGTGCTGACCCAGACTGCATCCCCGTGTGCAGCTGTGGAAAG  
CACAGTCACCCTCAATTGCCAGGCCAGTCAGAGTGTAAATTACAACCTACCT  
TGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCTCATCGCGATTCAAAGGCAGTGGATCTGGG  
ACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTAC  
TACTGTCTAGGCAGTTATGACTGTAGTACTGGTATTGTTGTTTCGGCGGA  
GGGACCGAGGTGGTGGTCAAACGT (SEQ ID NO: 201).

**[0425]** In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 62:

**[0426]** CAAGTGCTGACCCAGACTGCATCCCCGTGTGCAGCTGTGGAAAG  
CACAGTCACCCTCAATTGCCAGGCCAGTCAGAGTGTAAATTACAACCTACCT  
TGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCTCATCGCGATTCAAAGGCAGTGGATCTGGG  
ACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTAC  
TACTGTCTAGGCAGTTATGACTGTAGTACTGGTATTGTTGTTTCGGCGGA  
GGGACCGAGGTGGTGGTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGCCTGCTG  
AATAACTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT

CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA  
AAGAGCTAACAGGGAGAGTGTAG (SEQ ID NO: 202).

[0427] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 63:

[0428] CAGGAGCAGCTGAAGGAGTCCGGGGTCGCCTGGTCACGCCTGGGA  
CATCCCTGACACTCACCTGCACCGTCTCTGGAATCGACCTCAGTAACCACTACA  
TGCAATGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATGGAGTCGTT  
GGTATTAATGGTCGCACATACTACCGAGCTGGCGAAAGGCCGATTACCAT  
CTCCAGAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGGCTGACAACCG  
AGGACACGGCCACCTATTCTGTGCCAGAGGGACATCTGGGCCAGGCACC  
CTGGTCACCGTCTCGAGC (SEQ ID NO: 203).

[0429] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 64:

CAGGAGCAGCTGAAGGAGTCCGGGGTCGCCTGGTCACGCCTGGACATCCCT  
GACACTCACCTGCACCGTCTCTGGAATCGACCTCAGTAACCACTACATGCAAT  
GGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATGGAGTCGTTGGTATT  
AATGGTCGCACATACTACCGAGCTGGCGAAAGGCCGATTACCATCTCCAG  
AACCTCGTCGACCACGGTGGATCTGAAAATGACCAGGCTGACAACCGAGGACA  
CGGCCACCTATTCTGTGCCAGAGGGACATCTGGGCCAGGCACCCCTGGTC  
ACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTCCCCCTGGCACCCCTCC  
TCCAAGAGCACCTCTGGGGCACAGCGGCCCTGGCTGCCTGGTCAAGGACTA  
CTTCCCCGAACCGGTGACGGTGTGGAACTCAGGCGCCCTGACCAGCGCG  
TGCACACCTTCCGGCTGTCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCG  
TGGTGACCGTGCCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACGTG  
AATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCAAATCTT  
GTGACAAAACACACATGCCACCAGTGCCTGACCTGAACCTCCTGGGGGGA

CCGTCAGTCTCCTCTCCCCAAAACCCAAGGACACCCTCATGATCTCCGG  
ACCCCTGAGGTACATGCGTGGTGGACGTGAGCCACGAAGACCCTGAGGT  
CAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC  
CGCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTC  
CTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA  
AGCCCTCCCAGCCCCATCGAGAAAACCCTCAGCAAAGCCAAGGGCAGCCCC  
GAGAACACAGGTGTACACCCCTGCCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGT  
GGAGTGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCCCTCCC  
GTGCTGGACTCCGACGGCTCCTCTCCTCTACAGCAAGCTACCGTGGACAAG  
AGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTATGCATGAGGCTCT  
GCACAACCACACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA (SEQ  
ID NO: 204).

**[0430]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 205; SEQ ID NO: 206; and SEQ ID NO: 207 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 61 or the light chain sequence of SEQ ID NO: 62.

**[0431]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 208; SEQ ID NO: 209; and SEQ ID NO: 210 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 63 or the heavy chain sequence of SEQ ID NO: 64.

**[0432]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the

polynucleotide SEQ ID NO: 201 encoding the light chain variable sequence of SEQ ID NO: 61; the polynucleotide SEQ ID NO: 202 encoding the light chain sequence of SEQ ID NO: 62; the polynucleotide SEQ ID NO: 203 encoding the heavy chain variable sequence of SEQ ID NO: 63; the polynucleotide SEQ ID NO: 204 encoding the heavy chain sequence of SEQ ID NO: 64; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 205; SEQ ID NO: 206; and SEQ ID NO: 207) of the light chain variable sequence of SEQ ID NO: 61 or the light chain sequence of SEQ ID NO: 62; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 208; SEQ ID NO: 209; and SEQ ID NO: 210) of the heavy chain variable sequence of SEQ ID NO: 63 or the heavy chain sequence of SEQ ID NO: 64.

**[0433]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab7, the polynucleotides encoding the full length Ab7 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 202 encoding the light chain sequence of SEQ ID NO: 62 and the polynucleotide SEQ ID NO: 204 encoding the heavy chain sequence of SEQ ID NO: 64.

**[0434]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast *Pichia*. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab7 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab7 or Fab fragments thereof may be produced *via* expression of Ab7 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

Antibody Ab8

[0435] The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 71:

[0436] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTTCACAATTACAACCTACCT  
GCCTGGTATCAGCAGAAACCAGGGAAAGTCCTAAGCAACTGATCTATTCTAC  
ATCCACTCTGGCATCTGGGTCCCATCTCGTTCAGTGGCAGTGGATCTGGGAC  
AGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTA  
CTGTCTGGCAGTTATGATTGTAGTACTGGTGATTGTTTGTTCGGCGGAGG  
AACCAAGGTGGAAATCAAACGT (SEQ ID NO: 211).

[0437] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 72:

[0438] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAGTGTTCACAATTACAACCTACCT  
GCCTGGTATCAGCAGAAACCAGGGAAAGTCCTAAGCAACTGATCTATTCTAC  
ATCCACTCTGGCATCTGGGTCCCATCTCGTTCAGTGGCAGTGGATCTGGGAC  
AGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTA  
CTGTCTGGCAGTTATGATTGTAGTACTGGTGATTGTTTGTTCGGCGGAGG  
AACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCC  
GCCATCTGATGAGCAGTTGAAATCTGGAACCTGCCTCTGTTGTGCCTGCTGAA  
TAACCTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCTCC  
AATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCAC  
CTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC  
AAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAA  
GAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 212).

[0439] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 73:

[0440] GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGG  
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGAATCGACCTCAGTAACCACTACAT  
GCAATGGGTCCCGTCAGGCTCCAGGGAAAGGGGCTGGAGTGGTCCGGAGTCGTTG  
GTATCAATGGTCGACATACTACGCGAGCTGGCGAAAGGCCGATTCAACCATC  
TCCAGAGACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGC  
TGAGGACACTGCTGTGTATTCTGTGCTAGAGGGACATCTGGGCCAAGGGA  
CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 213).

[0441] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 74:

GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCT  
GAGACTCTCCTGTGCAGTCTCTGGAATCGACCTCAGTAACCACTACATGCAATG  
GGTCCGTAGGCTCCAGGGAAAGGGGCTGGAGTGGTCCGGAGTCGTTGGTATCA  
ATGGTCGCACATACTACGCGAGCTGGCGAAAGGCCGATTCAACCATCTCCAGA  
GACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGCTGAGGA  
CACTGCTGTGTATTCTGTGCTAGAGGGACATCTGGGCCAAGGGACCCTCG  
TCACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCC  
CCTCCAAGAGCACCTCTGGGGCACAGCGGCCCTGGCTGCCTGGTCAAGGAC  
TACTTCCCCGAACCGGTGACGGTGTGGAACTCAGGCGCCCTGACCAGCGG  
CGTGCACACCTTCCGGCTGCCTACAGTCCTCAGGACTCTACTCCCTCAGCAG  
CGTGGTGACCGTGCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACG  
TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGAGTTGAGGCCAAATC  
TTGTGACAAAACTCACACATGCCACCGTGCCAGCACCTGAACCTCCTGGGG  
GACCGTCAGTCTCCTCTTCCCCCAAAACCCAAAGGACACCCCATGATCTCCC  
GGACCCCTGAGGTACATGCGTGGTGGACGTGAGCCACGAAGACCCTGAG  
GTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAA  
GCCCGGGAGGAGCAGTACGCCAGCAGTACCGTGTGGTCAGCGTCCTCACCG

TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC  
AAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC  
CCGAGAACCAACAGGTGTACACCCTGCCCTGGTCAAAGGCTTCTATCCCAGCGACATGCC  
ACCAGGTAGCCTGACCTGCCCTGGTCAAAGGCTTCTATCCCAGCGACATGCC  
GTGGAGTGGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCC  
CCGTGCTGGACTCCGACGGCTCCTCTCCTACAGCAAGCTCACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTGATGCATGAGGCT  
CTGCACAACCACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA  
(SEQ ID NO: 214).

**[0442]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 215; SEQ ID NO: 216; and SEQ ID NO: 217 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 71 or the light chain sequence of SEQ ID NO: 72.

**[0443]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 218; SEQ ID NO: 219; and SEQ ID NO: 220 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 73 or the heavy chain sequence of SEQ ID NO: 74.

**[0444]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 211 encoding the light chain variable sequence of SEQ ID NO: 71; the polynucleotide SEQ ID NO: 212 encoding the light chain sequence of SEQ ID NO: 72; the polynucleotide SEQ ID NO: 213 encoding the heavy chain variable sequence of SEQ ID NO: 73; the polynucleotide SEQ ID NO: 214 encoding the heavy chain

sequence of SEQ ID NO: 74; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 215; SEQ ID NO: 216; and SEQ ID NO: 217) of the light chain variable sequence of SEQ ID NO: 71 or the light chain sequence of SEQ ID NO: 72; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 218; SEQ ID NO: 219; and SEQ ID NO: 220) of the heavy chain variable sequence of SEQ ID NO: 73 or the heavy chain sequence of SEQ ID NO: 74.

**[0445]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab8, the polynucleotides encoding the full length Ab8 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 212 encoding the light chain sequence of SEQ ID NO: 72 and the polynucleotide SEQ ID NO: 214 encoding the heavy chain sequence of SEQ ID NO: 74.

**[0446]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast *Pichia*. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab8 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab8 or Fab fragments thereof may be produced *via* expression of Ab8 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab9

**[0447]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following

polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 81:

[0448] CAAGTGCTGACCCAGACTCCATCCCCGTGTGCAGCTGTGGAAAG  
CACAGTCACCATCAATTGCCAGGCCAGTCAGAATGTTATAATAACAACCTACC  
TAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCAACTGATCTATTCT  
ACGTCCACTCTGGCATCTGGGTCTCATCGCGATTCAAGAGGCAGTGGATCTGG  
GACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTT  
ACTACTGTCTAGGCAGTTATGATTGTAGTCGTGGTATTGTTTGTTCGGCG  
GAGGGACCGAGGTGGTGGTCAAACGT (SEQ ID NO: 221).

[0449] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 82:

[0450] CAAGTGCTGACCCAGACTCCATCCCCGTGTGCAGCTGTGGAAAG  
CACAGTCACCATCAATTGCCAGGCCAGTCAGAATGTTATAATAACAACCTACC  
TAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCAACTGATCTATTCT  
ACGTCCACTCTGGCATCTGGGTCTCATCGCGATTCAAGAGGCAGTGGATCTGG  
GACACAGTTCACTCTCACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTT  
ACTACTGTCTAGGCAGTTATGATTGTAGTCGTGGTATTGTTTGTTCGGCG  
GAGGGACCGAGGTGGTGGTCAAACGTACGGTGGCTGCACCATCTGTCTTCATC  
TTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGCCTG  
CTGAATAACTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGC  
CCTCCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGAC  
AGCACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGA  
AACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCTGAGCTCGCCCGTC  
ACAAAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 222).

[0451] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 83:

[0452] CAGTCGCTGGAGGAGTCCGGGGTCGCCTGGTCACGCCTGGACACC  
CCTGACACTCACCTGCACAGTCTCTGGAATCGGCCTCAGTAGCTACTACATGCA

GTGGGTCCGCCAGTCTCCAGGGAGGGGGCTGGAATGGATCGGAGTCATTGGTA  
GTGATGGTAAGACATACTACGCGACCTGGCGAAAGGCCGATTCACCATCTCC  
AAGACCTCGTCGACCACGGTGGATCTGAGAATGCCAGTCTGACAACCGAGGA  
CACGGCCACCTATTCTGTACCAGAGGGGACATCTGGGGCCGGGGACCCTCG  
TCACCGTCTCGAGC (SEQ ID NO: 223).

**[0453]** In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 84:

CAGTCGCTGGAGGAGTCCGGGGTCGCCTGGTCACGCCTGGACACCCCTGAC  
ACTCACCTGCACAGTCTCTGGAATCGCCTCAGTAGCTACTACATGCAGTGGGT  
CCGCCAGTCTCCAGGGAGGGGGCTGGAATGGATCGGAGTCATTGGTAGTGATG  
GTAAGACATACTACGCGACCTGGCGAAAGGCCGATTCACCATCTCCAAGACC  
TCGTCGACCACGGTGGATCTGAGAATGCCAGTCTGACAACCGAGGACACGGC  
CACCTATTCTGTACCAGAGGGGACATCTGGGGCCGGGGACCCTCGTCACCG  
TCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCCCTCCTCCA  
AGAGCACCTCTGGGGCACAGCGGCCCTGGCCTGGTCAAGGACTACTTC  
CCCGAACCGGTGACGGTGTGGAACTCAGCGCCCTGACCAGCGCGTGCA  
CACCTTCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG  
GACCGTGCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACGTGAATC  
ACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCAAATCTGTGA  
CAAAACTCACACATGCCACCGTGCCCAGCACCTGAACCTCCTGGGGGACCGT  
CAGTCTCCTCTTCCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCC  
CTGAGGTCACATCGTGGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG  
TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG  
GGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGC  
ACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAGGTCTCCAACAAAGC  
CCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCCCGAG  
AACACAGGTGTACACCCCTGCCCTGCCCCATCCGGGAGGAGATGACCAAGAAC  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTGGA  
GTGGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTG

CTGGACTCCGACGGCTCCTCTTCCTCTACAGCAAGCTACCGTGGACAAGAGC  
AGGTGGCAGCAGGGAACGTCTCATGCTCCGTGATGCATGAGGCTTGCA  
CAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGTAAATGA (SEQ ID  
NO: 224).

**[0454]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 225; SEQ ID NO: 226; and SEQ ID NO: 227 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 81 or the light chain sequence of SEQ ID NO: 82.

**[0455]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 228; SEQ ID NO: 229; and SEQ ID NO: 230 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 83 or the heavy chain sequence of SEQ ID NO: 84.

**[0456]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 221 encoding the light chain variable sequence of SEQ ID NO: 81; the polynucleotide SEQ ID NO: 222 encoding the light chain sequence of SEQ ID NO: 82; the polynucleotide SEQ ID NO: 223 encoding the heavy chain variable sequence of SEQ ID NO: 83; the polynucleotide SEQ ID NO: 224 encoding the heavy chain sequence of SEQ ID NO: 84; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 225; SEQ ID NO: 226; and SEQ ID NO: 227) of the light chain variable sequence of SEQ ID NO: 81 or the light chain sequence of SEQ ID NO: 82; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 228;

SEQ ID NO: 229; and SEQ ID NO: 230) of the heavy chain variable sequence of SEQ ID NO: 83 or the heavy chain sequence of SEQ ID NO: 84.

**[0457]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab9, the polynucleotides encoding the full length Ab9 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 222 encoding the light chain sequence of SEQ ID NO: 82 and the polynucleotide SEQ ID NO: 224 encoding the heavy chain sequence of SEQ ID NO: 84.

**[0458]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast *Pichia*. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab9 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab9 or Fab fragments thereof may be produced *via* expression of Ab9 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab10

**[0459]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 91:

**[0460]** CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAATGTTACAATAACAACCTACCT

AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTCAGTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTGGCAGTTATGATTGTAGTCGTGGTATTGTTTGTTCGGCGGAG  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 231).

[0461] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 92:

[0462] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCAGGCCAGTCAGAATGTTACAATAACAACACTACCT  
AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTCAGTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTGGCAGTTATGATTGTAGTCGTGGTATTGTTTGTTCGGCGGAG  
GAACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 232).

[0463] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 93:

[0464] GAGGTGCAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGCCTGGGG  
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGAATCGGCCTCAGTAGCTACTACAT  
GCAATGGGTCCGTCAAGGCTCCAGGGAAAGGGCTGGAGTGGTCGGAGTCATTG  
GTAGTGATGGTAAGACATACTACGCGACCTGGCGAAAGGCCGATTCAACCATC  
TCCAGAGACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGC

TGAGGACACTGCTGTATTCTGTACCAAGAGGGACATCTGGGGCCAAGGGA  
CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 233).

[0465] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 94:

GAGGTGCAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGCCTGGGGGTCCCT  
GAGACTCTCCTGTGCAGTCTCTGGAATCGGCCTCAGTAGCTACTACATGCAATG  
GGTCCGTCAGGCTCCAGGAAGGGCTGGAGTGGTCGGAGTCATTGGTAGTG  
ATGGTAAGACATACTACGCGACCTGGCGAAAGGCCGATTACCATCTCCAGA  
GACAATTCCAAGACCACGGTGTATCTCAAATGAACAGCCTGAGAGCTGAGGA  
CACTGCTGTGTATTCTGTACCAGAGGGACATCTGGGGCCAAGGGACCCTCG  
TCACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCC  
CCTCCAAGAGCACCTCTGGGGCACAGCGCCCTGGCTGCCTGGTCAAGGAC  
TACTTCCCCGAACCGGTACGGTGTGGAACTCAGGCCTGACCAGCGG  
CGTGCACACCTCCCGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAG  
CGTGGTGACCGTGCCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACG  
TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCAAATC  
TTGTGACAAAACACACATGCCACCAGTGGCCAGCACCTGAACTCCTGGGG  
GACCGTCAGTCTCCTCTCCCCAAAACCAAGGACACCCTCATGATCTCCC  
GGACCCCTGAGGTACATGCCGTGGTGGACGTGAGCCACGAAGACCCCTGAG  
GTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAA  
GCCGCGGGAGGAGCAGTACGCCAGCAGTACCGTGTGGTCAGCGTCCTCACCG  
TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAGGTCTCCAAC  
AAAGCCCTCCAGCCCCATCGAGAAAACCCTCAGGAAAGCCAAAGGGCAGCC  
CCGAGAACACAGGTGTACACCCTGCCCTCCAGGCTCTATCCCAGCGACATGCC  
ACCAGGTACGCCGTGACCTGCCGTGGTCAAAGGCTCTATCCCAGCGACATGCC  
GTGGAGTGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCC  
CCGTGCTGGACTCCGACGGCTCCTCTACAGCAAGCTCACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTGATGCATGAGGCT

CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGTAAATGA  
(SEQ ID NO: 234).

**[0466]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 235; SEQ ID NO: 236; and SEQ ID NO: 237 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 91 or the light chain sequence of SEQ ID NO: 92.

**[0467]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 238; SEQ ID NO: 239; and SEQ ID NO: 240 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 93 or the heavy chain sequence of SEQ ID NO: 94.

**[0468]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 231 encoding the light chain variable sequence of SEQ ID NO: 91; the polynucleotide SEQ ID NO: 232 encoding the light chain sequence of SEQ ID NO: 92; the polynucleotide SEQ ID NO: 233 encoding the heavy chain variable sequence of SEQ ID NO: 93; the polynucleotide SEQ ID NO: 234 encoding the heavy chain sequence of SEQ ID NO: 94; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 235; SEQ ID NO: 236; and SEQ ID NO: 237) of the light chain variable sequence of SEQ ID NO: 91 or the light chain sequence of SEQ ID NO: 92; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 238; SEQ ID NO: 239; and SEQ ID NO: 240) of the heavy chain variable sequence of SEQ ID NO: 93 or the heavy chain sequence of SEQ ID NO: 94.

**[0469]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab10, the polynucleotides encoding the full length Ab10 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 232 encoding the light chain sequence of SEQ ID NO: 92 and the polynucleotide SEQ ID NO: 234 encoding the heavy chain sequence of SEQ ID NO: 94.

**[0470]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast *Pichia*. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab10 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab10 or Fab fragments thereof may be produced *via* expression of Ab10 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab11

**[0471]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 101:

**[0472]** CAGGTGCTGACCCAGACTGCATCCCCGTGTCTCCAGCTGTGGGAAG  
CACAGTCACCATCAATTGCCGGGCCAGTCAGAGTGTATTATAACAACTACCT  
AGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGG

ACACAGTTCACTCTACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTAC  
TACTGTCTAGGCAGTTATGATTGTAGTAATGGTATTGTTGTTTCGGCGGA  
GGGACCGAGGTGGTGGTCAAACGT (SEQ ID NO: 241).

[0473] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 102:

[0474] CAGGTGCTGACCCAGACTGCATCCCCGTGTCTCCAGCTGTGGGAAG  
CACAGTCACCATCAATTGCCGGGCCAGTCAGAGTGTATTATAACAACACTACCT  
AGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCTCATCGCGTTCAAAGGCAGTGGATCTGGG  
ACACAGTTCACTCTACCATCAGCGACGTGCAGTGTGACGATGCTGCCACTTAC  
TACTGTCTAGGCAGTTATGATTGTAGTAATGGTATTGTTGTTTCGGCGGA  
GGGACCGAGGTGGTGGTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAACTTGGAACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCTGAGCTCGCCCGTCACA  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 242).

[0475] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 103:

[0476] CAGTCGCTGGAGGAGTCCGGGGTCGCCTGGTCACGCCTGGAGGATC  
CCTGACACTCACCTGCACAGTCTCTGGAATCGACGTCACTAACTACTATATGCA  
ATGGGTCCGCCAGGCTCCAGGGAAAGGGCTGGAATGGATCGGAGTCATTGGTG  
TGAATGGTAAGAGATACTACGCGAGCTGGCGAAAGGCCATTACCATCTCC  
AAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAAGTCTGACAACCGAGGA  
CACGGCCACCTATTCTGTGCCAGAGGCGACATCTGGGGCCGGGACCCTCG  
TCACCGTCTCGAGC (SEQ ID NO: 243).

[0477] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 104:

CAGTCGCTGGAGGAGTCCGGGGTCGCCTGGTCACGCCTGGAGGATCCCTGAC  
ACTCACCTGCACAGTCTCTGGAATCGACGTCACTAACTACTATATGCAATGGGT  
CCGCCAGGCTCCAGGGAAAGGGGCTGGAATGGATCGGAGTCATTGGTGTGAATG  
GTAAGAGATACTACCGCGAGCTGGCGAAAGGCCGATTCACCATCTCCAAAACC  
TCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAACCGAGGACACGGC  
CACCTATTCTGTGCCAGAGGCGACATCTGGGGCCGGGACCCTCGTCACCG  
TCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCCCTCTCCA  
AGAGCACCTCTGGGGCACAGCGCCCTGGCTGCCTGGTCAAGGACTACTTC  
CCCGAACCGGTGACGGTGTGGAACTCAGGCGCCCTGACCAGCGCGTGCA  
CACCTTCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG  
GACCGTGCCTCCAGCAGCTGGGCACCCAGACCTACATCTGCAACGTGAATC  
ACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCAAATCTTGTGA  
CAAIAACTCACACATGCCACCGTGCCCAGCACCTGAACCTCCTGGGGGACCGT  
CAGTCTCCTCTTCCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCC  
CTGAGGTCACATGCGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAG  
TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG  
GGAGGAGCAGTACGCCAGCACGTACCGTGTGGCAGCGTCCCTCACCGTCTGC  
ACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACAAAGC  
CCTCCCAGCCCCATCGAGAAAACCCTCAGCCAAAGCCAAAGGGCAGCCCCGAG  
AACACAGGTGTACACCCCTGCCCATCCGGAGGAGATGACCAAGAACCAAG  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACAGCGACATGCCGTGGA  
GTGGGAGAGCAATGGCAGCCGGAGAACAAACTACAAGACCCACGCCTCCCGT  
CTGGACTCCGACGGCTCTTCTACAGCAAGCTCACCGTGGACAAGAGC  
AGGTGGCAGCAGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTTGCA  
CAACCACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA (SEQ ID  
NO: 244).

[0478] In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 245; SEQ ID NO: 246; and SEQ ID NO: 247 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 101 or the light chain sequence of SEQ ID NO: 102.

[0479] In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 248; SEQ ID NO: 249; and SEQ ID NO: 250 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 103 or the heavy chain sequence of SEQ ID NO: 104.

[0480] The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 241 encoding the light chain variable sequence of SEQ ID NO: 101; the polynucleotide SEQ ID NO: 242 encoding the light chain sequence of SEQ ID NO: 102; the polynucleotide SEQ ID NO: 243 encoding the heavy chain variable sequence of SEQ ID NO: 103; the polynucleotide SEQ ID NO: 244 encoding the heavy chain sequence of SEQ ID NO: 104; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 245; SEQ ID NO: 246; and SEQ ID NO: 247) of the light chain variable sequence of SEQ ID NO: 101 or the light chain sequence of SEQ ID NO: 102; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 248; SEQ ID NO: 249; and SEQ ID NO: 250) of the heavy chain variable sequence of SEQ ID NO: 103 or the heavy chain sequence of SEQ ID NO: 104.

[0481] In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab11,

the polynucleotides encoding the full length Ab11 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 242 encoding the light chain sequence of SEQ ID NO: 102 and the polynucleotide SEQ ID NO: 244 encoding the heavy chain sequence of SEQ ID NO: 104.

**[0482]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast Pichia. Suitable Pichia species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab11 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab11 or Fab fragments thereof may be produced *via* expression of Ab11 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable Pichia species include, but are not limited to, *Pichia pastoris*.

#### Antibody Ab12

**[0483]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 111:

**[0484]** CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCATCAATTGCCGGGCCAGTCAGAGTGTACTATAACAACTACCT  
AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCCTCGTTCAAGCAACTGATCTATTCTA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTGGCAGTTATGATTGTAGTAATGGTGATTGTTTGTTCGGCGGAG  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 251).

[0485] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 112:

[0486] CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCCTCAATTGCCGGGCCAGTCAGAGTGTACTATAACAACTACCT  
AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCCTCGTTCAGTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTGGCAGTTATGATTGTAGTAATGGTATTGTTGTTGGCAGGAG  
GAACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTC  
CCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 252).

[0487] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 113:

[0488] GAGGTGCAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGCCTGGGG  
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGAATCGACGTCACTAACTACTACAT  
GCAATGGGTCCGTAGGCTCCAGGGAAAGGGCTGGAGTGGTCGGAGTCATTG  
GTGTGAATGGTAAGAGATACTACCGCAGCTGGCGAAAGGCCGATTACCACATC  
TCCAGAGACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGC  
TGAGGACACTGCTGTATTCTGTGCCAGAGGGACATCTGGGCCAAGGGA  
CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 253).

[0489] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 114:

GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTGGTCCAGCCTGGGGGTCCCT  
GAGACTCTCCTGTGCAGTCTCTGGAATCGACGTCACTAACTACTACATGCAATG  
GGTCGTCAGGCTCCAGGGAAAGGGCTGGAGTGGTCGGAGTCATTGGTGTGA  
ATGGTAAGAGATACTACGCGAGCTGGCGAAAGGCCATTACCATCTCCAGA  
GACAATTCCAAGACCACGGTGTATCTCAAATGAACAGCCTGAGAGCTGAGGA  
CACTGCTGTGTATTCTGTGCCAGAGGGACATCTGGGCCAAGGGACCCTCG  
TCACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTTCCCCCTGGCACCCCT  
CCTCCAAGAGCACCTCTGGGGCACAGCGGCCCTGGCTGCCTGGTCAAGGAC  
TACTCCCCGAACCGGTGACGGTGTGGAACTCAGGCCTCAGGACTCTACTCCCTCAGCAG  
CGTGGTGACCGTGCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACG  
TGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGGCCAAATC  
TTGTGACAAAACTCACACATGCCACCGTGCCTACAGCCTCAGGACTCTACTCCCTCAGCAG  
GACCGTCAGTCTCCTCTTCCCCCAAAACCCAAGGACACCCCTCATGATCTCCC  
GGACCCCTGAGGTACATGCGTGGTGGACGTGAGCCACGAAGACCCCTGAG  
GTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAA  
GCCGCGGGAGGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCG  
TCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAAC  
AAAGCCCTCCCAGCCCCATCGAGAAAACCCTCTCAAAGCCAAGGGCAGCC  
CCGAGAACACAGGTGTACCCCTGCCCTCCAGGAGATGACCAAGA  
ACCAGGTAGCCTGACCTGCCTGGTCAAAGGCTTCTACAGCAAGCTACCGTGGACA  
GTGGAGTGGAGAGCAATGGCAGCCGGAGAACAAACTACAAGACCAACGCCTC  
CCGTGCTGGACTCCGACGGCTCCTTCTCCTACAGCAAGCTACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCTCATGCTCCGTATGCATGAGGCT  
CTGCACAAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGTAAATGA  
(SEQ ID NO: 254).

**[0490]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 255; SEQ ID NO: 256; and SEQ ID NO: 257 which correspond to polynucleotides encoding the complementarity-determining

regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 111 or the light chain sequence of SEQ ID NO: 112.

**[0491]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 258; SEQ ID NO: 259; and SEQ ID NO: 260 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 113 or the heavy chain sequence of SEQ ID NO: 114.

**[0492]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 251 encoding the light chain variable sequence of SEQ ID NO: 111; the polynucleotide SEQ ID NO: 252 encoding the light chain sequence of SEQ ID NO: 112; the polynucleotide SEQ ID NO: 253 encoding the heavy chain variable sequence of SEQ ID NO: 113; the polynucleotide SEQ ID NO: 254 encoding the heavy chain sequence of SEQ ID NO: 114; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 255; SEQ ID NO: 256; and SEQ ID NO: 257) of the light chain variable sequence of SEQ ID NO: 111 or the light chain sequence of SEQ ID NO: 112; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 258; SEQ ID NO: 259; and SEQ ID NO: 260) of the heavy chain variable sequence of SEQ ID NO: 113 or the heavy chain sequence of SEQ ID NO: 114.

**[0493]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab12, the polynucleotides encoding the full length Ab12 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 252 encoding the light chain sequence of SEQ ID NO: 112 and the polynucleotide SEQ ID NO: 254 encoding the heavy chain sequence of SEQ ID NO: 114.

**[0494]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast Pichia. Suitable Pichia species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab12 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab12 or Fab fragments thereof may be produced *via* expression of Ab12 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable Pichia species include, but are not limited to, *Pichia pastoris*.

Antibody Ab13

**[0495]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 121:

**[0496]** GCCATCGTGTGACCCAGACTCCATCTTCCAAGTCTGTCCCTGTGGGA  
GACACAGTCACCATCAATTGCCAGGCCAGTGAGAGTCTTATAATAACAAACGC  
CTTGGCCTGGTTTCAGCAGAAACCAGGGCAGCCTCCCAAGCGCCTGATCTATG  
ATGCATCCAAACTGGCATCTGGGTCATCGCGGTTAGTGGCGGTGGTCT  
GGGACACAGTTCACTCTCACCATCAGTGGCGTGCAGTGTGACGATGCTGCCAC  
TTACTACTGTGGAGGCTACAGAAGTGATAGTGTGATGGTGTGCTTCGCCGG  
AGGGACCGAGGTGGTGGTCAAACGT (SEQ ID NO: 261).

**[0497]** In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 122:

[0498] GCCATCGTATGCCAGACTCCATCTCCAAGTCTGTCCCTGTGGGA  
GACACAGTCACCATCAATTGCCAGGCCAGTGAGAGTCTTATAATAACAAACGC  
CTTGGCCTGGTTTCAGCAGAAACCAGGGCAGCCTCCCAAGCGCCTGATCTATG  
ATGCATCCAAACTGGCATCTGGGTCACCATCAGTGGCGTGCAGTGTGACGATGCTGCCAC  
GGGACACAGTTCACTCTCACCATCAGTGGCGTGCAGTGTGACGATGCTGCCAC  
TTACTACTGTGGAGGCTACAGAAGTGATAGTGTGATGGTGTGCTTCGCCGG  
AGGGACCGAGGTGGTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCT  
TCCC GCCATCTGATGAGCAGTTGAAATCTGGA ACTGCCTCTGTTGTGCTGC  
TGAATAACTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCC  
CTCCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACA  
GCACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAA  
ACACAAAGTCTACGCCCTGCGAAGTCACCCATCAGGGCCTGAGCTGCCCGTCA  
CAAAGAGCTCAACAGGGAGAGTGTAG (SEQ ID NO: 262).

[0499] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 123:

[0500] CAGTCGGTGGAGGAGTCCGGGGAGGCCTGGTCCAGCCTGAGGGAT  
CCCTGACACTCACCTGCACAGCCTCTGGATTGACTTCAGTAGCAATGCAATGT  
GGTGGGTCCGCCAGGCTCCAGGAAGGGCTGGAGTGGATGGATGCATTTCAT  
AATGGTGATGGCAGCACATACTACCGAGCTGGTGAATGGCCGATTCTCCAT  
CTCCAAAACCTCGTCGACCACGGTACTCTGCAACTGAATAGTCTGACAGTCG  
CGGACACGCCACGTATTATTGTGCGAGAGATCTGACTTGTGGGGCCCGGGC  
ACCCTCGTCACCGTCTCGAGC (SEQ ID NO: 263).

[0501] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 124:

CAGTCGGTGGAGGAGTCCGGGGAGGCCTGGTCCAGCCTGAGGGATCCCTGAC  
ACTCACCTGCACAGCCTCTGGATTGACTTCAGTAGCAATGCAATGTGGTGGGT  
CCGCCAGGCTCCAGGAAGGGCTGGAGTGGATGGATGCATTACAATGGTG  
ATGGCAGCACATACTACCGAGCTGGTGAATGGCCGATTCTCCATCTCCAAA

ACCTCGTCGACCACGGTGAECTCTGCAACTGAATAGTCTGACAGTCGCGGACAC  
GGCCACGTATTATTGTGCGAGAGAGATCTTGACTTGTGGGGCCCGGGCACCCCTCGT  
CACCGTCTCGAGCGCCTCCACCAAGGGCCCACCGGTCTCCCCCTGGCACCCCTC  
CTCCAAGAGCACCTCTGGGGCACAGCGCCCTGGCTGCCTGGTCAAGGACT  
ACTTCCCCGAACCGGTGACGGTGTGGAACTCAGCGCCCTGACCAGCGC  
GTGCACACCTTCCCGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC  
GTGGTGACCGTGCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACGT  
GAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGAGTTGAGCCAAATCT  
TGTGACAAAACTCACACATGCCACCGTGCCCAGCACCTGAACCTGGGGGG  
ACCGTCAGTCTCCTCTTCCCCAAAACCAAGGACACCCCTCATGATCTCCCG  
GACCCCTGAGGTACATGCGTGGTGGACGTGAGCCACGAAGACCCCTGAGG  
TCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAG  
CCGCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGT  
CCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCAACA  
AAGCCCTCCCAGCCCCATCGAGAAAACCCTCAAAAGCCAAAGGGCAGCCC  
CGAGAACCACAGGTGTACACCCTGCCCATCCCGGGAGGAGATGACCAAGA  
ACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACAGCGACATGCC  
GTGGAGTGGAGAGCAATGGCAGCCGGAGAACAAACTACAAGACCCACGCCTC  
CCGTGCTGGACTCCGACGGCTCCTCTACAGCAAGCTCACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTGATGCATGAGGCT  
CTGCACAACCACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA  
(SEQ ID NO: 264).

**[0502]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 265; SEQ ID NO: 266; and SEQ ID NO: 267 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 121 or the light chain sequence of SEQ ID NO: 122.

**[0503]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or

more of the polynucleotide sequences of SEQ ID NO: 268; SEQ ID NO: 269; and SEQ ID NO: 270 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 123 or the heavy chain sequence of SEQ ID NO: 124.

**[0504]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 261 encoding the light chain variable sequence of SEQ ID NO: 121; the polynucleotide SEQ ID NO: 262 encoding the light chain sequence of SEQ ID NO: 122; the polynucleotide SEQ ID NO: 263 encoding the heavy chain variable sequence of SEQ ID NO: 123; the polynucleotide SEQ ID NO: 264 encoding the heavy chain sequence of SEQ ID NO: 124; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 265; SEQ ID NO: 266; and SEQ ID NO: 267) of the light chain variable sequence of SEQ ID NO: 121 or the light chain sequence of SEQ ID NO: 122; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 268; SEQ ID NO: 269; and SEQ ID NO: 270) of the heavy chain variable sequence of SEQ ID NO: 123 or the heavy chain sequence of SEQ ID NO: 124.

**[0505]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab13, the polynucleotides encoding the full length Ab13 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 262 encoding the light chain sequence of SEQ ID NO: 122 and the polynucleotide SEQ ID NO: 264 encoding the heavy chain sequence of SEQ ID NO: 124.

**[0506]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast Pichia. Suitable Pichia species include, but are not limited to, *Pichia pastoris*. In one

embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab13 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab13 or Fab fragments thereof may be produced *via* expression of Ab13 polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

Antibody Ab14

**[0507]** The invention is further directed to polynucleotides encoding antibody polypeptides having binding specificity to CGRP. In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable light chain polypeptide sequence of SEQ ID NO: 131:

**[0508]** CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCCTCAATTGCCAGGCCAGTCAGAATGTTACAATAACAACCTACCT  
AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTCAGTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT  
ACTGTCTGGCAGTTATGATTGTAGTCGTGGTATTGTTTGTTCGGCGGAG  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 271).

**[0509]** In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the light chain polypeptide sequence of SEQ ID NO: 132:

**[0510]** CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGAC  
AGAGTCACCCTCAATTGCCAGGCCAGTCAGAATGTTACAATAACAACCTACCT  
AGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATTCTA  
CATCCACTCTGGCATCTGGGTCCCATCTCGTTCAGTGGCAGTGGATCTGGGA  
CAGATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATT

ACTGTCTGGGCAGTTATGATTGTAGTCGTGGTATTGTTTGTTCGGCGGAG  
GAACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTC  
CCGCCATCTGATGAGCAGTTGAAATCTGGAACACTGCCTCTGTTGTGCCTGCTG  
AATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCCCT  
CCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGC  
ACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAC  
ACAAAGTCTACGCCTCGAAGTCACCCATCAGGGCCTGAGCTCGCCCCGTACA  
AAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 272).

[0511] In another embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the variable heavy chain polypeptide sequence of SEQ ID NO: 133:

[0512] GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGG  
GTCCCTGAGACTCTCCTGTGCAGTCTCTGGAATCGGCCTCAGTAGCTACTACAT  
GCAATGGGTCCCGTCAGGCTCCAGGGAAGGGGCTGGAGTGGTCGGAGTCATTG  
GTAGTGATGGTAAGACATACTACGCGACCTGGCGAAAGGCCGATTACCACATC  
TCCAGAGACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGC  
TGAGGACACTGCTGTATTCTGTACCAGAGGGACATCTGGGCCAAGGG  
CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 273).

[0513] In one embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, the following polynucleotide sequence encoding the heavy chain polypeptide sequence of SEQ ID NO: 134:

GAGGTGCAGCTTGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGTCCCT  
GAGACTCTCCTGTGCAGTCTCTGGAATCGGCCTCAGTAGCTACTACATGCAATG  
GGTCCGTAGGCTCCAGGGAAGGGGCTGGAGTGGTCGGAGTCATTGGTAGTG  
ATGGTAAGACATACTACGCGACCTGGCGAAAGGCCGATTACCACATCTCCAGA  
GACAATTCCAAGACCACGGTGTATCTTCAAATGAACAGCCTGAGAGCTGAGGA  
CACTGCTGTATTCTGTACCAGAGGGACATCTGGGCCAAGGGACCCTCG  
TCACCGTCTCGAGCGCCTCCACCAAGGGCCATCGGTCTCCCCCTGGCACCC  
CCTCCAAGAGCACCTCTGGGGCACAGCGGCCCTGGCTGCCTGGTCAAGGAC  
TACTTCCCCGAACCGGTGACGGTGTGGAACTCAGGCGCCCTGACCAGCGG

CGTGCACACCTTCCCGCTGCTTACAGTCCTCAGGACTCTACTCCCTCAGCAG  
CGTGGTACCGTGCCCTCCAGCAGCTGGCACCCAGACCTACATCTGCAACG  
TGAATCACAAGCCCAGCAACACCAAGGTGGACGCGAGAGTTGAGCCCAAATCT  
TGTGACAAAACACTCACACATGCCACCAGTGGCACCTGAACTCCTGGGGGG  
ACCGTCAGTCTCCTCTTCCCCAAAACCCAAGGACACCCTCATGATCTCCCG  
GACCCCTGAGGTCACATGCGTGGTGGACGTGAGCCACGAAGACCCGTGAGG  
TCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAG  
CCGCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCCTCACCGT  
CCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA  
AAGCCCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCC  
CGAGAACACAGGTGTACACCCTGCCCATCCCGGAGGAGATGACCAAGA  
ACCAGGTAGCCTGACCTGCCTGGTCAAAGGCTTATCCCAGCGACATGCC  
GTGGAGTGGGAGAGCAATGGCAGCCGGAGAACAACTACAAGACCACGCCTC  
CCGTGCTGGACTCCGACGGCTCCTCTCCTACAGCAAGCTCACCGTGGACA  
AGAGCAGGTGGCAGCAGGGAACGTCTCATGCTCCGTATGCATGAGGCT  
CTGCACAACCACTACACGCAGAAGAGCCTCTCCGTCTCCGGTAAATGA  
(SEQ ID NO: 274).

**[0514]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 275; SEQ ID NO: 276; and SEQ ID NO: 277 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the light chain variable sequence of SEQ ID NO: 131 or the light chain sequence of SEQ ID NO: 132.

**[0515]** In a further embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one or more of the polynucleotide sequences of SEQ ID NO: 278; SEQ ID NO: 279; and SEQ ID NO: 280 which correspond to polynucleotides encoding the complementarity-determining regions (CDRs, or hypervariable regions) of the heavy chain variable sequence of SEQ ID NO: 133 or the heavy chain sequence of SEQ ID NO: 134.

**[0516]** The invention also contemplates polynucleotide sequences including one or more of the polynucleotide sequences encoding antibody fragments described herein. In one embodiment of the invention, polynucleotides encoding antibody fragments having binding specificity to CGRP comprise, or alternatively consist of, one, two, three or more, including all of the following polynucleotides encoding antibody fragments: the polynucleotide SEQ ID NO: 271 encoding the light chain variable sequence of SEQ ID NO: 131; the polynucleotide SEQ ID NO: 272 encoding the light chain sequence of SEQ ID NO: 132; the polynucleotide SEQ ID NO: 273 encoding the heavy chain variable sequence of SEQ ID NO: 133; the polynucleotide SEQ ID NO: 274 encoding the heavy chain sequence of SEQ ID NO: 134; polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 275; SEQ ID NO: 276; and SEQ ID NO: 277) of the light chain variable sequence of SEQ ID NO: 131 or the light chain sequence of SEQ ID NO: 132; and polynucleotides encoding the complementarity-determining regions (SEQ ID NO: 278; SEQ ID NO: 279; and SEQ ID NO: 280) of the heavy chain variable sequence of SEQ ID NO: 133 or the heavy chain sequence of SEQ ID NO: 134.

**[0517]** In a preferred embodiment of the invention, polynucleotides of the invention comprise, or alternatively consist of, polynucleotides encoding Fab (fragment antigen binding) fragments having binding specificity for CGRP. With respect to antibody Ab14, the polynucleotides encoding the full length Ab14 antibody comprise, or alternatively consist of, the polynucleotide SEQ ID NO: 272 encoding the light chain sequence of SEQ ID NO: 132 and the polynucleotide SEQ ID NO: 274 encoding the heavy chain sequence of SEQ ID NO: 134.

**[0518]** Another embodiment of the invention contemplates these polynucleotides incorporated into an expression vector for expression in mammalian cells such as CHO, NSO, HEK-293, or in fungal, insect, or microbial systems such as yeast cells such as the yeast Pichia. Suitable Pichia species include, but are not limited to, *Pichia pastoris*. In one embodiment of the invention described herein (*infra*), Fab fragments may be produced by enzymatic digestion (e.g., papain) of Ab14 following expression of the full-length polynucleotides in a suitable host. In another embodiment of the invention, anti-CGRP antibodies such as Ab14 or Fab fragments thereof may be produced *via* expression of Ab14

polynucleotides in mammalian cells such as CHO, NSO or HEK 293 cells, fungal, insect, or microbial systems such as yeast cells (for example diploid yeast such as diploid *Pichia*) and other yeast strains. Suitable *Pichia* species include, but are not limited to, *Pichia pastoris*.

**[0519]** In one embodiment, the invention is directed to an isolated polynucleotide comprising a polynucleotide encoding an anti-CGRP  $V_H$  antibody amino acid sequence selected from SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133, or encoding a variant thereof wherein at least one framework residue (FR residue) has been substituted with an amino acid present at the corresponding position in a rabbit anti-CGRP antibody  $V_H$  polypeptide or a conservative amino acid substitution.

**[0520]** In another embodiment, the invention is directed to an isolated polynucleotide comprising the polynucleotide sequence encoding an anti-CGRP  $V_L$  antibody amino acid sequence of 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, or 131, or encoding a variant thereof wherein at least one framework residue (FR residue) has been substituted with an amino acid present at the corresponding position in a rabbit anti-CGRP antibody  $V_L$  polypeptide or a conservative amino acid substitution.

**[0521]** In yet another embodiment, the invention is directed to one or more heterologous polynucleotides comprising a sequence encoding the polypeptides contained in SEQ ID NO:1 and SEQ ID NO:3; SEQ ID NO:11 and SEQ ID NO:13; SEQ ID NO:21 and SEQ ID NO:23; SEQ ID NO:31 and SEQ ID NO:33; SEQ ID NO:41 and SEQ ID NO:43; SEQ ID NO:51 and SEQ ID NO:53, SEQ ID NO:61 and SEQ ID NO:63; SEQ ID NO:71 and SEQ ID NO:73; SEQ ID NO:81 and SEQ ID NO:83; SEQ ID NO:91 and SEQ ID NO:93; SEQ ID NO:101 and SEQ ID NO:103; SEQ ID NO:111 and SEQ ID NO:113; SEQ ID NO:121 and SEQ ID NO:123; or SEQ ID NO:131 and SEQ ID NO:133.

**[0522]** In another embodiment, the invention is directed to an isolated polynucleotide that expresses a polypeptide containing at least one CDR polypeptide derived from an anti-CGRP antibody wherein said expressed polypeptide alone specifically binds CGRP or specifically binds CGRP when expressed in association with another polynucleotide sequence that expresses a polypeptide containing at least one CDR polypeptide derived from an anti-CGRP antibody wherein said at least one CDR is selected from those

contained in the  $V_L$  or  $V_H$  polypeptides of SEQ ID NO: 1, 3, 11, 13, 21, 23, 31, 33, 41, 43, 51, 53, 61, 63, 71, 73, 81, 83, 91, 93, 101, 103, 111, 113, 121, 123, 131, or SEQ ID NO:133.

[0523] Host cells and vectors comprising said polynucleotides are also contemplated.

[0524] The invention further contemplates vectors comprising the polynucleotide sequences encoding the variable heavy and light chain polypeptide sequences, as well as the individual complementarity-determining regions (CDRs, or hypervariable regions), as set forth herein, as well as host cells comprising said vector sequences. In one embodiment of the invention, the host cell is a yeast cell. In another embodiment of the invention, the yeast host cell belongs to the genus *Pichia*.

#### ***B-cell Screening and Isolation***

[0525] In one embodiment, the present invention contemplates the preparation and isolation of a clonal population of antigen-specific B cells that may be used for isolating at least one CGRP antigen-specific cell, which can be used to produce a monoclonal antibody against CGRP, which is specific to a desired CGRP antigen, or a nucleic acid sequence corresponding to such an antibody. Methods of preparing and isolating said clonal population of antigen-specific B cells are taught, for example, in U.S. patent publication no. US 2007/0269868 to Carvalho-Jensen *et al.*, the disclosure of which is herein incorporated by reference in its entirety. Methods of preparing and isolating said clonal population of antigen-specific B cells are also taught herein in the examples. Methods of “enriching” a cell population by size or density are known in the art. *See, e.g.*, U.S. Patent 5,627,052. These steps can be used in addition to enriching the cell population by antigen-specificity.

#### ***Methods of Humanizing Antibodies***

[0526] In another embodiment, the present invention contemplates methods for humanizing antibody heavy and light chains. Methods for humanizing antibody heavy and light chains which may be applied to anti-CGRP antibodies are taught, for example, in U.S. patent application publication no. US 2009/0022659 to Olson *et al.*, and in U.S. patent no.

7,935,340 to Garcia-Martinez *et al.*, the disclosures of each of which are herein incorporated by reference in their entireties.

***Methods of Producing Antibodies and Fragments thereof***

**[0527]** In another embodiment, the present invention contemplates methods for producing anti-CGRP antibodies and fragments thereof. Methods for producing anti-CGRP antibodies and fragments thereof secreted from polyploidal, preferably diploid or tetraploid strains of mating competent yeast are taught, for example, in U.S. patent application publication no. US 2009/0022659 to Olson *et al.*, and in U.S. patent no. 7,935,340 to Garcia-Martinez *et al.*, the disclosures of each of which are herein incorporated by reference in their entireties.

**[0528]** Other methods of producing antibodies are well known to those of ordinary skill in the art. For example, methods of producing chimeric antibodies are now well known in the art (See, for example, U.S. Patent No. 4,816,567 to Cabilly *et al.*; Morrison *et al.*, P.N.A.S. USA, 81:8651-55 (1984); Neuberger, M.S. *et al.*, Nature, 314:268-270 (1985); Boulianne, G.L. *et al.*, Nature, 312:643-46 (1984), the disclosures of each of which are herein incorporated by reference in their entireties).

**[0529]** Likewise, other methods of producing humanized antibodies are now well known in the art (See, for example, U.S. Patent Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370 to Queen *et al.*; U.S. Patent Nos. 5,225,539 and 6,548,640 to Winter; U.S. Patent Nos. 6,054,297, 6,407,213 and 6,639,055 to Carter *et al.*; U.S. Patent No. 6,632,927 to Adair; Jones, P.T. *et al.*, Nature, 321:522-525 (1986); Reichmann, L., *et al.*, Nature, 332:323-327 (1988); Verhoeyen, M., *et al.*, Science, 239:1534-36 (1988), the disclosures of each of which are herein incorporated by reference in their entireties).

**[0530]** Antibody polypeptides of the invention having CGRP binding specificity may also be produced by constructing, using conventional techniques well known to those of ordinary skill in the art, an expression vector containing an operon and a DNA sequence encoding an antibody heavy chain in which the DNA sequence encoding the CDRs required for antibody specificity is derived from a non-human cell source, preferably a

rabbit B-cell source, while the DNA sequence encoding the remaining parts of the antibody chain is derived from a human cell source.

**[0531]** A second expression vector is produced using the same conventional means well known to those of ordinary skill in the art, said expression vector containing an operon and a DNA sequence encoding an antibody light chain in which the DNA sequence encoding the CDRs required for antibody specificity is derived from a non-human cell source, preferably a rabbit B-cell source, while the DNA sequence encoding the remaining parts of the antibody chain is derived from a human cell source.

**[0532]** The expression vectors are transfected into a host cell by convention techniques well known to those of ordinary skill in the art to produce a transfected host cell, said transfected host cell cultured by conventional techniques well known to those of ordinary skill in the art to produce said antibody polypeptides.

**[0533]** The host cell may be co-transfected with the two expression vectors described above, the first expression vector containing DNA encoding an operon and a light chain-derived polypeptide and the second vector containing DNA encoding an operon and a heavy chain-derived polypeptide. The two vectors contain different selectable markers, but preferably achieve substantially equal expression of the heavy and light chain polypeptides. Alternatively, a single vector may be used, the vector including DNA encoding both the heavy and light chain polypeptides. The coding sequences for the heavy and light chains may comprise cDNA, genomic DNA, or both.

**[0534]** The host cells used to express the antibody polypeptides may be either a bacterial cell such as *E. coli*, or a eukaryotic cell such as *P. pastoris*. In one embodiment of the invention, a mammalian cell of a well-defined type for this purpose, such as a myeloma cell, a Chinese hamster ovary (CHO) cell line, a NSO cell line, or a HEK293 cell line may be used.

**[0535]** The general methods by which the vectors may be constructed, transfection methods required to produce the host cell and culturing methods required to produce the antibody polypeptides from said host cells all include conventional techniques. Although preferably the cell line used to produce the antibody is a mammalian cell line, any other

suitable cell line, such as a bacterial cell line such as an *E. coli*-derived bacterial strain, or a yeast cell line, may alternatively be used.

[0536] Similarly, once produced the antibody polypeptides may be purified according to standard procedures in the art, such as for example cross-flow filtration, ammonium sulphate precipitation, affinity column chromatography and the like.

[0537] The antibody polypeptides described herein may also be used for the design and synthesis of either peptide or non-peptide mimetics that would be useful for the same therapeutic applications as the antibody polypeptides of the invention. *See*, for example, Saragobi *et al*, *Science*, 253:792-795 (1991), the contents of which is herein incorporated by reference in its entirety.

### ***Screening Assays***

[0538] The invention also includes screening assays designed to assist in the identification of diseases and disorders associated with CGRP in patients exhibiting symptoms of a CGRP associated disease or disorder.

[0539] In one embodiment of the invention, the anti-CGRP antibodies of the invention, or CGRP binding fragments thereof, are used to detect the presence of CGRP in a biological sample obtained from a patient exhibiting symptoms of a disease or disorder associated with CGRP. The presence of CGRP, or elevated levels thereof when compared to pre-disease levels of CGRP in a comparable biological sample, may be beneficial in diagnosing a disease or disorder associated with CGRP.

[0540] Another embodiment of the invention provides a diagnostic or screening assay to assist in diagnosis of diseases or disorders associated with CGRP in patients exhibiting symptoms of a CGRP associated disease or disorder identified herein, comprising assaying the level of CGRP expression in a biological sample from said patient using a post-translationally modified anti-CGRP antibody or binding fragment thereof. The anti-CGRP antibody or binding fragment thereof may be post-translationally modified to include a detectable moiety such as set forth previously in the disclosure.

[0541] The CGRP level in the biological sample is determined using a modified anti-CGRP antibody or binding fragment thereof as set forth herein, and comparing the level of

CGRP in the biological sample against a standard level of CGRP (e.g., the level in normal biological samples). The skilled clinician would understand that some variability may exist between normal biological samples, and would take that into consideration when evaluating results. In one embodiment of the invention, the anti-CGRP antibodies of the invention may be used to correlate CGRP expression levels with a particular stage of cancerous development. One skilled in the art would be able to measure CGRP in numerous subjects in order to establish ranges of CGRP expression that correspond to clinically defined stages of cancerous development. These ranges will allow the skilled practitioner to measure CGRP in a subject diagnosed with a cancer and correlate the levels in each subject with a range that corresponds to a stage of said cancer. One skilled in the art would understand that by measuring CGRP in the patient at different intervals, the progression of the cancer can be determined.

**[0542]** The above-recited assay may also be useful in monitoring a disease or disorder, where the level of CGRP obtained in a biological sample from a patient believed to have a CGRP associated disease or disorder is compared with the level of CGRP in prior biological samples from the same patient, in order to ascertain whether the CGRP level in said patient has changed with, for example, a treatment regimen.

**[0543]** The invention is also directed to a method of *in vivo* imaging which detects the presence of cells which express CGRP comprising administering a diagnostically effective amount of a diagnostic composition. Said *in vivo* imaging is useful for the detection or imaging of CGRP expressing tumors or metastases, for example, and can be useful as part of a planning regimen for the design of an effective cancer treatment protocol. The treatment protocol may include, for example, one or more of radiation, chemotherapy, cytokine therapy, gene therapy, and antibody therapy, as well as an anti-CGRP antibody or fragment thereof.

**[0544]** The present invention further provides for a kit for detecting binding of an anti-CGRP antibody of the invention to CGRP. In particular, the kit may be used to detect the presence of a CGRP specifically reactive with an anti-CGRP antibody of the invention or an immunoreactive fragment thereof. The kit may also include an antibody bound to a substrate, a secondary antibody reactive with the antigen and a reagent for detecting a

reaction of the secondary antibody with the antigen. Such a kit may be an ELISA kit and can comprise the substrate, primary and secondary antibodies when appropriate, and any other necessary reagents such as detectable moieties, enzyme substrates, and color reagents, for example as described herein. The diagnostic kit may also be in the form of an immunoblot kit. The diagnostic kit may also be in the form of a chemiluminescent kit (Meso Scale Discovery, Gaithersburg, MD). The diagnostic kit may also be a lanthanide-based detection kit (PerkinElmer, San Jose, CA).

**[0545]** A skilled clinician would understand that a biological sample includes, but is not limited to, sera, plasma, urine, saliva, mucous, pleural fluid, synovial fluid and spinal fluid.

***Methods of Ameliorating or Reducing Symptoms of, or Treating, or Preventing, Diseases and Disorders Associated with, CGRP***

**[0546]** In another embodiment of the invention, anti-CGRP antibodies described herein, or fragments thereof, are useful for ameliorating or reducing the symptoms of, or treating, or preventing, diseases and disorders associated with CGRP. Anti-CGRP antibodies described herein, or fragments thereof, as well as combinations, can also be administered in a therapeutically effective amount to patients in need of treatment of diseases and disorders associated with CGRP in the form of a pharmaceutical composition as described in greater detail below.

**[0547]** In another embodiment of the invention, anti-CGRP antibodies described herein, or fragments thereof, are useful for ameliorating or reducing the symptoms of, or treating, or preventing, migraines (with or without aura), weight loss, cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, pain, hemiplegic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), and allergy-induced headaches or migraines.

**[0548]** In one embodiment of the invention, anti-CGRP antibodies described herein, or fragments thereof and/or with a second agent, are useful for ameliorating or reducing the

symptoms of, or treating, or preventing, the following non-limiting listing of diseases and disorders: pain, inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, chronic pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, abdominal pain, pain associated with sickle cell crises, and other nociceptive pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptive pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarian pain, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or pain or visceral pain associated with: gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, irritable colon, spastic colon, mucous colitis, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, pancreatitis, renal colic, dysmenorrhea, cystitis, including interstitial cystitis (IC), surgery associated with the ileus, diverticulitis, peritonitis, pericarditis, hepatitis, appendicitis, colitis, cholecystitis, endometriosis, chronic and/or acute pancreatitis, myocardial infarction, kidney pain, pleural pain, prostatitis, pelvic pain, trauma to an organ, chronic nociceptive pain, chronic neuropathic pain, chronic inflammatory pain, fibromyalgia, breakthrough pain and persistent pain, and cancer pain arising from malignancy or from cancer preferably selected from one or more of: adenocarcinoma in glandular tissue, blastoma in embryonic tissue of organs, carcinoma in epithelial tissue, leukemia in tissues that form blood cells, lymphoma in lymphatic tissue, myeloma in bone marrow, sarcoma in connective or supportive tissue, adrenal cancer, AIDS-related lymphoma, anemia, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoid tumours, cervical cancer, chemotherapy, colon cancer, cytopenia, endometrial cancer, esophageal cancer, gastric cancer, head cancer, neck cancer, hepatobiliary cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, Hodgkin's disease, lymphoma, non- Hodgkin's, nervous system tumours, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, urethral cancer, bone cancer, sarcomas cancer of the connective tissue, cancer of bone tissue, cancer of blood-forming cells, cancer of bone marrow,

multiple myeloma, leukaemia, primary or secondary bone cancer, tumours that metastasize to the bone, tumours infiltrating the nerve and hollow viscus, tumours near neural structures. Further preferably the cancer pain comprises visceral pain, preferably visceral pain which arises from pancreatic cancer and/or metastases in the abdomen. Further preferably the cancer pain comprises somatic pain, preferably somatic pain due to one or more of bone cancer, metastasis in the bone, postsurgical pain, sarcomas cancer of the connective tissue, cancer of bone tissue, cancer of blood-forming cells of the bone marrow, multiple myeloma, leukaemia, primary or secondary bone cancer.

**[0549]** In another embodiment of the invention, anti-CGRP antibodies described herein, or fragments thereof and/or with a second agent, are useful for ameliorating or reducing the symptoms of, or treating, or preventing, the following non-limiting listing of diseases and disorders: cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival.

**[0550]** In another embodiment of the invention, anti-CGRP antibodies described herein, or fragments thereof and/or with a second agent, are useful for ameliorating or reducing the symptoms of, or treating, or preventing, the following non-limiting listing of diseases and disorders: neurogenic, neuropathic or nociceptive pain. Neuropathic pain may include, but is not limited to, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarian pain, reflex sympathetic dystrophy and neurogenic pain. In other preferred embodiments, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, and other neuropathic pain.

**[0551]** In another embodiment of the invention, anti-CGRP antibodies described herein, or fragments thereof and/or with a second agent, are useful for ameliorating or reducing the symptoms of, or treating, or preventing, the following non-limiting listing of diseases and disorders: overactive bladder and other urinary conditions, gastro-esophageal reflux and visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, pruritis, or pancreatitis. Also, the subject CGRP antibodies and antibody fragments may be used alone or in conjunction with other active agents, e.g., opioids and non-opioid analgesics such as

NSAIDs to elicit analgesia or to potentiate the efficacy of another analgesic or to prevent or alleviate tolerance to a specific analgesic such as morphine or related opioid analgesics. Evidence for role of CGRP in blocking / reversing development of morphine – induced analgesia: is the fact that CGRP8-37 and CGRP Receptor antagonist (BIBN4096BS) reportedly prevent / reverse development of morphine tolerance -(Powell et al., 2000 J Brit J Pharmacol (131):875; Menard et al., 1996 J Neurosci (16):2342; Wang et al., 2009 FASEB J (23):2576; Wang et al., 2010 Pain (151):194)

**[0552]** The subject antibodies potentially may be combined with any opioid analgesic or NSAID or other analgesic, potentially another antibody, in order to increase or enhance pain management, or to reverse or suppress tolerance to an analgesic such as an opioid analgesic compound. This may allow for such analgesic compounds to be administered for longer duration or at reduced dosages thereby potentially alleviating adverse side effects associated therewith.

**[0553]** The term "opioid analgesic" herein refers to all drugs, natural or synthetic, with morphine-like actions. The synthetic and semi-synthetic opioid analgesics are derivatives of five chemical classes of compound: phenanthrenes; phenylheptylamines; phenylpiperidines; morphinans; and benzomorphans, all of which are within the scope of the term. Exemplary opioid analgesics include codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine or pharmaceutically acceptable salts thereof.

**[0554]** The term "NSAID" refers to a non-steroidal anti-inflammatory compound. NSAIDs are categorized by virtue of their ability to inhibit cyclooxygenase. Cyclooxygenase 1 and cyclooxygenase 2 are two major isoforms of cyclooxygenase and most standard NSAIDs are mixed inhibitors of the two isoforms. Most standard NSAIDs fall within one of the following five structural categories: (1) propionic acid derivatives, such as ibuprofen, naproxen, naprosyn, diclofenac, and ketoprofen; (2) acetic acid derivatives, such as tolmetin and slindac; (3) fenamic acid derivatives, such as mefenamic acid and meclofenamic acid; (4) biphenylcarboxylic acid derivatives, such as diflunisal and flufenisal; and (5) oxicams, such as piroxim, sudoxicam, and isoxicam. Another class of

NSAID has been described which selectively inhibit cyclooxygenase 2. Cox-2 inhibitors have been described, e.g., in U.S. Pat. Nos. 5,616,601; 5,604,260; 5,593,994; 5,550,142; 5,536,752; 5,521,213; 5,475,995; 5,639,780; 5,604,253; 5,552,422; 5,510,368; 5,436,265; 5,409,944; and 5,130,311, all of which are hereby incorporated by reference. Certain exemplary COX-2 inhibitors include celecoxib (SC-58635), DUP-697, flosulide (CGP-28238), meloxicam, 6-methoxy-2 naphthylacetic acid (6-MNA), rofecoxib, MK-966, nabumetone (prodrug for 6-MNA), nimesulide, NS-398, SC-5766, SC-58215, T-614; or combinations thereof.

**[0555]** In some embodiments, aspirin and/or acetaminophen may be taken in conjunction with the subject CGRP antibody or fragment. Aspirin is another type of non-steroidal anti-inflammatory compound.

**[0556]** Exemplary, non-limiting diseases and disorders that can be treated and/or prevented by the administration of the CGRP antibodies of the present invention include, pain resulting from any condition associated with neurogenic, neuropathic, inflammatory, thermal or nociceptive pain. Preferably the disorder will be associated with increased CGRP at the pain site. In certain embodiments of neuropathic pain, referred trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, reflex sympathetic dystrophy and neurogenic pain conditions are preferably treated. In other embodiments, cancer pain, particularly, bone cancer pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, post-operative incision pain, fracture pain, osteoporotic fracture pain, osteoporosis, gout joint pain, diabetic neuropathy, sciatica, pains associated with sickle cell crises, migraine, and other neuropathic and/or nociceptive pain are preferably treated. Thus, the present invention includes methods of treating, preventing, and/or ameliorating any disease or disorder associated with CGRP activity or CGRP upregulation (including any of the above mentioned exemplary diseases, disorders and conditions) through use of the antibodies and antibody fragments of the invention. The therapeutic methods of the present invention comprise administering to a subject any formulation comprising an anti-CGRP antibody as disclosed herein alone or in association with another active agent.

**[0557]** . The subject to which the pharmaceutical formulation is administered can be, e.g., any human or non-human animal that is in need of such treatment, prevention and/or

amelioration, or who would otherwise benefit from the inhibition or attenuation of CGRP-mediated activity. For example, the subject can be an individual that is diagnosed with, or who is deemed to be at risk of being afflicted by any of the aforementioned diseases or disorders. The present invention further includes the use of any of the pharmaceutical formulations disclosed herein in the manufacture of a medicament for the treatment, prevention and/or amelioration of any disease or disorder associated with CGRP activity (including any of the above mentioned exemplary diseases, disorders and conditions).

### ***Administration***

**[0558]** In one embodiment of the invention, the anti-CGRP antibodies described herein, or CGRP binding fragments thereof, as well as combinations of said antibodies or antibody fragments, are administered to a subject at a concentration of between about 0.1 and 100.0 mg/kg of body weight of recipient subject. In a preferred embodiment of the invention, the anti-CGRP antibodies described herein, or CGRP binding fragments thereof, as well as combinations of said antibodies or antibody fragments, are administered to a subject at a concentration of about 0.4 mg/kg of body weight of recipient subject. In a preferred embodiment of the invention, the anti-CGRP antibodies described herein, or CGRP binding fragments thereof, as well as combinations of said antibodies or antibody fragments, are administered to a recipient subject with a frequency of once every twenty-six weeks or less, such as once every sixteen weeks or less, once every eight weeks or less, once every four weeks or less, once every two weeks or less, once every week or less, or once daily or less.

**[0559]** Fab fragments may be administered every two weeks or less, every week or less, once daily or less, multiple times per day, and/or every few hours. In one embodiment of the invention, a patient receives Fab fragments of 0.1 mg/kg to 40 mg/kg per day given in divided doses of 1 to 6 times a day, or in a sustained release form, effective to obtain desired results.

**[0560]** It is to be understood that the concentration of the antibody or Fab administered to a given patient may be greater or lower than the exemplary administration concentrations set forth above in paragraphs [0552] and [0553].

[0561] A person of skill in the art would be able to determine an effective dosage and frequency of administration through routine experimentation, for example guided by the disclosure herein and the teachings in Goodman, L. S., Gilman, A., Brunton, L. L., Lazo, J. S., & Parker, K. L. (2006). Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; Howland, R. D., Mycek, M. J., Harvey, R. A., Champe, P. C., & Mycek, M. J. (2006). Pharmacology. Lippincott's illustrated reviews. Philadelphia: Lippincott Williams & Wilkins; and Golan, D. E. (2008). Principles of pharmacology: the pathophysiologic basis of drug therapy. Philadelphia, Pa., [etc.]: Lippincott Williams & Wilkins.

[0562] In another embodiment of the invention, the anti-CGRP antibodies described herein, or CGRP binding fragments thereof, as well as combinations of said antibodies or antibody fragments, are administered to a subject in a pharmaceutical formulation.

[0563] A "pharmaceutical composition" refers to a chemical or biological composition suitable for administration to a mammal. Such compositions may be specifically formulated for administration *via* one or more of a number of routes, including but not limited to buccal, epicutaneous, epidural, inhalation, intraarterial, intracardial, intracerebroventricular, intradermal, intramuscular, intranasal, intraocular, intraperitoneal, intraspinal, intrathecal, intravenous, oral, parenteral, rectally *via* an enema or suppository, subcutaneous, subdermal, sublingual, transdermal, and transmucosal. In addition, administration can occur by means of injection, powder, liquid, gel, drops, or other means of administration.

[0564] In one embodiment of the invention, the anti-CGRP antibodies described herein, or CGRP binding fragments thereof, as well as combinations of said antibodies or antibody fragments, may be optionally administered in combination with one or more active agents. Such active agents include analgesic, anti-histamine, antipyretic, anti-inflammatory, antibiotic, antiviral, and anti-cytokine agents. Active agents include agonists, antagonists, and modulators of TNF- $\alpha$ , IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-18, IFN- $\alpha$ , IFN- $\gamma$ , BAFF, CXCL13, IP-10, VEGF, EPO, EGF, HRG, Hepatocyte Growth Factor (HGF), Hepcidin, including antibodies reactive against any of the foregoing, and antibodies reactive against any of their receptors. Active agents also include but are not limited to 2-

Arylpropionic acids, Aceclofenac, Acemetacin, Acetylsalicylic acid (Aspirin), Alclofenac, Alminoprofen, Amoxiprin, Ampyrone, Arylalkanoic acids, Azapropazone, Benorylate/Benorilate, Benoxaprofen, Bromfenac, Carprofen, Celecoxib, Choline magnesium salicylate, Clofezone, COX-2 inhibitors, Dexibuprofen, Dexketoprofen, Diclofenac, Diflunisal, Droxicam, Ethenzamide, Etodolac, Etoricoxib, Faislamine, fenamic acids, Fenbufen, Fenoprofen, Flufenamic acid, Flunoxaprofen, Flurbiprofen, Ibuprofen, Ibuproxam, Indometacin, Indoprofen, Kebuzone, Ketoprofen, Ketorolac, Lornoxicam, Loxoprofen, Lumiracoxib, Magnesium salicylate, Meclofenamic acid, Mefenamic acid, Meloxicam, Metamizole, Methyl salicylate, Mofebutazone, Nabumetone, Naproxen, N-Arylanthranilic acids, Nerve Growth Factor (NGF), Oxametacin, Oxaprozin, Oxicams, Oxyphenbutazone, Parecoxib, Phenazone, Phenylbutazone, Phenylbutazone, Piroxicam, Pirprofen, profens, Proglumetacin, Pyrazolidine derivatives, Rofecoxib, Salicyl salicylate, Salicylamide, Salicylates, Substance P, Sulfinpyrazone, Sulindac, Suprofen, Tenoxicam, Tiaprofenic acid, Tolfenamic acid, Tolmetin, and Valdecoxib.

**[0565]** An anti-histamine can be any compound that opposes the action of histamine or its release from cells (e.g., mast cells). Anti-histamines include but are not limited to acrivastine, astemizole, azatadine, azelastine, betastastine, brompheniramine, buclizine, cetirizine, cetirizine analogues, chlorpheniramine, clemastine, CS 560, cyproheptadine, desloratadine, dexchlorpheniramine, ebastine, epinastine, fexofenadine, HSR 609, hydroxyzine, levocabastine, loratadine, methscopolamine, mizolastine, norastemizole, phenindamine, promethazine, pyrilamine, terfenadine, and tranilast.

**[0566]** Antibiotics include but are not limited to Amikacin, Aminoglycosides, Amoxicillin, Ampicillin, Ansamycins, Arsphenamine, Azithromycin, Azlocillin, Aztreonam, Bacitracin, Carbacephem, Carbapenems, Carbenicillin, Cefaclor, Cefadroxil, Cefalexin, Cefalothin, Cefalotin, Cefamandole, Cefazolin, Cefdinir, Cefditoren, Cefepime, Cefixime, Cefoperazone, Cefotaxime, Cefoxitin, Cefpodoxime, Cefprozil, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftriaxone, Cefuroxime, Cephalosporins, Chloramphenicol, Cilastatin, Ciprofloxacin, Clarithromycin, Clindamycin, Cloxacillin, Colistin, Co-trimoxazole, Dalfopristin, Demeclocycline, Dicloxacillin, Dirithromycin, Doripenem, Doxycycline, Enoxacin, Ertapenem, Erythromycin, Ethambutol,

Flucloxacillin, Fosfomycin, Furazolidone, Fusidic acid, Gatifloxacin, Geldanamycin, Gentamicin, Glycopeptides, Herbimycin, Imipenem, Isoniazid, Kanamycin, Levofloxacin, Lincomycin, Linezolid, Lomefloxacin, Loracarbef, Macrolides, Mafenide, Meropenem, Meticillin, Metronidazole, Mezlocillin, Minocycline, Monobactams, Moxifloxacin, Mupirocin, Nafcillin, Neomycin, Netilmicin, Nitrofurantoin, Norfloxacin, Ofloxacin, Oxacillin, Oxytetracycline, Paromomycin, Penicillin, Penicillins, Piperacillin, Platensimycin, Polymyxin B, Polypeptides, Prontosil, Pyrazinamide, Quinolones, Quinupristin, Rifampicin, Rifampin, Roxithromycin, Spectinomycin, Streptomycin, Sulfacetamide, Sulfamethizole, Sulfanilimide, Sulfasalazine, Sulfisoxazole, Sulfonamides, Teicoplanin, Telithromycin, Tetracycline, Tetracyclines, Ticarcillin, Tinidazole, Tobramycin, Trimethoprim, Trimethoprim-Sulfamethoxazole, Troleandomycin, Trovafloxacin, and Vancomycin.

**[0567]** Active agents also include Aldosterone, Beclometasone, Betamethasone, Corticosteroids, Cortisol, Cortisone acetate, Deoxycorticosterone acetate, Dexamethasone, Fludrocortisone acetate, Glucocorticoids, Hydrocortisone, Methylprednisolone, Prednisolone, Prednisone, Steroids, and Triamcinolone. Any suitable combination of these active agents is also contemplated.

**[0568]** A “pharmaceutical excipient” or a “pharmaceutically acceptable excipient” is a carrier, usually a liquid, in which an active therapeutic agent is formulated. In one embodiment of the invention, the active therapeutic agent is a humanized antibody described herein, or one or more fragments thereof. The excipient generally does not provide any pharmacological activity to the formulation, though it may provide chemical and/or biological stability, and release characteristics. Exemplary formulations can be found, for example, in Remington’s Pharmaceutical Sciences, 19<sup>th</sup> Ed., Gennaro, A., Ed., 1995 which is incorporated by reference.

**[0569]** As used herein “pharmaceutically acceptable carrier” or “excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, or sublingual administration.

Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

**[0570]** Pharmaceutical compositions typically must be sterile and stable under the conditions of manufacture and storage. The invention contemplates that the pharmaceutical composition is present in lyophilized form. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. The invention further contemplates the inclusion of a stabilizer in the pharmaceutical composition. The proper fluidity can be maintained, for example, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.

**[0571]** In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the alkaline polypeptide can be formulated in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are known to those skilled in the art.

[0572] For each of the recited embodiments, the compounds can be administered by a variety of dosage forms. Any biologically-acceptable dosage form known to persons of ordinary skill in the art, and combinations thereof, are contemplated. Examples of such dosage forms include, without limitation, reconstitutable powders, elixirs, liquids, solutions, suspensions, emulsions, powders, granules, particles, microparticles, dispersible granules, cachets, inhalants, aerosol inhalants, patches, particle inhalants, implants, depot implants, injectables (including subcutaneous, intramuscular, intravenous, and intradermal), infusions, and combinations thereof.

[0573] The above description of various illustrated embodiments of the invention is not intended to be exhaustive or to limit the invention to the precise form disclosed. While specific embodiments of, and examples for, the invention are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the invention, as those skilled in the relevant art will recognize. The teachings provided herein of the invention can be applied to other purposes, other than the examples described above.

[0574] These and other changes can be made to the invention in light of the above detailed description. In general, in the following claims, the terms used should not be construed to limit the invention to the specific embodiments disclosed in the specification and the claims. Accordingly, the invention is not limited by the disclosure, but instead the scope of the invention is to be determined entirely by the following claims.

[0575] The invention may be practiced in ways other than those particularly described in the foregoing description and examples. Numerous modifications and variations of the invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

[0576] Certain teachings related to methods for obtaining a clonal population of antigen-specific B cells were disclosed in U.S. Provisional patent application no. 60/801,412, filed May 19, 2006, the disclosure of which is herein incorporated by reference in its entirety.

[0577] Certain teachings related to humanization of rabbit-derived monoclonal antibodies and preferred sequence modifications to maintain antigen binding affinity were disclosed in International Application No. PCT/US2008/064421, corresponding to

International Publication No. WO/2008/144757, entitled “Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies”, filed May 21, 2008, the disclosure of which is herein incorporated by reference in its entirety.

**[0578]** Certain teachings related to producing antibodies or fragments thereof using mating competent yeast and corresponding methods were disclosed in U.S. Patent application no. 11/429,053, filed May 8, 2006, (U.S. Patent Application Publication No. US2006/0270045), the disclosure of which is herein incorporated by reference in its entirety.

**[0579]** Certain CGRP antibody polynucleotides and polypeptides are disclosed in the sequence listing accompanying this patent application filing, and the disclosure of said sequence listing is herein incorporated by reference in its entirety.

**[0580]** The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is herein incorporated by reference in their entireties.

**[0581]** The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (*e.g.* amounts, temperature, concentrations, *etc.*) but some experimental errors and deviations should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

## EXAMPLES

*Example 1 Preparation of Antibodies that Bind CGRP*

[0582] By using the antibody selection protocol described herein, one can generate an extensive panel of antibodies.

Immunization Strategy

[0583] Rabbits were immunized with human CGRP $\alpha$  (American Peptides, Sunnyvale CA and Bachem, Torrance CA). Immunization consisted of a first subcutaneous (sc) injection of 100  $\mu$ g of antigen mixed with 100  $\mu$ g of KLH in complete Freund's adjuvant (CFA) (Sigma) followed by two boosts, two weeks apart each containing 50  $\mu$ g antigen mixed with 50  $\mu$ g in incomplete Freund's adjuvant (IFA) (Sigma). Animals were bled on day 55, and serum titers were determined by ELISA (antigen recognition) and by inhibition of CGRP driven cAMP increase in SK-N-MC.

Antibody Selection Titer Assessment

[0584] To identify and characterize antibodies that bind to human CGRP $\alpha$ , antibody-containing solutions were tested by ELISA. Briefly, neutravidin coated plates (Thermo Scientific), were coated with N-term biotinylated human CGRP $\alpha$  (50 $\mu$ L per well, 1 $\mu$ g/mL) diluted in ELISA buffer (0.5% fish skin gelatin in PBS pH 7.4,) either for approximately 1hr at room temperature or alternatively overnight at 4°C. The plates were then further blocked with ELISA buffer for one hour at room temperature and washed using wash buffer (PBS, 0.05% tween 20). Serum samples tested were serially diluted using ELISA buffer. Fifty microliters of diluted serum samples were transferred onto the wells and incubated for one hour at room temperature for one hour. After this incubation, the plate was washed with wash buffer. For development, an anti-rabbit specific Fc-HARP (1:5000 dilution in ELISA buffer) was added onto the wells and incubated for 45 min at RT. After a 3x wash step with wash solution, the plate was developed using TMB substrate for two minutes at room temperature and the reaction was quenched using 0.5M HCl. The well absorbance was read at 450 nm.

Titer determination of serum samples by functional activity (Inhibition of CGRP driven cAMP levels)

[0585] To identify and characterize antibodies with functional activity, an inhibition of CGRP driven increase of cAMP levels assay was done using electrochemiluminescence (Meso Scale Discovery, MSD). Briefly, antibody preparations to be tested were serially diluted in MSD assay buffer (Hepes, MgCl<sub>2</sub>, pH 7.3, 1mg/mL blocker A, Meso Scale Discovery) in a 96 well round bottom polystyrene plate (Costar). To this plate, human CGRP $\alpha$  was added (10ng/mL final concentration) diluted in MSD assay buffer and incubated for one hour at 37C. Appropriate controls were used as suggested by the assay-kit manufacturer. Human neuroepithelioma cells (SK-N-MC, ATCC) were detached using an EDTA solution (5mM in PBS) and washed using growth media (MEM, 10% FBS, antibiotics) by centrifugation. The cell number was adjusted to 2 million cells per mL in assay buffer, and IBMX (3-Isobutyl-1Methylxanthine, Sigma) was added to a final concentration of 0.2mM right before loading cells onto cAMP assay plate. After the antibody human CGRP $\alpha$  solution was incubated for one hour 20 microliters of solution containing cells were transferred to the cAMP assay plate. All tested samples were run in duplicates with appropriate controls. Ten microliters of cells were added to the wells and the plate was incubated for 30 minutes with shaking at room temperature. While cells were being incubated with the CGRP solution, the stop solution was prepared by making a 1:200 solution of TAG labeled cAMP (MSD) in lysis buffer (MSD). To stop the cells-CGRP incubation, 20 microliters of stop solution was added to the cells and the plate was incubated for one hour with shaking at room temperature. The read buffer (MSD) was diluted four times with water and 100 microliters were added to all wells on the plate. The plate was then read using a Sector Imager 2400 (MSD) and the Prism software was used for data fit and IC50 determination.

Tissue Harvesting

[0586] Once acceptable titers were established, the rabbit(s) were sacrificed. Spleen, lymph nodes, and whole blood were harvested and processed as follows:

[0587] Spleen and lymph nodes were processed into a single cell suspension by disassociating the tissue and pushing through sterile wire mesh at 70 µm (Fisher) with a plunger of a 20 cc syringe. Cells were collected in PBS. Cells were washed twice by centrifugation. After the last wash, cell density was determined by trypan blue. Cells were centrifuged at 1500 rpm for 10 minutes; the supernatant was discarded. Cells were resuspended in the appropriate volume of 10% dimethyl sulfoxide (DMSO, Sigma) in FBS (Hyclone) and dispensed at 1 ml/vial. Vials were stored at -70°C in a slow freezing chamber for 24 hours and stored in liquid nitrogen.

[0588] Peripheral blood mononuclear cells (PBMCs) were isolated by mixing whole blood with equal parts of the low glucose medium described above without FBS. 35 ml of the whole blood mixture was carefully layered onto 8 ml of Lympholyte Rabbit (Cedarlane) into a 45 ml conical tube (Corning) and centrifuged 30 minutes at 2500 rpm at room temperature without brakes. After centrifugation, the PBMC layers were carefully removed using a glass Pasteur pipette (VWR), combined, and placed into a clean 50 ml vial. Cells were washed twice with the modified medium described above by centrifugation at 1500 rpm for 10 minutes at room temperature, and cell density was determined by trypan blue staining. After the last wash, cells were resuspended in an appropriate volume of 10% DMSO/FBS medium and frozen as described above.

#### B cell selection, enrichment and culture conditions

[0589] On the day of setting up B cell culture, PBMC, splenocyte, or lymph node vials were thawed for use. Vials were removed from LN2 tank and placed in a 37°C water bath until thawed. Contents of vials were transferred into 15 ml conical centrifuge tube (Corning) and 10 ml of modified RPMI described above was slowly added to the tube. Cells were centrifuged for 5 minutes at 2K RPM, and the supernatant was discarded. Cells were resuspended in 10 ml of fresh media. Cell density and viability was determined by trypan blue.

#### a) The following protocol was used for Ab1 and Ab13

**[0590]** Cells were pre-mixed with the biotinylated human CGRP $\alpha$  as follows. Cells were washed again and resuspended at 1E07 cells/80  $\mu$ L medium. Biotinylated human CGRP $\alpha$  was added to the cell suspension at the final concentration of 5 ug/mL and incubated for 30 minutes at 4°C. Unbound biotinylated human CGRP $\alpha$  was removed performing two 10 ml washes using PBF [Ca/Mg free PBS (Hyclone), 2 mM ethylenediamine tetraacetic acid (EDTA), 0.5% bovine serum albumin (BSA) (Sigma-biotin free)]. After the second wash, cells were resuspended at 1E07 cells/80  $\mu$ l PBF and 20  $\mu$ l of MACS® streptavidin beads (Miltenyi Biotech, Auburn CA) per 10E7 cells were added to the cell suspension. Cells and beads were incubated at 4°C for 15 minutes and washed once with 2 ml of PBF per 10E7 cells.

*b) The following protocol was used for Ab4, Ab7, Ab9 and Ab11:*

**[0591]** Biotinylated human CGRP $\alpha$  was pre-loaded onto the streptavidin beads as follows. Seventy five microliters of streptavidin beads (Miltenyi Biotec, Auburn CA) were mixed with N-terminally biotinylated huCGRP $\alpha$  (10ug/ml final concentration) and 300  $\mu$ l PBF. This mixture was incubated at 4°C for 30 min and unbound biotinylated human CGRP $\alpha$  was removed using a MACS® separation column (Miltenyi Biotec, with a 1ml rinse to remove unbound material. Then material was plunged out, then used to resuspend cells from above in 100ul per 1E7 cells, the mixture was then incubated at 4°C for 30min and washed once with 10 ml of PBF.

**[0592]** For both a) and b) protocols the following applied: After washing, the cells were resuspended in 500 $\mu$ l of PBF and set aside. A MACS® MS column (Miltenyi Biotec, Auburn CA) was pre-rinsed with 500 ml of PBF on a magnetic stand (Miltenyi). Cell suspension was applied to the column through a pre-filter, and unbound fraction was collected. The column was washed with 2.5 ml of PBF buffer. The column was removed from the magnet stand and placed onto a clean, sterile 1.5 ml eppendorf tube. 1 ml of PBF buffer was added to the top of the column, and positive selected cells were collected. The yield and viability of positive cell fraction was determined by trypan blue staining. Positive selection yielded an average of 1% of the starting cell concentration.

[0593] A pilot cell screen was established to provide information on seeding levels for the culture. Plates were seeded at 10, 25, 50, 100, or 200 enriched B cells/well. In addition, each well contained 50K cells/well of irradiated EL-4.B5 cells (5,000 Rads) and an appropriate level of activated rabbit T cell supernatant (See U.S. Patent Application Publication No. 20070269868)(ranging from 1-5% depending on preparation) in high glucose modified RPMI medium at a final volume of 250  $\mu$ l/well. Cultures were incubated for 5 to 7 days at 37°C in 4% CO<sub>2</sub>.

B-Cell culture screening by antigen-recognition (ELISA)

[0594] To identify wells producing anti-human CGRP $\alpha$  antibodies, the same protocol as described for titer determination of serum samples by antigen-recognition (ELISA) was used with the following changes. Briefly, neutravidin coated plates were coated with a mixture of both N- and C- terminally biotinylated human CGRP $\alpha$  (50 $\mu$ L per well, 1 $\mu$ g/mL each). B-cell supernatant samples (50 $\mu$ L) were tested without prior dilution.

Identification of functional activity in B-cell supernatants using CGRP driven cAMP production

[0595] To determine functional activity contained in B-cell supernatants, a similar procedure to that described for the determination of functional titer of serum samples was used with the following modifications. Briefly, B-cell supernatant (20 $\mu$ L) were used in place of the diluted polyclonal serum samples.

Isolation of antigen-specific B-cells

[0596] Plates containing wells of interest were removed from -70 °C, and the cells from each well were recovered using five washes of 200 microliters of medium (10% RPMI complete, 55 $\mu$ M BME) per well. The recovered cells were pelleted by centrifugation and the supernatant was carefully removed. Pelleted cells were resuspended in 100  $\mu$ l of medium. To identify antibody expressing cells, streptavidin coated magnetic beads (M280 dynabeads, Invitrogen) were coated with a combination of both N- and C- terminal biotinylated human CGRP $\alpha$ . Individual biotinylated human CGRP $\alpha$  lots were optimized

by serial dilution. One hundred microliters containing approximately 4x10E7 coated beads were then mixed with the resuspended cells. To this mixture 15 microliters of goat anti-rabbit H&L IgG-FITC (Jackson Immunoresearch) diluted 1:100 in medium were added.

[0597] Twenty microliters of cell/beads/anti-rabbit H&L suspension were removed and 5 microliter droplets were dispensed on a one-well glass slide previously treated with Sigmacote (Sigma) totaling 35 to 40 droplets per slide. An impermeable barrier of paraffin oil (JT Baker) was used to submerge the droplets, and the slide was incubated for 90 minutes at 37°C in a 4% CO2 incubator in the dark.

[0598] Specific B cells that produce antibody can be identified by the fluorescent ring around produced by the antibody secretion, recognition of the bead-associated biotinylated antigen, and subsequent detection by the fluorescent-IgG detection reagent. Once a cell of interest was identified it was recovered via a micromanipulator (Eppendorf). The single cell synthesizing and exporting the antibody was transferred into a microcentrifuge tube, frozen using dry ice and stored at -70°C.

Amplification and sequence determination of Antibody Sequences From Antigen-Specific B Cells

[0599] Antibody sequences were recovered using a combined RT-PCR based method from a single isolated B-cell. Primers containing restriction enzymes were designed to anneal in conserved and constant regions of the target immunoglobulin genes (heavy and light), such as rabbit immunoglobulin sequences, and a two-step nested PCR recovery was used to amplify the antibody sequence. Amplicons from each well were analyzed for recovery and size integrity. The resulting fragments are then digested with AluI to fingerprint the sequence clonality. Identical sequences displayed a common fragmentation pattern in their electrophoretic analysis. The original heavy and light chain amplicon fragments were then digested using the restriction enzyme sites contained within the PCR primers and cloned into an expression vector. Vector containing subcloned DNA fragments were amplified and purified. Sequence of the subcloned heavy and light chains were verified prior to expression.

Recombinant Production of Monoclonal Antibody of Desired Antigen Specificity and/or Functional Properties

**[0600]** To determine antigen specificity and functional properties of recovered antibodies from specific B-cells, vectors driving the expression of the desired paired heavy and light chain sequences were transfected into HEK-293 cells.

Antigen-recognition of recombinant antibodies by ELISA

**[0601]** To characterize recombinant expressed antibodies for their ability to bind to human-CGRP $\alpha$ , antibody-containing solutions were tested by ELISA. All incubations were done at room temperature. Briefly, Immulon IV plagues (Thermo Scientific) were coated with a CGRP $\alpha$  containing solution (1 $\mu$ g/mL in PBS) for 2 hours. CGRP $\alpha$ -coated plates were then washed three times in wash buffer (PBS, 0.05% Tween-20). The plates were then blocked using a blocking solution (PBS, 0.5% fish skin gelatin, 0.05% Tween-20) for approximately one hour. The blocking solution was then removed and the plates were then incubated with a dilution series of the antibody being tested for approximately one hour. At the end of this incubation, the plate was washed three times with wash buffer and further incubated with a secondary antibody containing solution (Peroxidase conjugated affinipure F(ab')2 fragment goat anti-human IgG, Fc fragment specific (Jackson Immunoresearch) for approximately 45 minutes and washed three times. At that point a substrate solution (TMB peroxidase substrate, BioFx) and incubated for 3 to 5 minutes in the dark. The reaction was stopped by addition of a HCl containing solution (0.5M) and the plate was read at 450 nm in a plate-reader.

**[0602]** Results: Figures 15-18 demonstrate that anti-CGRP antibodies Ab1-Ab14 bind to and recognize CGRP $\alpha$ .

Functional characterization of recombinant antibodies by modulation of CGRP driven intracellular cAMP levels and cross reactivity to rats

**[0603]** To characterize recombinant expressed antibody for their ability to inhibit CGRP $\alpha$  mediated increased cellular levels of cAMP assay, an electrochemiluminescence assay-kit (Meso Scale Discovery, MSD) was used. Briefly, antibody preparations to be

tested were serially diluted in MSD assay buffer (Hepes, MgCl<sub>2</sub>, pH 7.3, 1mg/mL blocker A,Meso Scale Discovery) in a 96 well round bottom polystyrene plate (Costar). To this plate, human CGRP $\alpha$  was added (25ng/mL final concentration) diluted in MSD assay buffer and incubated for one hour at 37°C. Appropriate controls were used as suggested by the assay-kit manufacturer. Human neuroepithelioma cells (SK-N-MC, ATCC) were detached using an EDTA solution (5mM) and washed using growth media (MEM, 10% FBS, antibiotics) by centrifugation. The cell number was adjusted to 2 million cells per mL in assay buffer, and IBMX (3-Isobutyl-1Methylxanthine, 50mM Sigma) was added to a final concentration of 0.2mM right before loading cells onto cAMP assay plate. The antibody human CGRP $\alpha$  solution was incubated for one hour after which 20 microliters of solution containing cells were transferred to the cAMP assay plate. All tested samples were run in duplicates with appropriate controls. Ten microliters of cells were added to the wells and the plate was incubated for 30 minutes with shaking. While cells were being incubated with the CGRP solution, the stop solution was prepared by making a 1:200 solution of TAG labeled cAMP (MSD) in lysis buffer (MSD). To stop the cells-CGRP incubation, 20 microliters of stop solution was added to the cells and the plate was incubated for one hour with shaking. The read buffer (MSD) was diluted four times with water and 100 microliters were added to all wells on the plate. The plate was then read using a Sector Imager 2400 (MSD) and the Prism software was used for data fit and IC<sub>50</sub> determination.

**[0604]** To test for the ability of recombinant antibodies to antagonize human CGRP $\beta$  a similar assay was performed with the substitution of the CGRP agonist (CGRP $\beta$  10ng/mL final concentration). Evaluation of the recombinant antibodies to recognize and inhibit rat CGRP-mediated cAMP generation was conducted using rat CGRP (5ng/mL final concentration) and the rat L6 cell line (ATCC).

**[0605]** Results: Figures 19-37 demonstrate that anti-CGRP antibodies Ab1-Ab14 inhibit CGRP $\alpha$ , CGRP $\beta$ , and rat CGRP mediated increased cellular levels of cAMP.

**Example 2: Enzymatic Production of Fab Fragments**

[0606] Papain digestions were conducted using immobilized papain (Thermo/Pierce) as per manufacturer's instructions. Briefly, purified antibodies were incubated in a cysteine/HCl-containing buffer with immobilized papain at 37°C with gentle rocking. The digestion was monitored by taking an aliquot and analyzing using SDS-PAGE for cleavage of the heavy chain. To stop the reaction, the immobilized papain was spun out and washed using 50 mM Tris pH 7.5 and filtered. Undigested full length antibody and Fc fragments were removed by using a MabSelectSure (GE) column.

**Example 3 Yeast Cell Expression**

Construction of Pichia pastoris expression vectors for heavy and light chain.

[0607] The humanized light and heavy chain fragments were commercially synthesized and subcloned into a pGAP expression vector. The pGAP expression vector uses the GAP promoter to drive expression of the immunoglobulin chain and the human serum albumin (HSA) leader sequence for export. In addition, this vector contains common elements such as a bacterial origin of replication, and a copy of the kanamycin resistance gene which confers resistance to the antibiotic G418 in *P. pastoris*. G418 provides a means of selection for strains that contain the desired expression vector integrated into their genome.

Transformation of expression vectors into haploid met1 and lys3 host strains of Pichia pastoris

[0608] All methods used for transformation of haploid *P. pastoris* strains and manipulation of the *P. pastoris* sexual cycle were done as described in Pichia Protocols (Methods in Molecular Biology Higgins, DR, and Cregg, JM, Eds. 1998. Humana Press, Totowa, NJ). Prior to transformation each vector was linearized within the GAP promoter sequences to direct the integration of the vector into the GAP promoter locus of the *P. pastoris* genome. Haploid strains were transfected using electroporation and successful transformants were selected on YPDS (yeast extract, peptone dextrose with sorbitol) G418 agar plates. Copy numbers of heavy and light chain genes were determined for haploid strains by Southern blot analysis. Haploid strains were then mated and selected for their

ability to grow in the absence of the amino acid markers (i.e., Lys and Met). Resulting diploid clones were then subjected to a final Southern blot to confirm copy numbers of heavy and light chain genes. A clone expressing the antibody of interest was selected using biolayer interferometry Protein-A biosensors to monitor expression (Octet, ForteBio).

***Example 4 Expression of Ab3, Ab6 and Ab14 in Pichia pastoris***

**[0609]** Three Pichia strains for expression of full-length antibody were made. For all the full length antibody expressing strains, haploids strains were created and subsequently mated. One haploid strain expressed full-length light chain sequence and another haploid strain expressed the full-length heavy chain sequence. Each diploid strain was used to generate a research cell bank and used for expression in a bioreactor.

**[0610]** First an inoculum was expanded using the research cell bank using medium comprised of the following nutrients (%w/v): yeast extract 3%, anhydrous dextrose 4%, YNB 1.34%, Biotin 0.004% and 100 mM potassium phosphate. To generate the inoculum for the fermenters, the cell bank was expanded for approximately 24 hours in a shaking incubator at 30°C and 300 rpm. A 10% inoculum was then added to Labfors 2.5L working volume vessels containing 1 L sterile growth medium. The growth medium was comprised of the following nutrients: potassium sulfate 18.2 g/L, ammonium phosphate monobasic 36.4 g/L, potassium phosphate dibasic 12.8 g/L, magnesium sulfate heptahydrate 3.72 g/L, sodium citrate dihydrate 10 g/L, glycerol 40 g/L, yeast extract 30 g/L, PTM1 trace metals 4.35 mL/L, and antifoam 204 1.67 mL/L. The PTM1 trace metal solution was comprised of the following components: cupric sulfate pentahydrate 6 g/L, sodium iodide 0.08 g/L, manganese sulfate hydrate 3 g/L, sodium molybdate dihydrate 0.2 g/L, boric acid 0.02 g/L, cobalt chloride 0.5 g/L, zinc chloride 20 g/L, ferrous sulfate heptahydrate 65 g/L, biotin 0.2 g/L, and sulfuric acid 5 mL/L.

**[0611]** The bioreactor process control parameters were set as follows: Agitation 1000 rpm, airflow 1.35 standard liter per minute, temperature 28°C and pH was controlled at six using ammonium hydroxide. No oxygen supplementation was provided.

**[0612]** Fermentation cultures were grown for approximately 12 to 16 hours until the initial glycerol was consumed as denoted by a dissolved oxygen spike. The cultures were

starved for approximately three hours after the dissolved oxygen spike. After this starvation period, a bolus addition of ethanol was added to the reactor to reach 1% ethanol (w/v). The fermentation cultures were allowed to equilibrate for 15 to 30 minutes. Feed addition was initiated 30 minutes post-ethanol bolus and set at a constant rate of 1 mL/min for 40 minutes, then the feed pump was controlled by an ethanol sensor keeping the concentration of ethanol at 1% for the remainder of the run using an ethanol sensing probe (Raven Biotech). The feed was comprised of the following components: yeast extract 50 g/L, dextrose 500 g/L, magnesium sulfate heptahydrate 3 g/L, and PTM1 trace metals 12 mL/L. For fermentation of the full length Ab6 and Ab14, sodium citrate dihydrate (0.5g/L) was also added to the feed. The total fermentation time was approximately 90 hours.

***Example 5 Methods of Humanizing Antibodies***

**[0613]** Methods of humanizing antibodies have been described previously in issued U.S. Patent No. 7935340, the disclosure of which is incorporated herein by reference in its entirety. In some instances, a determination of whether additional rabbit framework residues are required to maintain activity is necessary. In some instances the humanized antibodies still require some critical rabbit framework residues to be retained to minimize loss of affinity or activity. In these cases, it is necessary to change single or multiple framework amino acids from human germline sequences back to the original rabbit amino acids in order to have desired activity. These changes are determined experimentally to identify which rabbit residues are necessary to preserve affinity and activity. This is now the end of the variable heavy and light chain humanized amino acid sequence.

***Example 6 Inhibition of CGRP Binding to its Cellular Receptor***

**[0614]** To characterize recombinantly expressed antibodies for their ability to inhibit CGRP binding to its cellular receptor, a radioligand-binding assay was performed as previously described [Elshourbagy *et al*, Endocrinology 139:1678 (1998); Zimmerman *et al*, Peptides, 16:421 (1995)]. Membrane preparations of recombinant human CGRP receptors, calcitonin receptor-like receptor and RAMP1 (Chemiscreen, Millipore) were used. Antibody dilutions were preincubated with <sup>125</sup>I radiolabeld human CGRP $\alpha$  (0.03nM)

for 30 minutes at room temperature. Non-specific binding was estimated in the presence of 0.1 $\mu$ M human CGRP $\alpha$ . Membranes were filtered and washed. The filters were then counted to determine  $^{125}$ I radiolabeld human CGRP $\alpha$  specifically bound.

**[0615]** Results: Figure 38 demonstrates that anti-CGRP antibodies Ab1-Ab13 inhibit CGRP binding to its cellular receptor.

**Example 7 Inhibition of Neurogenic Vasodilation by Anti-CGRP Antibodies in Rats**

**[0616]** CGRP is a potent vasodilator (Nature 313: 54-56 (1985) and Br J. Clin. Pharmacol. 26(6):691-5. (1988)). A pharmacodynamic assay to measure CGRP receptor antagonist activity non-invasively was used to characterize anti-CGRP antibodies. The model relied on changes in dermal blood flow measured using a laser Doppler imaging following the topical application of a capsaicin solution. Capsaicin activates the transient receptor potential vanilloid type 1 receptor (TRPV-1), producing neurogenic inflammation and vasodilatation *via* the local release of vasoactive mediators including CGRP and substance P (Br. J. Pharmacol. 110: 772-776 (1993)).

**[0617]** On the day prior to the vasodilatation assay, animals were dosed with the test agent or control via IP (intraperitoneal). Following dosing, the animals were shaved and depilated in the lower back region of their dorsal side, in an area approximately 2x6cm. The animals were then returned to their cages overnight. On the day of test, approximately 24 hours post dosing, animals were anesthetized with isoflurane gas and placed on a temperature controlled heating pad and fitted with a nose cone for continuous delivery of isoflurane. A laser Doppler imager was used for the observation of vasodilatation. A beam of coherent red light generated by a 633 nm helium-neon laser was directed to the shaved area, a rectangle (2x6 cm), and scanned at a medium resolution mode. A baseline Doppler scan was obtained first and the location of O-ring placement predetermined by identifying two similar low flux areas. Two rubber O-rings (~1cm in diameter) were placed in the selected regions and a baseline scan was performed. Immediately after completion of the scan, 1mg of capsaicin in 5  $\mu$ L of an ethanol:acetone solution (1:1) was applied within each of the two O-rings. Doppler scans were repeated at 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5 and 30 minutes after the application of capsaicin. Percent change from baseline

mean Flux within each of the two O-rings, was plotted as the results of vasodilatation due to capsaicin.

[0618] In order to test recombinantly expressed antibodies for their ability to inhibit CGRP binding to its cellular receptor, a radioligand-binding assay was performed as previously described.

[0619] Results: Figures 39 and 40 demonstrates that anti-CGRP antibodies Ab3 and Ab6 reduced vasodilation in this model following capsaicin administration.

***Example 8 Effect of CGRP Antibody Administration on Overactive Bladder***

[0620] Experiments were conducted to assess the potential efficacy of an anti-CGRP antibody administration on bladder continence and overactive bladder. Bladder continence is a balance between urethral closure and detrusor muscle activity, and overactive bladder is a condition characterized by urgency, urinary incontinence, frequency and nocturia. Some anecdotal evidence reported in the literature suggests that CGRP may be involved with bladder continence and may correlate to and perhaps play a causal role in overactive bladder disease pathology. Accordingly, it was hoped that the inventive anti-CGRP antibodies, especially given their high affinity to CGRP, would potentially help prevent or alleviate this sometimes debilitating condition. (The evidence that that CGRP may play a role in overactive bladder includes the fact that CGRP is present in the urinary tract, DRG and spinal cord (Wharton et al., 1986 *Neurosci* (3):727) Also, C-fiber afferents are critical for carrying impulses involved in micturition to spinal cord (Yoshida et al., 2011 *J Pharmacol Sci* (112):128) and these fibers are affected by CGRP. Further, it has been reported that intravesical administration of Botox suppresses CGRP and significantly reduces intercontraction interval in an acetic acid induced bladder pain model (Chuang et al., 2004 *J Urol* (172):1529; Chuang et al., 2009 *J Urol* (182):786)). Moreover, it has been recently reported that the administration of an anti-CGRP antibody purportedly reduces the number of bladder contractions in turpentine-oil – induced overactive bladder model (Pfizer PCT Patent Application WO 2011/024113)).

[0621] **Materials and Methods**

[0622] **Animals:**

[0623] Female Sprague-Dawley rats (247 – 299 g) (Charles River Laboratories, Saint Germain sur l'Arbresle, France) were delivered to the laboratory at least 5 days before the experiments in order to be acclimatized to laboratory conditions. They were housed 3 per cage (polypropylene type E cages size: 1032 cm<sup>2</sup>) and given food (Teklad 2016 global rodents, Harlan, 03800 Gannat, France) and water *ad libitum*. Sawdust (Souralit 2912 plus, Souralit, 17080 Girona, Spain) bedding for rodent cages was changed twice weekly. The animal room temperature (20 ± 2 °C) was maintained with a 12/12 hour alternating light-dark cycle (light phase 7 am: 7 pm) and relative humidity maintained at 40-70%.

[0624] Laboratory equipment

[0625] Bladder catheters were connected *via* a T-tube to a strain gauge MX 860 Novatrans III Gold (Medex Medical SARL, Nantes-Carquefou, France) and a syringe pump (70-2208 Model II plus, Harvard Apparatus, Les Ullis, France and Razel R-99E, Fisher Bioblock, Illkirch, France). Intravesical pressure was recorded continuously using a PowerLab interface (ADInstruments Pty Ltd, Castle-Hill, Australia) and Chart® software running on a PC. Data were analyzed with Microsoft Excel ® software.

[0626] Test substances

[0627] Test Anti-CGRP antibody (Ab3)

[0628] Negative control antibody (Anti-digitoxin antibody).

[0629] Chemical reagents

[0630] Physiological saline (NaCl 0.9%) (batch n° 11043411, CAS n° 7647-14- 5) was purchased from B-Braun *via* Centravet (Lapalisse, France).

[0631] Anesthetic substances

[0632] Urethane (batch n° BCBC9294, CAS n° 51-79-6) and sodium pentobarbital (batch n° 150A1, CAS n°76- 74-4) were supplied by Sigma-Aldrich (St Quentin Fallavier, France) and Centravet (Lapalisse, France), respectively.

[0633] Experimental groups

[0634] Two experimental groups of 10 rats were used in the experiments. Each group was administered 10 mg/kg of either the control or the anti-CGRP antibody:

[0635] Study design

[0636] Experimental procedure

[0637] Female rats were administered test antibody or negative control antibody intravenously at a dose of 10 mg/kg, 18 hours prior to experiments using a tail vein injection. Fifteen (15) hours later, rats were anesthetized with urethane (1.2 g/kg, subcutaneous (s.c.). Three (3) hours after the s.c. administration of urethane, a polyethylene catheter (0.58 and 0.96 mm of internal and outer diameters, respectively) was inserted into the bladder through the dome and secured with a purse-string suture. Body temperature was maintained at  $37\pm 2^{\circ}\text{C}$  (TCAT-2LV controller, Physitemp, ADInstruments Pty Ltd., Castle Hill, Australia) throughout the experiment.

[0638] Cystometric experiment

[0639] Cystometric investigations were performed in anesthetized female rats after surgery. Physiological saline at room temperature was continuously infused into the bladder at a constant flow rate (2 mL/h) for a period of at least 30 min.

[0640] At the end of the cystometric experiments, animals were sacrificed by a lethal injection (1 mL) of sodium pentobarbital (54.7 mg/mL) (CAS n°76-74-4) followed by cervical dislocation.

[0641] Cystometric parameters

[0642] The cystometric parameters measured were:

[0643] Amplitude of micturition (AM), *i.e.* pressure between threshold pressure and Maximal pressure of micturition (mmHg),

[0644] Intercontraction interval (ICI), *i.e.* time between two subsequent micturitions (sec),

[0645] Micturition frequency (MF), *i.e.* number of micturition contractions /15 min (peaks/15 min).

[0646] Exclusion criteria

[0647] Two rats were excluded during the experiments: One was excluded as it presented with bladder hyperactivity during the saline intravesical infusion, and the other because the depth of anesthesia changed during the experiment inducing modifications of the cystometric profile.

[0648] Analysis of results

[0649] For each rat, values for AM and ICI were calculated as the mean of the last four or five micturitions during saline infusion. Values for MF were calculated as the mean of micturitions obtained for two intervals of 15 minutes during saline infusion.

[0650] Results are presented as mean values  $\pm$  standard error of the mean ( $\pm$  sem). Figures and statistical analyses were performed using GraphPad Prism<sup>®</sup> (Version 4; GraphPad Software Inc., La Jolla, CA, USA).

[0651] Statistical comparisons of values (saline infusion) in the anti-CGRP antibody group *versus* the control antibody group were performed using unpaired Student *t*-test.

[0652] A  $p < 0.05$  was accepted for statistical significance.

[0653] **Results:**

[0654] As shown in FIG. 41, ICI was significantly greater and MF was significantly lower in the anti-CGRP Ab-treated group (FIGS. 41A and B respectively;  $p < 0.05$ , unpaired Student *t*-test). No significant difference was observed for AM between groups (FIG. 41C,  $p > 0.05$ , unpaired Student *t*-test).

[0655] These results suggest that anti-CGRP antibodies may be useful in preventing or alleviating overactive bladder, improving urinary continency and treatment of related urinary conditions.

**Example 9 Relief of neuropathic pain in rats**

[0656] Damage to the peripheral nerves often leads to chronic referred pain that is neuropathic in origin. This pain syndrome consists of sensitivity to external stimuli (e.g., mechanical and/or thermal) that are not normally noxious. Consequently, neuropathic pain is refractory to traditional analgesic approaches, making it difficult to treat. Experimentally, neuropathic pain can be modeled in animals via surgical trauma to peripheral nerves. The Chung model is one such system where neuropathic pain is induced by ligation of the spinal nerves of L5 and L6.

[0657] In this Example, a spinal nerve ligation was performed on male Sprague Dawley rats. They were tested for pain sensitivity on Day 13 (allodynia confirmation) and then again after each administration of Ab2 using the von Frey test of mechanical allodynia to assess possible anti-allodynic activity.

**[0658]** *Methods*

**[0659]** Male Sprague Dawley rats (Harlan Laboratories) weighing 200-225g at arrival, were unpacked and placed in cages. A visual health inspection was performed on each animal to include evaluation of the coat, extremities and orifices. Each animal was also examined for any abnormal signs in posture or movement. All animals were found to be in good health and were placed on study.

**[0660]** The rats were acclimated for a minimum of two days prior to the commencement of the experimental procedures, with the exception of randomization body weights which were collected the day following arrival. The animals were housed individually in clear polycarbonate conventional cages or clear polycarbonate microisolator cages with certified irradiated contact bedding. Food and water were provided *ad libitum*. Environmental controls were set to maintain temperatures of 18° to 26°C (64° to 79°F) with a relative humidity of 30% to 70%. A 12:12 hour light:dark cycle was maintained.

**[0661]** Rats were tested for baseline threshold using the von Frey filaments on Days -4 or -1 of acclimation.

**[0662]** On Day 0, animals underwent a spinal nerve ligation procedure. All surgeries were performed under aseptic conditions. Prior to surgeries, the rats were anesthetized. The back region was shaved and prepared for aseptic surgery. The rats were placed in ventral recumbence and an incision was made just left of midline at the L4 – S2 region. The left paraspinal muscles were separated from the spinous processes (L4 – S2). The L6-S1 facet joint were nipped and the transverse process gently trimmed to provide space to access the L4 & L5 spinal nerve. The left L5 and L6 spinal nerves were isolated and ligated with 6.0 silk sutures. The incision was then closed with appropriate suture material and skin wound clips. Post-operatively, Lactated Ringer's Solution (3.0 – 5.0 mL) was administered via subcutaneous injection to the animals.

**[0663]** All animals in Groups 1 and 2 received a von Frey test on Days -4 or -1, 13, 14, and 17. The measurement on Day 13 was taken pre-dose. The von Frey test for mechanical allodynia assesses anti-nociceptive properties of analgesic compounds. In this test, animals were first habituated to the testing chamber so they were calm enough for their pain threshold to be assessed. A technician blind to the treatment groups applied light pressure

to the left hind paw of the rat using a series of graded nylon filaments (von Frey filaments) of increasing diameter. The filaments were pressed perpendicularly against the ventral surface of the paw until they bent. When considered painful, the rat responds by withdrawing its paw. Threshold allodynia was determined using the Chaplan up-down method (Chaplan et al., J Neurosci Methods, 53:55-63, 1994), which provides the precise force for withdrawal for each rat using a psychophysical scale of testing.

**[0664]** Animals were allocated into two treatment groups on Day 13, based on von Frey scores. Any animal that had a von Frey score greater than 6g was excluded from the study. The mean von Frey scores for each group were reviewed to ensure that the mean values and standard deviation satisfied the assumption of homogeneity. Doses were administered by IP injection once on Day 13 (13 days after surgery) for Group 1 (Ab2) and Group 2 (negative control antibody) (11 animals in each group; Ab2 and negative control antibodies were administered at 10 mg/kg). Group 1 received an additional IV bolus (un-anesthetized) injection of Ab2 on Day 17 prior to behavioral testing.

**[0665]** Blood samples for plasma were taken on Day 17 for Group 1 and analyzed for Ab2 titer.

**[0666]** Outside of the expected surgical site observations and paw dragging associated with the Chung surgery, no abnormal observations were documented. Treatment appeared to have no adverse effect on overall animal health nor did it disrupt the normal weight gain expected in rats this age.

**[0667]** *Results*

**[0668]** All animals that underwent baseline testing prior to surgery on Day 0 had a von Frey score of 15 (not shown) indicating normal sensitivity. On Day 13 (prior to antibody administration), all animals had von Frey scores lower than 6g, indicating that sensitivity to external mechanical stimuli had developed, except for two animals which were removed from the study. Average von Frey scores at day 13 were less than 3 g (FIG. 42, left group of bars). Following testing on day 13, animals were administered Ab2 or a negative control antibody (10 mg/kg). On days 14 and 17, von Frey scores were again tested and were higher in the Ab2-treated animals than controls (FIG. 42, middle group of bars and right group of bars, respectively).

[0669] These results indicate that treatment with an anti-CGRP antibody such as Ab2 may help prevent or alleviate neuropathic pain.

**Example 10 First Experiment Assessing Effect of Anti-CGRP Antibody Administration on Analgesia (Tail Flick Model)**

[0670] Three different experiments (Examples 10-12) were conducted to assess the potential efficacy of an anti-CGRP antibody administration on analgesia or pain. In all of these experiments a rodent tail flick (also referred to as tail withdrawal) response model was used as the rodent tail flick response to radiant heat is a commonly used model to detect potentially useful analgesic agents. This assay is particularly useful to discriminate between centrally acting morphine-like analgesics (active) and non-opioid or peripherally acting anti-inflammatory agents (inactive). This animal model and methods and materials used therein are described below.

**[0671] Materials and Methods**

[0672] **Animals:** Male Sprague Dawley derived male rats weighing  $150 \pm 20$  g.

[0673] **Test CGRP Antibody:** Ab2

[0674] **Vehicle:** 15 mM Histidine 250 mM Sorbitol, pH 5.5

[0675] **Analgesic Compound:** Morphine

[0676] **Tail Flick Response Procedures:** The time (seconds) required to elicit a tail flick response induced by focused radiant heat was measured as the pain threshold in groups of 10 Sprague Dawley derived male rats weighing  $150 \pm 20$  g. Baseline testing for the tail flick response was done on Day 0. The rats that have a tail flick response of 3-5 seconds were included in the study and assigned to balanced treatment groups based on baseline tail flick responses. A 15 second cut was used to avoid tissue damage.

**[0677] Development of morphine tolerance**

[0678] Each of 3 groups of 10 Male Sprague Dawley rats were dosed 2 x daily via i.p. administration with saline vehicle (2 ml/kg) in the morning and evening. One of the 3 groups was in addition administered i.p. analgesic (morphine) at a dosage of 5 mg/kg 2 x daily for 7 consecutive days. A second of the 3 groups of rats was administered i.p. an anti-CGRP antibody according to the invention (Ab2) at a dosage of 10 mg/kg as a single

bolus on day 0. The rats in the different groups were then each tested for tail flick response once per day 30 min after the morning dose.

**[0679]** A one-way ANOVA followed by Dunnett's t-test is applied for comparison between the vehicle control and test-compound treated groups. P<0.05 is considered significant.

**[0680]** The results of these experiments are shown in Figure 43. The results therein indicate that the test CGRP antibody when administered at 10 mg/kg elicited significant long-lasting analgesic effect to a thermal pain stimulus. Terminal blood samples were taken from all the tested rats via cardiac puncture and later analyzed for Ab2 titer.

*Example 11: Second Tail Flick Experiment Assessing Effect of-CGRP Antibody on Analgesia) (Antibody Dose Titration)*

**[0681]** A second set of tail flick experiments were conducted to assess the effects of different anti-CGRP antibody dosages on analgesia using an anti- CGRP antibody according to the invention (Ab2). The rats used in these experiments are the same type as in the previous experiment and the tail flick protocol substantially the same. In this experiment analgesia was compared in different groups of animals administered different anti-CGRP antibody dosages in order to assess whether the dosage has an effect on analgesia. In the second set of experiments, five groups of test animals were compared as follows. A first control group of animals were each administered the vehicle alone (15 mM Histidine 250 mM Sorbitol, pH 5.5), 3 groups of animals were each administered different dosages of the same anti-CGRP antibody contained in the vehicle (Ab2, respectively administered at dosages of 1 mg/kg, 3 mg/kg or 10 mg/kg on Day 0), and a fifth group of animals was administered 10 mg/kg of a negative control antibody (anti-digitoxin antibody) also on Day 0.

**[0682]** The tail flick protocols were otherwise substantially effected as above-described. The results were again assessed using one-way ANOVA followed by Dunnett's t-test for comparison between the vehicle control, negative control antibody and test-CGRP antibody treated groups. P<0.05 is considered significant.

**[0683]** The results of these experiments are shown in Figure 44. It can be seen therefrom that the higher antibody dosages of the test compound (inventive Ab2 anti-

CGRP antibody) elicited better analgesic effects than the lower dosages. As anticipated the negative control antibody did not elicit a perceptible effect on analgesia relative to the control groups.

***Example 12: Third Tail Flick Experiment Assessing Effect of Anti-CGRP Antibody/Morphine Co-administration on Analgesia***

**[0684]** A third set of tail flick experiments were also conducted to assess the effects of anti-CGRP antibody/morphine co-administration on analgesia. In these experiments a first group of animals was administered the same vehicle alone at a dosage of 5 ml/kg. A second group of animals was administered morphine on days 1-10 at a dosage of 5 mg/kg, administered twice daily, wherein such animals were on Day 0 were also administered the anti-CGRP antibody Ab2 at a dosage of 10 mg/kg. A third group of animals was administered morphine on only days 1-4 again at a dosage concentration of 5 mg/kg, administered twice daily, and were further administered the Ab2 antibody on Day 0, at a dosage of 10 mg/kg. All administrations were i.p.

**[0685]** Tail flick experiments were effected in each of these groups of animals daily from Day 0-10. The results of these tail flick experiments were again assessed using one-way ANOVA followed by Dunnett's t-test for comparison between the vehicle control, negative control antibody and the test anti-CGRP antibody treated group. P<0.05 is considered significant.

**[0686]** The results of these comparisons are summarized in Figure 45. The Ab2-treated animals receiving a daily dose of morphine throughout the experiment exhibited morphine tolerance, and after day 5 the tail flick time had decreased almost to the level of vehicle-treated control animals. In contrast, in Ab2-treated animals receiving morphine only until day 4, the tail flick time improved on day 5 and remained improved until day 8. The results suggest that the administration of an anti-CGRP antibody may have analgesic effects even after onset of morphine tolerance, which may be more pronounced upon withdrawal of morphine.

***Example 13 Relief of visceral pain in rats***

**[0687]** Patients suffering from irritable bowel syndrome (IBS) demonstrate a lower visceral sensory threshold to colorectal balloon distension (Ritchie, Gut, 1973, 14:125-32). It has been suggested in IBS that there is heightened pain sensitivity of the brain-gut axis, with a normal pattern of activation. It has previously been shown that injection of trinitrobenzene sulfonic acid (TNBS) into the proximal colon provoked chronic colonic hypersensitivity, measured in conscious rats by a decreased pain threshold in response to colonic distension (Diop et al., J. Pharmacol. Exp. Ther., 2002, 302:1013-22). This chronic hypersensitivity was found in the distal non-inflamed colon and persisted for 21 days. It mimicked certain characteristics of IBS and so it can be used as a model to experimentally explore the pathophysiological aspects of this disorder. This assay is used to determine the potential antihypersensitive effects of compounds for TNBS-induced colonic hypersensitivity.

**[0688]** Several studies have implicated CGRP in visceral pain (Friese et al., Regul Pept 1997;70:1-7; Gschossmann et al., Neurogastroenterol Motil 2001;13:229-36; Julia and Bueno, Am J Physiol 1997;272:G141-6; Plourde et al., Am J Physiol 1997;273:G191-6). CGRP is the most abundant peptide of capsaicin sensitive afferent fibers of gastrointestinal origin, accounting for up to 80% of overall peptide immunoreactivity (Clague et al., Neurosci Lett 1985;56:63-8; Sternini et al., Gastroenterology 1987;93:852-62). Additionally, injection of CGRP induces colonic hypersensitivity in a TNBS model (Delafoy et al., 2006, Gut 55:940-5), which is reversed by a CGRP antagonist peptide (CGRP 8-37).

**[0689]** This example describes testing of an anti-CGRP antibody in a model of visceral pain (TNBS-induced chronic colonic hypersensitivity) in rats.

**[0690]** *Methods*

**[0691]** Male Sprague-Dawley rats, weighing 390 to 450 g the day of surgery were included in this study. They were housed in a temperature (19.5°C - 24.5°C) and relative humidity (45 % - 65 %) controlled room with a 12 h - light/dark cycle. Animals were housed 2 or 3 per cage and an acclimation period (at least 5 days) was observed before testing. Each rat was identified by tail markings. The study was performed according to

the guidelines of the Committee for Research and Ethical Issue of the I.A.S.P. (1983) and the European guidelines 2010/63/UE.

[0692] Colonic sensitivity was induced by surgical administration of Trinitrobenzene sulfonic acid (TNBS, 50 mg/kg) 7 days before behavioral testing. Fasted (24 hours) animals underwent surgery. Briefly, under anesthesia (Acetaminophen 5 mg/kg / Ketamine 30 mg/kg), injection of TNBS (50 mg/kg, 1 ml/kg) was performed into the proximal part of the colon (1 cm from the caecum). After surgery, animals were returned to their cages in a regulated environment, and fed ad libitum until the testing day, 7 days later. “Naïve” animals (rats without surgery) were placed in the same housing conditions.

[0693] Animals were administered the anti-CGRP antibody Ab2 or a negative control antibody (both at 10 mg/kg) intravenously 24 hours prior to determination of colonic threshold. Three groups of rats were included in this study:

[0694] Group 1: A “Naïve” group composed of animals that did not undergo surgery or TNBS treatment on D-7 and were treated with the control antibody 24 hrs prior (i.e. D-1) to testing (i.e. measurements of the colonic distention threshold on D0) (n=7).

[0695] Group 2: A “TNBS” group composed of animals that underwent surgery on D-7 and were treated with control antibody (24 hrs prior (i.e. D-1) to testing (i.e. measurements of the colonic distention threshold on D0) (n=8).

[0696] Group 3: A “Treated” group composed of animals that underwent surgery on D-7 and were treated with Ab2 24 hrs prior (i.e. D-1) to testing day (i.e. measurements of the colonic distention threshold on D0) (n=8).

[0697] Seven days (D7) after TNBS injection, colonic sensitivity was assessed by measuring the intra-colonic pressure required to induce a behavioral response during colonic distension due to the inflation of a balloon introduced in the colon. The tests were conducted by a blinded experimenter. This response is characterized by an elevation of the hind part of the animal body and a clearly visible abdominal contraction corresponding to severe contractions (Al Chaer et al., Gastroenterology 2000, 119:1276-1285) and used as a pain marker (Bourdu et al., Gastroenterology. 2005:128, 1996-2008). The balloon (5 cm) was inserted intrarectally in a minimally invasive manner to 10 cm from the anus of fasted (24h) vigil animals, and the catheter was taped to the base of the tail. Rats were then placed

in the middle of a plexiglass box and the catheter was connected to an electronic barostat apparatus. After a 30 min-acclimation period with the inserted balloon, colonic pressure was gradually increased by 5 mmHg steps every 30 sec from 5 to 75 mmHg (cut off) until pain behavior is evidenced. Four determinations were performed, 30 min, 50 min, 70 min and 90 min after balloon insertion.

[0698] Using the data from each test, the percentage of activity on colonic hypersensitivity induced by the intracolonic administration of TNBS was calculated as follows

$$(Activity\ percentage)_{Treated} = \frac{Distention\ threshold_{Treated} - Distention\ threshold_{TNBS}}{Distention\ threshold_{Naive} - Distention\ threshold_{TNBS}} \times 100$$

[0699] *Distention threshold<sub>Treated</sub>* is the arithmetic mean of the values for the “Treated” group; *Distention threshold<sub>TNBS</sub>* is the arithmetic mean of the values for the “TNBS” group; and *Distention threshold<sub>Naive</sub>* is the arithmetic mean of the values for the “Naïve” group.

[0700] *Results*

[0701] The ability of an anti-CGRP antibody to alleviate visceral pain was tested in a rat model in which chronic colonic hypersensitivity was induced by administration of TNBS. Visceral pain was quantified by measuring the colonic distension threshold, i.e., the amount of abdominal pressure that the animals could tolerate before exhibiting a behavioral response (muscle contraction). Higher colonic distension threshold values indicate less sensitivity. As expected, TNBS treatment resulted in greatly decreased the colonic distension threshold compared to naïve animals (FIG. 46, compare middle bar (TNBS treated) and left bar (naïve)). Ab2 administration improved the colonic distension threshold compared to control animals (FIG. 46, compare right bar (Ab2 treated) and middle bar (control)). The improvement from Ab2 administration was statistically significant (p < 0.05 Student’s t-test, comparison to TNBS + Negative control group). The antihypersensitive activity of Ab2 was computed to be 27% (indicative of the degree of relief of the TNBS-induced hypersensitivity).

[0702] These results suggest that anti-CGRP antibodies may be useful in preventing or alleviating visceral pain.

## CLAIMS

*What is claimed is:*

- 1.) An anti-human CGRP antibody or antibody fragment which specifically binds to the same or overlapping linear or conformational epitope(s) and/or competes for binding to the same or overlapping linear or conformational epitope(s) on an intact CGRP polypeptide or fragment thereof as an anti-human CGRP antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13 or Ab14.
- 2.) The anti-human CGRP antibody or fragment of claim 1 which specifically binds to the same or overlapping linear or conformational epitope(s) and/or competes for binding to the same or overlapping linear or conformational epitope(s) on an intact human CGRP polypeptide or a fragment thereof as Ab3, Ab6, Ab13 or Ab14.
- 3.) The antibody fragment of claim 1, wherein said fragment is selected from a Fab fragment, a Fab' fragment, a F(ab')2 fragment, or a monovalent antibody such as "metMab".
- 4.) The antibody fragment of claim 3, wherein said fragment is a Fab fragment.
- 5.) An anti-human CGRP antibody or antibody fragment according to claim 1, that comprises the same CDRs as an anti-human CGRP antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13 or Ab14.
- 6.) The Fab fragment of claim 4, comprising a variable light chain comprising the CDR 1 sequence of SEQ ID NO:25, the CDR 2 sequence of SEQ ID NO:26, and the CDR 3 sequence of SEQ ID NO:27, and/or a variable heavy chain comprising the CDR 1 sequence of SEQ ID NO:28, the CDR 2 sequence of SEQ ID NO:29, and the CDR 3 sequence of SEQ ID NO:30.
- 7.) The Fab fragment of claim 4, comprising a variable light chain comprising the CDR 1 sequence of SEQ ID NO:55, the CDR 2 sequence of SEQ ID NO:56, and the CDR 3

sequence of SEQ ID NO:57, and/or a variable heavy chain comprising the CDR 1 sequence of SEQ ID NO:58, the CDR 2 sequence of SEQ ID NO:59, and the CDR 3 sequence of SEQ ID NO:60.

- 8.) The anti-human CGRP antibody or antibody fragment of claim 1 which comprises at least 2 complementarity determining regions (CDRs) in each of the variable light and the variable heavy regions which are identical to those contained in an anti-human CGRP antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13 or Ab14.
- 9.) The anti-human CGRP antibody or antibody fragment of claim 8 which comprises at least 2 complementarity determining regions (CDRs) in each of the variable light and the variable heavy regions which are identical to those contained in Ab3, Ab6, Ab7, Ab8, Ab13 or Ab14.
- 10.) The anti-human CGRP antibody or antibody fragment of claim 1 which is aglycosylated or if glycosylated only contains only mannose residues.
- 11.) The anti-human CGRP antibody or antibody fragment of claim 1 which is not N-glycosylated.
- 12.) The anti-human CGRP antibody or antibody fragment of claim 1 which contains an Fc region that has been modified to alter effector function, half-life, proteolysis, and/or glycosylation.
- 13.) The anti-human CGRP antibody or antibody fragment of claim 1 which is a humanized, single chain or chimeric antibody.
- 14.) The anti-human CGRP antibody or antibody fragment of claim 1 which specifically binds to CGRP expressing human cells and/or to circulating soluble CGRP molecules *in vivo*.

- 15.) The anti-human CGRP antibody or antibody fragment of claim 14 which specifically binds to CGRP expressed on or by human cells in a patient with a disease associated with cells that bind CGRP.
- 16.) The anti-human CGRP antibody or antibody fragment of claim 15 wherein the disease is migraine (with or without aura), a condition with CGRP- associated pain, weight loss, cancer or tumors, overactive bladder, urinary incontinence, pruritis, psoriasis, ulcer, a cardiac condition, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, migraines, chronic migraines, frequent episodic migraines, menstrual migraines, hemiplagic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), allergy-induced headaches or migraines, pain, TMJ, temporomandibular jaw disorders, inflammatory pain, visceral pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptive pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptive pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarian pain, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, or pancreatitis.
- 17.) The anti-human CGRP antibody or antibody fragment of claim 15 wherein the disease is selected from pain, visceral pain, TMJ, temporomandibular jaw disorders, headache, overactive bladder, urinary incontinence or migraine.
- 18.) The anti-human CGRP antibody or fragment of claim 17 wherein the disease is migraine.

- 19.) The anti-human CGRP antibody or fragment of claim 17 wherein the disease is migraine with or without aura.
- 20.) The anti-human CGRP antibody or fragment of claim 17 wherein the disease is one of the following types of migraines: chronic migraine, frequent episodic migraines, or menstrual migraines.
- 21.) The anti-human CGRP antibody or fragment of claim 17 wherein the disease is cluster headache.
- 22.) The anti-human CGRP antibody or fragment of claim 1 which is directly or indirectly attached to a detectable label or therapeutic agent.
- 23.) A nucleic acid sequence or nucleic acid sequences which result in the expression of an anti-human CGRP antibody or antibody fragment according to claim 1 or claim 5.
- 24.) The nucleic acid sequence or sequences of claim 23 which are comprised of yeast or human preferred codons.
- 25.) A vector comprising a nucleic acid sequence or sequences according to claim 24.
- 26.) The vector of claim 25 which is a plasmid or recombinant viral vector.
- 27.) A cultured or recombinant cell which expresses an antibody or antibody fragment according to any one of claims 1-22.
- 28.) The cell of claim 27 which is selected from a mammalian, yeast, bacterial, fungal, or insect cell.
- 29.) The cell of claim 28 which is a yeast cell.
- 30.) The cell of claim 29 which is a diploidal yeast cell.
- 31.) The yeast cell of claim 30 which is a *Pichia* yeast.

32.) A method of treatment comprising administering to a patient with a disease or condition treatable by the administration of a CGRP antagonist a therapeutically effective amount of at least one anti-human CGRP antibody or fragment according to claim 1 or 5.

33.) The method of Claim 32, wherein the disease or condition is one associated with CGRP expressing cells a therapeutically effective amount of at least one anti-human CGRP antibody or fragment according to claim 1 or 5.

34.) The method of claim 32 or 33 wherein the disease is selected from migraine (with or without aura), weight loss, cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, migraine, chronic migraine, frequent episodic migraines, or menstrual migraines hemiplegic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), allergy-induced headaches or migraines, pain, inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptive pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptive pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarian pain, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, or pancreatitis.

35.) The method of claim 32 or 33, wherein the condition comprises overactive bladder; urinary incontinence; pain; chronic pain; neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; post-surgical pain, trauma related pain, diabetes; non-insulin dependent diabetes mellitus and other inflammatory autoimmune disorders,

vascular disorders; inflammation; arthritis; bronchial hyperreactivity, asthma; shock; sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes in men and women; allergic dermatitis; psoriasis; encephalitis; brain trauma; epilepsy; neurodegenerative diseases; skin diseases including pruritis, neurogenic cutaneous redness, skin rosaceousness and erythema; inflammatory bowel disease, irritable bowel syndrome, cystitis; and dysmenorrhea.

- 36.) The method of claim 32 or 33 wherein the disease or condition is pain, overactive bladder, urinary incontinence, headache or migraine.
- 37.) The method of claim 32 or 33 wherein the treatment further includes the administration of another therapeutic agent or regimen selected from anti-histamines, anti-inflammatory agents, analgesics or antibiotics.
- 38.) The method of Claim 37, wherein the analgesic is an NSAID, an opioid analgesic, an antibody or antibody fragment or another analgesic biologic.
- 39.) The method of Claim 38, wherein the analgesic is an opioid and the method is used to reduce or prevent tolerance to the opioid.
- 40.) The method of claim 38, wherein the opioid is morphine or a morphine derivative.
- 41.) The method of Claim 37, wherein the other analgesic is a NGF antibody or antibody fragment.
- 42.) A method of *in vivo* imaging which detects the presence of cells which express CGRP comprising administering a diagnostically effective amount of at least one anti-human CGRP antibody or antibody fragment according to claim 1.
- 43.) The method of claim 42 wherein said administration further includes the administration of a radionuclide or fluorophore that facilitates detection of the antibody at CGRP expressing disease sites.

- 44.) The method of claim 42 wherein the results are used to facilitate design of an appropriate therapeutic regimen.
- 45.) An isolated anti-CGRP antibody or antibody fragment comprising a V<sub>H</sub> polypeptide sequence selected from: SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133, or a variant thereof that exhibits at least 90% sequence identity therewith; and/or a V<sub>L</sub> polypeptide sequence selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131, or a variant thereof that exhibits at least 90% sequence identity therewith, wherein one or more of the framework (FR) or CDR residues in said V<sub>H</sub> or V<sub>L</sub> polypeptide has been substituted with another amino acid residue resulting in an anti-CGRP antibody that specifically binds CGRP.
- 46.) An isolated anti-CGRP antibody or antibody fragment comprising a V<sub>H</sub> polypeptide sequence selected from: SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133, or a variant thereof that exhibits at least 95% sequence identity therewith; and/or a V<sub>L</sub> polypeptide sequence selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131, or a variant thereof that exhibits at least 90% sequence identity therewith, wherein one or more of the framework (FR) or CDR residues in said V<sub>H</sub> or V<sub>L</sub> polypeptide has been substituted with another amino acid residue resulting in an anti-CGRP antibody that specifically binds CGRP.
- 47.) The isolated antibody or antibody fragment of claim 45 or 46 wherein one or more of said FR residues are substituted with an amino acid present at the corresponding site in a parent rabbit anti-CGRP antibody from which the complementarity determining regions (CDRs) contained in said V<sub>H</sub> or V<sub>L</sub> polypeptides have been derived or by a conservative amino acid substitution.
- 48.) The isolated antibody antibody or antibody fragment of claim 45 or 46 wherein at most 1 or 2 of the residues in the CDRs of said V<sub>L</sub> polypeptide sequence are modified.
- 49.) The isolated antibody antibody or antibody fragment of claim 45 or 46 wherein at most 1 or 2 of the residues in the CDRs of said V<sub>H</sub> polypeptide sequence are modified.

- 50.) The antibody or antibody fragment of claim 45 or 46, wherein said antibody is humanized.
- 51.) The antibody or antibody fragment of claim 45 or 46, wherein said antibody is chimeric.
- 52.) The antibody or antibody fragment of claim 45 or 46 which comprises a single chain antibody.
- 53.) The antibody of claim 50 or 51, wherein said humanized or chimeric antibody comprises a human F<sub>c</sub>.
- 54.) The antibody or antibody fragment of claim 53, wherein said human F<sub>c</sub> is derived from IgG1, IgG2, IgG3, or IgG4.
- 55.) The antibody or antibody fragment of any one of claims 45-54, wherein said antibody inhibits the association of CGRP with CGRP-R and/or multimers thereof, one or more additional proteins in a CGRP-CGRP-R complex, and/or antagonizes the biological effects thereof.
- 56.) An isolated anti-CGRP antibody or antibody fragment comprising a polypeptide sequence having at least 90% or greater homology to any one of the polypeptide sequences of claim 45 or 46.
- 57.) An isolated anti-CGRP antibody or antibody fragment comprising a polypeptide sequence having at least 95% or greater homology to any one of the polypeptide sequences of claim 45 or 46.
- 58.) The antibody or antibody fragment of claim 56, wherein said antibody binds to CGRP with an off-rate (K<sub>off</sub>) of less than or equal to 10<sup>-4</sup> S<sup>-1</sup>, 5x10<sup>-5</sup> S<sup>-1</sup>, 10<sup>-5</sup> S<sup>-1</sup>, 5x10<sup>-6</sup> S<sup>-1</sup>, 10<sup>-6</sup> S<sup>-1</sup>, 5x10<sup>-7</sup> S<sup>-1</sup>, or 10<sup>-7</sup> S<sup>-1</sup>.

- 59.) The antibody or antibody fragment of any one of claims 45-58, wherein said antibody inhibits the production of a complex of CGRP with CGRP-R and/or multimers thereof, and the production of CGRP with CGRP-R and one or more additional proteins in a complex.
- 60.) An antibody fragment according to of any one of claims 45-59, wherein said fragment is selected from a Fab fragment, a Fab' fragment, or a F(ab')2 fragment.
- 61.) The antibody or antibody fragment of any one of claims 45-60, wherein said antibody or antibody fragment further comprises an effector moiety.
- 62.) The antibody or antibody fragment of claim 61, wherein the effector moiety is a detectable moiety or a functional moiety.
- 63.) The antibody of claim 62, wherein said detectable moiety is a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material.
- 64.) The antibody of claim 62, wherein said functional moiety is streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, or a radioactive material.
- 65.) A method of ameliorating or reducing symptoms of a disease or disorder treatable by the administration of a CGRP antagonist comprising administering to an individual in need thereof a therapeutically effective amount of a CGRP antibody or antibody fragment according to any one of claims 45-64.
- 66.) The method of Claim 65, wherein the disease is associated with increased CGRP.
- 67.) The method of claim 65 or 66, wherein said disease or disorder is selected from migraine (with or without aura), weight loss, cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, hemiplegic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), allergy-induced headaches

or migraines, pain, inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptive pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptive pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovariangia, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, or pancreatitis.

68.) The method of claim 65 or 66, wherein the condition comprises overactive bladder, pain; TMJ, temporomandibular jaw disorders, chronic pain; neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; post-surgical pain, trauma related pain, diabetes; non-insulin dependent diabetes mellitus and other inflammatory autoimmune disorders, vascular disorders; inflammation; arthritis; sarcoidosis, bronchial hyperreactivity, asthma; shock; sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes in men and women; allergic dermatitis; psoriasis; encephalitis; brain trauma; epilepsy; neurodegenerative diseases; skin diseases including pruritis, neurogenic cutaneous redness, skin rosaceousness and erythema; inflammatory bowel disease, irritable bowel syndrome, cystitis; and dysmenorrhea.

69.) The method of claim 65 or 66 wherein the disease or condition is pain, overactive bladder, headache, or migraine.

70.) The method of any of Claims 65-69, wherein the CGRP antibody or antibody fragment comprises the same CDRs as Ab3 or Ab6.

71.) The method of any of Claims 65-69, wherein the CGRP antibody or antibody fragment is administered in a therapeutic regimen for treatment of a specific disease or condition associated with pain that includes the administration of another therapeutic agent.

- 72.) The method of Claim 71, wherein the other therapeutic agent is selected from a chemotherapeutic, an analgesic, an anti-inflammatory, an immunosuppressant, a cytokine, an antiproliferative, an antiemetic and a cytotoxin.
- 73.) The method of Claim 71, wherein the other therapeutic agent is an analgesic.
- 74.) The method of Claim 73, wherein the other analgesic is an NSAID, an opioid analgesic, an antibody or a non-antibody biologic.
- 75.) The method of Claim 74, wherein the antibody is a NGF antibody or antibody fragment.
- 76.) The method of Claim 73, wherein the other analgesic is an NSAID is a cyclooxygenase 1 and/or cyclooxygenase 2 inhibitor.
- 77.) The method of Claim 76 wherein the NSAID is selected from (1) propionic acid derivatives including ibuprofen, naproxen, naprosyn, diclofenac, and ketoprofen; (2) acetic acid derivatives including tolmetin and slindac; (3) fenamic acid derivatives including mefenamic acid and meclofenamic acid; (4) biphenylcarboxylic acid derivatives including diflunisal and flufenisal; and (5) oxicams including piroxim, sudoxicam, and isoxicam.
- 78.) The method of Claim 73, wherein the other analgesic is a phenanthrene; phenylheptylamine; phenylpiperidine; morphinans; or benzomorphan compound.
- 79.) The method of Claim 73, wherein the other analgesic is an opioid analgesic selected from codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine or pharmaceutically acceptable salts thereof.
- 80.) The method of Claim 78 or 79, wherein the combined administration of the opioid analgesic and the CGRP antibody or antibody fragment increase the analgesic effect elicited thereby and/or alleviates tolerance to the analgesic.

81.) The method of claim 79, wherein the opioid analgesic is morphine or a morphine derivative or pharmaceutically acceptable salt thereof.

82.) A method of making the antibody or antibody fragment of claim 45 in a polyploid yeast culture that stably expresses and secretes into the culture medium at least 10-25 mg/liter of said antibody, comprising:

(i) introducing at least one expression vector containing one or more heterologous polynucleotides encoding said antibody operably linked to a promoter and a signal sequence into a haploid yeast cell;

(ii) producing by mating or spheroplast fusion a polyploidal yeast from said first and/or second haploid yeast cell;

(iii) selecting polyploidal yeast cells that stably express said antibody; and

(iv) producing stable polyploidal yeast cultures from said polyploidal yeast cells that stably express said antibody into the culture medium.

83.) The method of claim 82, wherein said yeast genera is *Pichia*.

84.) The method of claim 83, wherein the species of *Pichia* is selected from *Pichia pastoris*, *Pichia methanolica* or *Hansenula polymorpha* (*Pichia angusta*).

85.) The method of claim 83, wherein the species of *Pichia* is *Pichia pastoris*.

86.) An isolated polynucleotide comprising a polynucleotide encoding an anti-CGRP V<sub>H</sub> antibody amino acid sequence selected from SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123 or 133, or encoding a variant thereof which exhibits at least 90% sequence identity therewith.

87.) The isolated polynucleotide of Claim 86, wherein the polynucleotide sequence encodes an anti- CGRP V<sub>H</sub> antibody amino acid sequence wherein at least one framework residue (FR residue) has been substituted with an amino acid present at the corresponding position in a rabbit anti-CGRP antibody V<sub>H</sub> polypeptide or by a conservative amino acid substitution.

- 88.) A vector or host cell comprising the polynucleotide sequence of claim 86 or 87.
- 89.) The host cell of claim 88, wherein said host cell is a yeast cell belonging to the genus *Pichia*.
- 90.) The method of claim 82, wherein said heterologous polynucleotide further comprises a polynucleotide sequence encoding an anti-CGRP V<sub>L</sub> amino acid sequence selected from SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131, or a polynucleotide encoding a variant thereof which exhibits at least 90% sequence identity therewith.
- 91.) The method of claim 90, wherein the polynucleotide sequence which encodes an anti- CGRP V<sub>L</sub> antibody amino acid sequence comprises at least one framework residue (FR residue) which has been substituted with an amino acid present at the corresponding position in a rabbit anti-CGRP antibody V<sub>L</sub> polypeptide or by a conservative amino acid substitution.
- 92.) An isolated polynucleotide comprising the polynucleotide sequence encoding an anti-CGRP V<sub>L</sub> antibody amino acid sequence selected from SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131, or encoding a variant which exhibits at least 90% sequence identity therewith.
- 93.) The An isolated polynucleotide of Claim 92, wherein the polynucleotide sequence which encodes an anti- CGRP V<sub>L</sub> antibody amino acid sequence comprises at least one framework residue (FR residue) which has been substituted with an amino acid present at the corresponding position in a rabbit anti-CGRP antibody V<sub>L</sub> polypeptide or by a conservative amino acid substitution.
- 94.) A vector comprising the polynucleotide sequence of claim 92 or 93.
- 95.) A host cell comprising the vector of claim 94.
- 96.) The host cell of claim 95, wherein said host cell is a yeast cell belonging to the genus *Pichia*.

97.) The method of claim 90, wherein said heterologous polynucleotide comprises a sequence encoding the polypeptides contained in SEQ ID NO:1 and SEQ ID NO:3; SEQ ID NO:11 and SEQ ID NO:13; SEQ ID NO:21 and SEQ ID NO:23; SEQ ID NO:31 and SEQ ID NO:33; SEQ ID NO:41 and SEQ ID NO:43; SEQ ID NO:51 and SEQ ID NO:53, SEQ ID NO:61 and SEQ ID NO:63; SEQ ID NO:71 and SEQ ID NO:73; SEQ ID NO:81 and SEQ ID NO:83; SEQ ID NO:91 and SEQ ID NO:93; SEQ ID NO:101 and SEQ ID NO:103; SEQ ID NO:111 and SEQ ID NO:113; SEQ ID NO:121 and SEQ ID NO:123; or SEQ ID NO:131 and SEQ ID NO:133.

98.) An anti-CGRP antibody or antibody fragment that binds with the same or overlapping CGRP epitope and/or competes with an anti-CGRP antibody for binding to CGRP as an antibody or antibody fragment containing a sequence encoded by one of the polynucleotide sequences recited in claim 92 or 97.

99.) The anti-CGRP antibody or antibody fragment of claim 98 which binds to the same or overlapping CGRP epitope as an anti-CGRP antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13 or Ab14.

100.) An isolated anti-CGRP antibody or antibody fragment comprising one or more of the CDRs contained in the V<sub>H</sub> polypeptide sequences selected from: SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133 and/or one or more of the CDRs contained in the V<sub>L</sub> polypeptide sequences selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131.

101.) The isolated anti-CGRP antibody or antibody fragment of Claim 100, comprising at least 2 of the CDRs contained in a V<sub>H</sub> polypeptide sequences selected from: SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133 and/or at least 2 of the CDRs contained in the V<sub>L</sub> polypeptide sequences selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131.

102.) The isolated anti-CGRP antibody or antibody fragment of Claim 101 comprising all 3 the CDRs contained in the V<sub>H</sub> polypeptide sequences selected from: SEQ ID NO: 3, 13,

23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, or 133 and/or all 3 of the CDRs contained in the  $V_L$  polypeptide sequences selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131.

103.) The antibody or antibody fragment of claim 99, 100, 101 or 102, wherein said antibody or antibody fragment is humanized.

104.) The antibody of claim 99, 100, 101 or 102, wherein said antibody is chimeric.

105.) The antibody of claim 104, wherein said chimeric antibody comprises a human  $F_c$ .

106.) The antibody of claim 99, 100, 101, or 102, which comprises a single chain antibody.

107.) The antibody of claim 99 or 100 which comprises a monovalent antibody molecule.

108.) The antibody of claim 105 wherein said human  $F_c$  is derived from human IgG1, IgG2, IgG3, or IgG4.

109.) An isolated anti-CGRP antibody or antibody fragment comprising a  $V_L$  or  $V_H$  polypeptide sequence having at least 90% or greater homology to any one of the polypeptide sequences recited in claim 100 or 101.

110.) The antibody or antibody fragment of claim 109, wherein said antibody binds to CGRP with an off-rate ( $k_{off}$ ) of less than or equal to  $10^{-4} \text{ S}^{-1}$ ,  $5 \times 10^{-5} \text{ S}^{-1}$ ,  $10^{-5} \text{ S}^{-1}$ ,  $5 \times 10^{-6} \text{ S}^{-1}$ ,  $10^{-6} \text{ S}^{-1}$ ,  $5 \times 10^{-7} \text{ S}^{-1}$ , or  $10^{-7} \text{ S}^{-1}$ .

111.) The antibody or antibody fragment of any one of claims 99-110, wherein said antibody inhibits the association of CGRP with CGRP-R and/or multimers thereof, or the association of CGRP with its receptor (CGRP-R) and one or more additional proteins in a complex.

112.) An antibody fragment according to any one of claims 99-110, wherein said fragment is selected from a Fab fragment, a Fab' fragment, or a F(ab')2 fragment.

- 113.) The antibody or antibody fragment of any one of claims 99-110, wherein said antibody further comprises an effector moiety.
- 114.) The antibody of claim 113, wherein the effector moiety is a detectable moiety or a functional moiety.
- 115.) The antibody of claim 114, wherein said detectable moiety is a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material.
- 116.) The antibody of claim 114, wherein said functional moiety is streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, or a radioactive material.
- 117.) A method of ameliorating or reducing symptoms of a disease or disorder treatable by the administration of a CGRP antagonist, comprising administering to a patient in need thereof an effective amount of an antibody or antibody fragment according to any one of claims 99-116.
- 118.) The method of claim 117, wherein the disease or disorder is associated with increased CGRP.
- 119.) The method of claim 118, wherein said disease or disorder is selected from migraine (with or without aura), weight loss, cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, hemiplegic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), allergy-induced headaches or migraines, pain, inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptive pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptive pain, trigeminal neuralgia, post-

herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarian pain, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, or pancreatitis.

120.) The method of claim 118, wherein the condition comprises overactive bladder, pain; chronic pain; neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; post-surgical pain, trauma related pain, diabetes; non-insulin dependent diabetes mellitus and other inflammatory autoimmune disorders, vascular disorders; inflammation; arthritis; bronchial hyperreactivity, asthma; shock; sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes in men and women; allergic dermatitis; psoriasis; encephalitis; brain trauma; epilepsy; neurodegenerative diseases; skin diseases including pruritis, neurogenic cutaneous redness, skin rosaceousness and erythema; inflammatory bowel disease, irritable bowel syndrome, cystitis; and dysmenorrhea.

121.) The method of Claim 118, wherein the condition or disorder is migraine, overactive bladder, a pain associated disease or condition, or opioid analgesic tolerance.

122.) The method of Claim 118, wherein the CGRP antibody or antibody fragment is administered in a therapeutic regimen for treatment of a specific disease or condition associated with pain that includes the administration of another therapeutic agent.

123.) The method of Claim 122, wherein the other therapeutic agent is selected from a chemotherapeutic, an analgesic, an anti-inflammatory, an immunosuppressant, a cytokine, an antiproliferative, an antiemetic and a cytotoxin.

124.) The method of Claim 122, wherein the other therapeutic agent is an analgesic.

125.) The method of Claim 122, wherein the other analgesic is an NSAID, an opioid analgesic, an antibody or a non-antibody biologic.

126.) The method of Claim 125, wherein the antibody is a NGF antibody or antibody fragment.

127.) The method of Claim 125, wherein the other analgesic is an NSAID which comprises a cyclooxygenase 1 and/or cyclooxygenase 2 inhibitor.

128.) The method of Claim 127 wherein the NSAID is selected from (1) propionic acid derivatives including ibuprofen, naproxen, naprosyn, diclofenac, and ketoprofen; (2) acetic acid derivatives including tolmetin and slindac; (3) fenamic acid derivatives including mefenamic acid and meclofenamic acid; (4) biphenylcarboxylic acid derivatives including diflunisal and flufenisal; and (5) oxicams including piroxim, sudoxicam, and isoxicam.

129.) The method of Claim 124, wherein the other analgesic is a phenanthrene; phenylheptylamine; phenylpiperidine; morphinans; or benzomorphan compound.

130.) The method of Claim 124, wherein the other analgesic is an opioid analgesic selected from codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine or pharmaceutically acceptable salts thereof.

131.) The method of Claim 129 or 130, wherein the combined administration of the analgesic and the CGRP antibody or antibody fragment increase the analgesic effect elicited thereby and/or alleviates tolerance to the analgesic.

132.) The method of claim 131, wherein the analgesic is morphine or a morphine derivative or pharmaceutically acceptable salt thereof.

133.) A method of making the antibody of any one of claims 98-116 in a polyploid yeast culture that stably expresses and secretes into the culture medium at least 10-25 mg/liter of said antibody, comprising:

(i) introducing at least one expression vector containing one or more heterologous polynucleotides encoding said antibody operably linked to a promoter and a signal sequence into a haploid yeast cell;

(ii) producing by mating or spheroplast fusion a polyploidal yeast from said first and/or second haploid yeast cell;

(iii) selecting polyploidal yeast cells that stably express said antibody; and

(iv) producing stable polyploidal yeast cultures from said polyploidal yeast cells that stably express at least 10-25 mg/liter of said antibody into the culture medium.

134.) The method of claim 133, wherein said yeast genera is *Pichia*.

135.) The method of claim 134, wherein the species of *Pichia* is selected from *Pichia pastoris*, *Pichia methanolica* or *Hansenula polymorpha* (*Pichia angusta*).

136.) The method of claim 135, wherein the species of *Pichia* is *Pichia pastoris*.

137.) An isolated polynucleotide that expresses a polypeptide containing at least one CDR polypeptide derived from an anti-CGRP antibody wherein said expressed polypeptide alone specifically binds CGRP or specifically binds CGRP when expressed in association with another polynucleotide sequence that expresses a polypeptide containing at least one CDR polypeptide derived from an anti-CGRP antibody wherein said at least one CDR is selected from those contained in the V<sub>L</sub> or V<sub>H</sub> polypeptides of SEQ ID NO: 1, 3, 11, 13, 21, 23, 31, 33, 41, 43, 51, 53, 61, 63, 71, 73, 81, 83, 91, 93, 101, 103, 111, 113, 121, 123, 131 or 133.

138.) The isolated polynucleotide of Claim 137, that expresses a polypeptide containing 2 or 3 of the CDR polypeptides derived from an anti-CGRP antibody wherein said expressed polypeptide alone specifically binds CGRP or specifically binds CGRP when expressed in association with another polynucleotide sequence that expresses a polypeptide containing 2 or 3 of the CDR polypeptides derived from an anti-CGRP antibody wherein said CDR polypeptides are selected from those contained in the V<sub>L</sub> or V<sub>H</sub> polypeptides of SEQ ID NO: 1, 3, 11, 13, 21, 23, 31, 33, 41, 43, 51, 53, 61, 63, 71, 73, 81, 83, 91, 93, 101, 103, 111, 113, 121, 123, 131 or 133.

- 139.) A vector comprising at least one of the polynucleotide sequences of claim 137 or 138.
- 140.) A host cell comprising the vector of claim 139.
- 141.) The host cell of claim 140, wherein said host cell is a yeast cell belonging to the genus *Pichia*.
- 142.) The method of claim 133, wherein said heterologous polynucleotide comprises a polynucleotide sequences encoding at least one CDR contained in a V<sub>L</sub> or V<sub>H</sub> polypeptide selected from SEQ ID NO: 1, 3, 11, 13, 21, 23, 31, 33, 41, 43, 51, 53, 61, 63, 71, 73, 81, 83, 91, 93, 101, 103, 111, 113, 121, 123, 131 or 133.
- 143.) A pharmaceutical or diagnostic composition containing at least one CGRP antibody or fragment according to one of claims 1-22 or 99-116 and a pharmaceutically acceptable carrier.
- 144.) The pharmaceutical or diagnostic composition of claim 143 which further comprises at least one stabilizer.
- 145.) The pharmaceutical or diagnostic composition of claim 143 or 144 which is lyophilized.
- 146.) The pharmaceutical or diagnostic composition of claim 143 or 144 which comprises one or more anti-CGRP antibodies selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13 or Ab14, or a chimeric or humanized antibody, or fragment derived therefrom.
- 147.) The pharmaceutical or diagnostic composition of claim 143 or 144 which comprises an anti-CGRP antibody or fragment selected from Ab2 or a chimeric or humanized antibody, or fragment derived therefrom.

148.) The pharmaceutical or diagnostic composition of claim 143 or 144 which comprises an anti-CGRP antibody or fragment selected from Ab3 or a chimeric or humanized antibody, or fragment derived therefrom.

149.) The pharmaceutical or diagnostic composition of claim 143 or 144 which comprises an anti-CGRP antibody or fragment selected from Ab6 or a chimeric or humanized antibody, or fragment derived therefrom.

150.) A method of treating a disease or condition treatable or preventable by the administration of a CGRP antagonist comprising administering a therapeutically effective amount of a pharmaceutical composition according to one of claims 143-149.

151.) The method of claim 150, wherein the disease is selected from migraine (with or without aura), weight loss, cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, hemiplagic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis), allergy-induced headaches or migraines, pain, inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptive pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptive pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarian pain, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, or pancreatitis.

- 152.) The method of claim 150, wherein the disease is pain, a pain associated disorder, overactive bladder, headache, or migraine.
- 153.) The method of claim 150, wherein the condition comprises overactive bladder, pain; chronic pain; neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; post-surgical pain, trauma related pain, diabetes; non-insulin dependent diabetes mellitus and other inflammatory autoimmune disorders, vascular disorders; inflammation; arthritis; bronchial hyperreactivity, asthma; shock; sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes in men and women; allergic dermatitis; psoriasis; encephalitis; brain trauma; epilepsy; neurodegenerative diseases; skin diseases including pruritis, neurogenic cutaneous redness, skin rosaceousness and erythema; inflammatory bowel disease, irritable bowel syndrome, cystitis; and dysmenorrhea.
- 154.) The method of Claim 150, wherein the condition or disorder is migraine, overactive bladder, a pain associated disease or condition, or opioid analgesic tolerance.
- 155.) The method of Claim 150, wherein the CGRP antibody or antibody fragment is administered in a therapeutic regimen for treatment of a specific disease or condition associated with pain that includes the administration of another therapeutic agent.
- 156.) The method of Claim 155, wherein the other therapeutic agent is selected from a chemotherapeutic, an analgesic, an anti-inflammatory, an immunosuppressant, a cytokine, an antiproliferative, an antiemetic and a cytotoxin.
- 157.) The method of Claim 155, wherein the other therapeutic agent is an analgesic.
- 158.) The method of Claim 157, wherein the other analgesic is an NSAID, an opioid analgesic, an antibody or a non-antibody biologic.
- 159.) The method of Claim 158, wherein the antibody is a NGF antibody or antibody fragment.
- 160.) The method of Claim 157, wherein the other analgesic is an NSAID which comprises a cyclooxygenase 1 and/or cyclooxygenase 2 inhibitor.

161.) The method of Claim 160 wherein the NSAID is selected from (1) propionic acid derivatives including ibuprofen, naproxen, naprosyn, diclofenac, and ketoprofen; (2) acetic acid derivatives including tolmetin and slindac; (3) fenamic acid derivatives including mefenamic acid and meclofenamic acid; (4) biphenylcarboxylic acid derivatives including diflunisal and flufenisal; and (5) oxicams including piroxim, sudoxicam, and isoxicam.

162.) The method of Claim 157, wherein the other analgesic is a phenanthrene; phenylheptylamine; phenylpiperidine; morphinans; or benzomorphan compound.

163.) The method of Claim 157, wherein the other analgesic is an opioid analgesic selected from codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine or pharmaceutically acceptable salts thereof.

164.) The method of Claim 162 or 163, wherein the combined administration of the opioid analgesic and the CGRP antibody or antibody fragment increase the analgesic effect elicited thereby and/or alleviates tolerance to the opioid analgesic.

165.) The method of claim 164, wherein the opioid analgesic is morphine or a morphine derivative or pharmaceutically acceptable salt thereof.

166.) A method of *in vivo* imaging which detects the presence of cells which express CGRP comprising administering a diagnostically effective amount of a diagnostic composition according to any one of claims 143-149.

167.) The method of claim 166 which is used as part of a planning regimen for design of an effective treatment protocol for migraines (with or without aura), weight loss, cancer or tumors, angiogenesis associated with cancer or tumor growth, angiogenesis associated with cancer or tumor survival, hemiplegic migraines, cluster headaches, migrainous neuralgia, chronic headaches, tension headaches, general headaches, hot flushes, chronic paroxysmal hemicrania, secondary headaches due to an underlying structural problem in the head or neck, cranial neuralgia, sinus headaches (such as for example associated with sinusitis),

allergy-induced headaches or migraines, pain, inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptive pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptive pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarianalgia, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, or pancreatitis.

- 168.) The method of claim 167 wherein the treatment protocol includes one or more of anti-histamines, anti-inflammatory agents, or antibiotics.
- 169.) The method of claim 168 wherein the antibody comprises an anti-CGRP antibody or fragment according to one of claims 1-22 or 98-116.
- 170.) The antibody of claim 169 wherein the antibody fragment is a single chain antibody is selected from scFv, camelbody, nanobody, IgNAR, SMIP, or combinations, truncations or modifications thereof.
- 171.) An isolated anti-CGRP antibody that binds to CGRP and inhibits the association of CGRP with CGRP-R, and antagonizes the biological effects thereof.
- 172.) The isolated anti-CGRP antibody of claim 171, wherein the antibody is selected from Ab2, Ab3, Ab5, Ab6, Ab13, or Ab14.
- 173.) An isolated anti-CGRP antibody fragment that inhibits the association of CGRP with CGRP-R, and antagonizes the biological effects thereof.

- 174.) The isolated anti-CGRP fragment of claim 173, wherein the antibody fragment binds the same epitope as Ab2, Ab3, Ab5, Ab6, Ab13 or Ab14.
- 175.) The isolated anti-CGRP antibody or fragment of claim 174, wherein the antibody is Ab3, Ab6, Ab13 or Ab14 or a fragment thereof.
- 176.) The isolated anti-CGRP antibody or fragment of claim 174 which contains the same CDRs as Ab3, Ab6, Ab13 or Ab14.
- 177.) A method of treating pain, comprising administering an effective amount of an anti-CGRP antibody or fragment thereof which inhibits the association of CGRP with CGRP-R.
- 178.) The method of claim 177, wherein the antibody is Ab3, Ab6, Ab13 or Ab14 or a fragment thereof.
- 179.) The method of claim 177 wherein the antibody contains the same CDRs as Ab3, Ab6, Ab13 or Ab14.
- 180.) The method of claim 177, wherein the pain is associated with trauma to the musculoskeletal system, burn, or pre- or post-operative surgery, or is visceral pain associated with gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, ileitis, ulcerative colitis, renal colic, dysmenorrhea, cystitis, menstrual period, labor, menopause, prostatitis, psoriasis, IBD, or pancreatitis.
- 181.) The method of claim 180, wherein the antibody is Ab3, Ab6, Ab13 or Ab14, or an antibody fragment is derived from Ab3, Ab6, Ab13 or Ab14.
- 182.) The method of claim 180, wherein the antibody or antibody fragment contains the same CDRs as Ab3, Ab6, Ab13 or Ab14.
- 183.) A method of treating migraine, comprising administering an effective amount of an anti-CGRP antibody or fragment thereof which inhibits the association of CGRP with CGRP-R.

184.) The method of claim 183, wherein the antibody is Ab2, Ab3, Ab5, Ab6, Ab13 or Ab14, or the antibody fragment is derived from Ab2, Ab3, Ab5, Ab6, Ab13 or Ab14.

185.) A method of treating a non-migraine headache, comprising administering an effective amount of an anti-CGRP antibody or fragment thereof which inhibits the association of CGRP with CGRP-R.

186.) The method of claim 185, wherein the antibody is Ab2, Ab3, Ab5, Ab6, Ab13 or Ab14, or the antibody fragment is derived from Ab2, Ab3, Ab5, Ab6, Ab13 or Ab14.

187.) The method of claim 185, wherein the antibody or antibody fragment contains the same CDRs as Ab2, Ab3, Ab5, Ab6, Ab13 or Ab14.

188.) An anti-CGRP antibody or antibody fragment having binding specificity for CGRP and comprising variable light chain CDR1, CDR2, and CDR3 polypeptide sequences and variable heavy chain CDR1, CDR2, and CDR3 polypeptide sequences selected from the following:

	V <sub>L</sub> CDR1	V <sub>L</sub> CDR2	V <sub>L</sub> CDR3	V <sub>H</sub> CDR1	V <sub>H</sub> CDR2	V <sub>H</sub> CDR3
A	Seq ID No: 5	Seq ID No: 6	Seq ID No: 7	Seq ID No: 8	Seq ID No: 9	Seq ID No: 10
B	Seq ID No: 15	Seq ID No: 16	Seq ID No: 17	Seq ID No: 18	Seq ID No: 19	Seq ID No: 20
C	Seq ID No: 25	Seq ID No: 26	Seq ID No: 27	Seq ID No: 28	Seq ID No: 29	Seq ID No: 30
D	Seq ID No: 35	Seq ID No: 36	Seq ID No: 37	Seq ID No: 38	Seq ID No: 39	Seq ID No: 40
E	Seq ID No: 45	Seq ID No: 46	Seq ID No: 47	Seq ID No: 48	Seq ID No: 49	Seq ID No: 50
F	Seq ID No: 55	Seq ID No: 56	Seq ID No: 57	Seq ID No: 58	Seq ID No: 59	Seq ID No: 60
G	Seq ID No: 65	Seq ID No: 66	Seq ID No: 67	Seq ID No: 68	Seq ID No: 69	Seq ID No: 70
H	Seq ID No: 75	Seq ID No: 76	Seq ID No: 77	Seq ID No: 78	Seq ID No: 79	Seq ID No: 80
I	Seq ID No: 85	Seq ID No: 86	Seq ID No: 87	Seq ID No: 88	Seq ID No: 89	Seq ID No: 90
J	Seq ID					

	No: 95	No: 96	No: 97	No: 98	No: 99	No: 100
K	Seq ID No: 105	Seq ID No: 106	Seq ID No: 107	Seq ID No: 108	Seq ID No: 109	Seq ID No: 110
L	Seq ID No: 115	Seq ID No: 116	Seq ID No: 117	Seq ID No: 118	Seq ID No: 119	Seq ID No: 120
M	Seq ID No: 125	Seq ID No: 126	Seq ID No: 127	Seq ID No: 128	Seq ID No: 129	Seq ID No: 130
N	Seq ID No: 135	Seq ID No: 136	Seq ID No: 137	Seq ID No: 138	Seq ID No: 139	Seq ID No: 140

189.) The anti-CGRP antibody or antibody fragment of claim 188, wherein said antibody fragment is an scFv, camelbody, nanobody, IgNAR (single-chain antibodies derived from sharks), Fab, Fab', or F(ab')2 fragment.

190.) The anti-CGRP antibody fragment of claim 188, wherein said antibody fragment is a Fab fragment.

191.) The anti-CGRP antibody or antibody fragment of claim 188, comprising a variable light chain polypeptide sequence and a variable heavy chain polypeptide sequence selected from the following:

	Variable Light Chain	Variable Heavy Chain
A	Seq ID No: 1	Seq ID No: 3
B	Seq ID No: 11	Seq ID No: 13
C	Seq ID No: 21	Seq ID No: 23
D	Seq ID No: 31	Seq ID No: 33
E	Seq ID No: 41	Seq ID No: 43
F	Seq ID No: 51	Seq ID No: 53
G	Seq ID No: 61	Seq ID No: 63
H	Seq ID No: 71	Seq ID No: 73
I	Seq ID No: 81	Seq ID No: 83
J	Seq ID No: 91	Seq ID No: 93
K	Seq ID No: 101	Seq ID No: 103
L	Seq ID No: 111	Seq ID No: 113
M	Seq ID No: 121	Seq ID No: 123
N	Seq ID No: 131	Seq ID No: 133

192.) The anti-CGRP antibody or antibody fragment of claim 188, comprising a light chain polypeptide sequence and a heavy chain polypeptide sequence selected from the following:

	Light Chain	Heavy Chain
Ab1	Seq ID No: 2	Seq ID No: 4
Ab2	Seq ID No: 12	Seq ID No: 14
Ab3	Seq ID No: 22	Seq ID No: 24
Ab4	Seq ID No: 32	Seq ID No: 34
Ab5	Seq ID No: 42	Seq ID No: 44
Ab6	Seq ID No: 52	Seq ID No: 54
Ab7	Seq ID No: 62	Seq ID No: 64
Ab8	Seq ID No: 72	Seq ID No: 74
Ab9	Seq ID No: 82	Seq ID No: 84
Ab10	Seq ID No: 92	Seq ID No: 94
Ab11	Seq ID No: 102	Seq ID No: 104
Ab12	Seq ID No: 112	Seq ID No: 114
Ab13	Seq ID No: 122	Seq ID No: 124
Ab14	Seq ID No: 132	Seq ID No: 134

193.) An anti-CGRP antibody or antibody fragment according to any one of claims 188-192 wherein the variable light chain and variable heavy chain polypeptide sequences are each at least 90% identical to one of the variable light chain polypeptide sequences of SEQ ID NOS: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, or 131, and one of the variable heavy chain polypeptide sequences of SEQ ID NOS: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123 or 133, respectively.

194.) The anti-CGRP antibody or antibody fragment according to any one of claims 188-193 that is chimeric or humanized.

195.) The anti-CGRP antibody or antibody fragment according to any one of claims 188-194 that is aglycosylated or contains only mannose residues.

196.) The anti-CGRP antibody or antibody fragment according to any one of claims 188-193 that comprises a human constant domain.

- 197.) The anti-CGRP antibody or antibody fragment according to claim 196 that is an IgG1, IgG2, IgG3 or IgG4 antibody.
- 198.) The anti-CGRP antibody or antibody fragment according to any one of claims 188-196 which contains an Fc region that has been modified to alter at least one of effector function, half-life, proteolysis, and/or glycosylation.
- 199.) The anti-CGRP antibody or antibody fragment according to claim 198 wherein the Fc region contains a mutation that alters or eliminates glycosylation.
- 200.) The anti-CGRP antibody or antibody fragment according to any one of claims 188-199 which is directly or indirectly attached to a detectable label or therapeutic agent.
- 201.) The anti-CGRP antibody or antibody fragment according to any one of claims 188-199 which further comprises an effector moiety.
- 202.) The anti-CGRP antibody or antibody fragment according to claim 201 wherein the effector moiety is a detectable moiety or a functional moiety.
- 203.) The anti-CGRP antibody or antibody fragment according to claim 202 wherein said detectable moiety is a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material.
- 204.) The anti-CGRP antibody or antibody fragment according to claim 202 wherein said functional moiety is streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, or a radioactive material.
- 205.) An anti-CGRP antibody or antibody fragment according to any one of claims 188-204, wherein the variable light chain and variable heavy chain polypeptide sequences are each at least 95% identical to one of the variable light chain polypeptide sequences of SEQ ID NOS: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131, and one of the variable heavy chain polypeptide sequences of SEQ ID NOS: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123 or 133, respectively.

206.) An anti-CGRP antibody or antibody fragment according to any one of claims 188-205 wherein the variable light chain and variable heavy chain polypeptide sequences are each at least 98% identical to one of the variable light chain polypeptide sequences of SEQ ID NOS: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131, and one of the variable heavy chain polypeptide sequences of SEQ ID NOS: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123 or 133, respectively.

207.) An anti-CGRP antibody or antibody fragment according to any one of claims 188-206 wherein the variable light chain and variable heavy chain polypeptide sequences are each at least 99% identical to one of the variable light chain polypeptide sequences of SEQ ID NOS: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 or 131, and one of the variable heavy chain polypeptide sequences of SEQ ID NOS: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123 or 133, respectively.

208.) A composition containing an anti-CGRP antibody or antibody fragment according to 1-17 or any one of claims 188-207.

209.) The composition of claim 208 that is suitable for therapeutic or diagnostic use.

210.) The composition of claim 208 which further comprises at least one stabilizer.

211.) The composition of claim 208 which is lyophilized.

# Figure 1

## Ab1

### Ab1 Heavy chain (chimera) Full length protein sequence.

QSLEESGGRLVTPGTPLTLTCTVSGQLDLSSYYMQWVRQAPGKGLEWIGVIGINDNTYYASWAKGRFTISRASSSTVDLKMTS  
 LTTEDTATYFCARGDIWGPGLTVSSASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHFTPAV  
 LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMSRTP  
 EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTS  
 KAKGQPREPQWYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFLYSKLTVDKSRWQ  
 QGNVFSCSVVMHEALHNHYTQKSSLSPGK (SEQ ID NO: 4)

### Ab1 Variable region heavy chain (chimera) protein sequence.

QSLEESGGRLVTPGTPLTLTCTVSGQLDLSSYYMQWVRQAPGKGLEWIGVIGINDNTYYASWAKGRFTISRASSSTVDLKMTS  
 LTTEDTATYFCARGDIWGPGLTVSS (SEQ ID NO: 3)

### Ab1 Variable region heavy chain (chimera) protein sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

QSLEESGGRLVTPGTPLTLTCTVSGQLDLSSYYMQWVRQAPGKGLEWIGVIGINDNTYYASWAKGRFTISRASSSTVDLKMTS  
 LTTEDTATYFCARGDIWGPGLTVSS (SEQ ID NOS: 8, 9, 10, respectively)

### Ab1 Variable region heavy chain (chimera) DNA sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

CAGTCGGCTGGAGTCCGGGGTCTGGTCACGGCTCTGGACACCCCCCTGACACTCACCTGCACAGTCTCTGGACTCG  
 ACCTCAGTAGCTACTACATGCAATGGGTCCGGCAGGGCTGGGAAGGGCTGGAAATGGATCGGAGTCATTGGTATTAA  
 ATGATAACACATACTACGGAGCTGGCGAAAGGCCGATTCAACCATCTCCAGACGCCCTCGGACCCACGGTGGATCTGA  
 AAATGACCAGTCTGACAAACCGGAGGACACGGCCACCTATTCTGTGCCAGAGGGGACATCTGGGGCCAGGCACCTCGT  
 CACCGTCTCGAGC (SEQ ID NO: 143)

**Ab1 Heavy chain (chimera) Full length DNA sequence.**

CAGTGGCTGGAGGTCCGGCTGGTCACGGCCTGGGACACCCCTGACAGTCACCTGCACAGTCACCTGGACTCG  
 ACCTCAGTAGCTACTACATGGCAATGGTCCGGCCAGGGTCCAGGGAAAGGGCTGGAATGGATCGGAGTCATTGGTATTA  
 ATGATAACACATACTACGGCAGGCTGGCGAAAGGCCATTCAACCTCTCCAGAGGCCCTCGTGCACCCACGGTGGATCTGA  
 AAATGACCCAGTCTGACAACGGCACACGGGACATGGGACATCTGGGCCAGAGGGACATCTGGGGCCAGGCACCTCG  
 TCACCGTCTGGCTGGGCTGGCTGGTCAAGGGACTACTCCCGAACCGGGTGAACGGTGTGGAAACTCAGGGCCTGACCAG  
 AGCGGGCCCTGGGCTGGCTGGTCAAGGGACTACTCCCGAACCGGGTGAACGGTGTGGTGAACCGTGGCTCCAGC  
 CGGGTGCACACCTTCCGGCTACAGTCTCAGGGACTACTCCCTCAGCAGCGTGGTGAACCGTGGCTCCAGC  
 AGCTTGGCAGCCAGACCTACATCTGCAACGTGAATCAAAAGCCAGAACACCCAGAACAGGGGACAAAGAGTTGAGGCC  
 AGCTTGTGACAAAACATCACACATGCCACCGTGGCAGCAGTGAACACTCTGGGGGACCCGTGACATGGCTGGTGGAC  
 AAATCTGTGACAAAACATCACACATGCCACCGTGGCAGCAGTGAACATGGCTGGTGGACCCGTGAGCCACGAAG  
 CCCAAAAACCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTACACATGGCTGGTGGACCCGTGAGCCACGAAG  
 ACCCTGAGGTCAAGTCAACTGGTACCGTGGAGGGTGGAGGGTGGAGGGTGGAGGGTGGAGGGTGGAGGGAGGCAG  
 TACGGCAGCAGTACCGTCCCTCAGGGTGTGGTCAACCGGTCTCACCGTCCCTCACCGTCCCTCACCGTCCCTCACCG  
 AAGGGTCTCCAACAAAGGCCCTCCAGCCCCATCGAGAAAACCATCTCCAAAGGCCAGCCCCGAGAACCCACAG  
 GTGTACACCCCTGGCCCCATCCGGAGGAGATGACCAAGAACAGGTCAAGGTGACCTGGCTGAAAGGGCTCTATC  
 CCAGCGACATGCCGTGGAGTGGAGGAATGGGCAACTACAAGAACACTACAAGAACCCAGGCCCTGGCTGGACT  
 CCGACGGCTCTTCCCTACAGCAAGCTCACCCACTACAGCAACCAACTACAGCAGGCTCTCCCTGTGAC  
 CGTGATGGCATGAGGCTCTGCACAAACCAACTACAGCAGAACGGCTCTCCGGTAAATGA (SEQ ID NO: 144)

**Ab1 Light chain (chimera) Full length protein sequence.**

QVLTQTAASPVAAVGSTVTINCQASQSVYDNNYLAWYQQKPGQPPKQLIYSTSTLAVGVSSRFKGSGSGTQFQLTISDLECAD  
 AATYYCLGSYDCSSGDCFVFGGTEVVVKRTVAAPSVFIFPPSDEQLKSGTASVVCVCLNNNFYPREAKVQWVKVDNALQSGNS  
 QESVTEQDSKDTSTYSLSSSTLTLKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 2)

**Ab1 Variable region light chain (chimera) protein sequence.**

QVLTQTAASPVAAVGSTVTINCQASQSVYDNNYLAWYQQKPGQPPKQLIYSTSTLAVGVSSRFKGSGSGTQFQLTISDLECAD  
 AATYYCLGSYDCSSGDCFVFGGTEVVVKVR (SEQ ID NO: 1)

**Ab1 Variable region light chain (chimera) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

QVLQTASPVSAAVGSTVTINCQASQS**WYDNNYLA**WYQQKPGQPPKQLIYSTSTLASGVSSRFKGSGSGTQFTLTISDLECA  
DAATYYCLGSYDCSSGDCFVGGTEVVVKR (SEQ ID NOS: 5, 6, 7, respectively)

**Ab1 Variable region light chain (chimera) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

CAAGTGCTGACCCAGACTGCACTCCCCGGTGTCTGCAGCTGTGGAAAGCACAGTCACCTAATTGCCAATTGCCAGGCCAGTCAG  
**AGTGT**TTATGATAAACAACTACCTAGCCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCTAC  
ATCCACTCTGGCATCTGGGTCTCATCGGGTCTCATCGGGTCTCAAAAGGCAGTGGATCTGGGACACAGTTCACTCTCACCCATCAGG  
CTGGAGTGTCGCGATGCTGCCACTTACTACTGTCTAGGCAGTTATGATTGTTAGTGTGGATTGTTAGTGTGG (SEQ ID NO: 141)  
GGACCGAGGTGGTGGTCAAACGT (SEQ ID NO: 141)

**Ab1 Light chain (chimera) Full length DNA sequence.**

CAAGTGCTGACCCAGACTGCACTCCCCGGTGTCTGCAGCTGTGGAAAGCACAGTCACCTAATTGCCAATTGCCAGGCCAGTCAG  
AGTGTTTATGATAAACAACTACCTAGCCGTGGTCTCATCGGGTCTCACTGGGACACAGTCACTCTCACCCATCAGGACCT  
CCACTCTGGCATCTGGGTCTCATCGGGTCTCAACTACTGTCTAGGCAGTTATGATTGTTAGTGTGGTATTGTTAGTGTGGT  
GGAGTGTCGGGTGGTGGTCAAACCGTACGGTGGCTGACCCATCTGJCTTCATCTTCCGGCCATCTGATGAGCAGTTGAATC  
GGACCGAGGTGGTGGTCAAACCGTACGGTGGCTGACCCATCTGJCTTCATCTTCCGGCCATCTGATGAGCAGTTGA  
TGGAAACTGCCCCTGTGCTGCTGAATAACTTCTATCCCAGAGGCCCAAAGTACAGTGGAAAGGTGGATAACGCC  
CTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGCAAGGACACTACAGCCTCAGCAGCACCCCTG  
ACGCTGAGCAAAGCAGACTACGGAGAAACACAAAGTCTACGGCTGCGAAGTCACCCATCAGGGCTIGAGCTCGCCGTC  
ACAAAAGAGCTAACAGGGAGAGTGTAG (SEQ ID NO: 142)

Ab2

Figure 2

**Ab2 Heavy chain (humanized)** Full length protein sequence – mammalian produced.

EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYMQWVQRQAPGKGLEWVGVIGINDNTYASWAKGRTFTSRDN SKTTVYLMNLSLRAEDTAVYFCARGDIWGQGTIVTSSASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP A VILQSSGLYSLSSVVTVPSSSLGTQTYICNVNHNKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYASTYRVVSVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREGQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVWE SNGQOPENNYKTPPVLDSDGSFFLYSKLTVKSRWOOGNVESCSVMHEALHNHYTQKSLSPGK (SEQ ID NO: 14)

## **Ab2 Variable region heavy chain (humanized) protein sequence.**

EVQLVESGGGLVQPGGSLRLSCAVSGQLDLSSYYMQWVVRQAPGKGLEWVGIVIGNNDNTYYASWAKGRFTISRDNSKIIVYL  
QMNSLRAEDTAVYFCARGDIWGQGTIVTVSS (SEQ ID NO: 13)

**Ab2** Variable region heavy chain (humanized) protein sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYM**QWVVRQAPGKGLEWVG**VIGINDNTYYASWAKGRFTISRDNSKTTVYL  
OMNSLRAEDTAVYFCARGD**WVGQGTL**VTVSS (SEQ ID NOS: 18, 19, 20, respectively)

Ab2 Variable region heavy chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underline; CDR3: Italic.

GAGGTGCAGCTTGTGGAGTCTGGGGGAGGGCTTGGTCCAGCCTGGGGGTCCTGAGACTCTCCTGGCAGTCTCTGGAC  
TCGACCTCAGTAGCTACTACATGCAATGGGTCCCGTCAAGGGCTGGAGTGGTCTGGAGTGGCATTTGGTA  
TCAATGATAAACACATACTACCGAGCTGGCGAAAGGCCGATTCACCATCTCCAGAGACAATTCAGGACAGCTGGGCAAGGGAC  
ATCTTCAAATGAACAGGCTGAGAGCTGAGGGACACTGCTGCTGTATTCTGTGCTAGAGGGACATCTGGGCCAAGGGAC  
CTTGGTCACCGTCTGGAC (SEQ ID NO: 153)

**Ah2 Heavy chain (humanized) Full length DNA sequence – mammalian produced.**

GAGGTGCAGCTGGAGTCTGGGGGAGGCTGGTCCAGCCTGGAGACTCTCCCTGGCAGTCTCTGGAC  
TCGACCTCAGTAGCTACTACATGCAATGGGTCCAGGCTCAGGGAAAGGGCTGGAGTGGGTCATTGGTA  
TCAAATGATAACACATACTACCGGAGCTGGGAAAGGCCGATTCAACATCTCCAGAGACAATTCCAAGACCCGGTGT  
ATCTCAAAATGAACAGCCTGAGAGGACACTGCTGTGTTATTCTGTGCTAGAGGGGACATCTGGGGCCAAGGA  
CCCTCGTCAACCGTCTCGAGCCGCCTGGCTGGCTCAAGGACTACTTCCCGAACCGGTGACGGTGTGAACTCAGGGCCCT  
GGGCAACAGGGCCCTGGCTGGCTCAAGGACTACTCCCGTGTCTACAGTCAGCAGCTGGTGGACCGTGGCC  
GACCAAGGGCGTGCACACCTTCCGGCTGGCACCCTGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGGT  
TCCAGCAGCTTGGGCAACCCAGACCTACATCACATGGCCACCGTGCACCATGCCCACCGTGCACACTCACATGCAAC  
GAGGCCAAATCTTGTGACAAAAACTCACATGGTGGACATGGTCAACATGGTCAACATGGTGCACATGGTGGACGTGAGCCA  
TCTTCCCCAAACCCAAGGACACCCCTCATGATCTCCGGAAACCCCTGAGGTCAACATGGTGCATAATGCCAAGACA  
CGAAGACCCCTGAGGTCAAGTCAACTGGTACGGTGGACGGCGTGGAGGTGCAATGGTGAATGGCAAGGACTG  
AGCAGTACGCCAGCACGTACCGTGTGTCAGCGTCCCTCACCGTCCGGACCCAGGACTGGCTGAATGGCAAGGACTACA  
AGTGCAGGTCTCAACAAAGGCCCTCCAGCCCCCATCCCCGGAGATGACCAAGAACCGGTGACCTGGCTG  
CACAGGGTGTACACCCCTGGGGAGAACAACACTACAAGGACCCGGAGAATGGGAGGAGCAATGGGAGGAG  
TCTATCCCAAGCGACATGGCGTGGACTGGGAGGAGTGGGAGGAGCAATGGGAGGAGCAATGGGAGGAG  
TGGACTCCGACGGCTCCCTCTACAGGAAGCTACCGTGGACAAAGGAGCAGGTGGCAGCAGGGGAACGGTCT  
ATGCTCCGTGATGGCATGAGGCTCTCCCTGTCTCCCTGACAACACTACAGCAGAAGGAGCCTCTG  
NO: 154

Ab2 Light chain (humanized) Full length protein sequence.

QVLTQSPSSLASVGDRVTINCQASQSYDNNYLAWYQQKPGKVKQLIYSTSTLASGVPSRFGSGSGTDFLTITSSLQPED  
VATYYCLGSYDCSSGDCFVFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCNNFYREAKVQWKVDNALQSGNSQ  
ESVTEODSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 12)

Ab2 Variable region Light chain (humanized) protein sequence.

QVLTOQSPSSLASVGDRVTINCQASQSYBDNNYLAWYQQRPGVPLQLYSISLASGVFSRFSQSSSSQELIENQLEQ, LD  
VATYYCISYQDCSSGDFCFFGGTKVEIKR (SEQ ID NO: 11)

**Ab2 Variable region Light chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

QVLTQSPSSLASAVGDRVTINCQASQSYDNNY**L**AWYQQKPGKVPKQLIYSTTLASGVPSRFSGSGTDFTLTISSLQPED  
VATYYC<sup>1</sup>CLGSYDCSSGDCFVFGGGTKVEIKR (SEQ ID NOS: 15, 16, 17, respectively)

**Ab2 Variable region Light chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

CAAGTGCTGACCCAGTCTCCATCCATTCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAAATTGCCAGGCCAGTCAG  
**AGTGT**TTATGATAACAACTACCTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCCTAAAGCAACTGATCTATCTAC  
ATCCACTCTGGCATCTGGGTCCATCTCGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCACCATTCAGCAGC  
CTGCAGGCCCTGAAGATGTTGCAACTTTACTGTCTAGGGCAGTTATGATTGATTGATGTGGTGATTTGTAGTGGT  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 151)

**Ab2 Light chain (humanized) Full length DNA sequence.**

CAAGTGCTGACCCAGTCTCCATCCATTCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAAATTGCCAGGCCAGTCAG  
GTGTTTATGATAACAACTACCTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAGCAACTGATCTATTCTAC  
CACTCTGGCATCTGGGTCCATCTCCGTTCAGTGGCAGTGGATCTGGACAGATTTCACTCTCACCATTCAGCAGC  
CAGCCTGAAAGATGTTCCACTTACTCTGTCAGGCAGTTTATGTTAGTGGTGATTTGTTAGTGGT  
ACCAAGGTGGAAATCAAAACGTACGGGTGGCTTCATCTGTCTTCATCTCCGCCCATCTGTATGCAGTTGAAAATCT  
GGAAACTGCCTCTGTTTGTGTGCCTGTGAAATAACTTCTATCCCAAGGGCCAAAGGTGGAAAGGTGGATAACGCC  
TCCAATCGGGTAACTCCAGGGAGGTTCACAGGGCAAGGCACCTACGGCCCTAGGCACCCATCGCCCTGTGAAAGTCTACGGCCGTCA  
CGCTGAGCAAGGACTACGGGAAAACACAAAGGTCTACGGCCGTCA  
CAAAGAGGTCTCAACAGGGAGGTTTAG (SEQ ID NO: 152)

### Figure 3

#### Ab3

##### Ab3 Heavy chain (humanized) Full length protein sequence – yeast produced.

EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYMQWVVRQAPGKGLEWVGIGINDNTYYASWAKGRFTISRDN SKTTVYL  
 QMNSLRAEDTA<sup>VYFCARGDIWGGQTL</sup>TVSSA<sup>STKGPSV</sup>FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV  
 HTFP<sup>AVLQSSGGLYSLSSVVTV</sup>PSSSLGTQTY1C<sup>NVNHKPSNTKVDARVEPKSCDKT</sup>HICPPCPAPELLGGPSVFLFPPKPKDTL  
 MISRTPEVTCVVVDVSHEDP<sup>EVKFNWYV</sup>DGVEVHN<sup>NAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA</sup>  
 PIEKTISKAKGQQPREPQVYTLP<sup>PSREEMTKNQVSLTCLVKGFYPSDIA</sup>VEWESNGQPENNYK<sup>ITTPVVLDSDG</sup>SFFLYSKLTVD  
 KSRWQQGNVFSCSVMEALHNHYTQKSLSLSPGK (SEQ ID NO: 24)

##### Ab3 Variable region heavy chain (humanized) protein sequence.

EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYMQWVVRQAPGKGLEWVGIGINDNTYYASWAKGRFTISRDN SKTTVYL  
 QMNSLRAEDTA<sup>VYFCARGDIWGGQTL</sup>TVSS (SEQ ID NO: 23)

##### Ab3 Variable region heavy chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

EVQLVESGGGLVQPGGSLRLSCAVSGLDLSSYYMQWVVRQAPGKGLEWVGIGINDNTYYASWAKGRFTISRDN SKTTVYL  
 QMNSLRAEDTA<sup>VYFCARGDIWGGQTL</sup>TVSS (SEQ ID NOS: 28, 29, 30, respectively)

##### Ab3 Variable region heavy chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

GAGGTGCAGCTTGTGGAGTCTGGGGAGGGCTGGTCCAGCAGCTGGACTCTCTGTGAGACTCTCTGGAC  
 TCGACCTCAGTAGCTACTACATGCA<sup>ATGGGTCCGTCAAGG</sup>CTGGAGTGGCTGGAA<sup>GTCATGGTA</sup>  
 TCAATGATAACACATACTACCGAGCTGGGAAAGGCCGATCACCATCTCCAGAGACAATTCCAAGACCACGGTGT  
 ATCTTCAAATGAAACAGCCTGAGAGCTGAGGGACACTGCTGTGTATTCTGTGTGCTAGAGGGACATCTGGGCCAAGGGAC  
 CCTCCGTACCCGCTCCGAGC (SEQ ID NO: 163)

**Ab3 Heavy chain (humanized) Full length DNA sequence – yeast produced.**

GAGGTGCAAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGCCTGGGGTCCAGGCTCAGGCTCAGGGAAAGGGCTGGAGTGGGTGATGGTA  
 TCGACCTCAGTAGCTACTACATGCAATGGGTCCAGGCTCAGGGAAAGGGCTGGAGTGGGTGATGGTA  
 TCAATGATAAACACATACTACCGGAGCTGGGGAAAGGGGATTCACCATCTCCAGAGACAATTCCAAGAACACGGGT  
 ATCTTCAAATGAAACAGCCTGAGAGCTGAGGACACTGGGACACTGGCTGAGGACACTGGCTGAGGACACTGGGACACTGG  
 CCTCGTCAACCGTCTGGCCCTCCACCAAGGGCCCACCGGCTTCCACCTGGCTGGCTGGCAAGGACTACCTGGCTGG  
 GGGCACAGCGGCCCTGGCTGGCTGGCAAGGACTACCTGGCTGGCTGGCAAGGACTACCTGGCTGGCAAGGACTACCTGGCTGG  
 GACCGGGCGTGCACACCTTCCGGTGTCCAGTCCAGTCCAGTCCAGTCCAGTCCAGTCCAGTCCAGTCCAGTCCAGTCC  
 TCCAGCAGCTGGGACCCAGACCTAACATCTGCAACGCCCCAGCAACAGGCTGAACTACAAGGCCCCAGCAACACCAAGG  
 GAGGCCAAATCTTGTGACAAACTCACACATGCCAACCGTCCAGCACCTGAAACTCTGGGGGACCCCTGAGGT  
 TCTTCCCCCAAAACCCAAAGGACACCCCTCATGATCTCCGGGACCCCTGAGGTACATGCGTGGTGGACGTGAGCCA  
 CGAAGACCCCTGAGGTCAAGTCAACTGGTACCGTGGCTCAGGGTCTCAGGGTCTCAGGGTCTCAGGGTCTCAGGGT  
 AGCAGTACGGCAGCACGTACCGTACCGTACCGTACCGTACCGTACCGTACCGTACCGTACCGTACCGTACCGT  
 AGTCAAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGGCCAGAAC  
 CACAGGGTGTACACCCCTGGCCCCATCCCCGGAGGAGATGCCAAGAACAGGTCAAGGGTCTGACCTGGTCAAGGCT  
 TCTATCCCAGGGACATCGCCGGTCTCTTCTACAGCAAGCTCACCGTGGACAAGAGCAGGCAAGGCTCACCGT  
 TGGACTCCGACGGCTCTTCTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 22)  
 NO: 164)

**Ab3 Light chain (humanized) Full length protein sequence.**

QVLTQSPSSL SASVGD RVTINCQASQSVYDNNYLA WYQQKPGK VPKQLIYSTSTL ASGVPSRFSGSGTDFTL TISSLQPED  
 VATYYCLGSYDSSGD C VFQGGTKV EIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW KVVDNALQSGNSQ  
 ESVTEQDSK DSTS LSSSTL TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 22)

**Ab3 Variable region Light chain (humanized) protein sequence.**

QVLTQSPSSL SASVGD RVTINCQASQSVYDNNYLA WYQQKPGK VPKQLIYSTSTL ASGVPSRFSGSGTDFTL TISSLQPED  
 VATYYCLGSYDSSGD C VFQGGTKV EIKR (SEQ ID NO: 21)

**Ab3 Variable region Light chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

QVL TQSPSSL SASVGDRVTINQASQSVYDNNYLA WYQQKPGKVPKQLIY STSTL ASGV PSSRFSGSGTDFLT TISSLQPED  
VATYYCLGSYDCSSGDCFVFGGTKEIKR (SEQ ID NOS: 25, 26, 27, respectively)

**Ab3 Variable region Light chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCCATCAATTGCCAGGCCAGTCAG  
**AGTGT**TTATGATAAACAACTACCTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAAGCAACTGATCTTAC  
ATCCACTCTGGCATCTGGTGGTCCCATCTCGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCAC  
CTGCAGGCTGTGAAGATGTTGCAACTTAACTGTCTAGGCAGTTATGATTGGTAGTGGTAGTTGGTGAATTGTTTCTGGGGAG  
GAACCAAAGGTGGAAATCAAACGT (SEQ ID NO: 161)

**Ab3 Light chain (humanized) Full length DNA sequence.**

CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCCATCAATTGCCAGGCCAGTCAG  
GTGTTTATGATAAACAACTACCTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAAGCAACTGATCTTAC  
CACTCTGGCATTCTGGGTCCCCATCTCGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCAC  
CAGCCTGTGAAGATGTTGCAACTTAACTGTCTAGGCAGTTATGATTGTAGTAGTTGGTAGTTGGTGAATTGTTTCTGGGGAG  
AACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCCATCTGTCTTCACTCTCCGCCATCTGATGAGCAGTTGAATCT  
GGAACCTGCCTCTGTGTGCTGTGAATAACTTCTATCCCAGAGGGCCAAGTACAGTGGAAAGGTGGATAACGCC  
TCCAATCGGGTAACTCCCAGGAGAGTGTCAACAGAGCAGCAAGGACACCTACAGCCCTCAGCAGCACCC  
CGCTGAGCAAAGCAGACTACGAAAGTCAACGCTTGCGAAGTCACCCATCAGGGCCATCGAGCTCGCCGTCA  
CAAAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 162)

## Figure 4

### Ab4

#### Ab4 Heavy chain (chimera) Full length protein sequence.

QSLEESGGGRLVTPGTPPLTLTCVSIGIDLSGYMMNWVRQAPGKGLEWIGVIGINGATYYASWAKGRFTISKTSSTTVDLKMTS  
 LTTEDTATYFCARGDIWGPGLTVTSSASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV  
 LQSSGLYSLSSVVTVPSSSLGTQTYICNWNHKPSNTKVDKRKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP  
 EVTCVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTS  
 KAKGQPREPQVTLPSSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVVLDSDGSFFLYSKLTVDKSRWQ  
 QGNVFSCSVMEALHNHYTQKSLSLSPGK (SEQ ID NO: 34)

#### Ab4 Variable region heavy chain (chimera) protein sequence.

QSLEESGGGRLVTPGTPPLTLTCVSIGIDLSGYMMNWVRQAPGKGLEWIGVIGINGATYYASWAKGRFTISKTSSTTVDLKMTS  
 LTTEDTATYFCARGDIWGPGLTVTSS (SEQ ID NO: 33)

#### Ab4 Variable region heavy chain (chimera) protein sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

QSLEESGGGRLVTPGTPPLTLTCVSIGIDLSGYMMNWVRQAPGKGLEWIGVIGINGATYYASWAKGRFTISKTSSTTVDLKMTS  
 LTTEDTATYFCARGDIWGPGLTVTSS (SEQ ID NOS: 38, 39, 40, respectively)

#### Ab4 Variable region heavy chain (chimera) DNA sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

CAGTCGCTGGAGGAGTCCGGCTGGCTGGTCACGGCCTGGGACACCCCTGACACTCACCTGTTCCGGTCTGGCATTCG  
 ACCTCAGTGGCTACTACATGAACTGGTCCGGCCAGGCTCCAGGGAAAGGGGGCTGGAAATGGATCGGAGTCATTGGTATT  
 AATGGGTGCCACATACTACGCCAGGCTGGCGAAAGGCCGATTACCATCTCCAAAACCTCGTCAACCACGGGGCACCCCTC  
 AAAATGACCAGTCTCGAGC (SEQ ID NO: 173)  
 GTCACCGTCTCGAGC (SEQ ID NO: 173)

Ab4 Heavy chain (chimera) Full length DNA sequence.

**Ab4** Light chain (chimera) Full length protein sequence.

AB<sup>+</sup> LINE 2  
QVL TQTPSPV SAA VGSTV TIN CQASQSVY HNTY LA WY QQKPGQPPK QLIYDASTL ASGV P SRFSGSGT QF TLTISGV QCND  
AA YY CLGSY DCTNG DCF VFGGG TE VV V KRTV AAPS VFI FPPS D EQL KSGT ASV VCLNNF YPREAK V QW K VDNAL QSGNS  
QESV TE QD S K D S T Y SLS S T T L S K A D Y E K H K V Y ACE VTH QGL LSSP VTK SFN R GEC (SEQ ID NO: 32)

**Ab4** Variable region light chain (chimera) protein sequence.

QVLQTQTPSPVSAAVGSTVTINCQASQSVYHNTYLAWYQQKPGQPPKQLIYDASTLASGVPSRFSGSGTQFTLTISGVQCND  
AAAYYCLGSYDCTNGDCFVFGGGTEVVVKR (SEQ ID NO: 31)

**Ab4** Variable region light chain (chimera) protein sequence. CDR1: **Bold**; CDR2: **Underlined**; CDR3: **Italics**.

QVLQTQTPSPVSAAVGSTVTINCQASQSVYHNTYLAWYQQKPGQPPKQLIYDASTLASGVPSRFSGSGTQFTLTISGVQCN  
DAAVYVCGSYdCTNcDCEVFGGGTTEVVVKR (SEQ ID NOS: 35, 36, 37, respectively)

**Ab4** Variable region light chain (chimera) DNA sequence. CDR1: **Underlined**; CDR2: **Underlined**; CDR3: **Underlined**.

## Ab4 Light chain (chimera) Full length DNA sequence.

CAAGTGGTACCCAGACTCCATTCCCCGGTGTCTGCAGCTGTGGGAAGGCACAGTCACCATCAATTGCCAGGCCAGTCAGA  
GTGTTATCATAACACACTACCTGGCCTGGTATCAGCAGAAACCAAGGGCAGGCTCCAAACAACGTTGATCTGACATC  
CACTCTGGCGTCTGGGGTCCCATCGGGGTCAGGGCAGTGGACACAGTTCACCTCACCATCAGCGGGCTG  
CAGTGTAAAGATGCTGCCGCTTACTACTGTCTGGCAGTTATGGTACTAATGGTGATTGTTCTGAGCAGTTGAATCT  
GACCGAGGGTGGGTCAAACCTACGGTGGCTCATTCTGAGGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCC  
GGAACGTGGCTCTGTGTGCTGCTGTAATAACTTCTATCCCAGAGGAGGCCAAAGTACAGTGGAAAGGTGGATAACGCC  
TCCAATCGGGTAACCTCCCAGGAGAGGTGTACAGAGCAGCAAGGACACGCACCTACAGCCCTCAGCAGCACCC  
CGCTGAGCAAAGCAGACTACCGAGAAACACAAAGTCTAGCAGGGCTGAGCTACGGCCATCAGGGCCATCAGGG  
CAAAGAGCTCAACAGGGAGAGTGTAG (SEQ ID NO: 172)

## Figure 5

### Ab5

**Ab5 Heavy chain (humanized) Full length protein sequence – mammalian produced.**

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYMMNWRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDN SKTTVYL  
 QMNSLRAEDTA<sup>**V**</sup>YFCARGDIWGGQGT<sup>L</sup>VTVSSASTKGPSVFPLAPSSKTSGGTAALGCLVKD<sup>**F**</sup>PEPVTVSWNSGALTSGV  
 HTFP<sup>A</sup>VLOQSSGLYSLSSVVTVPSSSLGTQTYICNWNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD<sup>T</sup>L  
 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN<sup>**A**</sup>TKPREEFQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA  
 PIEKTISKAKGQPREPVYTLPPSREEMTKNQVSLTCLVK<sup>**G**</sup>FYPSDIAVEWESNGQPENNYK<sup>T</sup>PPVLDSDGSFFLYSKLTVD  
 KSRWQQGVNFSCSVMHEALHNHYTQKSLSPGK (SEQ ID NO: 44)

**Ab5 Variable region heavy chain (humanized) protein sequence.**

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYMMNWRQAPGKGLEWVG<sup>V</sup>IGINGATYYASWAKGRFTISRDN SKTTVYL  
 QMNSLRAEDTA<sup>**V**</sup>YFCARGDIWGGQ<sup>G</sup>TLVTVSS (SEQ ID NO: 43)

**Ab5 Variable region heavy chain (humanized) protein sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.**

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYMMNWRQAPGKGLEWVG<sup>V</sup>IGINGATYYASWAKGRFTISRDN SKTTVYL  
 QMNSLRAEDTA<sup>**V**</sup>YFCARGD<sup>W</sup>GGQ<sup>G</sup>TLVTVSS (SEQ ID NOS: 48, 49, 50, respectively)

**Ab5 Variable region heavy chain (humanized) DNA sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.**

GAGGTGCAGCTTGTGGAGTCTGGGGAGGGCTTGGTCCAGCCTGGGGTCCAGGCTCCAGGGAAAGGGCTGGAGTGGGTCGGAGTCAT<sup>TTGGT</sup>  
 TCGACCTCAGTGGCTACTACATGA<sup>**A**</sup>CTGGT<sup>CC</sup>ATG<sup>AA</sup>CTTCA<sup>AT</sup>GGCCATTCAAGACAAT<sup>CT</sup>CAAGAGA<sup>CA</sup>AT<sup>CT</sup>CAAGAGA<sup>CA</sup>ACTGCTGCTAGAGGGACAT<sup>CT</sup>GGGGCCAAAGGGAA  
 TATCTCAAA<sup>AT</sup>GAACAGCCTGAGAGCTGAGGGACACTGCTGCTAGAGGGACAT<sup>CT</sup>GGGGCCAAAGGGAA  
 CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 183)

**Ab5 Heavy chain (humanized) Full length DNA sequence – mammalian produced.**

GAGGTGCAGCTGTGGAGTCTGGGGAGGCTTGGCTCCAGCCTGGGGTCCAGGGCTCCAGGCTCCAGGGCTGGAGTGGGGAAAGGGGATGGTA  
 TCGACCCCTCAGTGGCTACTACATGAACCTGGTCCAGGCTGGCTGGGAAAGGGGATGGGATTCAACCAATTCCAAAGACCAACCGGTGTTA  
 TTAATGGTGCACATACTACGGCAGCTGGCTGAGAGCTGAGGACACTGGTGTGTTAGAGGGGACATCTGGGGCCAAGGGGAA  
 ATCTTCAAATGAAACAGCCTGAGAGCTGAGGACACTGGTGTGTTAGAGGGGACATCTGGGGCCAAGGGGAA  
 CTCCTCGTCACCGCTCTCGAGCGCCTCCACCAAGGGCCATCGGTCACCTCCAGGGACTCTACTCCCTCAAGCAGGGTGGTGAACCGTGC  
 CCCCTCCAGGGCTGGCTGGCTGGTCAAGGGACTACTTCCCCGAACCCGGTGAACGGGTGACTCAACTCAGGGACTCTACTCCCTCAAGCAGGGTGGTGAACCGTGC  
 GGGCACAGGGGCCCTGGCTGGCTGGTCAAGGGACTACTTCCCCGAACCCGGTGAACGGGTGACTCAACTCAGGGACTCTACTCCCTCAAGCAGGGTGGTGAACCGTGC  
 GACCAAGGGCCGTGCACACCTTCCCCGGCTGTCCTACAGTCCTCAGGGACTCTACTCCCTCAAGCAGGGTGGTGAACCGTGC  
 GACCAAGGGCCGTGGCAGGACACCTTACATGCAACCTGCAACATGCCACCATGGGACCCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGAACCGTGC  
 TCCAGCAGCTGGCAGGGACCCAGGACTTACATGCAACCTGCAACATGCCACCATGGGACCCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGAACCGTGC  
 GAGCCCAAATCTTGTGACAAAACCTCACACATGCCACCATGGGACCCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGAACCGTGC  
 TCTTCCCCCAAAACCCAAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGAACCGTGC  
 CGAAGAACCCCTGAGGTCAAGTTCAACTCGGTACCGTGTGGTCAGCGTCTCACCCTGACCCGGGACTGGCTGAATGGCAAGGGAGTACA  
 AGCAGTA CGGCCAGCAGCTACCGTGTGGTCAGCGTCTCACCCTGACCCGGGACTGGCTGAATGGCAAGGGAGTACA  
 AGTGCAGGGTCTCAAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAGGAGGAGATGACCAAGGAACCAAGGAGGAGATGACCTGGGTCAAAGGCT  
 CACAGGTGTAACCCCTGGGGCATCCCCCATCCCCGGAGAGATGACCAAGGAACCAACTACAAGACCAACCGCCTCCCGAGA  
 TCTATCCCAGCGACATCGCCGTGGAGTGGAGAGCAATGGGCAGCCGGAGAACA  
 TGGACTCCGACGGCTCTCTTACAGCAAGCTCACCGTGGACAAAGGAGGAGCTCACCGTGGACAAAGGAGGAGCTCTCCGTCTCCGTAAATGA (SEQ ID  
 NO: 184)

**Ab5 Light chain (humanized) Full length protein sequence.**

QVLTQSPSSL SASVGDRVTINQASQSVYHNTYLAWSQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPED  
 VATYYCLGSYDCTNGDCFVFGGGTKVEIKRTVAAPSVFPPSDEQLKSGTASVVCLLNNFYPREAKVQWVKVDNALQSGNS  
 QESVTEQDSKDDSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 42)

**Ab5 Variable region Light chain (humanized) protein sequence.**

QVLTQSPSSL SASVGDRVTINQASQSVYHNTYLAWSQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPED  
 VATYYCLGSYDCTNGDCFVFGGGTKVEIKR (SEQ ID NO: 41)

**Ab5 Variable region Light chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

QVLTQSPSSLASVGDRVTINQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGTDFTLTISSLQPED  
VATYYCLGSYDCTNGDCFVFGGKVEIKR (SEQ ID NOS: 45, 46, 47, respectively)

**Ab5 Variable region Light chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

CAAGTGGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAGGCCAGTCAG  
**AGTGT**TTATCATAAACACCTAACCTGGCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAAGCAACTGATCTATGATGC  
ATCCACTCTGGCATCTGGGTCCCCATCTCGTTCACTGGCAGTGGATCTGGGACAGATTCACTCTACCACATCAGCAGC  
CTGCAGGCTGGAAGATGTTGCAACTTAACTGTCCTGGCAGTTATGATTGACTAATGGTGAATGGTTTGTGTTTCGGCGAG  
GAACCAAAGGTGGAAATCAAACCGT (SEQ ID NO: 181)

**Ab5 Light chain (humanized) Full length DNA sequence.**

CAAGTGGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAGGCCAGTCAG  
GTGTTTATCATAAACACTAACCTGGCTGGTCCATCTGGGACTCTGGGATCTGGGACAGATTTCACCTCTCACCACATCAGCAGC  
CACTCTGGCATTCTGGGTCCCCATCTGGGACTCTGGGACAGATTTCACCTCTCACCACATCAGCAGC  
CAGCCCTGGAAGATGTTGCAACTTAACTGTCCTGGCAGTTATGATTGACTAATGGTGAATGGTTTGTGTTTCGGCGAG  
AACCAAGGTGGAAATCAAACCGTACGGTGGCTGGCCTGGGACTCTGGGACAGATTTCACCTCTCACCACATCAGCAGC  
GGAACCTGGCTCTGTTGCTGGCCTGGCTGAATAACTTCACTCCAGAGGGCCAAGTACAGTGGAAAGGTGGAATAACGCC  
TCCAATCGGGTAACTCCAGGAGAGTGTCAAGAGCAGGACAGCAAGGACACGACACTACAGCCCTCAGCAGC  
CGCTGAGCAAAGCAGACTACGAGAAACACAAGTCTACGGCTGCGAAGTCACCCATCAGGGCTTGAGCTGCCGTCA  
CAAAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 182)

Ab6

Figure 6

**Ab6 Heavy chain humanized**) Full length protein sequence – yeast produced.

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSSGYMMNWWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYL  
QMNSLRAEDTAVYFCARGDIWGQGTLVTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKDVFPEPVTVSSWNSGALTSGV  
HTFPAPLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDARVEPKSCDKTHTCPPCPAPPELLGGPSVFLFPPPKPKDTL  
MISRTPEVTCCVVVDVSHEDPEVKFNWYWDGVEVHNAKTKPREQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA  
PIEKTIKAKGQPREPQVYTLPPSREEMTKNQVQLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD  
KSRWOOGNVFSCSVMMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 54)

## Ab6 Variable region heavy chain (humanized) protein sequence.

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSSGYMMWVRQAPGKGLEWVGIVNGATYYASWAKGRFIIISRDNSKILIVL  
QMNSLRAEDTAVYFCARGDIWQGQTLVTVSS (SEQ ID NO: 53)

**1.5** *Variable section heavy chain (humanized) protein sequence, CDR1; Bold; CDR2; Underlined; CDR3; Italics.*

EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYM**NWVRQAPGKGLEWVGVIGNGATYYASWAKGRFTISRDNSKIVYL**  
QMNSLRAEDTAVYFCARGDWGQGTLVTVSS (SEQ ID NOS: 58, 59, 60, respectively)

**Ab6** Variable region heavy chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italic.

GAGGTGCAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGGCCCTGGGGTCCCTGAGACTCTCCTGTGAGCTGGCAGFTCTGGAA  
TCGACCTCAGTGGCTACTACATGAACTGGTCCAGGCTCAGGGCTGGAGTGGGTGGAGTCATTTGGT  
ATTAAATGGTGCCACATACTACGGCAGCTGGCGAAAGGCCATTCAAGAGACAATCCAAGGACAACTCTCCAGAG  
TATCTCAAAATGAACAGCCTGAGAGCTGAGGACACTGCTGTGTATTCTGTGCTAGAGGGACATCTGGGCCAAGGGA  
CCCTCGTCACCGCTCGAGC (SEQ ID NO: 193)

**Ab6 Heavy chain (humanized)** Full length DNA sequence – yeast produced.

GAGGTGCAGCTTGTGGAGTCTGGGGGCTTGGCTGGGGTCCAGGCTGGGGTCCCTGAGACTCTCTCTGGAA  
TCGACCTCAGTGGCTACTACATGAACACTGGGTCAGGCTCCAGGGAAAGGGCTGGAGTGGGGACTCATTGGTA  
TTAATGGTGCCACATACGGAGCTGGGGAAAGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGGGTG  
ATCTTCAAAATGAAACAGGCCTGAGGACTGAGGACTCTGGTGGAACTCAGGGCCCT  
CCCTCGTCACCGTCTCGAGCGCTCCAGGGCCCATCAAGGGCCATCGGTCTCCAGGAGCAGCCTCTGG  
GGGCACAGGGGCCCTGGGCTGGCTGGTCAAGGACTACTTCCCAGGGACTACTCCCTCAGGCAGCTGGCC  
GACCAGGGGGTGCACACCTTCCGGTGTCCACTACAGTCCAGGACTTACATGCAACAGCCAGCAACACCAAGGG  
TCCAGCAGCTTGGGACCCAGACCTACATCTGCAACCGTGAACCTGACATGCCACACATGCCACACAT  
GAGCCCCAAATCTTGTGACAAAACCTCACATGCCACACATGCCACACATGCCACACATGCCACACAT  
TCTTCCCCAAACCCCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTCAACATGGTGGTGGGGACT  
CGAAGACCCCTGAGGTCAAGTCAACTGGTACGGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC  
AGCAGTACGCCAGCACGTACCGTGTGGTCAGGGTCCCTCACCGTCTGCCAGGACTGGCTGAATGGCAAGGA  
AGTGCAGGGTCTCCAACAAAGGCCCTCCAGGCCCCCATCGAGAAAACCACATCTCCAAAGCCAAGGG  
CACAGGTGTACACCCCTGGCCCCCATCCCCGGAGAGATGACCAAGAACAGGGAGAACA  
TCTATCCCCAGGGACATCGCCGTGGAGTGGAGGCAATGGGCAAGGGCAGGGAGAACA  
TGGACTCCGACGGCTCCCTCTGCACAGGAAAGGCAAGGGTGGACAAGGCAAGGTGGCAGCAGGG  
ATGCTCCCGTGTGATGCATGAGGCTCTGCACAAACCAACTACACGGAGGCTCTGGTCTCCGGTAAATG  
NO: 194

Ab6 Light chain (humanized) Full length protein sequence.

QVLTQSPSSLASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASFVPSRFSGSGTDFTLTISLQPED  
VATYYCLGSYDCTNGDCFVFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWVKVDNALQSGNS  
QESVTEQDSKDKDSTYSSSLTSLSKADYEKKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 52)

**Ab6** Variable region Light chain (humanized) protein sequence.

QVLTQSPSSL SASVGDRVTINCQASQSVYHNTYLA WYQQKPGKVPKQLYI DASTLASGVPSRFGSGT DFTLTISSLQFED  
VATYYCIGSYDCTNGDCFVFGGTKVEIKR (SEQ ID NO: 51)

Alkyl-*omega*-hydroxy-*omega*-methyl Light chain (*humanized*) protein sequence: CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

**ABCB1** **ABCB1A1**  
QVLTQSPSSLASAVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGTDFLTISSSLQPED  
WATWYVCLCSVDCTNGDCEVEGGGTKEJKB (SEQ ID NOS: 55, 56, 57, respectively)

**Ab6** Variable region Light chain (humanized) DNA sequence. CDR1: **bold**; CDR2: **Underlined**; CDR3: **italic**.

Ab6 Light chain (humanized) Full length DNA sequence.

CAAGTGTGACCCAGTCTCCCATCCTCCCTGTCTGCATCTGTAGGGAGACAGAGTCACCATCAATTGCCAGGCCAGTCAGA  
GTGTTATCATAACACCTACCTGGCCTGGTATCAGCAGAAACCAGGGAAAGTTCTAAGCAACTGATCTATGATGCGATC  
CACTCTGGCATTCTGGGGTCCCACCTCCTTTCAGTGGCAGTGGATCTGGGACAGATTTCACACTCTCACCCATAGCAGCCCTG  
CAGCCCTGAAGATGTTGCAACTTATTACTGTCTGGCAGTTATGATTGTAACTAATTGGTGATTGTTCTGGGGAGG  
AACCAGGGTGGAAATCAAAACGTACGGTGGCTGCACCATCTGTCTTCATCTGATGAGCAGTTGAAATCT  
GGAAACTGGCTCTGTGCTGTGCTGCTGAATAACCTCTATCCCAGAGGGCCAAGTACAGTGGAAAGGTGGATAACGCC  
TCCAATCGGGTAACCTCCAGGAGAGTGTCAACAGAGCAGGACAGCAAGGACAGCACCTACAGCCCTCAGCAGCACCTGA  
CGCTGAGCAAAGCAGACTACCGAGAAACACAAAGTCACGGCTGGAAGTCACTCAGGGCTTGAGCTAGGGCTGAGGTGTTAG  
CAAAGAGCTTCAACAGGGAGAGTGTAG (SEQ ID NO: 192)

Figure 7

Ab7

$\Delta$ b7 Heavy chain (chimera) Full length protein sequence.

QEQLKESEGGRLVTPGTSLTLTCTVSGIDLSNHMYMQWVRQAPGKGLEWIGVVINGRRTYYASWAKGRTISRTSSTVVLKM  
TRLTTEDTATYFCARGIDIWGPGLTVTVSSASTKGPSVFLAPSSKSTSGGTAAALGCLVKDVFPEPVTVSWNSGALTSGVHTFP  
AVLQSSGLYSISSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPGCPAPELLGGPSVFLFPPKPKDTLMISR  
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT  
ISKAKGQPREPQVYTLPPSREEMTKKNQVSLTCLVKGFYPSDIAVEWESNGQOPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW  
QQGNVFSCSVIMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 64)

Ab7 Variable region heavy chain (chimera) protein sequence.

QEQLKESGGRLVTPGTSLSLTCTVSGIDLSNHYMQWVRQAPGKGLEWIGVVGINGRTYIASWAKGRFTISRTSSIVBLKM  
TRLTTEDTATYFCARGDIWGPGLTVSSS (SEQ ID NO: 63)

CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

**AB7▼ available region heavy chain**  
QEQLKESGGRLVTPPGTSLTLTCTVSGIDLSNHYM**MQWWVRQAPGKGLEWIGVVGINGRTRYASWAKGRFTISRTSSTVDLKM**  
TRLITTEDTATYFCARGD/WGPGTLYTVSS (SEQ ID NOS: 68, 69, 70, respectively)

**b7** Variable region heavy chain (chimera) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

CAGGAGCAGCTGAAGGAGTCCGGGGTGCGCCCTGGTCAACGCTGGGACATCCCTGACACTCACCTGCACCGTCTCTGGAAATCGACCTCAGTAACCACTACATGGCAATGGGTCCAGGGCTCCAGGGAAAGGGGCTGGAGTGGATCGGAGTCGTTGGTATTAATGGTCCGACATACTACGGGAGCTGGCGAAAGGCCATTCAACCACCTCCAGAACCTCGACCCATCTCCAGAACAGGGGACATCTGGGGCCAGGGCACACGGGACACGGGACACGGGACACGGGACATCTGGCCAGAGGGGACATTCTGTGCGACAAACCCTGACCCATTCTGGGGCTCGAGGAGCAGGAGCTCGAGC (SEQ ID NO: 203)

**Ab7 Heavy chain (chimera) Full length DNA sequence.**

CAGGAGCAGCTGAAGGAGTCCGGGCTGGTCACGCCCTGGGACATCCCTGACACTCACCTGCACCGGTCTGGG  
 ATCGACCTCAGTAACCAACTACATGCAATTGGGTCAGGCTCAGGGAAAGGGCTGGAGTGGATCGGAGTCGTTGGT  
 ATTAATGGTCCGACATACTACCGGAGCTGGGGAAAGGCCGATTCACCATCTCCAGAACCTCGTGCACCGGTGGAT  
 CTGAAAAATGACCCAGGGCTGACAAACCGAGGACACGGCCACCTATTCTGTGCCAGAGGGACATCTGGGCCAGGCC  
 CTGGTCACCGTCTCGAGGCCCTGGCTGGCTGGTCAAGGACTACTCCCGAACGGGTGACGGTGTGGAAACTCAGGCC  
 GCACAGGGCCCTGGCTGGCTGGTCAAGGACTACTCCCGAACGGACTCTACAGTCCTCAGGAACTCTCAGCAGCGTGG  
 CCAGGGGGGTGCACACCTCCGGCTGTCCTACAGTCCTCAGGAACTACTCCCTCAGGAACTCCCTCAGCAGCGTGG  
 CAGCAGCTGGGACCCAGACCTACATCTGCAACGTGAATCACAAGCCAGCAACCCAAGGGTGGACAAGAGAGTGA  
 GCCCAAATCTTGTGACAAAACATGCCCACCGTCCACCTGATCATGCCGGACCCCTGAGGTCAACTCCGGTGG  
 TTCCCCCAAACCCAAGGACACCCCTCATGATCATGCCGGACCCCTGAGGTCAACTCCGGTGG  
 AAGACCCCTGAGGTCAAGTTCAACTGGTACGTGACGGCGTGGAGGTGCATAATGCCAAGACAAGGCC  
 CAGTACGCCAGCACGTACCGTCCACCGTCCCTCAGCGTGGTCAGCGTCCCTGCACCCAGGACTGGCTGAATGGCAAGGAGTACAAG  
 TGCAAGGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCAAAGCCAAGGGCAGGCCGAGAACCA  
 CAGGTGTACACCCCTGCCCATTCGGGAGGAGATGACCAAGAACCGGTCAAGCTGGTCAAGGCC  
 TATCCCAGCGACATCGCCGTCTCTTCCCTACAGCAAGGCTCACCGTGGACAAGAGCAGGTGGCAGGG  
 GACTCCGACGGCTCCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGGG  
 GCTCCGGTGTGATGCAATGAGGGCTCTGCACAAACCAACTACACGGCAGAACAGCC  
 NO: 204)

**Ab7 Light chain (chimera) Full length protein sequence.**

QVLQTQASPVSAAVGSTVTINQASQSVVNNYLAWSQQKPGQPPKQLIYSTSTLAVGVSSRFKGSGSGTQFTLTISDVQCD  
 DAATYYCLGSYDCSTGDCFVFGGGTEVWVKRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWQVKVDNALQSGN  
 SQESVTEQDSKDSSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 62)

**Ab7 Variable region light chain (chimera) protein sequence.**

QVLQTQASPVSAAVGSTVTINQASQSVVNNYLAWSQQKPGQPPKQLIYSTSTLAVGVSSRFKGSGSGTQFTLTISDVQCD  
 DAATYYCLGSYDCSTGDCFVFGGGTEVWVKRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWQVKVDNALQSGN  
 SQESVTEQDSKDSSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 61)

**1-17** *Variable region light chain (chimera) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.*

QVLTIQTASPVSAAVGSTVTINCQASQSVVNYLAWYQQKPGQPPKQLIYSTSTLASGVSSRFKGSGSGTQFTLTISDVQCD  
DAATYYC/FSYDCSTGDCFVFGGGTEVVVKR (SEQ ID NOS: 65, 66, 67, respectively)

Ap7 Variable region light chain (chimera) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

CAAGTGGCTGACCCAGACTGGCATCCCCGGTGTCTGCAGCTGTCAGGTGGAAAGGCACAGTCACCATCAATTGCCAGGGCCAGTCAG  
AGTGTATAATTACAACCTTGCCTGGTATCAGCAGAAACCAGGGCAGGCCCTCCAAAGCAACTGATCTATCTTACA  
TCCACTCTGGCATCTGGGTCTCATCGGGATTCAAAGGCACTGGACACAGTCACTCTACCATCAGCGACG  
TGCAGTGTGACGATGCTGCCACTTACTACTGTCTAGGCAGTTATGACTGTAGTGGTATTGTTTCTGGCGGGAGG  
GACCGAGGTGGTCAAACG (SEQ ID NO: 201)

Ab7 Light chain (chimera) Full length DNA sequence.

CAAGTGGTACCCAGACTGCATCCCCGGTGTGGCTGAGCTGTGGAAAGGCCACAGTCACCATCAATTGCCAGGCCAGCAG  
AGTGTATAATTACAACACTACCTTGGCTGGTATCAGCAGAAACCAGGGCAGCCCTCCCAAGCAACTGATCTTATCTTACAT  
CCACTCTGGCATCTGGGTCTCATCGCGATTCAAAGGCAAGTGGATCTGGACACAGTTCACTCTCACCACAGGGAC  
GCAGTGTGACGATGCTGCCACCTACTGTCTAGGGCAGTTATGACTGTAGTACTGGTATTGTATTGTTTCGGGGAG  
GGACCGAGGTGGTGTGTCAAACGTACGGTGGCTGCACCATCTGTATCTGGTGGCTGAAATAACTCTTCCAGAGGGCCA  
TGGAAACTGCCTCTGTTGTCGCTGCTGTAATCTTACAGCCTACAGGCCACAGCAGGCCACCCCTG  
CTCCAATCGGTAACCTCCAGGAGGTGTCAAGAGCAGGACAGCAAGGACAGCACCACAGCAGGCCCTGAGCTGCCGTC  
ACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCCTGAGCTACCCATCAGGGCTACGGCAAGTCA  
ACAAAGAGCTCAACAGGGAGAGTGTAG (SEQ ID NO: 202)

## Figure 8

### Ab8

#### Ab8 Heavy chain (humanized) Full length protein sequence.

**EVQLVESGGGLVQPQGGSSLRLSCAVSGIDLSNHYMQWVVRQAPGKGLEWVGVVGINGRTYYASWAKGRFTISRDNSKTTVYL**  
**QMNSLRAEDTAVYFCARGDIWGGTTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV**  
**HTFPAPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNWNHKPSNTKVVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL**  
**MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA**  
**PIEKTISKAKGQPREPQWYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVVLSDGSFLYSKLTVD**  
**KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 74)**

#### Ab8 Variable region heavy chain (humanized) protein sequence.

**EVQLVESGGGLVQPQGGSSLRLSCAVSGIDLSNHYMQWVVRQAPGKGLEWVGVVGINGRTYYASWAKGRFTISRDNSKTTVYL**  
**QMNSLRAEDTAVYFCARGDIWGGTTLVTVSS (SEQ ID NO: 73)**

#### Ab8 Variable region heavy chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

**EVQLVESGGGLVQPQGGSSLRLSCAVSGIDLSNHYMQWVVRQAPGKGLEWVGVVGINGRTYYASWAKGRFTISRDNSKTTVYL**  
**QMNSLRAEDTAVYFCARGDIWGGTTLVTVSS (SEQ ID NO: 78, 79, 80, respectively)**

#### Ab8 Variable region heavy chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

**GAGGTGCAGCTTGTGGAGTCTGGTCCAGGCTGGGGTCCCTGAGACTCTCCCTGAGACTCTGGCAGTCTCTGGAA**  
**TCGACTCTCAGTAACCACATGCAATGGGTCCGTCAGGCTCAGGGAAAGGGCTGGAGTGGCTGGAGTCGTTGGTA**  
**TCAAATGGTCGCACATACTACGGCGAGCTGGGCAAAGGCCGATTCACCATCTCCAGAGACAATTCCAAGACCCACGGGTGT**  
**ATCTTCAAAATGAACACGCCCTGAGCTGAGGACACTGCTGTGTATTCTGTGTGTATTCTGTGTGTATTCTGTGTGT**  
**CCTCGTCACCGCTCGAGC (SEQ ID NO: 213)**

Ab8 Heavy chain (humanized) Full length DNA sequence.

GAGGGTGCAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGGCTGGGGTCCAGGCTGGGGTCCCTGGAGACTCTCCTGTGGCAGTCTGGAA  
TCGACCTCAGTAACCACTACATGCAATGGGTCCGTCAAGGCTCCAGGGAAAGGGGCTGGAGTCGGAGTCGGTGGTA  
TCAATTGGTCGACATACTACGGAGCTGGGGAAAGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACCAAGGGAA  
ATCTTCAGGAACTACGGCTGAGAGCTGAGGACACTGCTGTGTATTCTGTGGCTAGAGGGGACATCTGGGGCAAGGGAA  
CTCTCGTCACCGTCTCGAGCGCTCCACCAAGGGCCATCGGTCTCCAGGGGGAAACCCGGTGAAGGACTCAGGGCCCT  
GGGCACAGCGGCCCTGGCTGGCTGAAGGACTACTTCCCAGAAGGACTACTCCCTCAGGACTCTACTCCCTCAGGCTGGTGA  
GACCGGGGTGCACACCTTCCGGTGTCCCTACAGTCTCAGGACTCTCAGGACTCTACTCCCTCAGGCTGGTGA  
TCCAGCAGCTTGGCACCCAGACCTACATCTGCAACGTGAATCACAAGGCCAGCAACCAAGGTGGACAAGAGT  
GAGGCCAAATCTTGTGACAAAAGTCAACATGCCAACCGTGGCACCTGAACCTCTGGGGGACCCGTCAGTCTTCC  
TCTTCCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTACATGGTGGACTGCTGAATGGCAAGGAGC  
CGAAGACCCCTGAGGTCAAGTCAACTTGTACCGTGGTGTGTCAGGGTCTCAGGTCTCAGGGACTGGCTGAATGGCAAGGAGTACA  
AGCAGTACGGCAGCACGTACCGTGGTGTGTCAGGGTCTCAGGTCTCAGGGACTGGCTGAATGGCAAGGAGTACA  
AGTGCAGGGTCTCCAACAAAGCCCTCCAGCCCCATCGAGAAAACCAACTCTCCAAGGCAAGGGCAGCCCCGAGAAC  
CACAGGGTGTACACCCCTGGCCCCATCCCCGGAGAGATGACCAAGAACCCAGGAGGAGCAATGGGCAGGGAGAGCA  
TCTATCCAGCGACATGGCGTGGAGTGGAGGGAGCAACTACAAGAACCAACTACAAGAACCCAGGAGGAGCA  
TGGACTCCGACGGCTCCTCTACAGCAAGCTCACCGTGGACAAAGAGCAGGTGGCAGGGAGCAAGGGAAACGGTCTTC  
ATGCTCCGATGCAAGGGCTCTCCCTGTCTCCGGTAAATGA (SEQ ID  
NO: 214)

Ab8 Light chain (humanized) Full length protein sequence.

QVLTQSPSSLSASVGDRVTINCQASQSVYNNYLAWYQQKPGKVPKQLIYSTTLASGVPSRFGSGSTDFTLTISSLQPED  
VATYYCLGSYDCSTGDCFVFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWVKVDNALQSGNS  
QESVTEQDSKDSITYSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 72)

Ab8 Variable region Light chain (humanized) protein sequence.

QVL1QSPSSLSASVGDRVTINQCQASQSVYNNYLAWYQQKPGKVPKQLIYSTTLASGVPSRFSGSGTDFTLTISSLQPED  
VATYYCLGSSYDCSTGDCFVFGGTKEIKR (SEQ ID NO: 71)

**Ab8** Variable region Light chain (humanized) protein sequence. **CDR1: Bold; CDR2: Underlined; CDR3: Italic.**  
QVL**T**QSPSSLASVGDRVTIN**C**QASQ**S**VYNY**N**LA**W**Y**Q**QKPG**K**VPK**Q**LI**Y**ST**T**SL**A**SGV**P**SRF**S**GS**G**T**D**FT**L**TISS**L**Q**P**ED  
VAT**Y**YC**T**(*GSYD*)**C**ST**G**CF**V**GG**GT**K**V**E**I**K**R** (SEQ ID NOS: 75, 76, 77, respectively)

**Ab8 Variable region Light chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

**CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC**  
**AGTGTTTACAATTACAACTACCTTGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAAGGCAACTGATCTATCTAC  
ATCCACTCTGGCATCTGGGGTCCCATCTCGTTTTCAGTGGCAGTGGGATCTGGGACAGATTTCACTCTCACCACATCAGCAGC  
CTGCAGCCTGAAGATGTTGCAACTTATTACTGTCGGGCAGTTATGATTTACTGGTACTGGTACTGGTATTGATTTTCGGGGAG  
GAACCAAGGTGGAAATCAAAACGT (SEQ ID NO: 211)**

Ab8 Light chain (humanized) Full length DNA sequence.

Figure 9

Ab9

**Ab9 Heavy chain (chimera) Full length protein sequence.**

QSLEESGGRL VTPGTPLTL TCTVSGIGLSSYYMQWVRQSPGRGLIEWIGVIGSDGKTYYATWAKGRFTISKTSTTVDLRMAS  
LTTEDDTATYFCTRGDIWGPGLTVTVSSAATKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPBV  
LQSSGLYSLSSVTVPSSLGTQTYICNVNHNKPSPNTKVDKRVEPKSCDKTHCPCPAPELLGGPSVFLFPPKPKDTLMSRTP  
EVTCVUVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS  
KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVENEWSNGQOPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ  
OGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 84)

Ab9 Variable region heavy chain (chimera) protein sequence.

QSLEESGGRLVTPGTPLTLLCTVSGIGLSSYYMQWVRQSPGRGLEWIGVIGSDGKTYYATWAKGRFTISKTSSTVBLRMAS  
LTTEDTATYFCTRGDIWGPGLTVTSS (SEQ ID NO: 83)

**Ab9** Variable region heavy chain (chain a) protein sequence  
QSLEESGGRLVTPGTPTLTLCTVSGIGLSSYYMQWVRQSPGRGLEWIGVIGSDGKTYATWAKGRTISKTSSTTVDLRMAS  
LTTEDDATYFCTRGDIWGPGLTVTSS (SEQ ID NOS: 88, 89, 90, respectively)

**Ab9** Variable region heavy chain (chimera) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italic.

CAGTCGCTGGAGGTCCGGGGTCCGGCTGGTCACGGCCTGGGACACCCCTGACACTCACAGTCTCTGGAAATCG  
GCCTCAGTAGCTACTACATGCAGTGGTCCGGCCAGTCTCCAGGGAGGGCTGGAAATGGATCGGAGTCATGGTAGT  
GATGGTAAGACATACTACGGGACCTGGCGAAAGGGCCGATTCAACCATCTCCAAGACCTCGTCGACCACGGTGGATCTG  
AGAATGGCCAGTCTGACAACCGAGGACACGGGACACTTCTGTACAGGGGACATCTGGGGCCACCTATTCTG  
GTCACCGGTCTCGAGC (SEQ ID NO: 223)

**Ab9 Heavy chain (chimera) Full length DNA sequence.**

CAGTCCGCTGGAGGGAGTCCGGGGCTCGGTCACGCCCTGGGACACCCCTGACACTCACCTGCACAGTCTGGAAATCG  
 GCCTCAGTAGCTACTACATGCAGTGGCTCCGGCCAGTCTCCGGAAAGGGGCTGGGAATGGAGTCGAGTCATTGGTAGTGA  
 ATGGTAAGACATACTACCGGACCTGGCGAAAGGGATTCAACCAAGAACCTCGTCGACCCATCTCCAAAGGACCTGGGATCTGA  
 GAATGGCCAGTCTGACAAACCGAGGGACACGGCCACCTATTCTGTACCCAGAGGGACATCTGGGGGGGACCCCTCG  
 TACCCGCTCGAGCGCCTCCACCAAGGGCCCATCGGTCCTCCGGCTGGCTGGTCAAGGACTACCGGAACTCCGGTGGAAACTCAGGGCCCTGACCCAG  
 AGCGGGCCCTGGGCTGGCTGGTCAAGGACTACTCCCCGAACCCGGTGAACGGGTGTCCTGAGCAGCGTGGGTGACCCGTGCCCTCAGC  
 CGCGTGACACCTTCCCGGCTGTCCCTACAGTCCTCAGGGACTCTACTCCCTCAGCAGCGTGGGTGACCCGTGCCCTCAGC  
 AGCTTGGGACCCAGACCTACATCTGCAACGTGAATCACAAAGCCAGCAACACCAAGGTTGGACAAAGAGAGTGGAGCCC  
 AAATCTTGTGACAAAACCTCACACATGCCAACCGGTGGCTGGCACCCTGAAACTCCCTGAGGGTCAACATGCCGTGGTGGACGGCCACGAAG  
 CCCAAAAACCCAAAGGACACCCCTCATGATCTCCCGAACCCCATCGAGAAACCATCTCCAAAGGCCAAAGACAAAGGCCGGGGAGGGAGCAG  
 ACCCTGAGGTCAAGTTCAACTGGTACCGTGGACCGGGTGGGAGGGTGCATAATGCCAAAGGAGTACAAGTGC  
 TACGCCAGCACGTACCGTGTGGTCAGCGTCTCACCG1CCTGCACCAGGACTGGCTGAATGGCAAGGGCAGCCCCGAGAACCCACAG  
 AAGGTCTCCAACAAAGCCCTCCCAAGCCCCCATCGAGAAACCATCTCCAAAGGCCAAAGGCCAAAGGAGTGAACCGGTCAACCTGGCTGGTCAAGGGCT  
 GTGTACACCCCTGCCCTGCCGTGGAGTGGAGAGCAATTGGGCAGCCGAGCAACTACAAGGACCCACGCCCCGAGAACCCACAG  
 CCAGGGACATGCCGTGGAGAGCAACAGCAAGCTACCGTCTTCCCTACAGCAAGCTACCCAGAACCAACTACACGCCAGGGAGCAGGGTGGACAAAGGAGCAG  
 CCGACGGCTCTTCCCTACAGCAAGCTACCCAGAACCAACTACACGCCAGGGAGCAGGGTGGTCAAGGAGGCTCTCCCTGTCTCCGGGTAATGAGA (SEQ ID NO: 224)  
 CGTGATGTCATGAGGCTCTGCACAAACCAACTACACGCCAGGGAGCAGGGTGGTCAAGGAGGCTCTCCCTGTCTCCGGGTAATGAGA (SEQ ID NO: 224)

**Ab9 Light chain (chimera) Full length protein sequence.**

QVLQTQTPSPVSAAVGSTVTINQASQNVYNNYLAWSYQQKPGQPPKQLIYSTSTLAVGVSSRFRGSGSGTQFTLTISDVQCD  
 DAATYYCLGSYDCSRGDCFVFGGTTEVWVKRTVAAPSWFIFPPSDEQLKSQTASVVCNLFNPREAKVQWVKVDNALQSGN  
 SQESVTEQDSKDVDSTYLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 82)

**Ab9 Variable region light chain (chimera) protein sequence.**

QVLQTQTPSPVSAAVGSTVTINQASQNVYNNYLAWSYQQKPGQPPKQLIYSTSTLAVGVSSRFRGSGSGTQFTLTISDVQCD  
 DAATYYCLGSYDCSRGDCFVFGGTTEVWVKRTVAAPSWFIFPPSDEQLKSQTASVVCNLFNPREAKVQWVKVDNALQSGN  
 (SEQ ID NO: 81)

**Ab9 Variable region light chain (chimera) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italic.**

QVLQTQTPSPVSAAVGSTVTINQASQNVYNNYLA<sup>WY</sup>QOKPQPPKQLIYSTSTL**A**SGVSSRFRGSGSGTQF<sup>TL</sup>TISDVQCD  
DAATYYCLGSYDCSRGDCFVFGGTEVVVKR (SEQ ID NOS: 85, 86, 87, respectively)

**Ab9 Variable region light chain (chimera) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italic.**

CAAGTGCTGACCCAGACTCCATCCCCCGTGTCTGCAGCTGTGGGAAGGCACAGTCACCATCAATTGCCAAGGCCAGTCAG  
**A**ATGTTTATAATAACAAACTACTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCTAC  
GTCCACTCTGGCATCTGGCATTGGGTCTCATCGCGATTCAGAGGCAGTGGATCTGGGACACAGTTCACACTCACCATCAGCGAC  
GTGCAGTGTGACGATGCTGCCACTTACTACTGTCTAGGCAGTTAGTGTGATTGGTGTGATTGGTTGGTTGGAG  
GGACCGAGGTGGTCAAACAGT (SEQ ID NO: 221)

**Ab9 Light chain (chimera) Full length DNA sequence.**

CAAGTGCTGACCCAGACTCCATCCCCCGTGTCTGCAGCTGTGGGAAGGCACAGTCACCATCAATTGCCAAGGCCAGTCAG  
ATGTTTATAATAACAAACTACTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCTACGTC  
CACTCTGGCATCTGGGCTCTCATCGCGATTCAAGGCAGTGGATCTGGGACACAGTTCACACTCACCATCAGCGAC  
CAGTGTGACGATGCTGCCACTACTGTCTAGGCAGTTATGATTGTAGTCGTGGTGTGATTGTTTGTGATTGTTGGGAG  
GACCGAGGTGGTCAAACGTACGGGGCTGCACCATCTGGCTTCACTCTCCGGCCATCTGATGAGCAGTTGAAATCT  
GGAACATGGCCTCTGTGGCTGTGAATAACTTCTATCCAGAGGGCCAAGTACAGTGGAAAGGTGGATAACGCC  
TCCAATCGGGTAACTCCAGGAGGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCCTCAGCAGCACCCTGA  
CGCTGAGCAAAGCAGACTACGGAGAAACACAAAGTCTACGGCCTGCGAAGTCACCCATCAGGGCCTGAGCTGCCCCGTCA  
CAAAGAGCTCAACAGGGAGAGTGTAG (SEQ ID NO: 222)

## Figure 10

### Ab10

#### Ab10 Heavy chain (humanized) Full length protein sequence.

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVRQAPGKGLEWVGVIGSDGKTYYATWAKGRFTISRDNSKTTVYL  
 QMNSLRAEDTAVYFCTRQDIWGQGTLVTVSSA~~STK~~GPSVFPLAPSKSTSGGTAA~~ALGCL~~VKDYFPEPVTVSWNSGALTSGVH  
 TFPAVLQLQSSGLYSLSSVVTVPSSSLGTQTYICNVN~~HKP~~SNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD~~TL~~  
 ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI  
 EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDGSFFLYSKLTVDKS  
 RWQQGNVFSCSV~~M~~HEALHNHYTQKSLSLSPGK (SEQ ID NO: 94)

#### Ab10 Variable region heavy chain (humanized) protein sequence.

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVRQAPGKGLEWVGVIGSDGKTYYATWAKGRFTISRDNSKTTVYL  
 QMNSLRAEDTAVYFCTRQDIWGQGTLVTVSS (SEQ ID NO: 93)

#### Ab10 Variable region heavy chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVRQAPGKGLEWVGVIGSDGKTYYATWAKGRFTISRDNSKTTVYL  
 QMNSLRAEDTAVYFCTRQDIWGQGTLVTVSS (SEQ ID NOS: 98, 99, 100, respectively)

#### Ab10 Variable region heavy chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

GAGGTGCAGCTTGTGGAGTCTGGGTCCAGCCTGGGGAGGGCTGGTCCAGCAGACTCTCCCTGAGACTCTCTGGAA  
 TCGGCCTCAGTAGCTACTACATGCAATGGGTCCGTCAGGGCTCCAGGGAAAGGGCTGGAGTGGGGCTGGAGTCATTGGTA  
 GTGATGGTAAGACATACTACGGGACCTGGCCAAAGGCCGATTCACCATCTCCAGAGACAATTCCAAGACCACGGGAC  
 ATCTTCAAATGAAACAGCCTGAGAGCTGAGGACACTGCTGTATTCTGTGATTCAGAGGGACATCTGGGGACATCTGGGCCAAGGGAC  
 CCTCGTCACCGTCTCGAGC (SEQ ID NO: 233)

## Ah10 Heavy chain (humanized) Full length DNA sequence.

GAGGTGCAGCTTGTGGAGTCTGGGGAGGCTTGGTCCAGCCTGGGGTCCCTGAGACTCTCCCTGGCAGTCTCTGGAA  
TCGGCCTCAGTAGCTACTACATGCAATGGGTCTCGTCAGGGCTCCAGGGAAAGGGGCTGGAGTGGGGAGTCATTGGTA  
GTGATGGTAAGACATACTACCGGACCTGGCCAAAGGCCGATTCACCATCTCCAGAGACAATTCCAAGACCACGGGTGT  
ATCTCAAATGAAACAGCCTGAGAGCTGAGGACACTGGCTGTATTTCTGTACCCAGGGGACATCTGGGGCCAAGGGAA  
CCCTCGTCACCGTCTCGAGCGCTCCAGGGCCCATCGGTCTCCAGGGGCAACCCAGGGCTGGAACTCAGGGGCCCT  
GGGCACAGCGGCCCTGGCTGCCCTGAAGGACTACTTCCCAGGAACCGGTGACGGGTGTCGTGGAACTCAGGGGCCCT  
GACCGGGGGCAGCACCTTCCCAGCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGAACCGGTGCC  
TCCAGCAGCTGGCACCCAGACCTACATCTGCAACGTGAATACAAGGCCAGCAACACAAGGGGACCCGTCAGTCTTCC  
GAGCCCCAAATCTTGTGACAAAACATCACATGCCAACCGTGCACCTGAGGACTCCAGCACATGGGGGACCGTGAGCCA  
TCTTCCCCAAAACCCAAAGGACACCTCATGATCTCCCGAACCCCTGAGGTCACTGGGGACGGCGTGGAGGTGCATAATGCCAAG  
CGAAGACCCCTGAGGTCAAGTCAACTGGTACCGTGGACGGACTGGCTGAATGGCAAGGACTGAATGGCTGAATGGCAAGGACTACA  
AGCAGTACGGCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCTGGACCCAGGACTGGCTGAATGGCAAGGACTGAAC  
AGTGCAGGTCTCCAACAAGGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCCTGCCCTCACCCGGAGGAGATGACCAAGAACGGTCAGCCTGACCTGGCTGAAGAACA  
TCTATCCAGGGACATCGCCGTGGAGTGGAGAGCAATGGGCAGGCCAACTACAAGACCACCGCTCCCTCT  
TGGACTCCGACGGCTCCCTCTACAGGAAAGGCAAGGGTGGACAAAGGAGCAACGGTGGCAGCAGGGAAACGTTCT  
ATGCTCCGTGATGCACTGAGGCTCTGACAAACCAACTACACGCAAGGAGCAAGGAGCAAGGGTAAATGA (SEQ ID  
NO: 234)

Ab10 Light chain (humanized) Full length protein sequence.

QVLTQSPSSLASAVGDRVTINQASQNVNNYLAWSQQKPGKVPKQLIYSTSTLASGVPSRFSGSGTDFTLTISSLQPED  
VATYYCLGSYDCSRGDCFVFGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYREAKVQWVKVDNALQSGNS  
QESVTEQDSKDKDSTYSLSSSTLTSKADYEHKVVACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 92)

## Ab10 Variable region Light chain (humanized) protein sequence.

QVLTQSPSSLASVGDRVTINCQASQNQKPGKVPKQLIYSTSTLASGVPSRFSGSGTDFTLTISSLQPED  
VATYYCIGSYDCCSRGGDCFVEGGGTKEIKR (SEQ ID NO: 91)

**Ab10 Variable region Light chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

QVLTQSPSSLSAVGDRVTINCQASQNVNNYLA<sup>WY</sup>QQKPGKVPKQLIYSTSTLASGVPSRFSGSGTDFLTISLQPED  
VATYYCLGSYDCSRGDCF/FGGGTKVEIKR (SEQ ID NOS: 95, 96, 97, respectively)

**Ab10 Variable region Light chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

**CAAGT**GCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAGACTCAATTGCCAGGCCAGTCAG  
**AATGTT**TACAATAACAAACTACCTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAAGCAACTGATCTTATTC  
ATCCACTCTGGCATCTGGTCCCCATCTCGTTCAGTGGCAGTGGATCTGGGACAGATTCACTCTCACCACATCAGCAGC  
CTGCAGCCTGAAGATGTTGCAACITATTACTGTCTGGGCAGTTATGATTGTTGAGTGGTGATTGGTGATTGTTGTTTCGGGGAG  
GAACCAAAGGTGAAATCAAACGT (SEQ ID NO: 231)

**Ab10 Light chain (humanized) Full length DNA sequence.**

CAAGTIGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAGACTCAATTGCCAGGCCAGTCAG  
ATGTTTACAATAACAAACTACCTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAAGCAACTGATCTTATTC  
CACTCTGGCATCTGGGCTCCCATCTCGTTCAGTGGCAGTGGATCTGGGACAGATTCACTCTCACCACATCAGCAGC  
CAGCCTGAAGATGTTGCAACITATTACTGTCTGGCAGTTATGATTGTTGAGTGGTGATTGGTGATTGTTGAAATCT  
AACCAAGGTGGAAAATCAAACCTACGGGGTGCACCATTCTGTCTTCACTCTCCGGCATTCTGATGAGCAGTTGAA  
GGAAACTGCCTCTGTGTTGCTGCTGAATAACTCTATCCCAGAGGGCAAGTACAGTGGAAAGGTGATAACGCC  
TCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCCTACAGCAGC  
CGCTGAAGCAAAGCAGACTACGAGAAACACAAAGTCTACGGCTGCGAAGTCACCCATCAGGGCTGAGCTCGCCGTCA  
CAAAGAGCTCAACAGGGAGAGTGTAG (SEQ ID NO: 232)

## Figure 11

### Ab11

#### Ab11 Heavy chain (chimera) Full length protein sequence.

QSLEESGGRLVTPGGSLTLTCTVSGIDVTNYYMQWVRQAPGKGLEWIGVINGKRYYASWAKGRFTISKTSSTTVDLKMT  
 SLTTEDDATATYFCARGDIWGPGLTLVTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKKDVFPEPVTVSWNSGALTSGVHTFPA  
 VLQSSGLYSLSSVVTVPSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT  
 PEVTCVVVVVDVSHEDPEVKFNWYVDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI  
 SKAKGQPREPQQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQOPENNYKTTPPVILDSDGSFFLYSKLTVDKSRWQ  
 QGNVVFCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 104)

#### Ab11 Variable region heavy chain (chimera) protein sequence.

QSLEESGGRLVTPGGSLTLTCTVSGIDVTNYYMQWVRQAPGKGLEWIGVIGVNGKRYYASWAKGRFTISKTSSTTVDLKMT  
 SLTTEDDATATYFCARGDIWGPGLTLVTVSS (SEQ ID NO: 103)

#### Ab11 Variable region heavy chain (chimera) protein sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

QSLEESGGRLVTPGGSLTLTCTVSGIDVTNYYMQWVRQAPGKGLEWIGVIGVNGKRYYASWAKGRFTISKTSSTTVDLKMT  
 SLTTEDDATATYFCARGDIWGPGLTLVTVSS (SEQ ID NOS: 108, 109, 110, respectively)

#### Ab11 Variable region heavy chain (chimera) DNA sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

CAGTCGGCTGGAGGTCCGGGGTCGGCTGGAGGATCCCTGACACTCACGCTCTGGAAATCG  
 ACGTCACTAACTACTATATGCAATGGGTCCAGGGCAGGGCTGGAAATGGGATCGGAGTCATTTGGTGTGA  
ATGGTAAGAGATACTACCGCAGGCTGGCCGAAAGGCCGATTCACCCATCTCCAAAACCTCGTGCACCACGGGTGGATCTGA  
 AAATGACCAGTCTGACAACCGAGGAACACGGCCACCTATTCTGTGCCAGAGGGGACATCTGGGGGGACCCCTCGT  
 CACCGTCTCGAGC (SEQ ID NO: 243)

**Ab11 Heavy chain (chimera) Full length DNA sequence.**

CAGTCCGCTGGAGGAGTCCGGGGTCGGCTCGGTCACGCCCTGGAGGATCCACTCACACTGCACAGTCTGGAAATCG  
 ACGTCACTAACTACTATGCAATGGGATCCGGCTCCAGGGCTCCAGGGAAAGGGCTGGGAATGGATCGGAGTCATGGGTGATCTGA  
 ATGGTAAGAGATACTACCGGAGCTGGCGAAAGGGCAATTCAACCCATCTCCAAACCTCGACACCGGGACATCTGGGGGGACCCCTCG  
 AAATGACCAAGTCTGACAAACCGAGGACACGGCCACCTGGGACAGGGACACGGGCACTTCTGTGCCAGAGGGACATCTGGGGGGAC  
 TCACCCGCTCGAGCGCCTCCACCAAGGGCCCATCGGTCTTCTGGTCAAGGACTACTCCCCGAACCGGTGACGGGTGCTGGAAACTCAG  
 AGCGGGCCCTGGCTGCTGGTCAAGGACTACTCCCCGAACCGGTGACGGGTGCTGGAAACTCAGGGCCCTGACCC  
 CGCGTGCACACCTTCCGGCTGTCTACAGTCTCAGGGACTCTCAGGGACTCTACTCCCTCAGCAGCGTGGTGACCCGTGCCCCCTCCAGC  
 AGCTTGGGCACCCAGAACCTACATCTGCAACGGTGAATACAAGGCCAGCAACCCAAGGGTGGACAAGAGAGTTGAGGCC  
 AAATCTTGTGACAAAACCTCACACATGCCAACCGCTCATGATCTCCGGACCCCTGAGGGTCACATGCCAACGGGAGGGTGCATA  
 CCCAAACCCAAAGGACACCCCTCATGATCTCCGGACCCCTGAGGGTGGACAAGAGAGTTGAGGCC  
 ACCCTGAGGTCAAGTTCAACTGGTACGGTGTGGTCAAGCGTCTCACCCTGCAACGGACTGGCTGAATGGCAAGGGAGTACAAGTGC  
 TAGGCCAGCAGTACCGTGTGGTCAAGCGTCTCACCCTGCAACGGACTGGCTGAATGGCAAGGGCAGCCCCGAGAACCCACAG  
 AAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAGGAAACTACAAGGACCAAGAACAAAGGCC  
 GTGTACACCCCTGGCCCCCATCCCCGGAGATGACCAAGAACCCAGGTCAAGCCTGCCGTCAAGGCC  
 CCAGCGACATCGCCGCTCTTCTCTACAGCAAGCTCACCGTGGAGAGGCAATGGGAGGGAGAACGAGGTGGCAGCAGGGAAACGTC  
 CGTGATGCATGAGGCTCTGCACAAACCTACACGGCAGAACGAGGCCCTCTCCGGGTAAATTGA (SEQ ID NO: 244)

**Ab11 Light chain (chimera) Full length protein sequence.**

QVLQTQTAASPVSPAVGSTVTINCRASQSVYYNNYLAWYQQKPGQPPKQLIYSTSTLASGVSSRFKGSGSGTQFTLTISDVQCDD  
 AATYYCLGSYDCSNGDCFVFGGGTEVVVKRTVAAPSVFIFPPSDFEQLKSGTASVVCVLLNNNFTPREAKVQWVKVDNALQSGNS  
 QESVTEQDSKDDSTYSLSSLTLSKADYEHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 102)

**Ab11 Variable region light chain (chimera) protein sequence.**

QVLQTQTAASPVSPAVGSTVTINCRASQSVYYNNYLAWYQQKPGQPPKQLIYSTSTLASGVSSRFKGSGSGTQFTLTISDVQCDD  
 AATYYCLGSYDCSNGDCFVFGGGTEVVVK (SEQ ID NO: 101)

**Ab1.1** Variable region light chain (chimera) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italic.

QVLTTQTAASPVS<sup>1</sup>AVGSTV<sup>2</sup>TINCRASQSV<sup>3</sup>YYNNYLAWYQQKPGQPPKQLIY<sup>4</sup>STSTL<sup>5</sup>ASGV<sup>6</sup>SSRFKGSGSGTQ<sup>7</sup>QFTLTISDVQCD<sup>8</sup>  
DAATYXYC<sup>1</sup>GSYDC<sup>2</sup>CSNG<sup>3</sup>DCF<sup>4</sup>FGGGT<sup>5</sup>EV<sup>6</sup>V<sup>7</sup>KR (SEQ ID NOS: 105, 106, 107, respectively)

Ab11 Variable region light chain (chimera) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

ADULT variance control 3  
CAGGTGCTGACCCAGACTGCATCCCCGGTCTCCAGCTTCCAGCTGGGAAGCACAGTCACCATCAATTGCCGGCAGTCAG  
AGTGTATTATAACAACTACCTAGCCTGGTATCAGCAGAAACCAGGGCAGGCCCTCCAAAGCAACTGATCTATCTAC  
ATCCACTCTGGCATCTGGGTCTCATGGGGTCAAAGGCAGTGGATCTGGGACACAGTCACCTCACCACATCAGCGAC  
GTGCAGTGTGACGA  
GGACCGAGGTGGTCAAACGT (SEQ ID NO: 241)

Ab11 Light chain (chimera) Full length DNA sequence.

CAGGTGACTGACCCAGACTGGCATCCCCGGTGTCTCCAGCTGTGGGAAGCACAGTCACCATCAATTGCCGGUCAGUCAGA  
GTGTTATTAAACAACCTACCTAGCCCTGGTATCAGCAGAAACCAGGGCAGCCTCCAAAGCAACTGATCTATTCTACATC  
CACTCTGGCATTCTGGGTCTCATCGGGGTCAATCGGGGTCTCATCGGGGTCAAAAGGCAGTGGATCTGGGACACAGTCACCTC  
CAGTGTGACGATGCTGCCACTTACTACTGTCTAGGCAGTTATGATTGTAGTAATTGGTGATTGTTTGGGAGG  
GACCGAGGGTGTGGTCAAAACGTAACGGTACGGTGGCTGCACCATCTGTCTTCATCTGGCAGTGGAGGTGATAACGCC  
GGAACCTGCCTCTGTGTGCTGTGAATAACCTCTATCCCAGAGGGCCAAGTACAGTGGAAAGGTGGATAACGCC  
TCCAATCGGGTAACACTCCAGGAGAGTGTACAGAGCAGGACAGCAAGGGACAGCACCTACAGCCCTCAGCAGGACCC  
CGCTGAGCAAAGCAGACTACCGAGAAACACAAAGTCTACGGCCTGAGCTACGGCCATCAGGGCCATCAGGGC  
CAAAGAGCTCAACAGGGAGAGTGTAG (SEQ ID NO: 242)

## Figure 12

### Ab12

#### Ab12 Heavy chain (humanized) Full length protein sequence.

**EVQLVESGGGLVQPGGSLRLSCAVSGIDVTNYYMQWVRQAPGKGLEWVGIVNGKRYYASWAKGRFTISRDN SKTTVYL**  
**QMNSLRAEDTAVYFCARGDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDVFPEPVTVSWNSGALTSGV**  
**HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNWNHKPSNTKVVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL**  
**MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAAKTKPREEQQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA**  
**PIEKTIKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVVLSDGSFLYSKLTVD**  
**KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 114)**

#### Ab12 Variable region heavy chain (humanized) protein sequence.

**EVQLVESGGGLVQPGGSLRLSCAVSGIDVTNYYMQWVRQAPGKGLEWVGIVNGKRYYASWAKGRFTISRDN SKTTVYL**  
**QMNSLRAEDTAVYFCARGDIWGQGTLVTVSS (SEQ ID NO: 113)**

#### Ab12 Variable region heavy chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

**EVQLVESGGGLVQPGGSLRLSCAVSGIDVTNYYMQWVRQAPGKGLEWVGIVNGKRYYASWAKGRFTISRDN SKTTVYL**  
**LQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS (SEQ ID NOS: 118, 119, 120, respectively)**

#### Ab12 Variable region heavy chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

**GAGGTGCAGCTTGTGGAGTCTGGGGAGGCTGGTCCAGCCTGGACTCCCTGAGACTCTCCCTGTGCAGTGTCTGGAA**  
**TCGACGTCACTA~~ACTACATGCA~~ATGGGTCCGTCAGGCTCAGGGAAAGGGCTGGAGTGGGAGTCATTGGTG**  
**TGAATGGTAAGAGATACTACGCCAGAGCTGGGGAAAGGCCATTCCAGAGACAATTCCAAGACCACGGGT**  
**ATCTTCAAATGAAACAGCCTGAGGACACTGCTGTGATTTCTGTGTGACATCTGGGGAGACATCTGGGCCAAGGGAC**  
**CCTCGTCACCGTCTCGAGC (SEQ ID NO: 253)**

**Ab12 Heavy chain (humanized) Full length DNA sequence.**

GAGGTGCAGCTGTGGAGTCTGGGGAGGGCTTGGTCCAGCCTGGAGACTCTCTGTGCAGTCTCTGGAA  
 TCGACCGTCACTAACTACTACATGCAATGGTCTCGTCAAGGCTCCAGTCAAGGGAAAGGGGTTGGAGTGGGTGATTGGT  
 TGAATGGTAAGAGATACTACGGGAGGCTGGGGGAAAGGGGATTCACCATCTCCAGAGACAATTCCAAGAACACGGGTG  
 ATCTTCAAATGAAACAGCCTGAGGACACTGGTGTGTAATTCTGTGCCAGAGGGACATCTGGGCCAACGGCAAGGGAA  
 CCTCGTCACCGTCTCGAGGCCATCGGGTCTGGCTCAAGGGACTACTTCCCCGAAACGGGTGACGGTGAACGGTGCCT  
 GGGCACAGGGCCCTGGGCTGCCCTACAGTCCTCAGGGACTCTACTCCCTCAGCAGGGTGGAAACTCAGGGCAGCTCTGG  
 GACCAAGGGGGTGCACACCTCCGGGTGACAGTCACTGGGACACCCCTCATGATCTCCGGACCCCTGAGGTACATGCGT  
 TCCAGCAGCTTGGCACCCAGACCTAACATCTGCAACGTGAATCACATGCCACCGTGGCCAGCAGCTGAACCTGA  
 GAGCCCCAAATCTTGTGACAAACTCACACATGCCACCGTGGCCAGCAGCTGAACATGCGTGGTGGACCTGAGGAGTACA  
 TCTTCCCCAAAACCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGGACAAAGACA  
 CGAAGACCCCTGAGGTCAAGGTTAACCTGGGACGGGTTGGAGGGTGGCATATAATGCCAAGACA  
 AGCAGTACGGCCAGCACGTACCGTGTGGTCAGCGTCTCAGCGTCCAGGCAAAAGCCAAAGGCA  
 AGTGAAGGGTCTCCAACAAAGGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAGGCA  
 CACAGGGTGTACACCCCTGCCCATCCCCGGAGGAGATGACCAAGAACCA  
 TCTATCCCAGGGACATCGCCGTGGAGTGGAGCAATGGGCAAGGAGCA  
 TGGACTCCGACGGCTCCTCTACAGCAAGCTCACAGCAAGAGCA  
 ATGGCTCCGGTGTGATGCAATGAGGCTCTGCACAAACCAACTACACGCAGAAC  
 NO: 254)

**Ab12 Light chain (humanized) Full length protein sequence.**

QVLTQSPSSLASVGDRVTINCRASQSVYYNNYLAWYQQKPGKVPKQLIYSTSTLASGVPSRFSGSQGTDFTLTISSLQPEDV  
 ATYYCLGSYDCSNGDCDFVFGGTKEIKRTVAPSVFIFPPSDEQLKSGTASVVFQWVKVDNALQSGNSQ  
 ESVTEQDSKDSSTYSLSSSTTLSKADYEKHKVYACEVTHQGLSSSPVTKSFNRGEC (SEQ ID NO: 112)

**Ab12 Variable region Light chain (humanized) protein sequence.**

QVLTQSPSSLASVGDRVTINCRASQSVYYNNYLAWYQQKPGKVPKQLIYSTSTLASGVPSRFSGSQGTDFTLTISSLQPEDV  
 ATYYCLGSYDCSNGDCDFVFGGTKEIKR (SEQ ID NO: 111)

**Ab12 Variable region Light chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

QVL<sup>T</sup>QSPSSLSAVGDRV<sup>T</sup>INCRASQS<sup>V</sup>V<sup>V</sup>NNYLAWYQQKPGKVPKQLIY<sup>ST</sup>ST<sup>SL</sup>ASGVPSRFS<sup>G</sup>SGTDF<sup>T</sup>LTISS<sup>L</sup>QPED  
VATYYCLGSYDCSNG/DCFVFGGT<sup>K</sup>VEIKR (SEQ ID NOS: 115, 116, 117, respectively)

**Ab12 Variable region Light chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

**CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCACATCAA<sup>TT</sup>GGCCAGTCAG**  
**AGTGT<sup>T</sup>TACTATAACAA<sup>CT</sup>ACCTAGCCTGGT<sup>A</sup>TTCAGCAGAAACCAGGGAAAGTCC<sup>T</sup>AA<sup>G</sup>C<sup>A</sup>ACTGATCTATTCTAC**  
**ATCCACTCTGGCATCTGGT<sup>C</sup>CCATCTCGTT<sup>T</sup>ICAGTGGCAGTGGATCTGGACAGATTC<sup>A</sup>CTCTACCACATCAGCAGC**  
**CTGCAGCCTGAAAGATGTTGCAACTTATTACTGTCTGGGCAGTTGATTGTAGTA<sup>A</sup>TGGTGATTGTTGTTTCGGCGAG**  
GAACCAAGGTGAAATCAAAACGT (SEQ ID NO: 251)

**Ab12 Light chain (humanized) Full length DNA sequence.**

CAAGTGCTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCACATCAA<sup>TT</sup>GGCCAGTCAG  
GTGTTACTATAACAA<sup>CT</sup>ACCTAGCCTGGT<sup>A</sup>TTCAGCAGAAACCAGGGAAAGTCC<sup>T</sup>AA<sup>G</sup>C<sup>A</sup>ACTGATCTATTCTACATC  
CACTCTGGC<sup>A</sup>TCTGGGGT<sup>CC</sup>CATCTCGTT<sup>T</sup>ICAGTGGCAGTGGATCTGGACAGATTC<sup>A</sup>CTGTTGTTTCGGCGAGG  
CAGCCTGAAAGATGTTGCAACTTATTACTGTCTGGCAGTTATGATTGTAGTA<sup>A</sup>TGGTGATTGTTG<sup>A</sup>TTGTTGAAATCT  
AACCAAGGTGAAATCAAACGTACGGTGGCTGCC<sup>A</sup>CCATCTGTCTTC<sup>T</sup>CCGCCATCTGATGAGCAGTTGAAATCT  
GGAACCTG<sup>C</sup>CTGTGTGCTGCTGCTGAAATAACTCTATCCCAGAGGGCCAAGTACAGTGGAAAGGTG<sup>G</sup>ATAACGCC  
TCCAATCGGGTA<sup>A</sup>CTCCCAGGGAGGT<sup>G</sup>TCA<sup>A</sup>CAGAGCAGCAAGGAGACTACAGGAGAAACACAAAGTCTACGGC<sup>T</sup>TCAG  
CGCTGAAGCAAAGCAGACTACAGGAGAAACACAAAGTCTACGGC<sup>T</sup>TCAGGAGTCA<sup>A</sup>CCCATCAAGGGCTGAGCTGCCC<sup>G</sup>TCA  
CAAAGAGTTCAACAGGGAGAGTGT<sup>T</sup>AG (SEQ ID NO: 252)

## Figure 13

### Ab13

#### Ab13 Heavy chain (chimera) Full length protein sequence.

QSVEESEGGGLVQPEGSLTLTCTASGFDFSSNAMVWWVRQAPGKGLEWIGCIYNGDGSTYYASWVNNGRFISIKTSSTTVTQLQ  
 NSLTVA~~ADTATYYCARDL~~WGPGLTVTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT  
 FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHPNSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDITLMI  
 SRTPEVTCVVVDVSHDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE  
 KTISKAKGQPREPQVYTLPSSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR  
 WQQGNVFSVMHEALHNHYTQKSLSPGK (SEQ ID NO: 124)

#### Ab13 Variable region heavy chain (chimera) protein sequence.

QSVEESEGGGLVQPEGSLTLTCTASGFDFSSNAMVWWVRQAPGKGLEWIGCIYNGDGSTYYASWVNNGRFISIKTSSTTVTQLQ  
 NSLTVA~~ADTATYYCARDL~~WGPGLTVTVSS (SEQ ID NO: 123)

#### Ab13 Variable region heavy chain (chimera) protein sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

QSVEESEGGGLVQPEGSLTLTCTASGFDFSSNAMVWWVRQAPGKGLEWIGCIYNGDGSTYYASWVNNGRFISIKTSSTTVTQLQ  
 NSLTVA~~ADTATYYCARDL~~WGPGLTVTVSS (SEQ ID NOS: 128, 129, 130, respectively)

#### Ab13 Variable region heavy chain (chimera) DNA sequence. CDR1: **Bold**; CDR2: Underlined; CDR3: *Italics*.

CAGTCGGTGGAGGTCCGGCTGGTCCAGGCTGAGGGATCCCTGACACTCACGCCCTCTGGATTC  
 GACTTCAGTAGCAATGCAATGTTGGTGGTCCAGGGCTGGAGTGGATCGGATGCATTACAA  
TGGTGATGGCACACATACTACGGCAGCTGGTGAATGGCCGATTCTCCATCTCCAAAACCTCGTGACCCACGGTGA  
CTGCAACTGAATAGTCTGACAGTCGCGGACACGGCCACGTATTATGTGCGAGAGATCTTGACTTGTGGGGCCGGCA  
 CCCTCGTCACCGTCTCGAGC (SEQ ID NO: 263)

## Ab13 Heavy chain (chimera) Full length DNA sequence.

ABISITE  
CAGTCGGTGGAGGACTCCGGGGCTGGGAGGGCTCCAGGCTGAGGGATCCCTGACACTCACCTGCACAGCCCTCTGGATTG  
GACTTCAGTAGCAATGCAATGTTGGTGGGGCTCCAGGGCTCCAGGGTCCAGGGTGGAGTGGATCGGATTC  
GGTGATGGCAGCACATFACTACGGGACTACGGGAGCTGGGAATGGCCGATTCTCCATCTC  
TGCAACTGAATAGTCTGACAGTTCGCGGACACGGGCCACGTATTATTGTGGAGAGATCTTGACTTGTGGGGGGC  
CCTCGTCACCCGTCAGGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAAGAGCACCTGG  
GGCACAGGGGCTGGGCTGGTGCACACCTCCGGCTGTCAACGTTGAACTCACAAGGCCACCAAGGGGACCGTGG  
ACCAGGGGGCTGGCACCCAGACCTACATCTGCAACGTTGAACTCACAAGGCCACCAAGGGGACCGTCAAGTCT  
CCAGCAGCTGGGCAACGACCTACATCTGCAACGTTGAACTCACAAGGCCACCCAGTGGCTGCCAGCACCTGA  
AGCCCCAAATCTTGTGACAAAACCTCACACATGCCAACCGTGGCTGCCAGCACCTGA  
CTTCCCCCAAAACCCAAAGGACACCCCTCATGATCTCCGGACCCCTGAGGGTCACATGGCTGGTGGACUGTGAGGCC  
GAAGAACCCCTGAGGTCAAGTTCAACTGGTACGGTGGACGGCGTGGAGGTGCAATAATGCCAAGACAAAGGCC  
GCAGTACGGCCAGCAGTACCCGGTGGTCAAGGGTGGAGAGCTGGCTGAACCGTCCCTCACCGTCA  
GTGCAAGGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAGGGCAGCCCCGAGAAC  
ACAGGGTGTACACCCCTGCCCTGCCCATCCCCATCCCCGAGATGACCAAGAACCTACAAGAACCTACAAGG  
CTATCCCCAGGACATCGCCGTGGAGGGAGAGCAATGGGAGAGCTGGCAGGGAGAACAAACTACAAGAAC  
GGACTCCGACGGGCTCCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTTGGAGGGAAACGGTCTCTCA  
TGCTCGTGTAGCATGAGGCTCTGCACAAACCAACTACACGCAGAAGGCTCTCCCTGTCTCCGGTAAATGA (SEQ ID  
NO: 264)

Ah13 Light chain (chimera) Full length protein sequence.

ALV3\_ELR\_C1  
AIVMTQTSSSKSVPVGDTVTINQASESLYNNNALAWFQQKPGQPPKRILYDASKLASFVPSRFSGGSGTQFTLTISSGVQCD  
DAATYYCGGYRSDSVDTGVAFAGGTEVVVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWVQVDNALQSGN  
SQESVTQDSKDTSYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 122)

**Ab13** Variable region light chain (chimera) protein sequence.

AIYMTQTPSSKSVPVGDTVTINCQASESLYNNNALAWFQQKPGQPPKRLIYDASKLASGVPSRFSGGGSGTQFTLTIISGVQCD  
DAATXXCCGYBRSDFSYDGVAFAGGTEVVKR (SEQ ID NO: 121)

**Ab13 Variable region light chain (chimera) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

AIVM**T**QTPSSK SVPVGDTVTIN**C**QASES**L**YNNNA**L**AWFQ**Q**KPQ**P**PKR**L**IY**D**ASK**L**AS**G**VPSRFSGGGSGTQFTLTISGVQCD  
DAATYYCYGGYRS**D**SV**D**GVAFAGGT**V**V**V**KR (SEQ ID NOS: 125, 126, 127, respectively)

**Ab13 Variable region light chain (chimera) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.**

**G**CCAT**C**GTGAT**G**AC**C**CA**G**ACT**CC**AT**T**CC**A**AG**T**CT**G**T**C**CC**T**G**C**AC**A**G**T**G**A**G**A**C**A**G**T**C**A**ATT**G**CC**A**GG**C**CA**G**T**G**  
**G**AG**A**G**T**C**T**T**A**ATA**A**ACA**A**CG**C**CT**T**GG**C**CT**T**GG**G**T**T**TC**A**GG**C**AG**A**AA**A**CC**A**GG**G**CA**G**GG**C**AG**A**AC**A**GG**G**CT**G**T**G**GG**G**T**C**T**G**GG**G**A**C**A**C**AG**T**T**C**ACT**C**ACC**A**CC**A**  
**T**GC**C**AT**CC**AA**A**CT**GG**C**A**T**C**T**GG**GT**C**CC**A**T**C**GG**G**GT**C**ACT**A**CT**A**CT**G**T**C**ACT**T**GT**G**G**C**T**A**CG**A**AG**T**G**A**T**G**G**T**T**G**  
GG**C**GT**G**C**A**GT**G**T**G**AC**G**G**A**T**G**T**G**C**G**T**C**ACT**A**CT**G**T**G**G**C**T**A**CG**A**AG**T**G**A**T**G**G**T**T**G**  
GG**A**CG**A**GG**T**GG**G**T**G**GT**C**AA**A**AC**G**T**C**AA**A**CG**A**GG**G**CC**A**A**A**GT**C**AG**A**GG**G**AC**A**GG**G**CA**G**AC**A**GG**G**CT**C**AG**A**GG**G**CT**T**CG**C**CG**G**  
GG**A**CG**A**GG**G**TT**G**GT**G**GT**C**AA**A**AC**G**T**C**AA**A**CG**A**GG**G**CC**A**A**A**GT**C**AG**A**GG**G**ATA**A**CG**G**  
T**G**GA**A**ACT**GG**C**T**CT**G**C**T**GT**G**T**G**GT**C**GT**G**GA**A**TA**A**CT**T**CT**G**C**T**GT**G**T**G**GT**C**AG**A**GG**G**CT**C**AG**A**GG**G**CT**T**CG**C**CG**G**  
CT**CC**AA**A**CT**GG**GT**A**ACT**CC**AG**G**AG**G**GT**T**CA**C**AG**A**GG**G**AC**A**GG**G**CA**G**AC**A**GG**G**CT**C**AG**A**GG**G**CT**T**CG**C**CG**G**  
AC**G**T**G**AG**G**CA**A**AG**G**ACT**A**CG**A**GA**G**AA**A**AC**A**CA**A**AG**G**CT**A**CG**C**CT**G**GA**A**GT**C**AC**CC**AT**C**AG**G**GT**T**AG**G**  
AC**AA**AA**A**AG**G**CT**A**AC**G**GT**T**GT**G**GT**C**AG**A**GG**G**AG**G**AT**G**GT**G**GT**C**AG**A**GG**G**CT**T**CG**C**CG**G** (SEQ ID NO: 262)

**Ab13 Light chain (chimera) Full length DNA sequence.**

**G**CCAT**C**GTGAT**G**AC**C**CA**G**ACT**CC**AT**T**CC**A**AG**T**CT**G**T**C**CC**T**G**C**AC**A**G**T**G**A**G**A**C**A**G**T**C**A**ATT**G**CC**A**GG**C**AG**T**  
**G**AG**A**G**T**C**T**T**A**ATA**A**ACA**A**AC**G**CC**T**GG**C**CT**T**GG**G**T**T**TC**A**GG**C**AG**A**AA**A**CC**A**GG**G**CA**G**GG**C**AG**A**AC**A**GG**G**CT**G**T**G**AT**C**ACT**C**AC**A**CT**C**AC**A**GG**G**  
**A**T**CC**AA**A**ACT**GG**C**A**T**C**T**GG**GT**C**CC**A**CT**C**GG**G**GT**T**TC**A**GT**G**GG**G**CT**A**CG**A**AG**T**G**A**T**G**G**T**T**G**  
GT**G**C**A**GT**G**T**G**AC**G**AT**G**T**G**CC**A**CT**A**CT**G**T**G**G**G**GT**C**AC**A**CT**G**T**G**G**G**GT**C**AC**A**CT**G**T**G**G**G**GT**C**AT**C**T**T**CG**C**CT**C**AT**C**T**T**CC**CC**AT**C**T**G**T**G**AT**G**  
GG**A**CG**A**GG**G**TT**G**GT**G**GT**C**AA**A**AC**G**T**C**AA**A**CG**A**GG**G**CC**A**A**A**GT**C**AG**A**GG**G**ATA**A**CG**G**  
T**G**GA**A**ACT**GG**C**T**CT**G**C**T**GT**G**T**G**GT**C**GT**G**GA**A**TA**A**CT**T**CT**G**C**T**GT**G**T**G**GT**C**AG**A**GG**G**AC**A**GG**G**CT**C**AG**A**GG**G**CT**T**CG**C**CG**G**  
CT**CC**AA**A**CT**GG**GT**A**ACT**CC**AG**G**AG**G**GT**T**CA**C**AG**A**GG**G**AC**A**GG**G**CA**G**AC**A**GG**G**CT**C**AG**A**GG**G**CT**T**CG**C**CG**G**  
AC**G**T**G**AG**G**CA**A**AG**G**ACT**A**CG**A**GA**G**AA**A**AC**A**CA**A**AG**G**CT**A**CG**C**CT**G**GA**A**GT**C**AC**CC**AT**C**AG**G**GT**T**AG**G**  
AC**AA**AA**A**AG**G**CT**A**AC**G**GT**T**GT**G**GT**C**AG**A**GG**G**AG**G**AT**G**GT**G**GT**C**AG**A**GG**G**CT**T**CG**C**CG**G** (SEQ ID NO: 262)

## Figure 14

### Ab14

#### Ab14 Heavy chain (humanized) Full length protein sequence.

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVVRQAPGKGLEWVGIGSDGKTYYATWAKGRFTISRDN SKTTVYL  
 OMNSLRAEDTAVYFCTRQDIWQGQGTLVTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH  
 TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDARVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDLM  
 ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI  
 EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVVLDSDGFFLYSKLTVDKS  
 RWQQGNVFSCSVVMHEALHNHYTQKSLSPGK (SEQ ID NO: 134)

#### Ab14 Variable region heavy chain (humanized) protein sequence.

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVVRQAPGKGLEWVGIGSDGKTYYATWAKGRFTISRDN SKTTVYL  
 OMNSLRAEDTAVYFCTRQDIWQGQGTLVTVSS (SEQ ID NO: 133)

#### Ab14 Variable region heavy chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

EVQLVESGGGLVQPGGSLRLSCAVSGIGLSSYYMQWVVRQAPGKGLEWVGIGSDGKTYYATWAKGRFTISRDN SKTTVYL  
 OMNSLRAEDTAVYFCTRQDIWQGQGTLVTVSS (SEQ ID NOS: 138, 139, 140, respectively)

#### Ab14 Variable region heavy chain (humanized) DNA sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

GAGGTGCAGCTTGTGGAGTCTGGGAGGGCTCCAGCCTGGCTGGGAGGACTCTCCCTGAGACTCTCTGGAA  
 TCGGCCTCAGTAGCTACTACATGCAATGGGTCCGTCAGGCTCCAGGGCTGGAGTGGGCTGGAGTGGTCAATTGGTA  
 GTGATGGTAAGACATACTACGGGACCTGGCCAAAGGCCGATTCACCATCTCCAGAGACAATTCCAAGACCACGGTGT  
 ATCTTCAAAATGAACACGCCCTGAGACTGCTGAGGACACTGCTGTATTTCTGTACCAAGAGGGACATCTGGGGACATCTGGGGCAAGGGAC  
 CCTCGTCACCGTCTCGAGC (SEQ ID NO: 273)

**Ab14 Heavy chain (humanized) Full length DNA sequence.**

GAGGTGAGCTTGTGGAGTCTGGGGAGGCTTGGCCAGCCTGGGGCTCCAGGGCTCAGGGCTCCAGGGAAAGGGTGGAGTGGGGCTGGAGCTGGTATGGTA  
 TCGGCCCTCAGTAGCTACTACATGCAATGGGTCCCGTCAGGGCTCCAGGGAAAGGGTGGAGTGGGGCTGGAGCTGGTATGGTA  
 GTGATGGTAAGACATACTACCGGACCTGGGGAAAGGGGATTCAACATCTCCAGAGACATCTGGGGACATCTGGGGCCAAGGGGA  
 ATCTTCAAATGAAACAGCCTGAGAGCTGAGGACACTGCTGTGTTACCTGAGGGACACTGCTGTGTTACCTGAGGGACATCTGGGGCCAAGGGGA  
 CCCTCGTCACCGTCTCGAGGGCCTCCAGGGCTCCACCAAGGGCCATCGGTCTCCCTGGCACCCCTCCAGGGACATCTGGGGCCAAGGGGA  
 GGGCACAGGGCCCTGGCTGGTCAAGGACTACTCCCCGAACCGGGTGAACGGTGAACCTGAGGACTACTCCCTCAGCAGGGCTGGTGAACCGTGC  
 GACCAAGGGGGTGCACACCTTCCGGTGCACAGTCCTCAGGACTACTCCCTCAGGACTACTCCCTCAGCAGGGCTGGTGAACGGCAGAGTT  
 TCCAGCAGCTTGGGACCCAGACCTACATCTGCAACCTGAAATACAAGCCCAGCAACACCAAGGGTGAACCTGAGGACTACTCCCTCAGGACT  
 GAGGCCAAATCTTGACAAAACCTCACACATGCCACCCCTCAATGATCTCCGGACCCCTCAATGCAATCTGGTGCACATGGCTGGTGGACCGTGA  
 TCTTCCCCAAAAACCCAAGGGACACCCCTCAACTGGTACCTGGGACCCGGTGGAGGTGCATAATGCCAAAGACAAAGCCGGGGAGG  
 CGAAGAACCCCTGAGGTCAAGGTCAACTGGTACCTGGTCAAGGGACTGGCTGAATGGCAAGGGAGTACA  
 AGCAGTACGCCAGCACGTACCGTGTGGTCAACGGTCTACCGTCCCTGCAACGGACTCTCCAGGGGAAACCATCTCCAAAGCCAAAGGGCAGGG  
 AGTGCAGGGTCTCCAACAAAGCCCTCCAGGGGGCATCCCCCATCGAGAAAACCATTCTCCAGGGGAGATGACCAAGAACAGGGTCAACGG  
 CACAGGTGTACACCCCTGGCCATCCCCGGAGATGACCAAGAACAGGGGAGATGACCAAGAACAGGGGAGATGACCAAGAACAGGG  
 TCTATCCCAGGGACATCGCCGTGGAGTGGGAGAGCTCTCTACAGCAAGGCTCACCGTGGACAAGAGCAGGAGCTCCCTGTC  
 TGGACTCCGACGGCTCCTTCTTCTACAGCAAGGCTCACCGTGGACAAGAGCAGGAGCTCCCTGTC  
 ATGCTCCGTGATGCATGAGGCTCTGCACAAACCAACTACACGGCAGAAGAGCCTCTCCCTGTC  
 NO: 274)

**Ab14 Light chain (humanized) Full length protein sequence.**

QVLTQSPSSL SASVGD RVTINCQASQNVYNNNYLAWYQQKPGKVPKQLIYSTSTLASGVPSRFSGSGSGTDFLTLSLQPED  
 VATYYCLGSYDCSR GDCFVFGGKVEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLNNFYREAKVQW KVVDNALQSGNS  
 QESVTEQDSK DSTDYSLSSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 132)

**Ab14 Variable region Light chain (humanized) protein sequence.**

QVLTQSPSSL SASVGD RVTINCQASQNVYNNNYLAWYQQKPGKVPKQLIYSTSTLASGVPSRFSGSGSGTDFLTLSLQPED  
 VATYYCLGSYDCSR GDCFVFGGKVEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLNNFYREAKVQW KVVDNALQSGNS  
 QESVTEQDSK DSTDYSLSSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 131)

**Ab14** Variable region I light chain (humanized) protein sequence. CDR1: Bold; CDR2: Underlined; CDR3: Italics.

QVLTQSPSSLASVGDRVTINCQASQNQQKPKVPLIYSTSTLASGVPSRFGSGTDFTLTSSQLQPED  
WATWYCLGSYDCSRGDCVFEGGGTKVEIKR (SEQ ID NOS: 135, 136, 137, respectively)

Ab4 Variable region Light chain (humanized) DNA sequence. CDR1: bold; CDR2: Underlined; CBK3: italics.

CAAGTGGCTGACCCAGTCTCCATCCTCCCTGCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAGGGCCAGTCAG  
**AATGTTTACAATAACCAACTACCTAGCCCTGTTATCAGCAGAA** ACCAGGGAAAGTCCCTTAAGCAACTGATCTTAC  
ATCCACTCTGGCATTCTGGGGTCCCCATCTCGTTTCAGTGGCAGTGGATCTGGGACAGATTCAC TCACTCTCAGCAGC  
CTGCAGCTGAAGATGTGTGCAACTTAACTACTGTCTGGGAGTGTGATTACTGATGTTGTTGTTGTTCTGGGGAG  
GAACCAAGGTGGAAATCAAACGT (SEQ ID NO: 271)

Ab14 Light chain (humanized) Full length DNA sequence.

CAAGTGCTGACCCAGTCTCCCATCTCCCTGTCATCTGTAGGAGACAGAGTCACCATCAATTGCCAGGCCAG  
ATGTTACAATAACAACCTACCTAGCCTGGTATCAGCAGAAACCCAGGGAAAGTTCTTAAGCAACTGATCTTCTACATC  
CACTCTGGCACTCTGGGGTCCCCATCTCGTTCACTGTCAGTGGCAGTGGATCTGGACAGATTTCACATCTCACCATAGCAGGCCCTG  
CAGCCCTGAAGATGTTGCAACTTAACTGCTGGCAGTTATGATTGTAAGTCTGGTGTGATTGTTCTGGGGAGG  
AACCAGGTTGAAATCAAAACGTACGGTGGCTGCACCATCTGTCTTCATCTGAGCAGTTGAAAGGTGATAACGCC  
GGAACCTGCCCTCTGTTGCTGCTGCTGAATAACCTCTATCCCAAGAGGGCCAAGTACAGTGGAAAGGTGATAACGCC  
TCCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCCTCAGCAGGCC  
CGCTGAGCAAAGCAGACTACCGAGAAACACAAAGTCTACGCCTGCGAAAGTCACCCATCAGGGCC  
CAAAGAGCTCAACAGGGGAGAGTGTAG (SEQ ID NO: 272)

**Figure 15**

**Human CGRP $\alpha$  ELISA**




Figure 16

Human CGRP $\alpha$  ELISA




Figure 17

Human CGRP $\alpha$  ELISA





Figure 18


Human CGRP $\alpha$  ELISA





**Figure 19**

**Human CGRP $\alpha$  cAMP**

**Inhibition of CGRP-driven cAMP production**





**Figure 20****Human CGRP $\alpha$  cAMP**


**Figure 21****Human CGRP $\alpha$  cAMP****Inhibition of CGRP-driven cAMP production**


**Figure 22**

**Human CGRP $\alpha$  cAMP**




**Figure 23****Human CGRP $\alpha$  cAMP****Inhibition of CGRP-driven cAMP production**

**Figure 24****Human CGRP $\alpha$  cAMP**

**Figure 25****Human CGRP $\beta$  cAMP**


**Figure 26**


**Human CGRP $\beta$  cAMP**



**Figure 27**

**Human CGRP $\beta$  cAMP**




**Figure 28****Human CGRP $\beta$  cAMP**


**Figure 29**

**Human CGRP $\beta$  cAMP**

Inhibition of human CGRP $\beta$ -driven cAMP production




**Figure 30**  
**Rat CGRP cAMP**




**Figure 31**

**Rat CGRP cAMP**





**Figure 32**  
**Rat CGRP cAMP**



**Figure 33**


**Rat CGRP cAMP**



**Figure 34****Rat CGRP cAMP**

**Figure 35**


**Rat CGRP cAMP**



**Figure 36**


**Rat CGRP cAMP**

**Inhibition of rtCGRP-driven cAMP Production**



**Figure 37**


**Rat CGRP cAMP**



**Figure 38**

**Inhibition of Radioligand Binding**

	<b>IC<sub>50</sub> (nM)</b>	<b>K<sub>i</sub> (nM)</b>
<b>Ab1</b>	0.585	0.46
<b>Ab2</b>	0.482	0.378
<b>Ab3</b>	2.49	10.96
<b>Ab4</b>	0.579	0.455
<b>Ab5</b>	0.586	0.461
<b>Ab6</b>	2.46	1.94
<b>Ab7</b>	4.53	3.56
<b>Ab8</b>	0.936	0.736
<b>Ab9</b>	2.03	1.6
<b>Ab10</b>	0.28	0.22
<b>Ab11</b>	2.26	1.78
<b>Ab12</b>	0.315	0.248
<b>Ab13</b>	0.335	0.264

**Figure 39****Reduction in Vasodilatation Following Capsaicin Administration**



**Figure 40****Reduction in Vasodillatation Following Capsaicin Administration**

FIG. 41






FIG. 42





FIG. 43

FIG. 44






FIG. 45




FIG. 46